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 L-Broth 
 50 g   Tryptone 
 25 g   Yeast Extract 
 25 g   Sodium chloride 
 
 L-Agar 
 50 g  Tryptone 
 25 g  Yeast Extract 
 50 g   Sodium Chloride 
  
 Make up to 5 litres with dH2O, adjust pH to 7.2.  Pour into a bottle and add         
            75 g of Agar. Store at 4oC until use. Microwave to melt prior to use. 
Make up to 5 litres with dH2O, pH to 7.2.  Store at 4
oC.   
 Orange G loading dye 
 3 g  Ficoll 400 (Sigma) 
 50 µl  20% SDS (Fisher) 
 800 µl  0.5M EDTA (Sigma) 
 25 µg  Orange G (Sigma) 
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 Make up to 1 litre with dH2O and store at room temperature. 
 
 TBE Buffer (5x) 
 54 g  Tris (hydroxymethyl) aminomethane (Sigma) 
 27.5 g  Boric Acid (Sigma) 
 20 ml  0.5M EDTA (Sigma) 
  
 Make up to 1 litre with dH2O.  Store at 4
oC. 
 Dilute to 0.5x for preparing and running agarose gels. 
 
 TE buffer 
 10mM  Tris-HCl, pH 7.5 
  1 mM   EDTA 
 in dH2O 
 
 
2. Neuronal cell culture 
 
 Borate buffer 
 50 mM Boric Acid (Sigma) 
 in dH2O, adjust pH to 8.0 
 
 Poly D-Lysine solution 
 25 ml  0.3M Borate buffer (Sigma) 
 2.5 ml  500 µg/ml Poly D-Lysine (Sigma) 
 22.5 ml dH2O 
  
 Dissection buffer (for primary neuronal culture) 
 500 ml  HBSS (with CaCl2 and MgCl2) 
 5 ml  L-Glutamate  
 3.5 ml  HEPES (cell culture standard, pH7.3-7.5)  
  
 For trypsinisation of dissected brain tissue, 20mls of Tryple Express     
            (Invitrogen) is added to 30mls dissection buffer. 
  
 Neurobasal Medium 
 All reagents are from Gibco (Invitrogen). 
 500 ml  Neurobasal medium  
 10 ml  B27 supplement 
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 5 ml  GlutaMAX-1 supplement  
 2.5 ml  Penicillin/Streptomycin solution  
 
 
3. Protein purification and biochemistry 
  
 Citrate buffer 
 2.1 g   Citric Acid (Sigma) 
 Make up to 1 litre dH2O, adjust pH to 6.0 
 
 Guanidine Hydrochloride solution 
 6 M Gndn-HCl (Sigma) 
 50 mM Tris-HCl, pH 7.5 
 in dH2O 
 
IMAC ‘buffer A’ 
 25 mM  Na2HPO4 
 500 mM  NaCl 
 20 mM Imidazole 
 in ddH2O, adjust pH to 7.4 
 
 IMAC ‘buffer B’ 
 25 mM  Na2HPO4 
 500 mM  NaCl 
 500 mM  Imidazole 
 in ddH2O, adjust pH to 7.4 
 
 Laemmli protein sample buffer 
 100mM Tris-HCl pH 6.8 (Fisher) 
 20% v/v Glycerol (Promega) 
 4% w/v SDS (Fisher) 
 in dH2O 
  
 Add bromophenol blue (Sigma) to colour. Store at room temperature. Before    
            use Dithiothreitol (DTT, from 1M stock) is added at 100 mM final    
            concentration. 
  
 MOPS-SDS-Tris running buffer 
 62.8 g   MOPS 
 72.6 g   Tris Base 
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 10 g   SDS 
 6.5 g   Na Bisulfite 
  
 Make up to 10 litres dH2O. Store at room temperature 
 
 Mowiol/Dapi mounting solution 
 7.5 g  Mowiol (Sigma) 
 10 ml  Glycerol (Promega) 
 25 ml  dH2O 
  
 Solution is left overnight at room temperature. 
 Add 50 ml 200 mM Tris-HCl pH 8.5 (Fisher). 
 Heat the solution in 100 oC water bath for 20 minutes and leave to cool.  
 Add 1.75 g DABCO (Sigma). 
 Mowiol can be stored at -20 oC. Dapi is added at a final concentration of  
 50 µg/ml and can be stored at 4 oC. 
 
 Phosphate buffered saline (PBS), pH 7.3-7.5 
 From tablets (Invitrogen) containing: 
 10 mM Phosphate 
 150mM NaCl 
  
 Ponceau S stain 
 1 g  Ponceau S (Sigma) 
 4 ml  Acetic Acid (Fisher) 
  
 Make up to 200 ml with dH2O. Store at room temperature.  
   
 RIPA Lysis Buffer 
 50mM  Tris-HCL pH 7.5 (Fisher) 
 150 mM NaCl (Fisher) 
 1% v/v  IGEPAL/NP-40 (Sigma) 
 0.5% w/v Sodium Deoxicholate (Fisher) 
 0.1% v/v SDS (Fisher) 
 in dH2O, store at -20 or 4°C.  
 
 Before use add protease inhibitor cocktail tablets (Roche) at a concentration  
             of 1 tablet per 50ml of solution.  
  
  Semi-dry transfer buffer  
 48 mM  Tris (5.82 g) 
 39 mM  glycine (2.93 g) 
 20% v/v methanol (200 ml) 




 Size Exclusion Buffer 
 1x PBS tablets (Invitrogen) in 1 litre ddH2O 
 10% v/v glycerol  
 
 Sodium Phosphate (20 mM) with NaF (100 mM)  pH 7.0  
 (Circular Dichroism  buffer) 
 16 mM  Na2HPO4 
 4 mM   NaH2PO4 
 100 mM  NaF 
 in dH2O  
  
 Tris Buffered Saline (TBS) 
 50 mM  Tris (hydroxymethyl) aminomethane (Fisher) 
 150 mM  NaCl 
  
 in dH2O, adjust pH to 7.5 with HCl. Store at room temperature 
  
 
4. Mass spectrometry sample preparation buffers 
 
 500mM ABC [NH4HCO3] 
988 mg NH4HCO3 (Ammonium bicarbonate) 
25 ml  dH2O 
 
 200mM ABC / 50% ACN (v/v, Acetonitrile) 
6 ml  500 mM ABC 
1.5 ml  dH2O 
7. 5ml  Acetonitrile 
 
 20mM DTT / 200mM ABC / 50% ACN v/v 
300 µl  1 M DTT 
1.2 ml  500 mM ABC 
1.5 ml  Acetonitrile 
 
 50mM IAA / 200mM ABC / 50% ACN v/v 
100 µl  500 mM IAA (Iodoacetamide) 
400 µl  500 mM ABC 




 20mM ABC / 50% ACN (v/v, enough for 6-8 bands) 
600 µl  500 mM ABC x 18 = 10.8 ml 
5.4 µl  dH2O             x 18 = 97.2 µl 
7.5 µl  Acetonitrile    x 18 = 135 µl 
 
 50mM ABC 
50 µl  500 mM ABC x 10 = 500 µl 
450 µl  dH2O              x 10 = 4.5 ml 
 
Sinapinic acid (3,5-Dimethoxy-4-hydroxycinnamic acid) matrix for MALDI  
mass spectrometry  
 (10 mg/ml) 
Mix 10 mg Sinapinic acid with 400 µl dH2O 
Add 100 µl 3% v/v trifluoroactetic acid (TFA) in dH2O 
Add 500 µl acetonitrile (ACN) and mix. 
 
 Ammonium Acetate buffer for ESI MS 
 10 mM  Ammonium acetate in dH2O 






G protein-coupled receptors (GPCRs) form a link between the cell and their 
environment when signaling pathways are activated upon ligand binding. However, 
the ligands and functions for many GPCRs remain to be determined. G protein-
coupled receptor 50 (GPR50) is one such orphan, and its exact role is yet unknown. 
There is however emerging functional and genetic evidence suggesting a function for 
GPR50 in psychiatric illness and lipid metabolism. It was hypothesised that 
investigating GPR50’s protein-protein interactions would lead to a greater 
understanding of the role of GPR50 in normal brain functioning and in mental 
illness. Putative protein interactors were initially isolated by a yeast two-hybid study 
and were further tested here. To address GPR50’s links to mental illness, the 
GPR50∆502-505 deletion variant associated with mood disorders was also investigated.  
To test this hypothesis I sought to confirm some of the key yeast two-hybrid 
interactions. Using co-immunoprecipitation and immunocytochemistry the 
interaction of GPR50 with reticulon family members Nogo-A, Nogo-C and RTN3, 
and with cell-cell adhesion molecule CDH8 and lipid-associated protein ABCA2 
were validated.  
In order to identify the location of interactions, subcellular fractionation of mouse 
brain and rt-PCR and immunohistochemistry in developing and adult mouse brain 
were performed. GPR50 and several interactors were found to be enriched at the 
synapse by subcellular fractionation of whole adult brain, and at embryonic day 18 
(E18) and 5 weeks by rt-PCR. Colocalisation of GPR50 and interactors was found in 
the amygdala, hypothalamus, cortex and specific brain stem nuclei by 
immunohistochemistry. The discovery of GPR50 expression in noradrenergic, 
serotonergic and dopaminergic nuclei in the adult brain stem suggests a further role 
for GPR50 in neurotransmitter signaling and stress.   
To investigate the function of GPR50 two assays were performed that measure 
processes which are known to be affected by Nogo and RTN3: The first assay was a 
neurite outgrowth assay in Neuroscreen-1 cells, a PC12 cell clone. A significant 
increase in neurite length was detected after transient overexpression of GPR50 and 
this effect was increased in the GPR50∆502-505/T532A variant. Additionally GPR50-
 
 xvii 
overexpression resulted in an increase in filopodia formation suggesting a role in 
actin dynamics. As a second functional assay in vitro BACE1 activity assays were 
performed in HEK293 cells. GPR50 but not GPR50∆502-505/T532A overexpression 
resulted in a significant increase in BACE1 activity.  
Lastly a final series of pilot experiments were performed to gain insight into the 
secondary structure of the C-terminal domain and the effects of the polymorphisms 
on structure. The 35kDa GPR50 C-terminal domain was purified and Circular 
Dichroism studies indicated a predominantly unstructured protein with increased α-
helical content in the GPR50∆502-505 variant.  
The results in this thesis indicate a role for GPR50 in neuronal development and 
synaptic functioning. The results also strengthen an association with major mental 
illness, with links to several disease mechanisms. 
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1 Chapter One: Introduction 
 
1.1 Mental illness 
 
Psychiatric disorders are a major health problem in the world today. One in four 
people are affected by mental disorders during their lives, according to the World 
Health Report 2001 (WHO, 2001). The cost of major mental illness to society is 
enormous. In 2006 mental disorders were joint 3rd (with cancer) in total expenditures 
for medical conditions in the United States (US), after heart conditions and trauma-
related disorders (AHRQ/NIMH, 2006). It is difficult to place an exact number on 
the total cost as it does not only involve direct healthcare costs but also loss of 
earnings, income support, homelessness and even inprisonment. The total economic 
burden in the US in 2002 was estimated as greater than $317 billion, or an equivalent 
of $1000 per individual in the US that year (Insel, 2008; Kessler et al., 2008). Three 
of the most common major psychiatric disorders are bipolar disorder, major 
depressive disorder and schizophrenia. Bipolar disorder and major depressive 
disorder are affective (mood) disorders whilst schizophrenia is a psychotic disorder. 
 
Bipolar affective disorder (BP) (formerly termed manic depressive disorder) is 
characterised by repeated episodes of mania and depression. Episodes of mania 
consist of elevated mood and increased energy, activity and productivity, and 
unpredictable behaviour. Depressive episodes feature lowered mood and decreased 
energy, activity and productivity. Feelings of hopelessness, worthlessness and 
suicidal thoughts are common during depressive episodes (WHO, 1992). The DSM-
IV (Diagnostic and Statistical Manual of Mental Disorders) (American Psychiatric 
Association, 1994) and the ICD-10 (International Classification of Diseases of the 
World Health Organisation (WHO, 1992)) recognise several subtypes of bipolar 
disorders: bipolar I, which includes one or more manic episodes; bipolar II, which 
involves one or more hypomanic epicodes and one or more depressive episodes; 
cyclothymia, which is a milder form of bipolar disorder and includes episodes of 
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hypomania with periods of depression that do not meet the criteria for major 
depressive disorder; and bipolar disorder not otherwise specified (NOS), which 
includes all other forms of the disease (APA, 2000). Bipolar disorder can be rapid 
cycling, meaning at least four separate episodes over a 12-month period (Dunner and 
Fieve, 1974). Approximately 13-20% of bipolar patients experience rapid cycling 
(Mackin and Young, 2004). 
 
Major depressive disorder (MDD), or unipolar depression, is characterised by the 
depressive symptoms present in bipolar disorder, without the manic episodes.  
 
Schizophrenia (SCZ) on the other hand is characterised by ‘positive’ symptoms such 
as hallucinations, delusions, thought disorder, and ‘negative’ symptoms such as 
social withdrawal, blunted affect and lack of motivation (WHO, 1992; APA, 2000). 
Although not included in the diagnostic criteria of DSM-IV (TR), cognitive 
symptoms such as working memory deficits and impaired executive functions are 
common to schizophrenia, and are more severe than in affective disorders (Keefe and 
Fenton, 2007). 
 
Major depressive disorder has a lifetime prevalence (ie the proportion of people 
having at least one episode during their lives) of 20% (men) to 30% (women) 
(Kruijshaar et al., 2005), although the 12-month risk is substantially lower at 
approximately 7% overall (Kessler et al., 2003). Both bipolar disorder and 
schizophrenia are believed to affect 1-2% of the population, and both cause severe 
disability. General onset of symptoms of schizophrenia and bipolar disorder is in 
adolescence and early adulthood. Bipolar disorder affects both men and women 
equally, although 70% or more of rapid cycling bipolar patients are women (Mackin 
and Young, 2004). There is no sex difference in prevalence of schizophrenia, 
although the age of onset is lower in men (Saha et al., 2005) and other differences 
have also been found, for instance in substance abuse, brain and cognitive 
abnormalities and responsiveness to antipsychotics (Leung and Chue, 2000).  
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These prevalence percentages are however dependent on the diagnostic criteria used 
and recognition of various subtypes of these illnesses. A recent study, using DSM-IV 
criteria, estimated the lifetime prevalence of schizophrenia at 0.87%, but estimated 
the risk for combined psychotic disorders (including schizophrenia, schizoaffective 
disorder, schizophreniform disorder, delusional disorder, bipolar I disorder, major 
depressive disorder with psychotic features, substance-induced psychotic disorders, 
psychotic disorders due to a general medical condition) to be 3% (Perala et al., 
2007). Another recent study estimated the 12-month prevalence of bipolar disorder at 
2.6% (Kessler et al., 2005). The next version of the diagnostic and statistical manual, 
DSM-5, which is due in May 2013, is expected to change the number of subtypes 
(reduced in the case of schizophrenia) and the lifetime risk may therefore change. It 
is important to note that none of the diagnostic manuals to date are based on solid 
biological criteria for distinguishing between diseases. The DSM-5 will not change 
this (Hyman, 2007).   
 
A reason for this lack of biological criteria is that the aetiology of psychiatric 
illnesses is still poorly understood. These are regarded as complex disorders, with a 
multitude of genetic, epigenetic and environmental factors playing a role in the 
development of disease. Patients with bipolar disorder are treated with mood 
stabilizers such as lithium, but up to 50% remain unresponsive to monotherapy 
(Sachs, 1996; Gershon and Soares, 1997). Strategies using combinations of Lithium 
with antipsychotics and antidepressants are common but are far from satisfactory as 
side effects are common (Solomon et al., 1998; Nemeroff et al., 2001; Sachs et al., 
2007). Individual differences and needs of patients have so far been poorly 
accounted for in the development of drugs. A better understanding of the biology of 
mental illness will increase the likelihood of improving diagnostics, therapeutic 
interventions and quality of life of people with psychiatric illness.  
 
There is a strong genetic component to psychiatric illness, as is clear from family, 
twin and adoption studies (Kinney and Matthysse, 1978). However, as it turns out, 
this high heritibility does not mean causative gene variants for mental illness are 
easily found. Research in the last decades has focused on finding candidate genes for 
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major mental disorders using methods to detect cytogenetic abnormalities, by linkage 
and association analyses, and through copy number variation (CNV) studies.  
 
An example of a cytogenetic abnormality is a chromosomal translocation. This is 
caused by the rearrangement of nonhomologous chromosomes, resulting in possible 
disruption of genes at the breakpoints of the chromosomes. Chromosomal 
abnormalities have been found to cosegregate with mental illness in a number of 
cases (MacIntyre et al., 2003). Linkage analysis searches for genetic loci or alleles 
that are inherited together with disease markers, usually in large pedigrees or sets of 
sib-pairs or parent-offspring trios (Kruglyak et al., 1996). Case-control association 
studies are either hypothesis-driven candidate gene studies with a limited number of 
markers (variants) or hypothesis-free genome-wide association studies (GWAS), 
where markers cover the entire genome (>100.000 single nucleotide polymorphisms, 
SNPs) (Manolio, 2010). In both types of association the frequency of variants is 
compared between case and control populations of unrelated individuals. In 
association studies it is of importance that the control population has similar 
characteristics to the cases in order to control for selection bias and population 
stratification (differences that are due to differences in ethnic origin rather than the 
risk variant).  
 
Despite high hopes GWAS has not lead to the enormous increase in the number of 
gene associations with major mental illness, as was the case for other common 
illnesses such as diabetes (WTCCC, Scott et al., 2007; 2007), obesity (Frayling et al., 
2007) and inflammatory bowel disease (Duerr et al., 2006; WTCCC, 2007). Only a 
limited number of variants have been identified, each of which appears to carry a 
small effect (Ferreira et al., 2008; Sullivan et al., 2008; Cichon et al., 2011). Some 
large studies found no association at all (Belmonte Mahon et al., 2011). When 
psychiatric illness is as much as 89% heritable (McGuffin et al., 2003) this raises the 
question of the ‘missing heritability’ and the genetic absolution of those disorders 
(Maher, 2008). 
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The main theory behind GWAS is the ‘common disease-common variant’ 
hypothesis, which states that common illness is caused by (multiple) disease 
alleles/loci that are present in all human populations (at relatively high frequencies) 
(Reich and Lander, 2001). These variants are not necessarily causative but have 
different frequencies in the diseased population. In the last couple of years the 
common disease, common variant hypothesis has gradually lost its shine and been 
replaced with the idea that multiple rare variants may better explain the genetics of 
common complex mental disorders (Gershon et al., 2011). Perhaps the answer lies in 
copy number variations (CNVs, which refer to deletions, duplications or 
rearrangements of large regions of the genome (1 kilobase to several megabases), 
that are either inherited or the result of de novo mutations. They are very common 
from of variation in the human genome (Sebat et al., 2004). Several rare CNVs have 
recently been found to be associated with mental illness (Sebat et al., 2007; Cook and 
Scherer, 2008; Vacic et al., 2011). 
 
The picture that emerges from these studies is a complex pattern of inheritance with 
common gene mutations of small effect and rare mutations with large effects 
(Sullivan, 2005). Epigenetic and gene-environment interactions will need to be added 
into the equation. Detailed (‘deep’) and costly sequencing efforts of candidate genes 
will be necessary to identify all the rare variants that may be associated with disease. 
A strong candidate gene will not only need to stand up to replication studies using 
various methods but will also need a strong biological and functional body of 
evidence in order to convince the critics (Crow, 2007). 
 
Despite these difficulties some promising candidate genes were identified through 
multiple methods and substantial effort has been put into strengthening their 
functional links to illness (Craddock et al., 2005). Disrupted in Schizophrenia-1 
(DISC1) (Millar et al., 2000), Dysbindin (DTNBP1) (Straub et al., 2002) and 
Neuregulin 1 (NRG1) (Stefansson et al., 2002) are some of the most commonly 
studied, and although there is a lack of consistency in the specific variants involved 
(Sullivan, 2005), recent functional biological evidence is encouraging (Stefansson et 
al., 2004; Clapcote et al., 2007; Duan et al., 2007; Mao et al., 2009). DISC1 and 
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NRG1 are primarily candidate genes for schizophrenia but are also associated with 
bipolar disorder and other mental illnesses (Craddock et al., 2005).  
 
It seems that bipolar disorder is somewhat lagging behind in the number of candidate 
genes identified and researched. This may be due to a limited research effort 
compared to some of the schizophrenia genes (Craddock et al., 2005). Some of the 
recently identified and replicated bipolar loci are present in D-amino acid oxidase 
activator DAOA(G72)/G30 (Hattori et al., 2003; Chen et al., 2004a), brain derived 
neurotrophic factor BDNF (Neves-Pereira et al., 2002; Sklar et al., 2002; Geller et 
al., 2004) and Ankyrin 3 (ANK3) (Ferreira et al., 2008; Smith et al., 2009; Takata et 
al., 2011), although more genetic and functional evidence is needed. No doubt their 
time will come. 
 
Interestingly several of these candidate genes have not been associated with a single 
illness but were shown to associated with schizophrenia, bipolar disorder, major 
depression, autism, and also with neurodegenerative disorders such as Alzheimer’s 
disease (AD) (Kilpinen et al., 2008; Morgan et al., 2008; Di Maria et al., 2009; 
Hennah et al., 2009; Voineskos et al., 2011). This points to converging biological 
pathways and may  indicate a role in common mental illness ‘phenotypes’ such as 
reduced grey/white matter in the brain, abnormalities in brain development, 
mania/psychosis and social and cognitive deficits. Candidate genes are commonly 
‘validated’ by providing functional evidence for a role in brain development, 
pathology and behaviour that links back to these phenotypic abnormalities. 
 
Recently, G protein-coupled receptor 50 (GPR50) was identified as a risk gene for 
major mental illness in women through case-control association (Thomson et al., 
2005; Macintyre et al., 2010). In this thesis I will focus on GPR50 and its possible 
role in brain functioning and mental disorders. 
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1.2 GPR50 Structure and function 
 
1.2.1 G protein-coupled receptors 
 
GPR50 belongs to the 7-transmembrane (7TM) G protein-coupled receptor (GPCR) 
superfamily of over 1000 members. GPCRs form a link between the cell and its 
environment, moderating 80% of intracellular molecular signalling, by triggering 
several, highly interconnected, secondary messenger pathways in response to ligand 
binding (Marinissen and Gutkind, 2001; Lundstrom, 2006) (Figure 1.1). Secondary 
messenger systems are activated through the interaction with heterotrimeric G 
proteins (consisting of α, β and γ-subunits, Fig 1.1). Upon activation by a ligand, the 
GPCR associates with the G protein complex resulting in exchange of GDP into 
GTP-bound Gα. Gα is then dissociated from the Gβγ complex and from the 
receptor. The various types of Gα then bind to effector molecules, such as adenylyl 
cyclases and phospholipase C, resulting in the inhibition or activation of classic 
second messengers such as cAMP, diacyl glycerol (DAG) and phosphoinositides like 
Phosphatidylinositol 3,4,5-trisphosphate (PIP3). This can then lead to the opening of 
Ca2+ or K+ channels activation of further secondary messenger pathways (Flower, 
1999; Marinissen and Gutkind, 2001). Ultimately this results in gene expression 
changes and the regulation of diverse functions such as neurotransmitter release, cell 
growth, apoptosis, chemotaxis and physiological responses (Harmar et al., 2009) (Fig 
1.1). However, not all cellular responses are mediated by G proteins, nor does 
activation of a specific receptor lead to a single biochemical route, creating a 
multitude of intricate and interconnected pathways that lead to a biological response 
(Marinissen and Gutkind, 2001).  




Figure 1.1. GPCRs control a wide variety of signalling networks. GPCRs can be 
activated by binding various ligands, including biogenic amines, amino acids, ions, 
lipids, peptides and proteins, light and odorants. Through heterotrimeric G protein-
dependent and –independent pathways effector molecules can be activated, 
resulting in diverse biological responses such as proliferation, differentiation, cell 
survival and cancer. Abbreviations: DAG, diacylglycerol; FSH, follicle-stimulating 
hormone; GEF, guanine nucleotide exchange factor; LH, leuteinizing hormone; LPA, 
lysophosphatidic acid; PAF, platelet-activating factor; PI3K, phosphoinositide 3-
kinase; PKC, protein kinase C; PLC, phospholipase C; S1P, sphingosine-1-
phosphate; TSH, thyroid-stimulating hormone. Figure published in Marinissen and 
Gutkind, 2001. Trends in Pharmacological Sciences. Copyright 2001, Elsevier 
Science Ltd. (Note: G-proteins bind 3rd intracellular loop of GPCR and not TM region 
as suggested here).   
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G protein-coupled receptors are interesting candidates for psychiatric disorders as 
they are involved in many disease pathways and are considered important targets for 
therapeutic interventions. G protein-coupled receptor signaling is believed to play an 
important role in the aetiology and treatment of major mental illness. Of the drugs 
currently in development or on the market 25-30% target GPCRs, which represent 
15% of the ‘druggable genome’ (Hopkins and Groom, 2002). Examples of drugs 
targeting GPCRs and GPCR signaling networks are Fluoxetine (Prozac, a 5-HT 
reuptake inhibitor or transporter blocker), Haloperidol and other typical 
antipsychotics (Dopamine D2 receptor antagonist), Clozapine and other atypical 
antipsychotics (Dopamine and 5-HT receptor antagonists) and inositol signalling (eg. 
Lithium, Carbamazepine and Valproic acid) (Harwood, 2003).  
 
In humans, 354 non-sensory GPCRs have been identified, of which 214 have a 
known (endogenous) ligand (Harmar et al., 2009). The rest, which are classed 
‘orphans’, have been resistant to current deorphanisation strategies by industry and 
academia. Their signaling mechanism and function remains to be identified. 
Although most of the functions of GPCRs are attributed to signaling in response to 
ligand binding and G protein-coupling, ligand-independent functions of GPCRs have 
also been proposed (Levoye et al., 2006). 
 
GPR50 was originally cloned from cDNA of the human pituitary (Reppert et al., 
1996), suggesting a role in neuroendocrine function. The GPR50 protein is 45% 
identical in amino acid sequence to members of the melatonin receptor family, hence 
it is also known as the melatonin-related receptor (Fig 1.2). Despite this homology it 
does not bind melatonin or any other known ligand and therefore remains an orphan 
G protein-coupled receptor (Reppert et al., 1996).  
 
1.2.2 Melatonin and melatonin receptors 
 
Melatonin is a neurohormone released by the pineal gland which has a regulatory 
role in seasonal and circadian rhythms and other physiological processes (Arendt, 
1998; Dawson and van den Heuvel, 1998; Zawilska et al., 2009). It is rhythmically 
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secreted with peak expression during the night. Besides a function as circadian 
pacemaker it controls the hypothalamus-pituitary-adrenal (HPA)-axis and has role in 
energy metabolism, circulating lipid levels, growth and differentiation, stress 
responses and cell protection and cell survival (Dawson and van den Heuvel, 1998; 
Morgan et al., 1998; Hardeland, 2009; Luchetti et al., 2010).  
 
Several melatonin receptor subtypes have been cloned: MT1 (Mel1A) and MT2 
(Mel1B) from mammals, and Mel1c, which is expressed in non-mammalian 
vertebrates (birds, amphibians, fishes) (Ebisawa et al., 1994; Reppert et al., 1994; 
Reppert et al., 1995b; Reppert et al., 1995a). A third melatonin binding site has been 
identified, MT3, otherwise known as ML-2 or quinone reductase (QR) (Jockers et 
al., 2008), which has low affinity for melatonin (Duncan et al., 1988) (5-50 times 
less than MT1 and MT2) but has a specific ligand called 5-methoxycarbonylamino-
N- acetyltryptamine (MCA-NAT) (Molinari et al., 1996).  
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Figure 1.2 Sequence alignment of human MT1, MT2 and GPR50 with bovine 
rhodopsin (transmembrane domains only). Sequence identities are reported white 
on a black background, whereas sequence similarities are boxed (A). The positions 
of the transmembrane helices, as observed in the bovine rhodopsin structure, are 
reported above its sequence. Arrows indicate the positions of the amino acids that, 
in GPR50, evolved under positive selection. Stars indicate amino acids, which have 
been shown to play a key role for melatonin binding in MT1 (dark blue), MT2 (light 
blue) or both (red) (Conway et al., 1997, 2000; Gubitz & Reppert., 2000; Mazna et 
al., 2004). A ribbon representation of the GPR50 3D structure model is represented 
(B), with transmembrane helices coloured according to the sequence alignment. 
Amino acids evolving under positive selection and amino acids important for 
melatonin binding in MT1/MT2 are shown according to the colours reported in the 
sequence alignment. From Dufourny et al., (2008), BMC Evolutionary Biology. 
Copyright 2008, BioMed Central Ltd. 




Human MT1 and MT2 show 55% homology at the amino acid level with 70% in the 
transmembrane domains only (reviewed in Jockers et al., 2008). The melatonin 
receptors form a specific receptor cluster within the rhodopsin family of GPCRs 
(Vassilatis et al., 2003). Although ubiquitously expressed in non-mammalian 
vertebrates, MT1 receptor distribution is restricted to low density in the pars tuberalis 
of the anterior pituitary, the suprachiasmatic nucleus (SCN), and also in the 
hippocampus, cortex, thalamus cerebellum and eye. MT2 expression was detected in 
the SCN, retina, hippocampus and cerebellum (reviewed in Zawilska et al., 2009). 
MT1 and MT2 preferentially couple through Gi, but also through Gq11 proteins, 
thereby inhibiting cAMP, PKA and phosphorylation of cAMP, but stimulating 
MEK1, MEK2, ERK1, ERK2 and JNK phosphorylation (reviewed in Jockers et al., 
2008). 
 
Like many GPCRs, the melatonin receptors can homo- and heterodimerise, and bind 
non-G proteins to their C-terminal domain, expanding the possible signaling 
pathways, functional effects and therapeutic interventions (Jockers et al., 2008). 
Melatonin receptor density decreases with aging (van Coevorden et al., 1991; 
Savaskan et al., 2005; Savaskan et al., 2007; Wu et al., 2007) and further decreased 
MT1 and MT2 expression was found in the postmortem brain of Alzheimer’s disease 
patients (Savaskan et al., 2005; Savaskan et al., 2007; Wu et al., 2007). 
 
GPR50 is the mammalian ortholog of Mel1c (Dufourny et al., 2008), although it does 
not bind 2-[125I] iodomelatonin or [3H] melatonin (Reppert et al., 1996; Levoye et al., 
2006). A study using MT1/GPR50 chimeric receptors indicated transmembrane 
domains (TM) 4 and 6 of MT1 are necessary for 2-[125I] iodomelatonin binding and 
modulation of cAMP levels. Chimeric GPR50 including TM4 and 6 of MT1 did 
result in melatonin binding, albeit with low affinity (Conway et al., 2000; Gubitz and 
Reppert, 2000). Site directed mutagenesis pointed to the critical importance of non-
conserved residue Gly258 in TM6 in melatonin binding (Fig, 1.2, Conway et al., 
2000; Gubitz and Reppert., 2000; Dufourny et al, 2008). This residue may be 
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necessary for maintaining the structure of the ligand binding pocket, and the 
hydroxyl-containing sidechain of Thr257 in GPR50 may disrupt this (Conway, 2000; 
Gubitz and Reppert., 2000). Something similar may be the case for MT2 residue 
Leu272 which has been replaced for Val258 in GPR50 (Fig 1.2) (Mazna et al., 
2004). Other residues that have been shown to be important for MT ligand binding 
are however conserved in GPR50 (Fig 1.2) (Conway et al., 1997; Kokkola et al., 
1998; Dufourny et al., 2008). Dufourny et al. (2008) modelled sites of positive 
selection in GPR50 (Fig 1.2). Although these sites were not previously shown to be 
important for ligand binding, they are in close proximity to such sites in a 3D model 
(Fig 1.2B). In addition several are found at the top of the ligand binding pocket and 
may therefore interfere with ligand binding (Fig 1.2B). 
 
1.2.3 GPR50 interacts with MT1 and MT2 
 
GPR50 has been shown to interact with the melatonin receptors in a ligand-
independent way under overexpressed conditions. GPR50 can homodimerize, and 
form heterodimers with melatonin receptors MT1 and MT2 (Levoye et al., 2006). 
This formation of GPR50/MT1 heterodimers disrupts ligand binding to MT1, 
moreover, the presence of GPR50 prevents further G protein signalling through MT1, 
by inhibiting Gi protein coupling and β-arrestin binding (Levoye et al., 2006; See Fig 
1.3). However under basal conditions (no melatonin), the binding between MT1 with 
β-arrestin was increased in the presence of GPR50, indicating possible constitutive 
activity of the MT1/GPR50 heterodimer (Levoye et al., 2006). This effect of GPR50 
on MT1 function seems to be dependent on the presence of the C-terminal domain 
(CTD) of GPR50, possibly through steric hindrance of the relatively long CTD. This 
interaction is intruiging and opens up the possibility for ligand-independent functions 
for GPR50. It is however important to note that endogenous interactions between 
GPR50 and MT1 have not been investigated or described, although GPR50 and MT1 
are both found to be expressed in the pituitary and hypothalamus (Reppert et al., 
1996; Wu et al., 2006), indicating a possible functional site of interaction.   
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Figure 1.3 GPR50-MT1 heterodimers. GPR50-MT1 heterodimerisation inhibits 
melatonin (agonist) binding, G-protein-coupling and β-arrestin binding, only in the 
presence of the GPR50 C-terminal domain. Image by Jockers et al., 2008. British 
Journal of Pharmacology.  Copyright 2008, British Pharmacological Society.  
 
1.2.4 GPR50 expression 
 
GPR50 is most highly expressed in the brain, but is also found in the adrenal glands, 
testes, ovary, eye, lung, kidney, intestines and heart of the rat and mouse by rt-PCR 
(Drew et al., 2001; Izzo et al., 2010), and in retina and retinal pigment epithelium of 
the sheep (Drew et al., 1998). Within the brain GPR50 was found to be mainly 
expressed in the pituitary and hypothalamic regions in the adult human, mouse, rat, 
hamster and sheep by in situ hybridization and immunohistochemistry (Reppert et 
al., 1996; Drew et al., 1998; Drew et al., 2001; Vassilatis et al., 2003; Barrett et al., 
2006; Sidibe et al., 2010), and is therefore possibly involved in lipid metabolism and 
body weight control, circadian rhythms, and mood (Reppert et al., 1981; McAllister-
Williams et al., 1998). By immunocytochemistry overexpressed GPR50 was detected 
on the plasma membrane of HEK293 cells (Hamouda et al., 2007). Western blotting 
revealed a monomeric form of GPR50 at 66 kDa and a dimeric form at 130 kDa 
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(Hamouda et al., 2007). The authors also detected an increase in GPR50-
immunoreactivity in cells showing degenerative changes in patients with 
Alzheimer’s disease (AD) as compared to healthy controls (Hamouda et al., 2007), 
which although tentative, may suggest a role for GPR50 in neurodegenerative 
disorders. 
 
1.2.5 GPR50 and psychiatric illness 
 
The GPR50 gene is located on Xq28 (Gubitz and Reppert, 1999), a region implicated 
in several linkage and association studies in bipolar disorder (Massat et al., 2002). 
GPR50 consists of two exons separated by a single intron, generating a single 
GPR50 splice variant of 617 amino acids (Fig 1.4, GenBank accession number 
GI:73909216). Three GPR50 common variants were identified as putative functional 
polymorphisms in bipolar disorder and major depression, all located within the CTD: 
a 12-bp in-frame deletion, which results in the loss of four amino acids from the 
protein sequence (∆502-505), and two single nucleotide polymorphisms (SNPs) that 
result in amino acid substitutions, T532A (rs561077) and V606I (rs13440581) 
(Figure 1.4, Thomson et al., 2005). T532A is in complete linkage disequilibrium 
with the deletion polymorphism. Two intronic SNPs were studied in GPR50, C-
16X2GPR50T (rs1202874) and rs2072621 (Thomson et al., 2005; Bhattacharyya et 
al., 2006). Recently rare variant S493N (rs62620754) was identified in a Swedish 
population (Jonsson et al., 2010) (Fig 1.4). 
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Figure 1.4 GPR50 gene structure and the positions of the polymorphisms. Figure 
adapted from Thomson et al., 2005. Molecular Psychiatry. Copyright 2005, Nature 
Publishing Group.   
 
In a case-control association study of 264 subjects with bipolar disorder (BPD), 226 
with major depressive disorder (MDD), 263 with schizophrenia (SCZ) and 562 
matched controls the ∆502-505 deletion was found to be significantly associated 
with both BPD and MDD (global p-values 0.007 and 0.011 respectively, Thomson et 
al., 2005). ). These associations were seen in females only, where the allele 
frequency of the ∆502-505 polymorphism was 51.0% in BP and 47.7% in MDD 
compared to 37.6% in controls (p-values 0.00023 and 0.0064 respectively). In 
addition intronic SNP rs2072621 was found to be significantly associated with the 
female schizophrenic sample (p=0.0014) only (Thomson et al., 2005). There is no 
reported gender bias in bipolar disorder or schizophrenia, but major depression is 
twice as common in females as in males, where the condition can be triggered by a 
postpartum episode (Sharma and Mazmanian, 2003). This sex difference is intriguing 
and suggests that hormones such as estrogen may mediate the risk of GPR50 in 
mental illness. 
 
Chapter 1: Introduction 
 18 
The association of GPR50 with mood disorders failed to replicate in a Hungarian 
sample of children and adolescents with childhood–onset mood disorders (girls: 215 
boys: 253) (Feng et al., 2007) or Swedish cohort (Alaerts et al., 2006). The failure to 
replicate may be due to genetic heterogeneity of the populations, a smaller cohort 
(Alaerts et al., 2006), grouping of BPD and MDD together (Feng et al., 2007), or an 
example of the ‘winner’s curse’. This effect is common to association studies and 
means that the genetic effect size of the original finding is overestimated, resulting in 
the subsequent studies being underpowered (smaller sample size) and therefore not 
be able to reach the same significance (Lohmueller et al., 2003; Zollner and 
Pritchard, 2007; Xiao and Boehnke, 2009; Macintyre et al., 2010).  
 
The association of variants within the GPR50 locus with bipolar disorder was 
however recently replicated using an expanded Scottish population sample of 338 
patients with BD, 359 patients with major depressive disorder (MDD) and 913 
control individuals (Macintyre et al., 2010). Significant association was found 
between BPD and women with intronic SNP rs1202874 (p=0.0035). Although 
initially no association was found with ∆502-505, when this sample was combined 
with a previous sample (Thomson et al., 2005) significant association was detected in 
females only (p=0.0006). In this study the clinical phenotype and treatment response 
was also investigated in a subgroup of 56 patients with early-onset MDD. In this 
subgroup association was found between ∆502-505 and age of onset, number of 
episodes, manic symptoms and initial thinking time in women and age of onset in 
men (Macintyre et al., 2010).  
 
Studying a small French Caucasian sample (106 patients, 80 females, 26 males; 120 
controls) intronic SNP rs2072621 was recently found to be associated with seasonal 
affective disorder (SAD) in women only (p=0.049) (Delavest et al., 2011). However, 
no multiple testing correction was performed on this p-value. Although the male 
sample is very small this result may reflect the higher incidence of SAD in women 
compared to men (3.5:1) (Lee and Chan, 1998). 
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GPR50 rare variant S493N was not found to be associated with autism in a study 
using a cohort of 109 Swedish people with autistic spectrum disorders (ASD) and 
118 controls, although the control group was not age- and gender matched (Jonsson 
et al., 2010). In a larger mixed-ethnic cohort of 295 cases and 362 controls common 
variants in GPR50 were investigated (Chaste et al., 2010). The frequency of ∆502-
505 and T532A was significantly decreased in ASD males only, although this did not 
withstand Bonferroni’s multiple testing correction (Chaste et al., 2010). No 
significant associations were found in females although the frequency of ∆502-505 
and T532A appeared to be higher in female ASD cases than controls, suggesting a 
possible difference between sexes. This needs to be further investigated however 
possibly using a bigger cohort.  
 
1.2.6 GPR50 and lipid metabolism 
 
Studying an English Caucasian population of 500 and 585 individuals, 
(Bhattacharyya et al., 2006) report an association between GPR50 variants ∆502-
505, T532A, V606I and intronic SNP rs1202874 and elevated circulating fasting 
triglyceride levels. Rs1202874 was also associated with lower circulating HDL 
(High Density Lipoprotein, ‘good’ cholesterol) levels. No association was found 
between GPR50 variants and obesity (body mass index) (Bhattacharyya et al., 2006). 
In agreement with a role in lipid metabolism, Ivanova et al. (2007) report that the 
GPR50 knockout mice have an altered metabolism, with apparent resistance to 
obesity when kept on a high-energy diet. 
 
A link of GPR50 to lipids would be interesting as cholesterol is a major component 
of the brain and myelin, and differences in cholesterol levels could therefore 
influence the development and cytoarchitecture of the brain (Dietschy and Turley, 
2001; Puglielli et al., 2003). Cholesterol, glycolipids and sphingolipids are often 
organized into lipid rafts domains in the cell membrane, which are important in cell 
signalling, also in relation to psychiatric illness (Allen et al., 2007). Interestingly, 
cholesterol metabolism has also been linked to AD pathology (Puglielli et al., 2003). 
Chapter 1: Introduction 
 20 
1.2.7 GPR50 loss-of-function models 
 
Several GPR50 knockout mouse models have been developed, by Astra Zeneca and 
Organon/Schering Plough/Merck, and recently stemcells were made available for 
generating mouse lines from the knockout mouse model repository (KOMP). 
However, only the Astra Zeneca mouse has so far been described in the literature 
(Barrett et al., 2006; Ivanova et al., 2008).  The mice are viable and have a metabolic 
phenotype as they display attenuated weight gain and reduced body fat on a high-
energy diet as compared to wild-type animals. Moreover, on comparison, GPR50 
knockout mice displayed hyperactive behaviour and a heightened metabolic rate. To 
my knowledge none of these mice have been tested for major mental illness 
phenotypes. 
 
1.2.8 The GPR50 C-terminal domain 
 
The GPR50 C-terminal domain (CTD), which is over 300 amino acids long, is large 
compared to that of the melatonin receptors and its non-mammalian ortholog Mel1c 
(Dufourny et al., 2008) (Fig 1.5, see also snake-like diagram in Fig 1.3), which 
suggests it is important for its function. This is reflected by recent functional and 
genetic findings. The inhibitory effect of GPR50 on MT1 signalling appears to be 
dependent on the presence of the GPR50 CTD. Genetic variants associated with 
BPD, MDD and elevated triglycerides are found in the CTD (Thomson et al., 2005; 
Bhattacharyya et al., 2006; Macintyre et al., 2010). The C-terminal region is likely to 
be involved in protein binding and the activation of downstream signalling pathways. 
The GPR50 CTD has high homology to the RNA polymerase II CTD (Dufourny et 
al., 2008) where the CTD has been shown to be key to protein binding and 
functioning. The GPR50 CTD is a proline-rich region, which may indicate binding to 
PDZ, SH2 or SH3 domain-containing proteins (Marinissen and Gutkind, 2001). 
Understanding protein interactions with the CTD might therefore give insight into 
GPR50 functioning. 




MT1             MQGNGS------ALPNASQPVLRGDG-ARPS------WLASALACVLIFTIVVDILGNLL 47 
MT2             MSENGSFANCCEAGGWAVRPGWSGAGSARPSRTPRPPWVAPALSAVLIVTTAVDVVGNLL 60 
Mel1c           MAMTKANLSCLDSLSQGNN--CLTARSTSPG-------VAATLAGVLIFTTVADIVGNLL 51 
GPR50           MG---------PTLAVPTPYGCIGCKLPQPE---YPPALIIFMFCAMVITIVVDLIGNSM 48 
                *           :              . *        :   :  .::.* ..*::** : 
MT1             VILSVYRNKKLRNAGNIFVVSLAVADLVVAIYPYPLVLMSIFNNGWNLGYLHCQVSGFLM 107 
MT2             VILSVLRNRKLRNAGNLFLVSLALADLVVAFYPYPLILVAIFYDGWALGEEHCKASAFVM 120 
Mel1c           VILSVYRNKKLRNAGNIFVVSLSVADLVVALYPYPLALIAIFHNDWTMGSLHCQLSGFIM 111 
GPR50           VILAVTKNKKLRNSGNIFVVSLSVADMLVAIYPYPLMLHAMSIGGWDLSQLQCQMVGFIT 108 
                ***:* :*:****:**:*:***::**::**:***** * ::  ..* :.  :*:  .*:  
MT1             GLSVIGSIFNITGIAINRYCYICHSLKYDKLYSSKNSLCYVLLIWLLTLAAVLPNLRAGT 167 
MT2             GLSVIGSVFNITAIAINRYCYICHSMAYHRIYRRWHTPLHICLIWLLTVVALLPNFFVGS 180 
Mel1c           GLSVIGSVFNITAIAINRYCYICHSLRYDRLYSRRNTCLYLLLTWMLTALATVPNFLVGS 171 
GPR50           GLSVVGSIFNIVAIAINRYCYICHSLQYERIFSVRNTCIYLVITWIMTVLAVLPNMYIGT 168 
                ****:**:***..************: *.:::   ::  :: : *::*  * :**:  *: 
MT1             LQYDPRIYSCTFAQSVSSAYTIAVVVFHFLVPMIIVIFCYLRIWILVLQVRQRVKPDRKP 227 
MT2             LEYDPRIYSCTFIQTASTQYTAAVVVIHFLLPIAVVSFCYLRIWVLVLQARRKAKPESRL 240 
Mel1c           LKYDPRVFSCTFTQTASSSYTVCVVLIHFLVPLGVVSFCYLRIWTLVIRVKGRVRPNPK- 230 
GPR50           IEYDPRTYTCIFNYLNNPVFTVTIVCIHFVLPLLIVGFCYVRIWTKVLAARDPAGQNPD- 227 
                ::**** ::* *    .. :*  :* :**::*: :* ***:***  *: .:  .  :    
MT1             KLKPQDFRNFVTMFVVFVLFAICWAPLNFIGLAVASDPASMVPRIPEWLFVASYYMAYFN 287 
MT2             CLKPSDLRSFLTMFVVFVIFAICWAPLNCIGLAVAINPQEMAPQIPEGLFVTSYLLAYFN 300 
Mel1c           -VRAADLRNFLTMFVVFVLFAVCWAPLNFIGLAVAINPAKVAPNIPEWLFVTSYFMAYFN 289 
GPR50           -NQLAEVRNFLTMFVIFLLFAVCWCPINVLTVLVAVSPKEMAGKIPNWLYLAAYFIAYFN 286 
                  :  :.*.*:****:*::**:**.*:* : : ** .* .:. .**: *::::* :**** 
MT1             SCLNAIIYGLLNQNFRKEYRRIIVSLCTARVFFV-------------------------- 321 
MT2             SCLNAIVYGLLNQNFRREYKRILLALWNPRHCIQ-------------------------- 334 
Mel1c           SCLNAVVYGLLNQNFRQEYKLILRALCTPRALFT-------------------------- 323 
GPR50           SCLNAVIYGLLNENFRREYWTIFHAMRHPIIFFSGLISDIREMQEARTLARARAHARDQA 346 
                *****::*****:***:**  *: ::  .   :                            
MT1             --------------------------DSSNDVADRVKWKPSPLMTNNNVVKVDSV----- 350 
MT2             --------------------------DASKGSHAEGLQSPAPPIIG-VQHQADAL----- 362 
Mel1c           --------------------------DSSRYNTEAIKSKQSPAGTNNNVKEANAYKGGVT 357 
GPR50           REQDRAHACPAVEETPMNVRNVPLPGDAAAGHPDRASGHPKPHSRSSSAYRKSASTHHKS 406 
                                          *::            *   .    . .:       
MT1             ------------------------------------------------------------ 
MT2             ------------------------------------------------------------ 
Mel1c           HTLF-------------------------------------------------------- 361 
GPR50           VFSHSKAASGHLKPVSGHSKPASGHPKSATVYPKPASVHFKADSVHFKGDSVHFKPDSVH 466 
                                                                             
MT1             ------------------------------------------------------------ 
MT2             ------------------------------------------------------------ 
Mel1c           ------------------------------------------------------------ 
GPR50           FKPASSNPKPITGHHVSAGSHSKSAFSAATSHPKPTTGHIKPATSHAEPTTADYPKPATT 526 
                                                                             
MT1             ------------------------------------------------------------ 
MT2             ------------------------------------------------------------ 
Mel1c           ------------------------------------------------------------ 
GPR50           SHPKPTAADNPELSASHCPEIPAIAHPVSDDSDLPESASSPAAGPTKPAASQLESDTIAD 586 
                                                                             
MT1             ------------------------------- 
MT2             ------------------------------- 
Mel1c           ------------------------------- 
GPR50           LPDPTVVTTSTNDYHDVVVIDVEDDPDEMAV 617 
 
Figure 1.5 Multiple sequence alignment of the human Melatonin receptor 1 (MT1), 2 
(MT2), the zebrafish (Danio rerio) Melatonin 1c receptor (Mel1c) and human 
GPR50, indicating the long C-terminal domain (residues 297-617) of GPR50 
compared to its gene family members. The alignment was created using ClustalW. 
"*" indicates the residues in that column are identical in all sequences in the 
alignment; ":" indicates conserved substitutions have been observed; "." means that 
semi-conserved substitutions are observed. Sequences used: MT1: GI:60498974; 
MT2: GI:69122993; Mel1c: GI:238814399; GPR50: GI:73909216.   
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1.2.9 Approaches to identifying GPCR function 
 
GPCRs cannot be easily be purified and crystallised and therefore rational drug 
design, as applied in drug discovery of soluble enzymes is difficult. Functional cell-
based assays have therefore been developed in order to identify GPCR ligands. 
Generally this involves overexpression of the GPCR in immortalized cell lines and 
performing high-throughput screening methods. Traditionally these are automated, 
methods, where a change in intracellular second messengers such as cAMP (for 
GPCRs coupled to GαS or Gαi), IP3 or Ca
2+ (Gαo or Gαq) is measured in response to 
the addition of ligand libraries, or tissue extracts.  
 
Another method is to measure GTPγS binding to the receptor, in response to ligand 
binding, using either radiolabelled or non-radiolabelled GTP-analogues. An 
advantage of this method is that it is independent of the type of G protein or second 
messenger involved, which is likely to be unknown in the case of an orphan (Eglen et 
al., 2007). However, there are indications that GPR50 may couple to Gαi and Gαq 
(Levoye et al., 2006), and may therefore inhibit cAMP or activate PKC and IP3. It is 
known that the mitogen-activated protein kinase (MAPK) system is regulated by the 
activation of most (all) types of G proteins (Marinissen and Gutkind, 2001), and an 
assay where extracellular regulated kinase (ERK) MAPK activity is measured could 
therefore be used for the ligand screening of all types of GPCR (Eglen et al., 2007). 
One such assay is called AlphaScreen SureFireTM (Perkin Elmer).  
 
Another universal method utilises β-arrestin translocation to the C-terminal domain 
of the receptor upon agonist stimulation. The interaction of the receptor to β-arrestin 
can then be measured by FRET (Förster (fluorescence) resonance energy transfer) or 
BRET (bioluminescence resonance energy transfer) techniques (Eglen et al., 2007). 
More sensitive techniques, using β-galactosidase enzyme complementation assays to 
measure β-arrestin translocation or receptor internalisation have also been developed 
(O'Dowd et al., 2005; Wehrman et al., 2005; Eglen et al., 2007) 
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Exogenous GPR50 has been shown to homodimerise and heterdimerise with the 
melatonin MT1 and MT2 receptors (Levoye et al., 2006). It is possible that GPR50 
only binds its ligand in the presence of MT receptors. An example of this mechanism 
is GABA receptor signaling, where the GABAB1 receptor has ligand-binding 
properties but does not couple to G proteins or adenylyl cyclase (AC) whereas the 
GABAB2 receptor couples to G proteins and AC but does not bind GABA on its own 
(reviewed in Eglen et al., 2007). Although an endogenous system of GPR50/MT1/2 
heterodimerisation has yet to be identified, an approach whereby GPR50/MT1/2 
heterodimers are used in a cell-based screen may nevertheless be useful in 
identifying a ligand. 
 
As GPR50 is a GPCR located within a linkage region with bipolar disorder, interest 
was raised by the pharmaceutical industry. Attempts to deorphanise GPR50 were 
undertaken (a least by Organon to my knowledge). Nothing however appears to have 
been found as no papers or patents have been published. One can however only 
speculate as to what methods were attempted and it is unclear whether GPR50 is still 
being investigated.  
 
When it was clear deorphanisation experiments were being undertaken by industry it 
was decided to adopt a different strategy to investigate the function of GPR50. As it 
is known that GPCRs can bind many different proteins to their C-terminal domain 
(Marinissen and Gutkind, 2001), and given that the GPR50 CTD is relatively large 
compared to similar receptors, it was decided to identify interacting proteins with the 
GPR50 CTD. These interactions may provide clues to the function of GPR50. The 
initial method that was used was a yeast two-hybrid screen. This work was 
performed prior to the start of my PhD.   
 
Chapter 1: Introduction 
 24 
1.3 Identifying possible GPR50 interactors 
 
1.3.1 Yeast two-hybrid 
 
Apart from G proteins, many other intracellular proteins may interact with the C-
terminal tail and trigger or alter downstream signaling (Marinissen and Gutkind, 
2001). To investigate the possible interactors of GPR50, a yeast-two-hybrid screen 
was performed by Hybrigenics (S.A., Paris, France, http://www.hybrigenics-
services.com) (Grünewald et al., 2009), prior to the start of this PhD. The screen was 
performed using both ‘insertion’ and ‘deletion’ forms of the GPR50 CTD as bait. 
The insertion form corresponded to the coding sequence for amino acids 292-617 of 
human GPR50 (GenBank accession number GI:73909216), presenting the mutation 
S320P. The deletion form corresponded to the same coding sequence of human 
GPR50, deleted for amino acids 502-505 and presenting the mutation T532A 
(Grünewald et al., 2009). The baits were screened against a human adult brain cDNA 
library using both LexA- and Gal4-based systems (Grünewald et al., 2009). To each 
of the ‘prey’ interactors a confidence score was attributed, Global PBS (Predicted 
Biological Score) A-E, indicating the likelihood of it being a true interactor. A, B 
and C are high confidence interactions identified through two or more overlapping 
fragments. PBS D corresponds to protein interactions with moderate confidence. The 
letter E indicates proteins that are considered ‘sticky’, i.e. that have been identified as 
prey in 6 or more independent Y2H screens (Grünewald et al., 2009).  
 
1.3.2 GO analysis 
 
Gene Ontology Tree Machine analysis (Zhang et al., 2004) was performed of the 
genes isolated in the screens with PBS scores A-E (Grünewald et al., 2009), prior to 
the start of this PhD. Two broad classes of biological processes enriched in the 
putative interactors were identified (Fig 1.6): neuron development/differentiation 
(neuron development p=0.004) and sterol/cholesterol metabolism (steroid 
metabolism p=0.001) (Grünewald et al., 2009). The identification of functional 
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classes of putative interactors involved in aspects of lipid metabolism and 
neurodevelopment is entirely compatible with the biological processes implicated in 
previous genetic association studies (Thomson et al., 2005; Bhattacharyya et al., 
2006). However, these results should be interpreted with caution until the 
interactions between these genes and GPR50 have been confirmed in a relevant cell 
system. 
 
Figure 1.6 Directed Acyclic Graph (DAG) produced using the Gene Ontology Tree 
Machine (GOTM).  Visualised in red are significantly enriched GO categories of 
GPR50 Y2H interactors. Analysis included interactors with PBS of A-E only. 
Performed by Pippa Thomson. Figure published as supplementary material in 
Grünewald et al., 2009. Molecular and Cellular Neuroscience. Copyright 2009, 
Elsevier Science Ltd. 
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1.3.3 Yeast two-hybid interactors 
 
In the screen 23 putative protein interactors of the GPR50 CTD were identified. They 
are listed in Table 1 according to their PBS score. Proteins in several areas of interest 
were identified: neurodevelopment (ABCA2, CDH8, PCDH9, PAX6, RTN3, RTN4, 
SHOT1), stress response and apoptosis (SATB1, RTN3, RTN4, ST13, MADD), lipid 
and glucose metabolism (ABCA2, OSBP2, SREBP2, SATB1, MADD), and 
regulation of NMDA receptors and GABA transmission (PICK1, SLC12A5/ KCC2, 
MADD) (Grünewald et al., 2009). In terms of mechanisms several proteins appear to 
be involved in intracellular transport and sorting or molecules (SNX5, SNX6, CNST, 
RTN3, RTN4, ABCA2, OSBP2, KCC2) and actin and cytoskeletal remodeling 
(RTN4, SHOT1, PICK1, SPTAN1). The melatonin receptors, MT1 or MT2, were 
not identified in our yeast two-hybrid screen. The study by Levoye and colleagues 
(2006) indicates that GPR50 heterodimerises with these proteins through the 
transmembrane region of GPR50, which was not included in the bait sequence.  
 
In this thesis the interaction with some of these proteins will be further investigated. 
Past research on some of the key interactors and their functions, relevant to this 
study, is briefly summarised below. 
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Table 1.1 GPR50 Yeast-two-Hybrid (Y2H) screen hits, as performed by 
Hybrigenics. Shown are: symbol, full gene name and splice variant number, 
followed by the number of times each variant was captured by either the insertion 
(Ins), or the deletion (∆502-505/T532A, Del) form of the GPR50 C-terminal tail. 
 
1.3.3.1 RTN3 and RTN4 (Nogo) 
Reticulon family (RTN1-4) member RTN4, also known as Nogo (Schwab, 2010), 
scored highest in the yeast two-hybrid GPR50 interaction screen (Table 1.1). Nogo 
was identified as a putative partner in screens for both naturally occurring forms of 
GPR50: C-terminal GPR50 and GPR50∆502-505/T532A, but only considered as an 
interactor with the highest confidence in the GPR50 screen (PBS=A). A total of 7 
Nogo variant 5 clones and 2 Nogo-C (variant 3) clones were identified in the screens 
(Grünewald et al., 2009).  
 
Three main isoforms of Nogo are generated as a result of alternative splicing and 
promoter use (Oertle et al., 2003a): Nogo-A (RTN4 variant 1; 1192 amino acids, aa), 
-B (variant 2; lacking aa 186-1004) and -C (variant 3; lacks aa 186-1004 and has a 
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smaller N-terminal domain (Chen et al., 2000; GrandPre et al., 2000)) (Fig 1.7). 
Nogo variant 5 is a short form of Nogo-A, which lacks the first 206 aa. The isoforms 
share a C-terminal domain of 188 residues, the reticulon homology domain (RHD), 
found in all members of the reticulon family (Oertle and Schwab, 2003) (Fig 1.7) 
(Grünewald et al., 2009). 
 
In addition, four RTN3 variant 2 clones were identified in the screen of the C-
terminal GPR50∆502-505/T532A form (Grünewald et al., 2009). RTN3 has multiple 
isoforms that are differentially expressed in tissues (Di Scala et al., 2005). The 
nomenclature of the RTN3 isoforms is confusing and varies according to the source 
used. The isoform identified in the yeast two-hybrid screen (gi: 41393607) 
corresponds to RTN3A3b (Di Scala et al., 2005), RTN3 variant 2 (ncbi) or RTN3-
202 (Ensembl), contains 8 exons (including the large exon 3 and the common RHD, 
but not exon 2), and is 1013aa long with a predicted molecular weight of 110kDa 
(Fig 1.7). However according to Di Scala et al. (2005) this isoform is not expressed 
in any of the tissues investigated and their data suggests that exon 2 and 3 are only 
spliced together, yielding isoform RTN3A4b with a detected mass of 100kDa. Tissue 
distribution studies indicate that RTN3A1, RTN3A2 and RTN3A4b are more highly 
expressed in the CNS than in other tissues, especially in the cortex (Di Scala et al., 
2005) and more in gray (neurons) than white (oligodendrocytes) matter (He et al., 
2004). 
 





Figure 1.7 RTN4/Nogo isoforms Nogo-A, Nogo-B and Nogo-C, and RTN3 variant 2. 
All reticulons share a C-terminal domain of 188 residues, the reticulon homology 
domain (RHD), consisting of the Nogo-66 domain flanked by two large 
transmembrane domains. They differ in the N-terminus. 
 
 
Reticulons play an important part under ER stress conditions and apoptosis (Teng 
and Tang, 2008). Overexpression of RTNs results in “ER overload response”, ER 
calcium depletion and activation of apoptotic pathways such as the JNK-c-Jun 
pathway and Caspase 12 (Qu et al., 2002; Kuang et al., 2005; Chen et al., 2006; 
Xiang et al., 2006; Zhu et al., 2007; Lee et al., 2009). The majority of studies 
however indicate an important role for reticulon/Nogo proteins in neuronal 
regeneration, degenerative disorders and at the synapse (Chang et al., 2010; Schwab, 
2010).  
 
Of the three Nogo isoforms, Nogo-A has been the most extensively studied, and it is 
a potent inhibitor of neurite outgrowth in vitro and in vivo (Caroni and Schwab, 
1988; Oertle et al., 2003b; Schwab, 2010).  Neuronal receptors to Nogo-66 has been 
identified: Nogo-receptor (NgR) (Fournier et al., 2001), and recently Paired 
Immunoglobulin-like receptor B (PirB) (Atwal et al., 2008). This receptor also binds 
other outgrowth inhibitors, present in CNS myelin: Myelin-Associated Glycoprotein 
(MAG) (Liu et al., 2002) and Oligodendrocyte-Myelin glycoprotein (OMgp) (Wang 
et al., 2002). Through this receptor, signalling pathways are activated which lead to 
neurite outgrowth inhibition via regulation of the actin cytoskeleton (Niederost et al., 
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2002; Montani et al., 2009; Schwab, 2010). Recently a role for neuronal Nogo-A and 
other myelin-associated inhibitors has been suggested as a negative regulator of 
functional and structural plasticity in the hippocampus (Raiker et al., 2010; Delekate 
et al., 2011) and in limiting ocular dominance plasticity by modifying the critical 
period (McGee et al., 2005), linking experience driven, activity dependent and injury 
induced plasticity (Akbik et al., 2011). The beneficial effects of Nogo-inhibition after 
spinal cord injury are currently being investigated (Gonzenbach et al., 2010; Schwab, 
2010).  
 
In relation to psychiatric illness, a significant increase in Nogo-C mRNA expression 
was found in the postmortem frontal cortex of individuals with schizophrenia as 
compared to age- and sex matched non-neurological controls (Novak and Tallerico, 
2006). Additionally, there was a non-significant increase in expression in Nogo-A in 
schizophrenia, whereas Nogo-B was significantly reduced in the frontal cortex of 
major depressive patients (Novak and Tallerico, 2006). An insertion/deletion 
polymorphism in the 3’ UTR of Nogo has shown association to schizophrenia in 
some, but not all studies (Novak et al., 2002; Tan et al., 2005). Mice lacking Nogo-A 
or the NgR showed behavioural changes that mimic symptoms of schizophrenia 
(Budel et al., 2008; Willi et al., 2009; Willi et al., 2010). 
 
Reticulon proteins have also been implicated in Alzheimer’s disease (AD). The 
expression of the NgR is increased in the CA1 and CA2 regions of the hippocampus 
in AD and is co-expressed with hyperphosphorylated Tau (Zhu et al., 2007). 
Recently it was shown that the NgR can regulate amyloid deposition by interacting 
with APP (Zhou et al., 2011). Further, Nogo-B/C and RTN3 were shown to inhibit 
BACE1-activity (beta-site amyloid precursor protein-cleaving enzyme 1, also known 
as β-secretase), thereby reducing the conversion of amyloid precursor protein (APP) 
to β-amyloid (He et al., 2006). RTN3 was also found to accumulate in dystrophic 
neurites and senile plaques in AD, and in neurofibrillary tangles and lewy bodies (Hu 
et al., 2007; Heath et al., 2010; Prior et al., 2010). Abnormal accumulation of β-
amyloid and hyperphosphorylated Tau (‘plaques and tangles’) are believed to 
contribute to the onset of Alzheimer’s disease (Bancher et al., 1989; Tanzi and 
Chapter 1: Introduction 
 31 
Bertram, 2005). Nogo has also been shown to modulate axonal sprouting in AD 
models in a mechanism seemingly distingt from the regulation of BACE1 activity 
and APP processing as seen with RTN3 and NgR (Masliah et al., 2010). The 
identification of reticulon proteins as cellular modulators of BACE1 (Hu et al., 2006) 
makes them possible targets for therapeutic interactions. Interestingly, BACE1 has 
many other substrates among which are NRG1 type III, Cadherins, Semaphorins and 
Ephrins (Lichtenthaler et al., 2003; Hu et al., 2006; Willem et al., 2006; Kim et al., 
2007; Hemming et al., 2009). BACE1 and reticulon proteins are therefore implicated 
in myelination, cell adhesion, contact-dependent intercellular communication and 
cognitive functions.  
 
1.3.3.2 CDH8  
Cadherins are calcium-dependent, single-pass transmembrane, cell-cell adhesion 
molecules. They play a role in embryonic development and brain regionalisation, by 
establishing cell polarity and cell sorting according to their tissue type (Wheelock 
and Johnson, 2003). Cell types with different fates are found to express different 
types of cadherins (Inoue et al., 2001; Taniguchi et al., 2006) and a cell expressing a 
certain cadherin will almost exclusively adhere to another expressing the same type 
(homophilic binding specificity). Cadherins are highly expressed in the central 
nervous system, different cadherins by distinct neuronal groups (Suzuki et al., 1997; 
Gil et al., 2002; Saarimaki-Vire et al., 2011).  
 
There is increasing evidence for the involvement of cadherins in neuronal 
functioning, most of which is based on research on N-Cadherin. In addition to brain 
regionalization, they are believed to play a role in CNS synaptic transmission and 
synapse formation (Togashi et al., 2002). Furthermore, it is thought that cadherins 
mediate the lock-and key mechanism (chemoaffinity hypothesis, (Sperry, 1963), 
which could account for the specificity of synaptic partners (Shapiro and Colman, 
1999). 
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The cell-cell adhesion/dissociation mechanism of N-cadherin is mediated by 
Presenilin-1 (PS1) through a high molecular weight complex with γ-secretase 
(Parisiadou et al., 2004). Mutations in PS1 are linked to familial Alzheimer’s disease 
(FAD) and γ-secretase performs the second cleavage of APP to liberate Aβ into the 
extracellular space. These mutations in PS1 are found to disrupt the normal cleavage 
of cadherins and thereby impair subsequent downregulation of CREB-mediated 
transcription (Parisiadou et al., 2004). In this model, alterations in the transcription 
mechanism could contribute to the pathogenesis of AD through interfering with 
cadherin signalling. 
 
Cadherin 8 (CDH8, Table 1.1) is expressed in the dorsal horn of the spinal cord and 
in the dorsal root ganglia (DRG), and was found to play a role in synaptic 
transmission of cold sensation (Suzuki et al., 2007). CDH8 is also found in the 
thalamocortical afferents from medial posterior nucleus of the thalamus (POm) to the 
rat barrel cortex, and in the mouse somatosensory cortex, where it is expressed in a 
distinct laminar pattern (Gil et al., 2002; Krishna et al., 2011). CDH8 may be 
involved in radial migration of neurons during development in rhombomere 6 (Garel 
et al., 2000). In relation to mental illness, a recent genetic study indicated a role for 
CDH8 in the susceptibility of autism and learning disabilities (Pagnamenta et al., 
2011). CDH8 is also one of two genes, the other being Phosphodiesterase 4B 
(PDE4B), that is disrupted in a balanced t(1;16)(p31.2;q21) translocation detected in 
a proband with schizophrenia, and a cousin with psychosis, carrying the translocation 
(Millar et al., 2005).  
 
1.3.3.3 ABCA2  
ATP-binding cassette sub-family A member 2 (ABCA2) is a multispan 
transmembrane protein primarily found to be expressed in the endolysosomal 
compartment of the cell. It is found to be highly expressed in the brain, most notably 
in the subventricular zone of the lateral ventricle and the dentate gyrus, regions 
important in adult neurogenesis (Broccardo et al., 2006). It is expressed by 
oligodendrocytes and by a subset of GABAergic and glutamatergic neurons in the 
Chapter 1: Introduction 
 33 
CNS (Broccardo et al., 2006) and by Schwann cells in the PNS (Saito et al., 2007). 
ABCA2 shares the highest homology with the HDL cholesterol transporter ABCA1 
and may also influence cholesterol transport (Kaminski et al., 2001) and homeostasis 
(Davis, 2011) and sphingolipid metabolism (Sakai et al., 2007; Mack et al., 2011).  
Furthermore, ABCA2 regulates the expression of the LDL-cholesterol receptor and 
modulates the mobilisation of plasma membrane (but not lipid raft) cholesterol to 
apolipoprotein receptors and the trafficking of plasma membrane cholesterol to the 
ER for esterification (Davis et al., 2004; Davis, 2011). With respect to brain function, 
cholesterol is a key constituent of myelin and a function for ABCA2 in myelination 
of spinal cord and PNS is also indicated (Zhou et al., 2002).  
 
Like RTN3, RTN4 and CDH8, ABCA2 has been implicated in Alzheimer’s disease. 
Mace et al., (2005) identified a SNP in exon 14 (rs908832, C2037T) associated with 
early onset AD in a French Caucasian sample. However this association may be 
population dependent. The result was replicated in a Western European population 
(Wollmer et al., 2006), but not in a Southern European population (Wollmer et al., 
2006). In the Japanese population on the other hand the T allele was not found 
(Wollmer et al., 2006). The T allele was also associated with heightened cholesterol 
levels in the cerebrospinal fluid (CSF) (Wollmer et al., 2006). In a Caucasian 
American sample no significant association was found between this SNP and early or 
late onset AD (Minster et al., 2009). In further support of a role in AD, ABCA2 
colocalizes with APP and Aβ, and overexpression of ABCA2 results in an increase in 
intracellular protein levels of APP and Aβ (Chen et al., 2004b). ABCA2 expression 
was also linked to the oxidative stress response, oxidative damage being another 
pathological characteristic of AD (Chen et al., 2004). Finally, cholesterol is believed 
to play a distinct role in the pathogenesis of Alzheimer’s disease as it is indicated to 
regulate β-amyloid generation and deposition (Puglielli et al., 2003). 
 
Abca2 knockout mice display ‘skittish behaviour’ of hyperactivity, tremor and 
reduced body weight, perhaps reflective of changes in myelin ultrastructure or 
sphyngolipid composition (Mack et al., 2007). This behaviour was most notable in 
females as compared to males, suggesting the involvement of hormonal pathways. 
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Contrary to findings in Nogo-knockout mice (Woolf, 2003), Abca2-knockouts 
showed abnormal myelin structure in the CNS as compared to wild type littermates 
(Mack et al., 2007). Another study of Abca2-null mice however does not report this 
difference (Sakai et al., 2007). 
 
1.3.3.4 SREBP2/SREBF2 
Sterol regulatory element binding transcription protein 2 (SREBP2), or sterol 
regulatory element binding transcription factor 2 (SREBF2), is a ubiquitously 
expressed transcription factor that controls cholesterol homeostasis by stimulating 
transcription of sterol-regulated genes. When low cholesterol levels are detected in 
the ER SREBP2 precursor protein is sequestered/chaperoned to Golgi where it is 
cleaved by 2 proteases, releasing the transcriptionally active N-terminal domain. 
(Briggs et al., 1993; Goldstein et al., 2006). It is subsequently transported to the 
nucleus where it regulates the transcription of genes involved in lipid biosynthesis. 
At high sterol concentrations, SREBF2 disappears from the nuclear fraction, but not 
the (ER) membrane (Wong et al., 2006). SREBF/P2 expression has been researched 
mainly in the liver and not much is known about its activity in the CNS. As 
cholesterol is synthesised de novo in the brain, there could be a major role for 
SREBFs in processing fatty acids necessary for key processes such as myelination. 
In the adult mouse brain Srebf2 mRNA expression is high in the cortex, olfactory 
bulb and hippocampal formation as measured by in situ hybridisation (Allen Brain 
Atlas, Lein et al., 2006). 
 
SREBF2 has been studied in relation to AD. Variants in SREBF2 are potential 
candidates for CSF biomarkers in AD (Kim et al., 2011) and SREBF2 may also be a 
risk factor in vascular dementia (Kim et al., 2005). Transgenic mice overexpressing 
SREBP2 showed accumulation of mitochondrial cholesterol and increased neuronal 
death in response to Aβ1-42 compared to controls (Fernandez et al., 2009).  
  
An association in the German and Scandinavian population between several SNPs in 
SREBF2 and schizophrenia was reported (Le Hellard et al., 2008). Drug related 
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metabolic effects in schizophrenic patients (weight gain) were also found to be 
associated with INSIG2, a gene involved in the SREBF2 pathway of activation of 
cholesterol and fatty acids production (Le Hellard et al., 2009). Interestingly, a 
functional SREBF2 pathway is required for ABCA1 transcription (Wong et al., 
2006). 
 
To briefly summarise, putative interactors RTN3, RTN4, CDH8, ABCA2 and 
SREBF2 are involved in neuronal development and plasticity and lipid metabolism. 
Interestingly each of them has been independently linked with psychiatric illness and 
neurodegenerative diseases. Investigating these interactions in more detail might give 
insight into the function of GPR50 and its association with mental disorders. 
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1.4 Aims of this thesis 
 
The aim of my PhD was to gain more insight into the function of orphan GPR50.  
 
This was subdivided into four objectives: 
 
1. Verify a subset of putative interactors of GPR50 as identified by the yeast 
two-hybrid screen 
2. Investigate the developmental expression pattern of Gpr50 and the confirmed 
interactors. 
3. Investigate the functional consequence of GPR50s protein-protein 
interactions 
4. Investigate the significance of the GPR50 C-terminal domain and the 
polymorphisms. 
 
In Chapter Two, the physical interaction between GPR50 and RTN3, Nogo-A, Nogo-
C, CDH8 and ABCA2 was further investigated by performing in vitro binding assays 
and colocalisation studies.  
 
In Chapter Three, the developmental expression of Gpr50, Nogo, Cdh8, Abca2 and 
Srebf2 in the mouse brain was investigated by subcellular fractionation, rt-PCR and 
immunohistochemistry.  
 
In Chapter Four, two functional assays relating to the function of the reticulon 
proteins were performed: neurite outgrowth and BACE1 activity.  
 
In Chapter Five, the secondary structure of the GPR50 C-terminal domain was 
further investigated using biochemical and biophysical techniques.





Validation of GPR50’s interactions 
Chapter 2: Validation of GPR50’s Interactions 
 38 




The first aim of this thesis was to confirm the interaction of GPR50 with some of its 
interactors. As several members of the reticulon family of proteins were identified in 
the yeast-two-hybrid (Y2H) screen, the interaction of GPR50 with Nogo-A, Nogo-C 
and RTN3 was further investigated. Additionally the interaction with cell-cell 
adhesion molecule CDH8 and lipid-associated protein ABCA2 was investigated 
because of the known role of cadherins in the development of the CNS and the links 
in the literature of GPR50 with lipid metabolism respectively. Initially, the 
interaction with C-terminal only GPR50 was investigated and later full-length 
GPR50 and the full-length GPR50∆502-505/T532A variant associated with mood 
disorders (Thomson et al., 2005; Macintyre et al., 2010) were tested.  
 
2.1.1 GPR50’s interactors and mental illness 
 
From previous findings it appears that the putative interactors of GPR50 are related 
to neuronal development, lipid metabolism and stress responses. Interestingly, 
several have also been associated with neurodegenerative and psychiatric disorders. 
GPR50, Nogo, CDH8 and ABCA2 may all have distinct roles in the pathology of 
Alzheimer’s disease: though affecting BACE1 and Aβ (Nogo, He et al, 2004), lipid 
metabolism (ABCA2 and GPR50, Macé et al., 2005), or the interaction with 
Presenilin1 (cadherins, Parisiadou et al, 2004). Therefore, confirmation of these 
interactions would perhaps tell us more about the relationship between GPR50 and 
mental illness. 
 
In this introduction to Chapter two past research on the cellular expression of GPR50 
and the putative interactors that are investigated in this thesis is briefly summarised. 
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Developmental expression will be investigated and discussed in the next chapter 
(Chapter 3). 
 
2.1.2 GPR50 expression 
 
As is expected of a GPCR, overexpressed GPR50 is present at the cell surface of 
HEK293 cells (Levoye et al., 2006; Hamouda et al., 2007). Endogenous expression 
is found in human endothelial cerebral CMEC/D3 cells (Levoye et al., 2006) and in 
1-10% of HEK293 cells, depending on the source/passage number of the HEK cells 
(our own unpublished observations). Overexpressed and endogenous GPR50 is 
detected at 66/67 kDa by Western blotting (Hamouda et al., 2007; Grünewald et al., 
2009). It is common for GPCRs to oligomerise (Bouvier, 2001) and dimerisation is 
thought to be of functional importance (Milligan, 2004). Using various in-house 
produced and commercially available antibodies GPR50 was detected as a dimer by 
Western blotting, by us and others, endogenously and when overexpressed (Levoye 
et al., 2006; Hamouda et al., 2007; Grünewald et al., 2009). 
 
2.1.3 RTN3 and RTN4 (Nogo) expression 
 
Reticulons (RTNs) are primarily localized to the endoplasmic reticulum (ER) but are 
also found in the plasma membrane (Oertle et al., 2003b). They are involved in 
membrane shaping of tubular ER (Voeltz et al., 2006; Anderson and Hetzer, 2008). 
Within the reticulon homology domain (RHD) are two long (30-35 residues) 
hydrophobic segments, which determine the membrane topology with the ER and 
plasma membrane (Voeltz et al., 2006; Teng and Tang, 2008). Many different 
membrane topologies have been suggested (GrandPre et al., 2000; Thomson et al., 
2005; Voeltz et al., 2006) reviewed in (Teng and Tang, 2008) (Fig 2.1). Most 
experimental evidence supports a topology where the Nogo-A and -B (and perhaps –
C) N-terminus and Nogo-66 domain face the extracellular/ER luminal side and C-
terminus faces the cytoplasm (Fig 2.1A-B) (Oertle et al., 2003b; Acevedo et al., 
2004; Dodd et al., 2005; Miao et al., 2006). In this conformation Nogo-A and –B can 
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interact via their N-terminal and Nogo-66 domains with their receptors, in trans 
(when proteins are present on a different cell/membrane)(Schwab, 2010). The first 
hydrophobic segment of Nogo-C has been shown to form a hairpin structure within 
the ER membrane (Voeltz et al., 2006) (Fig 2.1 C). The second hydrophobic segment 
may also form a hairpin (Fig 2.1C) although this has not been confirmed (Voeltz et 
al., 2006). Therefore a topology where the Nogo-C C-terminus faces the ER lumen is 
also possible (Teng and Tang, 2008) (Fig 2.1D). For RTN3 on the other hand it has 
been shown that both hydrophobic domains can adopt this hairpin topology (He et 
al., 2007) (Fig 2.1E). 
 
Nogo-A, -B and –C are a found on the plasma membrane of oligodendrocytes and in 
myelin (Huber et al., 2002), and also in neurons, myoblasts and 3T3 cells (Dodd et 
al., 2005). Neuronal Nogo-A is known to be expressed at the synapse (Lee et al., 
2008). Endogenous and overexpressed Nogo proteins can complex together in 
various cell types (Dodd et al., 2005) and this may apply to all RTNs. On the cell 
surface a punctate staining of Nogo proteins was found, an indication of expression 
in distinct microdomains (Acevedo et al., 2004; Dodd et al., 2005), perhaps on lipid 
rafts (Acevedo et al., 2004). Nogo-A is expressed as 200 kDa, Nogo-B as 55 kDa 
and Nogo-C as 25 kDa protein by Western blotting using several different antibodies 
(Oertle and Schwab, 2003; Dodd et al., 2005).  
 
The three main RTN3 isoforms detected in tissues are RTN3A1, RTN3A2 and 
RTN3A4b (Di Scala et al., 2005). RTN3A1 migrates at approximately 24 kDa. 
RTN3A2, the isoform interacting with BACE1 (He et al., 2004; Murayama et al., 
2006) was detected at 27 kDa and corresponds to RTN3 transcript variant 1 (NCBI) 
or RTN3-204 (Ensmbl). RTN3A4b (corresponding to RTN3 variant 2 (NCBI) or 
RTN3-202 (Ensembl)) has a mass of approximately 100 kDa. Like the RTN4 
isoforms RTN3A1, RTN3A2 and RTN3A4b are enriched in the ER/microsomal 
fraction of the cell (Di Scala et al., 2005).  






Figure 2.1 Membrane topologies of reticulon proteins. Pictured is a schematic of 
some of the proposed membrane topologies as supported by experimental 
evidence. (A) The N-terminus and Nogo-66 domain of Nogo-A were shown to have 
neurite outgrowth inhibiting and growth cone collapsing characteristics via 
interaction with or modulation of the Nogo-receptor (Oertle et al., 2003b) and are 
therefore likely to face the extra cellular side. Similarly, the N-terminus of Nogo-B is 
shown to interact with the Nogo-B receptor (Miao et al., 2006). (B) RTNs are 
however predominanlty present in the ER membrane and the same topology as in 
(A) may be present there. (C, E) However most studies suggest a topology where 
the N- and C-termini of Nogo-C and RTN3 face the cytosol where the relatively long 
(30-35 residues) transmembrane domains are likely to form hairpin structures 
(Grandpre et al., 2000, He et al., 2007, Voeltz et al., 2006). Yet another topology is 
also possible (D) (Voeltz et al., 2006; Teng and Tang, 2008).  
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2.1.4 CDH8 expression 
 
Cadherins are calcium-dependent, single-pass transmembrane, cell-cell adhesion 
molecules. CDH8 is therefore expected to be expressed on the plasma membrane, at 
cell-cell contacts, as was shown after overexpression in L cells (Kido et al., 1998). 
Cdh8 is expressed in a punctate pattern in the dorsal horn of the mouse spinal cord 
and at the synapse (Suzuki et al., 2007).  
 
In human and mouse the full-length isoform is predicted to be 88 kDa (Ensembl).   
Two forms of Cdh8 have been detected by western blotting in rat brain, a weakly 
expressed 130 kDa and a 95 kDa (truncated) form. The truncated form was present in 
the soluble fraction and the (more characteristic of classic cadherins) 130 kDa 
isoform in the insoluble fraction after untracentrifugation of whole brain homogenate 
(Kido et al., 1998). The authors suggest the 130 kDa isoform is full-length Cdh8 but 
is sensitive to trypsin digestion. In addition the 130 kDa isoform was shown to co-
immunoprecipitate with cadherin binding partner beta-catenin.  
 
2.1.5 ABCA2 expression 
 
ABCA2 is a multipass transmembrane protein suggesting it is also expressed on the 
cell surface. When overexpressed it is however primarily localised to the lysosomes 
as shown by colocalisation with marker LAMP1, and to some extent to the ER and 
Golgi in HEK293 and HeLa cells (Vulevic et al., 2001). A more cytoplasmic staining 
pattern of endogenous Abca2 was previously reported in (Broccardo et al., 2006), 
indicating a likely difference in localisation between endogenous and overexpressed 
ABCA2. Human ABCA2 is expressed as a 270 kDa isoform by Western blotting of 
transfected HEK293 cells using a protein-specific antibody (Vulevic et al., 2001). 
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2.1.6 Introduction to experiments 
 
The putative interactors as shown in Table 1.1 (Chapter 1) were identified in yeast. 
This system has limitations as proteins are expressed in the nucleus only whereas 
previous data suggests our proteins of interest are only expressed in the plasma 
membrane and in light membrane containing compartments such as the ER, Golgi 
and endolysosome in mammalian cells. Also, as mechanisms like protein folding 
could differ between yeast and mammalian cells, we sought to verify the yeast-two-
hybrid results by performing co-immunoprecipitation (co-IP) and 
immunocytochemistry in mammalian cells.  
 
Co-IP experiments were performed by overexpressing GFP-tagged and untagged 
constructs of GPR50, Nogo-A, Nogo-C, RTN3, CDH8 and ABCA2 in HEK293 
(Human Embryonic Kidney) or HEK293T cells. HEK293T cells are HEK293 cells 
transformed by expression of the large T antigen from SV40 virus, and therefore 
have a higher transfection efficiency of plasmids with an SV40 origin of replication. 
For immunocytochemistry both overexpressed and endogenous proteins were 
investigated in HEK293 and SH-SY5Y neuroblastoma cell lines and primary 
cultured mouse neurons. In addition the effects of co-expressing the reticulons and 
GPR50 on GPR50 localisation was also investigated. 





2.2.1 Expression constructs 
All expression construct used in this thesis are listed in Table 2.1. Ultimate ORF 
entry clones containing full-length human GPR50 (IOH63602) and RTN4 transcript 
variant 1 (Nogo-A, IOH53642), RTN4 transcript variant 3 (Nogo-C, IOH4069), 
RTN3 (transcript variant 1, IOH10268) and CDH8 (IOH42822) in pENTR221, were 
obtained from Invitrogen (Paisley, UK). Additionally, a True Clone™ full-length 
clone termed GPR50-TTC was obtained from Origene (Rockville, USA). Full length 
ABCA2 in a pcDNA3.1/Hygro© vector (Invitrogen) was a kind gift from Kenneth 
Tew (Medical University of South Carolina, MUSC). The eGFP construct (pEGFP-
N1, Clontech) was a kind gift from Laura Hyndman (University of Edinburgh). The 
Tif1α in pDEST53 (Invitrogen) was used as a control and was made by Christoph 
Grünewald (MMC, UoE, unpublished). The GPR50 C-terminal domain (GPR50 
CTD) and GPR50∆502-505/T532A CTD constructs were made by Hazel Kinnell and 
Alison Condie (University of Edinburgh). GPR50∆502-505/T532A was made from 
GPR50 (IOH63602) using site-directed mutagenesis (see 2.2.4 below).  
 
Entry clones were cloned by recombination into pDEST40, pDEST47 and pDEST53 
vectors to create untagged and N-terminal GFP tagged constructs (LR clonase II, 
Gateway®, Invitrogen, Table 2.1). Untagged proteins were expressed by not 
removing the stop codons present in Invitrogen ORF entry clones, otherwise 
resulting in C-terminally V5/GFP-tagged proteins. Subcloning of these constructs 
was performed during my MSc in Neuroscience by Research project.  
 
To select for expression constructs, the vectors were used to transform competent E. 
coli (One Shot Omnimax 2-Ti, Invitrogen) or DH5α (Invitrogen), and plasmid DNA 
was extracted using Qiagen Miniprep or Maxiprep kits (Crawley, UK) as per 
manufacturer’s instructions. All clones were sequenced (see 2.2.5 below) and 
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checked for expression of proteins of the expected molecular weight by Western Blot 
(see 2.2.14 below) in HEK293 cells. 
 
Name Tag Vector/Promoter Residues Accession 




pDEST53, CMV 1-617 GI:73909216 
GPR50  - pDEST40, CMV 1-617 GI:73909216 
GPR50
∆502-505/T532A
 - pDEST40, CMV 1-613 GI:166714277 





GFP (N-term) pDEST53, CMV 283-613 GI:166714277 
GFP-Nogo-A  GFP (N-term) pDEST53, CMV 1-1192 GI:47519561 
Nogo-A - pDEST47, CMV 1-1192 GI:47519561 
RTN3 GFP (N-term) pDEST53, CMV 1-236 GI:41393611 
Nogo-C GFP (N-term) pDEST53, CMV 1-199 GI:47519538 
GFP-CDH8 GFP (N-term) pDEST53, CMV 1-799 GI:16306538 





TIF1α GFP (N-term) pDEST53, CMV 1-1050 GI:47419910 
eGFP  pEGFP-N1, CMV   
 
Table 2.1 Expression constructs used in this study. Subcloning of the constructs 
was performed during my MSc Neurosience Neuroscience by Research project. 
 
2.2.2 Primer design 
Primers were designed using The Primer 3 http://frodo.wi.mit.edu/primer3/ (Rozen 
and Skaletsky, 2000). Genomic sequence information was obtained from the 
University College Santa Cruz (UCSC) genome browser and Ensembl 
(www.ensembl.org). The following parameters were used to select primers: Primer 
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Tm Min: 55, Opt: 60, Max: 63; Max Tm difference: 1, Primer GC%: Min: 20, Opt: 
50, Max: 80; GC clamp: 1. Specificity of the primer sequence was checked using 
UCSC In-silico PCR (Kent et al., 2002), which searches a sequence database with a 
pair of PCR primers. The primers were synthesised by Sigma Aldrich. All primers 
were diluted to 100µM with TE buffer upon receipt and stored at -20°C. Primers and 
conditions used in this thesis are described in Table 2.2. These primer sequences 
were designed by Pippa Thomson (a) or Invitrogen (b-c) and were kindly provided 
by Pippa Thomson, Ben Pickard and Christoph Grünewald, which is noted in the 
legend of Table 2.2. Primers were either used for touch-down PCR (TD) and/or for 
sequencing (BD 3.1) (Table 2.2). 
 






















































































Table 2.2 Primers used for PCR and Sequencing. aProvided by Dr Pippa Thomson; 
bprovided by Dr Christoph Grünewald, cprovided by Dr Ben Pickard.  
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2.2.3 Polymerase chain reaction (PCR)  
 
The PCR reactions were performed in a Thermo non-skirted 96-well plate. 
Invitrogen reagents were used in 10 µl reactions: 1 µl 10x PCR buffer, 0.3 µl 50 mM 
MgCl2, 0.2 µl 20 nM dNTPs, 0.2 µl of each 100 µM primer, 0.1 µl Taq polymerase; 
(Invitrogen), 1 µl 50-100 ng dsDNA). All amplification were performed in a PCR 
thermal cycler, PTC-225 (MJ Research) using touch-down (TD) 53 and 55 
programmes at an initial denaturation of 93 ºC for 1 min, followed by 10 cycles of 93 
ºC for 20 s, touch-down annealing from 63ºC to 53ºC (or 65ºC to 55ºC) for 30 s, and 
72ºC for 1 min, followed by 10 cycles at an annealing temperature of 53ºC (or 55ºC), 
and a final extension of 72ºC for 10 min. The PCR products were mixed with Orange 
G loading buffer and were resolved on 1-2% agarose gel against a 1kb ladder 
(Invitrogen). Electrophoresis was performed in 0.5% TBE buffer at 100 V for 30-45 
min. 
 
2.2.4 Site-directed mutagenesis 
 
GPR50∆502-505/T532A was generated using the Stratagene QuikChange II Site Directed 
Mutagenesis kit (Agilent Technologies) in two consecutive steps: first removing 
residues 502-505 (TTGH), and subsequently generating the Thr532Ala point 
mutation that is in linkage disequilibrium (LD) with the deletion, from the GPR50 
pENTR221 (Invitrogen) construct. Primers incorporating the mutations were 
designed using Stratagene’s QuikChange online primer design programme: 
http://www.stratagene.com/qcprimerdesign 
The first set of primers used to remove 12 base pairs at residues 1552-1563 were: 
sense: 5'-cagccaccctaaacccatcaagccagctaccagcca-3' and 
antisense: 5'-tggctggtagctggcttgatgggtttagggtggctg-3'. The second set used create a 
single base pair change from A to G at position 1594 were:  
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Site-directed mutagenesis reaction mixes were prepared as follows: 
5 µl of 10× reaction buffer (Agilent Technologies) 
5 or 50 ng of dsDNA template 
125 ng of sense primer 
125 ng of antisense primer 
1 µl of dNTP mix (Agilent) 
ddH2O to a final volume of 50 µl 
1 µl of PfuUltra high fidelity DNA polymerase (Agilent) 
Negative control reaction mixes contained 50 ng of DNA and only the sense primer. 
 
The mutated DNA was amplified by PCR reaction. Cycling conditions were as 
follows: Hot start at 95ºC for 30s, then 18 cycles of 95ºC for 30 s, 55ºC for 1 min, 
and 68ºC for 4 min. 
 
Dpn1 restriction enzyme was then added to the reaction and incubated at 37ºC for 1 
hour to digest the non-mutated parental DNA. The Dpn1-treated DNA was then 
transformed in to super competent XL1 Blue E coli cells (Agilent Technologies). 
Colonies were screened by PCR using GPR50 ‘indel’ exon 2 primers (Table 2.2) and 
PCR programme TD55 and were further confirmed by sequencing using Big Dye 3.1 




The PCR Sequencing reactions were performed in a thermo non-skirted 96-well 
plate, using BigDye® Terminator Ready Reaction Mix v3.1 (Applied Biosystems) in 
a total volume of 10 µl, with 1µl BDv3.1, 2µl 5x sequencing buffer (Applied 
Biosystems), 3pmol primer, 150-500 ng dsDNA, up to 10µl dH20. The primers used 
for sequencing are listed in Table 2. Sequencing reactions were performed on a PTC-
225 Peltier thermal cycler (MJ Research). Cycling conditions were as follows: Hot 
start at 96ºC for 1min, then 25 cycles of 96ºC for 10s, 50ºC for 5s, and 60ºC for 4 
min. 
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Sequencing products were purified by ethanol/EDTA precipitation. To each well 5 µl 
125 mM EDTA was added, followed by 60 µl ethanol. After incubation for 10 min in 
the dark, reactions were centrifuged at 3000 g for 30 min at 8ºC in a Jouan CR422 
centrifuge. This was followed by a wash with 70% ethanol and centrifugation at 
3000 g for 15 min at 8ºC. Samples were air dried for 10min in the dark and stored at 
-20ºC. Nucleic acid sequences were read by Agnes Gallacher at the Medical Research 
Council Human Genetics Unit. Sequences were checked using Chromas Lite version 
2.01 (Technelysium Pty Ltd). 
 
2.2.6 Mammalian cell culture  
 
All media and chemicals were purchased from Invitrogen, unless stated otherwise. 
HEK293, HEK293T and SH-SY5Y cells (ECACC) were cultured in DMEM with 
10% fetal bovine serum (FBS). Cultures were kept at 37oC with constant humidity, 
95% air and 5% CO2. For transient transfections Lipofectamine 2000 was used 
according to the manufacturer’s instructions (see 2.2.8 below). 
 
2.2.7 Primary neuronal culture 
 
Hippocampal and cortical neuronal cultures were prepared from embryonic day 18 
(E18) CD1 mice as described previously (Okabe et al., 2003; Bradshaw et al., 2008). 
Date of plug was considered E0. Neurons were seeded at 50-100 cells/mm2 on poly-
D-Lysine (Sigma-Aldrich, St. Louis, USA) coated coverslips in 12 well cluster 
plates, and cultured in neurobasal medium supplemented with 2% B-27, 2mM 
Glutamax-1 and Penicillin/Streptomycin for 14-28 days-in-vitro (DIV). Cultures 
were kept at 37oC with constant humidity, 95% air and 5% CO2.  For transient 
transfections Lipofectamine 2000 was used according to the manufacturer’s 
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2.2.8 Lipofectamine transfection protocol 
 
The total amount of OptiMeM, DNA and Lipofectamine used per transfection are 
shown in Table 2.3. First, the plasmids and Lipofectamine 2000 were incubated in 2 
separate vials with OptiMeM for 5 min. The two solutions were added together and 
incubated for a further 20 min. Before addition of the transfection mix the plated 
cells were briefly washed with OptiMeM. The transfection mix was added to the 
cells and left to incubate for 6 hours at 37oC with 5% CO2. After 6 hours the medium 
was replaced with prewarmed DMEM/FBS (HEK/SHSY5Y cells) or 
Neurobasal/B27/Glutamax (neurons), and left overnight, for a period of 14-16 hours. 
 
 
 10 cm  6 wells 12 wells 24 wells 
DNA 12 µg 4 µg 2 µg 1 µg 
Lipofectamine  40 µl 8 µl 4 µl 2 µl 
OptiMeM  4 ml 750 µl 500 µl 200 µl 
 
Table 2.3 Lipofectamine 2000 transfections  
  
 




The primary antibodies used in this thesis are listed in Table 2.4a-b. 
 
 






Within residues 400-450 of GPR50 of 
human origin (accession 
number Q13585) 
 
Santa Cruz Biotechnology, 







C-terminal peptide residues of 
human GPR50  
 
Abcam, Cambridge, UK 






C-terminal peptide residues 378-392 
HPDRASGHPKPHSRS of human 
GPR50 
 
In-house (produced by 







C-terminal peptide residues 516-530 
TTADYPKPATTSHPK of human 
GPR50 







Within residues 701-1000 of human  
Nogo-A 
 







N-terminus of human Nogo  
 





N-terminal peptide residues 44-55 
LELNSLGEEQRILNR of human 
CDH8 
 





C-terminal peptide residues 785-799 
(RLGELYSVGESDKET) of human 
CDH8 
 






Peptide mapping at the C-terminus of 
human Cadherin-8  
 





Residues 1499–1522 of human 
ABCA2 
 
Kenneth Tew, MUSC (Vulevic 
et al., 2001), rabbit polyclonal 
 
Table 2.4a Antibodies used in this thesis. 
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et al., 2003). 
 




2.2.10 Immunocytochemistry  
 
Cells were fixed 24 hours after transfection by incubation with ice cold methanol for 
10 min. Cells were washed with PBS containing 0.02% bovine serum albumin (BSA, 
Sigma-Aldrich) and blocked for 30 minutes in PBS/BSA with 10% serum from 
secondary antibody host. The following primary antibodies in PBS/BSA were 
incubated for 1 hour at room temperature: anti-GPR50 (C-ter, Abcam, 1:1000), anti-
GPR50 (G-15, Santa Cruz, 1:1000); anti-GPR50 E62 (1:1000), anti-GPR50 E63 
(1:1000), anti Nogo-A (H-300, 1:1000), anti-TUJ1 (1:2000), anti-CDH8 E61 
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(1:1000), anti-GFP (1:1000), anti-β-actin (1:100,000). Secondary antibodies 
Alexafluor 488 goat anti-mouse or -rabbit (1:500, Molecular probes, Invitrogen), 
Alexafluor 594-conjugated goat anti-mouse or -rabbit IgG (1:800), Alexafluor 
488/594 donkey anti-goat, -rabbit or –mouse IgG (1:500/1:800) in PBS/BSA with 
10% serum, were applied for one hour at room temperature. Glass coverslips were 
mounted onto slides using a drop of mowiol (Sigma-Aldrich) with DAPI 




Confocal images of neurons and SH-SY5Y cells (Figs 2.8, 2.14, 2.17) were captured 
sequentially (line) on an Olympus Fluoview 1000 confocal laser scanning 
microscope (UPlanSApo 60x/1.35 oil objective) at image size 1024x1024 using 
Kalman filter mode 3. The remaining images were taken on a Zeiss Axioskop 2 
fluorescent microscope (Zeiss Plan-Neofluar 40x/1.3 and 100x/1.3 oil objectives).  
 
2.2.12 Colocalisation Image analysis 
 
The Intensity Correlation Analysis (ICA) plugin for image J is described in detail in 
Li et al., (2004), the Pearson’s and Manders’ correlation coefficients in Manders’ et 
al., (1993). Briefly, the ICA generates the Intensity Correlation Coefficient (ICQ), 
which describes if the intensities of two images vary in synchrony i.e. are dependent. 
The ICQ values are distributed between -0.5 and +0.5. Random staining: ICQ~0; 
segregated staining: 0>ICQ>-0.5; dependent staining 0<ICQ≤+5.0. Manders' 
Overlap coefficient is based on the Pearson's correlation coefficient with average 
intensity values being taken out of the mathematical expression, meaning that it will 
indicate positive overlap when one signal is stronger then the other at the same 
location. The values are distributed from 0 to 1, the former corresponding to non-
overlapping images and the latter reflecting 100% co-localisation between both 
images. 
There instructions on how to use the ICA plugin were followed: 
http://www.uhnresearch.ca/facilities/wcif/software/Plugins/ICA.html. Briefly, 
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representative confocal images showing staining of GPR50 and Nogo-A were 
selected and Olympus .oib files were imported into image J using the bioformats 
importer plugin (http://www.loci.wisc.edu/ome/formats-imagej.html). Images were 
background subtracted and thresholds were set. Image Correlation Analysis was 
selected for axonal/dendritic regions of interest (ROI). Frequency, scatter plots and 
ICA plots were selected. The results spreadsheet displayed Pearson’s R (Rr), 
Manders’ Overlap Coefficient (Manders, 1993)(R), red:green pixel ratio (Ch1:Ch2, 
was ~1 for selected images) and the Intensity Correlation Coefficient (ICQ) (Li et al., 
2004). To determine if ICQ values are higher then 0, statistical analysis of N number 
of images/cells was performed using single sample t-Tests. Values are presented as 
mean (± SE).  
 
2.2.13 Quantitative analysis of GPR50 distribution 
 
SH-SY5Y cells were seeded at 1x105 cells on glass coverslips in 12 well dishes. 
Cells were transfected with untagged GPR50 or GPR50∆502-505/T532A and GFP-RTN3, 
GFP-Nogo-C, untagged Nogo-A or eGFP as a control using Lipofectamine 2000. 
Immunocytochemistry was performed using GPR50 G-15 (1:1000), ER marker 
Calreticulin (1:1000) and GFP (1:1000) or Nogo-A (H-300, 1:1000). Over three 
independent experiments 120 images were randomly collected, blind to the 
condition. The number of cells that showed GPR50 staining in the plasma 
membrane, ER or both was counted. A two-way ANOVA with Bonferroni’s post-test 
was performed using Prism. A graph showing the percentage of GPR50 transfected 
cells (±SE) where GPR50 is in the plasma membrane, ER or both was also produced 
in Prism. 
 
2.2.14 Immunoprecipitation and Western blotting 
 
HEK293T cells were grown on 10 cm dishes until 95% confluent and then 
transfected as above. Twenty-four hours after initiation of transfection, cells were 
lysed using RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS, 
0.5% sodium deoxycholate, plus protease inhibitors (Complete, Roche)). Lysates 
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were incubated on a rotary wheel for 30 min at 4oC, and subsequently cleared from 
insoluble material at 13,000 rpm at 4oC. The supernatant was incubated for 2 hours 
with 3 µg of anti-GPR50 (SC). Protein G-sepharose beads (Sigma) were added to the 
lysate, and incubated for 90 min. Beads were collected by centrifugation for 3 min at 
10,000 rpm and washed three times with RIPA (all at 4oC). The beads were 
resuspended in 40 µl Laemmli sample buffer with 100 mM DTT and boiled for 5 
minutes or heated at 40oC for 10min in non-denaturing conditions and to allow better 
GPR50 detection. Supernatants were analysed by Western blotting. 
Immunoprecipitation and 10-15 µg lysate samples were separated on 4-12% NuPage 
Bis-Tris or 3-8% NuPage Tris-Acetate gels (Invitrogen) against Precision Plus all 
blue protein standards (Biorad) and transferred onto PVDF membrane (Invitrogen). 
Membranes were stained briefly using Ponceau S (Sigma) to verify transfer of 
proteins from the gel and to determine equal loading. After blocking for 1 hour at 
room temperature in PBS with 0.2% Tween-20 (PBS-T) plus 5% skimmed milk 
powder, the membranes were incubated overnight at 4oC with the following primary 
antibodies in PBS-T with 5% milk: anti-GPR50 (G-15, 1:5000), anti-GPR50 C-ter 
(1:1000), anti-GPR50 E62 (1:5000), anti-GPR50 E63 (1:5000), anti-Nogo-A (H-300, 
1:2000), anti-Nogo (N-18, 1:1000), anti-ABCA2 (1:1000), anti-CDH8 E61 (1:3000), 
anti-GFP (1:1000). Membranes were incubated with horseradish peroxidase 
conjugated secondary antibodies: swine anti-rabbit (1:3000; DAKO A/S, Glostrup, 
Denmark), rabbit anti-goat (1:5000, DAKO), rabbit anti-mouse (1:2000, DAKO) in 
PBS-T for 30 min at room temperature. After incubations membranes were washed 3 
x 15 min with PBS-T. The signals were detected using chemiluminescence (ECL-
Plus, Amersham Biosciences, GE healthcare, Chalfont St.Giles, UK) and exposure to 
X-ray film. 





2.3.1 Antibody characterisation 
 
Throughout this thesis several in-house produced and commercially available 
antibodies were used. To test these antibodies I overexpressed GFP-tagged and 
untagged proteins (see Table 2.1) for detection in HEK293(T) cells by Western 
Blotting and immunocytochemistry. Detection of endogenous protein expression was 
tested in primary cultured mouse neurons and HEK293(T) cells. The antibodies are 
briefly described here and details are provided in Table 2.4a. Marker antibodies used 
are described in Table 2.4b. 
2.3.1.1 GPR50 antibodies   
Overexpressed GPR50 was previously detected in the plasma membrane of HEK293 
cells using C-terminal antibodies produced by Hamouda et al. (2007). Using these 
antibodies GPR50 was detected by Western blotting at 66 kDa (monomer) and 130 
kDa (dimer) (Hamouda et al., 2007). In this thesis, two commercially available 
GPR50 antibodies were used, a rabbit polyclonal from Abcam and goat polyclonal 
from Santa Cruz (G-15, SC). As shown in Fig 2.2 both antibodies detect both 
overexpressed untagged GPR50 (Fig 2.2A) and endogenous (Fig 2.2D-E) GPR50 on 
the cell surface of HEK293T cells. However N-terminally GFP-tagged GPR50 does 
not localise correctly to the plasma membrane (Fig 2.2B), likely because of the 
absence of a signal sequence mediating receptor integration into the plasma 
membrane upstream of the GFP sequence. Approximately 1% of HEK239T cells 
express GPR50 endogenously. Both antibodies colocalise with plasma membrane 
marker pan-Cadherin (Fig 2.2A). Endogenous Gpr50 was detected by the G-15 
antibody in a punctate pattern in cortical mouse neurons seeded at E18 and cultured 
for 28 days (Fig 2.2F). Both antibodies detect overexpressed untagged GPR50 at 
approximately 67 kDa, and GFP-GPR50 at 92 kDa by Western Blotting (Fig 2.2C). 
Possible dimers are detected in untransfected HEK293T cells but in GPR50 
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overexpressing cells these are masked by a smear (Fig 2.2C, see paragraph on 
GPR50 oligomeriation below). 
 
Additionally, rabbit polyclonal antisera GPR50 E62 and E63 were raised against 
sequence derived C-terminal peptide residues 378-392 and 516-530 of human 
GPR50 (Fig 2.3A, Table 2.4a). Final bleeds from immunized rabbits were affinity-
purified against their respective peptides by Eurogentec (Double XP program), and 
these purified antisera were used in all experiments. 
 
GPR50 E62 and E63 detect overexpressed GFP-GPR50 in HEK293T cells (Fig 
2.3B). GPR50 E63 also detected endogenous GPR50 on the cell surface of 
HEK293T cells (Fig 2.3C). E62 did however not detect any endogenous GPR50 in 
one experiment and it was therefore decided to use E63 only in future experiments. 
Both antibodies however detect overexpressed GPR50 in HEK293T cells by Western 
blotting at 67 kDa (Fig 2.3D). GPR50 E63 detects immunoprecipitated GPR50 from 
HEK293T cells transfected with various full-length and C-terminal only GPR50 
constructs (Fig 2.3E). Again a high molecular weight smear is detected with these 
antibodies when overexpressing full length GPR50, which is absent from the C-
terminal domain only sample (Fig 2.3E). This indicates the transmembrane domains 
and/or cell surface expression is important for this pattern to emerge. 
2.3.1.2 GPR50 oligomerisation 
GPR50 is known to dimerise (Levoye et al., 2006) and dimers were also detected 
here (Fig 2.2-2.3) and by others (Hamouda et al., 2007) by Western blotting. The 
high molecular weight smear detected with all four GPR50 antibodies in this thesis 
may indicate further oligomerisation. It may also indicate glycosylation of GPR50 
(Lanctot et al., 2005). There are however no consensus N-glycosylation sites present 
in the GPR50 sequence (Hamouda et al., 2007). The high molecular weight smear 
however disappeared when samples were heated at 40°C for 10 min prior to loading 
on SDS-PAGE instead of boiling (Fig 2.3F). This suggests that boiling increases 
GPR50 high molecular weight aggregates which are unable to migrate properly into 
the gel. This is known to be the case for multi-pass transmembrane proteins (Ren et 
al., 2009)




Figure 2.2 Characterisation of GPR50 C-terminal antibodies: Abcam ab13190 (C-
ter) and Santa Cruz SC50590 (G-15). (A) HEK293T cells were transfected with 
untagged GPR50-TTC. Both C-ter and G-15 antibodies colocalise to the plasma 
membrane as indicated by plasma membrane marker pan-cadherin. The 
background signal from the secondary antibodies (DAG, donkey anti-goat Alexafluor 
488 and GAR, goat anti-rabbit Alexafluor 594) is minimal in the absence of the 
primary antibodies. (B) HEK293T cells were transfected with GPR50-GFP. Both C-
ter and G-15 antibodies colocalise with the GPR50-GFP signal, which appears to be 
more internal than GPR50 TTC (untagged). Cells were counterstained with DAPI. 
Scale bars: 50 µm (C) HEKT cells were transfected with several GPR50 constructs: 
1. Untransfected, 2.GPR50-TTC, 3. untagged GPR50 (pDEST40), 4. GFP-GPR50. 
Western Blotting of lysates shows that anti-C-ter and anti-G-15 both recognize 
overexpressed GPR50 at the correct sizes (GPR50TTC=67 kDa; untagged 
GPR50=67 kDa, GPR50-GFP=92 kDa). GPR50 dimers are also detected at 134 
kDa in both overexpressed and untransfected samples. This Figure was partly 
published as supplementary material in Grünewald et al., 2009. Molecular and 
Cellular Neuroscience. Copyright Elsevier 2009.




 Figure 2.2. Characterisation of GPR50 C-terminal antibodies: Abcam ab13190 (C-
ter) and Santa Cruz SC50590 (G-15). 
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Figure 2.2. Characterisation of GPR50 C-terminal antibodies: Abcam ab13190 (C-
ter) and Santa Cruz SC50590 (G-15). Endogenous GPR50 in HEK293 cells and 
primary neurons. (D) HEK293T cells were stained with C-ter and G-15, which 
recognize endogenous GPR50 in the plasma membrane. (E) The signal of both 
GPR50 antibodies overlaps in the plasma membrane of HEK293T cells. (F) Primary 
cortical mouse neurons were stained with G-15, which recognises endogenous 
Gpr50 in a punctate pattern. Application of the secondary antibody (Alexafluor 
donkey anti-sheep, DAS, 488) only gives minimal background staining. Cells were 
counterstained with DAPI. Scale bars: 50 µm. Parts of this Figure published as 
supplementary material in Grünewald et al., 2009. Molecular and Cellular 
Neuroscience. Copyright Elsevier 2009.
 









Figure 2.3 Characterisation GPR50 C-terminal antibodies: E62 and E63. (A) 
Antibodies E62 an E63 were raised against C-terminal amino acid residues 378-392 
and 516-530 of human GPR50 respectively. (B) HEK293T cells were transfected 
with GFP-GPR50 and stained with E62 and E63. (C) HEK293T cells were stained 
with E63 for detection of endogenous GPR50 E63 for detection of endogenous 
GPR50. HEK293T cells were also stained with a goat anti-rabbit secondary antibody 
(GAR, Alexafluor 594) only and minimal background staining was detected. Cells 
were counterstained with DAPI for nuclear staining. Scale bars: 50µm. (D) HEKT 
cells were transfected with GPR50 TTC. Lysates were run on SDS-PAGE and 
membranes were probed with serial dilutions of the E62 and E63 antibodies. Both 
antibodies recognise overexpressed GPR50 at 67kDa and also possible oligomers, 
similar to the GPR50 C-term antibody (Abcam) but stronger. (E) HEK293T cells 
were transfected with various GPR50 constructs: 1. untagged, 2. GPR50 TTC (67 
kDa), 3. untagged GPR50 (pDEST40) (67 kDa), 4. GFP-GPR50 (92kDa), 5. GFP-
CTD (75 kDa). Cells were lysed and immunoprecipitated using the G-15 antibody. 
GPR50 was detected by Western blotting using E63. (F) The high molecular weight 
smear that is detected by Western blotting of overexpressed GPR50 using G-15, C-
ter, E62 and E63 antibodies disappears when heating the samples to 40°C instead 
of boiling prior to loading on SDS-PAGE. HEK293 cells were left untransfected (1) 
or were transfected with untagged GPR50 (2). Shown is a representative Western 
blot when using G-15.





Figure 2.3 Characterisation GPR50 C-terminal antibodies: E62 and E63.  
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2.3.1.3 Nogo-A antibodies 
I this thesis a rabbit polyclonal anti-Nogo-A (H-300, Santa Cruz) antibody is used 
that has previously been reported to detect Nogo-A at 180 kDa in human 
medulloblastoma cells (Satoh et al., 2005; Wojcik et al., 2007) and in in the cell 
soma, axons and dentrites of neurons in the rat somatosensory cortex (Shin et al., 
2006). Polyclonal goat anti Nogo-A (N-18, Santa Cruz) has been previously shown 
to detect Nogo-A and Nogo-B at 180 and 46 kDa respectively by Western blotting of 
cultured human muscle fibers and COS7 cells (Acevedo et al., 2004; Wojcik et al., 
2007), and Nogo-B by immunocytochemistry in cultured human muscle fibers 
(Wojcik et al., 2007) and a human endothelial cell line (Acevedo et al., 2004).  
 
The H-300 antibody specifically detects endogenous and overexpressed Nogo-A in 
the ER and plasma membrane in HEK293 cells (Fig 2.4A-C) and in GFP-Nogo-A 
overexpressing and untransfected cultured mouse neurons (Fig 2.4D-F). H-300 
detects overexpressed untagged Nogo-A and GFP-Nogo-A in HEK293 cell lysates at 
approximately 200 and 225 kDa respectively (Fig 2.4G). Overexpressing GFP-Nogo 
also results in an increase in untagged Nogo-A, perhaps in indication of the loss of 
the GFP tag (Fig 2.4G). The pan-Nogo N-18 antibody also detects overexpressed 
Nogo-A and GFP-Nogo-A at 200 and 225kDa by Western blotting (Fig 2.4G) and 
band at 50 kDa, which is possibly Nogo-B (Acevedo et al., 2004; Wojcik et al., 
2007). 





Figure 2.4 Characterisation of commercially available Nogo-A antibodies. Nogo-A 
(H-300, Santa Cruz) detects overexpresssed and endogenous Nogo-A in 
mammalian cells. (A) HEK293T cells were stained with H-300 for endogenous 
Nogo-A detection and costained with ER marker calreticulin. (B) HEK293T cells 
were stained for calreticulin and a goat anti-rabbit secondary antibody (GAR, 
Alexafluor 594) only as control, and minimal background staining was detected. (C) 
HEK293 cells were stained with Nogo-A and plasma membrane marker pan-
cadherin. Colocalisation signal is indicated by arrow. (D) Primary hippocampal 
mouse neurons at 14 DIV were transfected with GFP-tagged Nogo-A and 
overexpressed Nogo-A is detected by H-300. (E) This Nogo-A antibody also detects 
endogenous Nogo-A in primary hippocampal and cortical neurons cultured for 21 
days. (F) Cortical neurons were stained with secondary antibody donkey anti-rabbit 
(DAR, Alexafluor 594) only, which gives minimal background staining. Cells were 
counterstained with DAPI for nuclear staining. Scale bars: 50 µm. (G) HEK293T 
cells were left untransfected (1) or transfected with GFP-Nogo-A (2). Lysates were 
processed for Western blotting with two Nogo-A antibodies: Nogo-A H-300 and N-
18. Overexpressed Nogo-A was detected at 200 and 225 kDa.  




Figure 2.4 Characterisation of commercially available Nogo-A antibodies.  
 
Chapter 2: Validation of GPR50’s Interactions 
 64 
2.3.1.4 CDH8 antibodies 
Exogenous CDH8 was previously detected in the plasma membrane at cell-cell 
contacts in L-cells (Kido et al., 1998). Punctate Cdh8 expression was earlier 
observed in the mouse spinal cord (Suzuki et al., 2007). CDH8 was detected as 130 
and 95 kDa species by Western blotting of adult rat brain (Kido et al., 1998).  
 
Rabbit polyclonal antisera CDH8 E60 and CDH8 E61 were developed, which were 
raised against sequence derived N-terminal peptide residues 44-55 and C-terminal 
peptide residues 785-799 of human CDH8 (Fig 2.5A, Table 5). Final bleeds from 
immunized rabbits were affinity-purified against both peptides by Eurogentec 
(Double XP program), and these purified antisera were used in all experiments. In 
addition a polyclonal goat antibody from Santa Cruz was used (C-18) for Western 
blotting only. All three antibodies detect overexpressed GFP-tagged human CDH8 at 
125 kDa (Fig 2.5B), indicating a molecular weight of full-length CDH8 of 100kDa 
without the GFP tag. CDH8 E60 antibody detects a stronger additional band at 
approximately 60 kDa which not visible when using the other antibodies. CDH8 E61 
detects overexpressed GFP-CDH8 on the cell surface of HEK293T cells (Fig 2.5C). 
Multiple sequence alignment of human and mouse peptide residues indicate high 
conservation in the C-terminal region but not at the N-terminus (Fig 2.6) suggesting 
E61 but not E60 is able to detect mouse CDH8 as well. CDH8 E61 detects 
endogenous Cdh8 in a punctate pattern in primary cortical mouse neurons seeded at 
E18 and cultured for 28 days (Fig 2.5D-E).  
 
2.3.1.5 ABCA2 antibody 
The ABCA2 antibody was first characterised in (Vulevic et al., 2001). 
Overexpressed ABCA2 in HEK293 and HeLa cells was shown to be expressed in 
endolysosomes and the trans-Golgi network (Vulevic et al., 2001; Broccardo et al., 
2006). However, a more cytoplasmic staining pattern of endogenous Abca2 was 
reported in the soma and proximal processes of adult mouse oligodendrocytes and 
neurons (Broccardo et al., 2006), indicating a likely difference in localisation 
between endogenous and overexpressed ABCA2.  
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Here, the ABCA2 antibody was able to detect overexpressed ABCA2 in vesicle-like 
compartments of the cell soma by immunocytochemistry in HEK293T cells (Fig 
2.7A), and primary cortical mouse neurons (Fig 2.7B). Note the neuron is colabelled 
with TUJ1, a marker for neurons (Fig 2.7B). In primary hippocampal mouse neurons 
and glia, cultured for 28 days, endogenous Abca2 shows a cytosolic expression 
pattern, more highly expressed in glia than neurons (Fig 2.7C-D). The ABCA2 
antibody specifically detects overexpressed ABCA2 in HEK293T cells by Western 
blotting as a doublet at ~270 kDa (Fig 2.5E). In Vulevic et al. (2001) overexpressed 
ABCA2 from HEK293 cells was detected as a diffuse/smeary band above 250 kDa, 
possibly as a result of glycosylation (Vulevic et al., 2001). On the datasheet of a 
commercially availably antibody from Abcam (ab91571) the images show ABCA2 
as a clear doublet at 270 kDa from HEK293T lysates, which much resembles the 
data in Fig 2.5E. The bottom band appears to correspond to ABCA2 as shown by IP 
on the abcam datasheet http://www.abcam.com/ABCA2-antibody-ab91571.html.




Figure 2.5 Characterisation of CDH8 E60 and E61 antibodies. (A) Antibodies E60 
an E60 were raised against amino acid residues 44-58 (N-term) and 785-799 (C-
term) of human CDH8 respectively (Designed by Pippa Thomson) and produced by 
Eurogentec. HEK293 cells were transfected with GFP-tagged full length human 
CDH8. Lysates were run on SDS-PAGE and membranes were probed with a 
commercial CDH8 antibody and serial dilutions of the E60 and E61 antibodies. (C) 
HEK293T cells were transfected with GFP-tagged CDH8 and stained for GFP and 
CDH8 E61. (D) Primary cortical mouse neurons at E18 were cultured for 28 days 
and were stained using CDH8 E61 to detect endogenous Cdh8. The E61 antibody 
detects faint endogenous CDH8 in neurons in a punctate pattern. Primary cortical 
mouse neurons were stained with donkey anti-rabbit (DAR Alexafluor 584) only. 
Minimal background staining is observed. Cells were counterstained with DAPI for 
nuclear staining. Scale bars: 50 µm.




Figure 2.5 Characterisation of CDH8 E60 and E61 antibodies.  
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Mouse Cdh8      MPERLAETLMDLWTPLIILWITLPSCVYTAPMNQAHVLTTGSPLELSRQSEDMRILSRSK 60 
human CDH8      MPERLAEMLLDLWTPLIILWITLPPCIYMAPMNQSQVLMSGSPLELNSLGEEQRILNRSK 60 
                ******* *:**************.*:* *****::** :******.  .*: ***.*** 
 
mouse           RGWVWNQMFVLEEFSGPEPILVGRLHTDLDPGSKKIKYILSGDGAGTIFQINDITGDIHA 120 
human           RGWVWNQMFVLEEFSGPEPILVGRLHTDLDPGSKKIKYILSGDGAGTIFQINDVTGDIHA 120 
                *****************************************************:****** 
 
mouse           IKRLDREEKAEYTLTAQAVDFETNKPLEPPSEFIIKVQDINDNAPEFLNGPYHATVPEMS 180 
human           IKRLDREEKAEYTLTAQAVDWETSKPLEPPSEFIIKVQDINDNAPEFLNGPYHATVPEMS 180 
                ********************:**.************************************ 
 
mouse           ILGTSVTNVTATDADDPVYGNSAKLVYSILEGQPYFSIEPETAIIKTALPNMDREAKEEY 240 
human           ILGTSVTNVTATDADDPVYGNSAKLVYSILEGQPYFSIEPETAIIKTALPNMDREAKEEY 240 
                ************************************************************ 
 
mouse           LVVIQAKDMGGHSGGLSGTTTLTVTLTDVNDNPPKFAQSLYHFSVPEDVVLGTAIGRVKA 300 
human           LVVIQAKDMGGHSGGLSGTTTLTVTLTDVNDNPPKFAQSLYHFSVPEDVVLGTAIGRVKA 300 
                ************************************************************ 
 
mouse           NDQDIGENAQSSYDIIDGDGTALFEITSDAQAQDGVIRLRKPLDFETKKSYTLKVEAANI 360 
human           NDQDIGENAQSSYDIIDGDGTALFEITSDAQAQDGIIRLRKPLDFETKKSYTLKVEAANV 360 
                ***********************************:***********************: 
 
mouse           HIDPRFSSRGPFKDTATVKIVVEDADEPPVFSSPTYLLEVHENAALNSVIGQVTARDPDI 420 
human           HIDPRFSGRGPFKDTATVKIVVEDADEPPVFSSPTYLLEVHENAALNSVIGQVTARDPDI 420 
                *******.**************************************************** 
 
mouse           TSSPIRFSIDRHTDLERQFNINADDGKITLATPLDRELSVWHNITIIATEIRNHSQISRV 480 
human           TSSPIRFSIDRHTDLERQFNINADDGKITLATPLDRELSVWHNITIIATEIRNHSQISRV 480 
                ************************************************************ 
 
mouse           PVAIKVLDVNDNAPEFASEYEAFLCENGKPGQVIQTVSAMDKDDPKNGHFFLYSLLPEMV 540 
human           PVAIKVLDVNDNAPEFASEYEAFLCENGKPGQVIQTVSAMDKDDPKNGHYFLYSLLPEMV 540 
                *************************************************:********** 
 
mouse           NNPNFTIKKNEDNSLSILAKHNGFNRQKQEVYLLPIVISDSGNPPLSSTSTLTIRVCGCS 600 
human           NNPNFTIKKNEDNSLSILAKHNGFNRQKQEVYLLPIIISDSGNPPLSSTSTLTIRVCGCS 600 
                ************************************:*********************** 
 
mouse           NDGVVQSCNVEAYVLPIGLSMGALIAILACIILLLVIVVLFVTLRRHKNEPLIIKDDEDV 660 
human           NDGVVQSCNVEAYVLPIGLSMGALIAILACIILLLVIVVLFVTLRRHKNEPLIIKDDEDV 660 
                ************************************************************ 
 
mouse           RENIIRYDDEGGGEEDTEAFDIATLQNPDGINGFLPRKDIKPDLQFMPRQGLAPVPNGVD 720 
human           RENIIRYDDEGGGEEDTEAFDIATLQNPDGINGFLPRKDIKPDLQFMPRQGLAPVPNGVD 720 
                ************************************************************ 
 
mouse           VDEFINVRLHEADNDPTAPPYDSIQIYGYEGRGSVAGSLSSLESTTSDSDQNFDYLSDWG 780 
human           VDEFINVRLHEADNDPTAPPYDSIQIYGYEGRGSVAGSLSSLESTTSDSDQNFDYLSDWG 780 
                ************************************************************ 
 
mouse           PRFKRLGELYSVGESDKET 799 
human           PRFKRLGELYSVGESDKET 799 
                ******************* 
 
Figure 2.6 Multiple sequence alignment of human and mouse CDH8 amino acid 
sequences. Underlined are the two epitopes of the N- and C-terminal antibodies 
E60 and E61. The sequence is well conserved except for the N-terminus, indicating 
that the E61 antibody is likely to also detect mouse Cdh8 contrary to the N-
terminally raised E60 antibody.  






Figure 2.7 Characterisation of the ABCA2 antibody (K.Tew). (A) HEK293T cells 
were transfected with ABCA2 and stained with ABCA2. Minimal background staining 
is observed in the absence of the primary antibody and application of goat anti-
rabbit (GAR, Alexafluor 594). (B) Primary cortical mouse neurons of E18 were 
cultured for 14 days and transfected with ABCA2. Cells were stained with TUJ1 (B-
tubulin III) and ABCA2. (C) Primary hippocampal mouse neurons of E18 were 
cultured for 28 days and were stained for ABCA2. The ABCA2 antibody detects 
endogenous ABCA2 in putative glia and neurons. (D) Primary hippocampal mouse 
neurons were stained with donkey anti-rabbit (DAG Alexafluor 584) only. Minimal 
background staining is observed. (E) HEK293T cells were transfected with ABCA2. 
Lysates were processed for Western blotting with the ABCA2 antibody, resulting in a 
band at 270 kDa in transfected sample (2) but not in untransfected lysate sample 
(1). Cells were counterstained with DAPI for nuclear staining. Scale bars: 50 µm
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2.3.2 GPR50 interacts with Nogo-A, Nogo-C, RTN3, CDH8 and 
ABCA2 
 
2.3.2.1 Testing the interactions 
In order to investigate the interactions in more detail various full-length and deletion 
constructs were made (see Table 2.1 for more details) and binding of RTN3, Nogo-
A, Nogo-C, CDH8 and ABCA2 with these forms of GPR50 was tested. This was 
tested by performing immunocytochemistry and immunoprecipitation. Firstly, to 
directly replicate the Y2H study, GPR50 CTD only constructs were used. Secondly, 
experiments were performed using GFP-tagged full-length GPR50 (insertion only). 
Thirdly, after cloning of full length GPR50∆502-505/T532A, differential binding of 
untagged GPR50 and GPR50∆502-505/T532A was investigated.  
 
2.3.2.2 Interactions with GPR50 CTD only 
In the Y2H screen, the C-terminal domain (CTD) of both the GPR50 (‘insertion’) 
and GPR50∆502-505/T532A (‘deletion’) were used as bait (Grünewald et al., 2009). 
Nogo-A was captured by both forms, as was ABCA2 (see Table 1.1, Chapter 1). 
CDH8 was only isolated when using the deletion form, as was RTN3. Nogo-C on the 
other hand was only captured when the insertion form of GPR50 was used 
(Grünewald et al., 2009). However, because the number of clones that were isolated 
in each case was too low to reach significance levels, the interaction with both 
insertion and deletion forms needs to be tested. 
 
Therefore HEK293T cells were cotransfected with GFP-tagged Nogo-A, CDH8 or 
untagged ABCA2, and either GFP-tagged C-terminal insertion (GFP-CTD) or –
deletion (GFP-CTD∆502-505/T532A) constructs of GPR50 (Figure 2.8). These constructs 
spanned residues 283 to 617 (613 deletion), were made by Hazel Kinnell and Alison 
Condie (University of Edinburgh) and were already available in the lab. When 
pulling down GPR50 CTD using the GPR50 G-15 antibody, GFP-Nogo-A was 
predominantly co-precipitated by the H-300 antibody at 225 kDa but also some 
untagged Nogo-A, as indicated by a fainter band at 200 kDa. Similarly GFP-CDH8 
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was co-precipitated by Western blot at 125 kDa respectively using protein-specific 
antibodies. This was the case for both insertion and deletion forms of GPR50, 
indicating no difference in possibility to bind (Fig 2.8). These results were repeated 
twice. Although ABCA2 was co-precipitated as a doublet at 260-270 kDa with 
GPR50 CTD once (Fig 2.8), this could not be replicated. This result therefore needs 
to be treated with caution. 
 





Figure 2.8 The GPR50 CTD interacts with Nogo-A, CDH8 and ABCA2, irrespective 
of the deletion polymorphism. HEK293T cells were transfected with GFP-GPR50 
CTD or GFP-GPR50 CTD∆TTGH or co-transfected with GFP-Nogo-A, GFP-CHD8 
or untagged ABCA2. When lysates were precipitated with GPR50, Nogo-A, CHD8 
and ABCA2 were all co-precipitated with both the CTD and CTD ∆TTGH, as shown 
by Western Blotting. Whereas the interaction of GPR50 CTD with Nogo-A and 
CDH8 could be replicated, this was not the case with ABCA2 and therefore this 
result needs to be treated with caution.  
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2.3.2.3 Full length GPR50 interacts with Nogo-A 
Because GPR50 CTD only does not localise correctly to the plasma membrane, the 
differential binding of full length GPR50 was investigated as well. In addition to co-
IPs immunocytochemistry was performed in primary cultured neurons in order to test 
whether colocalisation could be detected and where this could be found. 
 
For immunocytochemistry, primary cortical neurons were cultured for 15 days in 
vitro (DIV), and transfected with untagged GPR50 and GFP-Nogo-A. We detected 
some colocalisation between overexpressed untagged GPR50 and exogenous GFP-
Nogo-A although GPR50 appears to be expressed more in dendrites and spines than 
Nogo-A (Fig. 2.9A, Grünewald et al., 2009). This indicates that GPR50 and Nogo-A 
may be available to interact in mammalian cells. As expected exogenous GPR50 is 
predominantly expressed in the plasma membrane and Nogo-A at a more 
intracellular location, most likely the ER or the cytoplasm. Interestingly 
overexpressed GPR50 also localises more strongly than Nogo-A to the tips of 
dendrites and spines (Fig 2.9B). In order to establish whether there is colocalisation 
between endogenous Nogo-A and Gpr50, immunocytochemistry was performed on 
primary cortical mouse neurons after 28 DIV. Endogenous colocalisation of a 
proportion of both proteins was found along dendrites, possibly in synaptic spines 
(Fig 2.9B).  
 
In order  to quantify colocalisation between exogenous and endogenous GPR50 and 
Nogo-A Pearson’s correlation coefficient (exogenous: Rr = 0.61± 0.05; endogenous: 
Rr = 0.43 ± 0.01) and Manders’ Overlap Coefficient (Manders, 1993) were 
calculated for axonal regions in several cells (N=6), indicating moderate to strong 
colocalisation (Grünewald et al., 2009). In addition the Intensity Correlation 
Analysis (Li et al., 2004) was used to test whether GPR50 and Nogo-A staining in 
axonal/dendritic sections (enlargement) was associated (Fig 2.9C for exogenous 
GPR50 and Nogo-A) see materials and methods Chapter 2.2.12). A dependent 
staining pattern was indicated by positively skewed ICA scatter plots (Fig 2.9C). In 
addition the ICQ values were consistently positive and highly significant (exogenous 
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+0.24 ± 0.03; p < 0.001; N=6; endogenous: +0.17 ± 0.01; p < 0.001; the values for 
the cells in Fig 2.9A and 2.9B only are given in the figure legend), arguing for a 
dependent association between exogenous and endogenous GPR50 and Nogo-A.  
 
Next, imunoprecipitations were performed in HEK293T cells using GFP-tagged full-
length GPR50 (insertion only) and GFP-Nogo-A. HEK293T cells were transiently 
transfected and a 225 kDa Nogo-A band was detected by western blot after 
immunoprecipitation with anti-GPR50 (G-15, Fig. 2.9C). The untagged Nogo-A 
appears however not to be co-precipitated with GFP-GPR50 this time. This may 
indicate dimerisation of the GFP tags and perhaps a false positive result. Therefore 
the experiment was repeated with untagged GPR50 and Nogo-A (see 2.3.2.4). 
 
2.3.2.4 Full-length untagged GPR50 and GPR50∆502-505/T532A also bind 
reticulons Nogo-A, Nogo-C and RTN3  
Differential binding of untagged GPR50 and GPR50∆502-505/T532A with Nogo-A and 
with reticulon family members Nogo-C and RTN3 was investigated next. To this end 
full-length GPR50 residues 502-505 were removed, and Thr was substituted by Ala 
at position 532 using site-directed mutagenesis (see materials and methods section 
2.2.4 for more details).  
First, immunocytochemistry was performed to test if GPR50 and GPR50∆502-505/T532A 
both localise to the plasma membrane. This was performed in SH-SY5Y cells, as 
these are larger than HEK293 and have less of a tendency to form cell clumps and 
because neuroblastoma cells are more representative of neurons. Subcellular 
localisation in individual cells is therefore easier to detect. SH-SY5Y cells were 
transiently transfected with untagged GPR50 or untagged GPR50∆502-505/T532A. After 
colabelling cells with GPR50 (G-15) and plasma membrane marker pan-Cadherin, 













Figure 2.9 GPR50 interacts with Nogo-A in mammalian cells. (A) Primary cortical 
mouse neurons at E18 were cultured for 15 DIV. Neurons were co-transfected with 
untagged GPR50 and GFP-Nogo-A and stained the following day with GPR50 (SC) 
and GFP. The merged image (see enlargement) shows colocalisation in 
axons/dendrites (Grünewald et al., 2009). (B) Primary cortical mouse neurons were 
cultured for 28 days and stained for endogenous Nogo-A and Gpr50, indicating co-
expression in dendrites and possibly synaptic spines. Intensity correlation analysis 
was performed on dentritic regions of interest (see enlargements in A and B) and 
the plots for exogenous GPR50 to Nogo-A together and individually shown below in 
(C). (C) Intensity correlation plots of Nogo-A versus GPR50. Red/green correlation 
plot with yellow pixels denoting colocalisation (left), respective plots of Nogo-A 
(middle) and GPR50 (right) against their (A-a) (B-b) values indicating the 
dependence of the stain of one protein versus the other (Li et al., 2004). Note the 
positive skew of the ICA plots indicating dependent staining. Values for these 
images only: A (exogenous): ICQ=+0.26. Rr = 0.66, R = 0.89; B (endogenous): ICQ 
= +0.17; Rr= 0.40; R = 0.83. Scale bar: 50µm. (D) HEK293T cells were transfected 
with full-length human GFP-Nogo-A and GFP-GPR50 constructs, individually or in 
combination. Lysates were immunoprecipitated with anti-GPR50 (SC) antibody and 
Nogo-A was co-precipitated in the GPR50 co-transfected sample only, as shown by 
Western blot analysis (Grünewald et al., 2009). Cells were counterstained with DAPI 
for nuclear staining. Scale bars: 50 µm. Figure adapted from Grünewald et al., 2009. 
Molecular and Cellular Neuroscience. Copyright Elsevier 2009.
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Figure 2.10 Full-length GPR50∆502-505/T532A localises to the plasma membrane, 
similar to GPR50. SHSY5Y cells were transfected with GPR50 or GPR50 ∆502-
505/T532A and stained for GPR50 and plasma membrane marker pan-cadherin. 
Immunocytochemistry results show similar colocalisation of GPR50 and GPR50 ∆502-
505/T532A   with pan-cadherin at the plasma membrane. Cells were counterstained with 
DAPI. Scale bars: 50 µm.  
 
Next colabelling of GPR50 and GPR50∆502-505/T532A with the reticulon proteins was 
performed. Colocalisation with Nogo-A as well as Nogo-C and reticulon family 
member RTN3 was investigated. Again SH-SY5Y cells were used for the reasons 
stated in the previous paragraph. Cotransfecting SH-SY5Y cells with GPR50 and 
Nogo-A resulted in costaining in the plasma membrane but mostly in ER-like 
structures (Fig 2.11). A similar pattern was seen with Nogo-C and RTN3 (Fig 2.12). 
Although the GPR50∆502-505/T532A variant did not appear to visibly alter colocalisation 
compared to GPR50 (Fig 2.11-2.12), the GPR50 localisation seemed to be changed 
when cotransfected with reticulon proteins RTN3, Nogo-C and Nogo-A compared to 
GPR50 by itself (Fig 2.2). A larger fraction of GPR50 was present in what appeared 
to be the ER instead of the plasma membrane. This apparent difference was 
intriguing and was further investigated in 2.3.3. 
 




Figure 2.11 Full-length GPR50 ∆502-505/T532A shows a similar colocalisation pattern as 
GPR50 with Nogo-A. SHSY5Y cells were cotransfected with GPR50 or GPR50 ∆502-
505/T532A and Nogo-A. Immunocytochemistry results show similar colocalisation of 
GPR50 with Nogo-A at the plasma membrane and the ER. Cells were 
counterstained with DAPI. Scale bars: 50 µm.  
 
Next, to further test the binding of GPR50 to the reticulin proteins, 
immunoprecipitations were performed. HEK293 cells were transfected with 
untagged GPR50 or untagged GPR50∆502-505/T532A, and either untagged Nogo-A or 
GFP-tagged Nogo-C or GFP-tagged RTN3. After precipitating GPR50 using the G-
15 (SC) antibody Nogo-A was repeatedly co-precipitated with both GPR50 and 
GPR50∆502-505/T532A at 200 kDa (Figure 2.13) using a Nogo-A specific antibody (H-
300). Similarly, Nogo-C (47 kDa) and RTN3 (50 kDa) (Fig 2.13) were repeatedly 
coprecipitated  with GPR50 using a GFP antibody, indicating Nogo-A, Nogo-C and 
RTN3 bind GPR50 irrespective of the polymorphisms.  
 
Interestingly, although equal amounts of GPR50 were precipitated (Fig 2.13) more 
Nogo-C and RTN3 seemed to be co-precipitated with GPR50∆502-505/T532A compared 
to GPR50 (Fig 2.13). Although this needs to be replicated in future experiments, a 
preference in binding of RTN3 to GPR50∆502-505/T532A is suggested by the Y2H results 
(Table 1.1).




Figure 2.12 Full-length GPR50∆502-505/T532A shows a similar colocalisation pattern as 
GPR50 with Nogo-C and RTN3. SHSY5Y cells were cotransfected with GPR50 or 
GPR50 ∆502-505/T532A and Nogo-C (A) or RTN3 (B). Immunocytochemistry results (A,B) 
show similar colocalisation of GPR50 with Nogo-C and RTN3  at the plasma 
membrane and the ER. Cells were counterstained with DAPI. Scale bars: 50 µm.  




Full length GPR50 interacts with CDH8 and ABCA2 
Similarly, in order to test interactions of full-length GPR50 with CDH8 and ABCA2, 
immunocytochemistry and co-immunoprecipitations were perfomed. 
 
Immunocytochemistry experiments were performed in HEK293T cells and primary 
neurons (Fig 2.9A-B). In HEK293T cells overexpressed GPR50TTC colocalises with 
GFP-CDH8 in the plasma membrane (Fig 2.14A). In primary hippocampal neurons 
cultured for 28 DIV endogenous Gpr50 colocalises with CDH8 was found at 
synaptic contacts in primary cortical neurons cultured for 28 days (Fig 2.14B, 
enlargement). 
 
In HEK293T cells overexpressed GFP-GPR50 colocalises with exogenous untagged 
ABCA2 in the cytoplasmic vesicles in a subset of cells, likely corresponding to the 
endolysosomal compartment (Fig 2.14C). However, the colocalisation may be 
affected by the N-terminal GFP tag of GPR50 (see also Fig 2.2). In primary 
hippocampal neurons cultured for 28DIV endogenous Gpr50 colocalises with Abca2 
in axons and dendrites (Fig 2.14D, enlargement). The punctate staining pattern of 
Gpr50 and Abca2 may also indicate an (intracellular) pool of (peptide) molecules. 
 
For co-immunoprecipiations HEK293T cells were transiently transfected with 
GPR50-GFP and CDH8-GFP or untagged ABCA2. CDH8 and ABCA2 were 
repeatedly detected by Western blotting as doublet bands after immunoprecipitation 
with anti-GPR50 (G-15, Fig 2.14E). The doublet band for ABCA2 had been detected 
previously in different experiments (Fig 2.7, 2.8) however the CDH8 doublet was 
not. This may indicate co-precipitation of the untagged form of CDH8 at 100 kDa as 
well as the tagged form at 125 kDa. However, because both GPR50 and CDH8 were 
GFP-tagged there is again the possibility that the positive co-IP result is caused by 
the dimerisation of GFP. Therefore the interaction needs to be investigated with 
untagged proteins. 
 







Figure 2.13 Full-length GPR50∆502-505/T532A also interacts with Reticulons Nogo-A, 
Nogo-C and RTN3. HEK293 cells were cotransfected with GPR50 or  
GPR50 ∆502-505/T532A and untagged Nogo-A, or GFP-tagged Nogo-C or RTN3. 
GPR50 was precipitated using the GPR50 G-15 SC antibody and co-precipitated 
Nogo-A was revealed by Western blotting with anti-Nogo-A (H-300, left hand figure). 
Co-precipitated Nogo-C and RTN3 were detected by immunoblotting with anti-GFP 
(right hand figure). More Nogo-C and RTN3 appears to be co-precipitated with 
GPR50∆502-505/T532A compared to GPR50. (B) To further test this SHSY5Y cells 
were co-transfected with GPR50 or GPR50 ∆502-505/T532A and Nogo-A, Nogo-C 
or RTN3. After performing immunocytochemistry 120 images were randomly taken 
per condition and cells which showed colocalisation between GPR50 and the 
interactors were scored. Means of three experiments were compared and T-tests 
were performed using Graphpad Prism. These showed a non-significant increase in 
colocalisation of RTN3 with GPR50 ∆502-505/T532A compared to GPR50. A similar 
increase was not seen with Nogo-A or Nogo-C. 
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Figure 2.14 GPR50 interacts with CDH8 and ABCA2 in mammalian cells. (A) 
HEK293T cells were co-transfected with GPR50-TTC and GFP-CDH8 and stained 
with GPR50 (C-term) and GFP. (B) Primary cortical mouse neurons were cultured 
for 28 days and stained with GPR50 G-15 or CHD8 E61 for detection of 
endogenous colocalisation. (C) HEK293T cells were co-transfected with GFP-
GPR50 and ABCA2 and stained with GFP and ABCA2. (D) Primary cortical mouse 
neurons were cultured for 28 days and stained with GPR50 G-15 or ABCA2 for 
detection of endogenous colocalisation. Cells were counterstained with DAPI for 
nuclear staining. Scale bars: 50 µm. (E) HEK293T cells were transfected with full 
length human GFP-CDH8 or ABCA2 and GFP-GPR50, individually or in 
combination. Lysates were immunoprecipitated with anti-GPR50 (G-15, SC) 
antibody and CDH8 and ABCA2 were co-precipitated in the GPR50 co-transfected 
sample only, as shown by Western blot analysis.  
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2.3.2.5 Interactions of untagged GPR50 and GPR50∆502-505/T532A with CDH8 
and ABCA2 
Next, colocalisation and co-IP experiments were repeated using untagged GPR50 or 
GPR50∆502-505/T532A with untagged CDH8 and ABCA2.  
 
Performing immunohistochemistry using SH-SY5Y cells, GPR50 and GPR50∆502-
505/T532A both colocalised with CDH8 in the plasma membrane at cell-cell contacts. 
Colocalisation with ABCA2 was found in cytoplasmic vesicles in a small subset of 
cells. Again, no apparent difference in colocalisation was found between using 
GPR50 or GPR50∆502-505/T532A in SH-SY5Y cells (Fig 2.15). This suggests CDH8 and 
ABCA2 have the ability to bind both forms of GPR50.  
 
Co-immunoprecipitation studies of untagged GPR50 or GPR50∆502-505/T532A with 
untagged CDH8 and ABCA2 were attempted in HEK293 cells. After 
immunoprecipitating GPR50 untagged CDH8 is expected to be detected by Western 
blotting at 100 kDa (Fig 2.16). However at this molecular weight non-specific bands 
are visible in the co-IP blot possibly blocking any real co-precipitated CDH8 (Fig 
2.16). Reciprocal IP’s using CDH8 E61 as IP antibody were performed but were so 
far unsuccessful and need further troubleshooting before conclusions can be drawn.   
In the case of ABCA2 there were issues with either the ABCA2 plasmid and/or the 
antibody resulting in apparent reduced (lysate) expression signal of ABCA2 by 
Western blotting (Fig 2.16). These technical issues meant no conclusions could be 
drawn and the experiments need to be repeated. 
 




Figure 2.15 Full-length GPR50∆502-505/T532A shows a similar colocalisation pattern as 
GPR50 with CDH8 and ABCA2. SHSY5Y cells were cotransfected with GPR50 or 
GPR50∆502-505/T532A  and CDH8 (A) or ABCA2 (B). Immunocytochemistry results show 
similar colocalisation of GPR50 with CDH8 at the plasma membrane at cell-cell 
contacts (A) and at a lysosome-like location with ABCA2 (B). Cells were 
counterstained with DAPI. Scale bars: 50 µm.  




Figure 2.16 Attempts to co-immunoprecipitate CDH8 and ABCA2 with GPR50 and 
GPR50∆502-505/T532A were unsuccessful. HEK293 cells were cotransfected with 
GPR50 or GPR50∆502-505/T532A and untagged CDH8 or ABCA2. GPR50 was 
precipitated using the GPR50 G-15 SC antibody but Western blotting with anti-
ABCA2 didn’t result in a positive signal (top arrow). The lysate signal of ABCA2 was 
very weak (bottom arrow) indicating problems with the plasmid and/or antibody. 
Similary, Western Blotting with anti-CDH8 61 resulted in a non-specific band at 
100kDa (middle arrow), obscuring the results.  
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2.3.2.6 Summary of interactions 
The combined results of the colocalisation and co-immunoprecipitation findings are 



















NT NT Co-IP, ICC Co-IP, ICC 
GFP-Nogo-C NT NT NT Co-IP, ICC Co-IP, ICC 
GFP-RTN3 NT NT NT Co-IP, ICC Co-IP, ICC 

























Table 2.5 Results from interaction study. Indicated are replicable (3x) positive 
interaction/colocalisation results from co-immunoprecipitation (co-IP) and 
immunocytochemistry (ICC). When results were inconclusive this was indicated. NT, 
not tested.   
 
2.3.3 Reticulon proteins alter cellular localisation of GPR50 
 
The colocalisation results in SH-SY5Y cells above (Fig 2.11-2.13) indicate 
colocalisation of GPR50 with RTN3, Nogo-C and Nogo-A in the ER, whereas 
GPR50 is normally predominantly found in the plasma membrane (Fig 2.2). This 
suggests an alteration of GPR50 localisation if favour of the ER. In order to test this, 
reticulon proteins or GFP as control were cotransfected with GPR50 or GPR50∆502-
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505/T532A into SH-SY5Y cells (Fig 2.17A). After performing immunocytochemistry 
the number of cells showing GPR50 at the plasma membrane, ER or both were 
scored (Fig 2.17B). Initial pilot studies for this experiment were performed by S. 
Hempel, under my supervision, as part of her MSc project. The results indicate a 
significant decrease in plasma membrane localisation of GPR50∆502-505/T532A in the 
presence of overexpressed RTN3 (p<0.05) or Nogo-C (p<0.05) and a significant 
increase in ER localisation of GPR50∆502-505/T532A with RTN3 (p<0.05) compared to 
eGFP. There was also a non-significant but consistent decrease in plasma membrane 
and increase in ER localisation of GPR50 with RTN3, Nogo-A and Nogo-C, and of 
GPR50∆502-505/T532A with Nogo-A, as compared to eGFP (Fig 2.17B). No difference 
was found between GPR50∆502-505/T532A and GPR50 in any of the conditions. This 
experiment was not performed for CDH8 and ABCA2 because of time contraints. 
Although the localisation of GPR50 did not appear to be altered in the presence of 
CDH8 (Fig 2.15), there may be a difference with ABCA2 (compare Fig. 2.2 with 
2.15), which needs to be further investigated. 
 




Figure 2.17A Reticulon proteins alter the cellular localisation of GPR50. (A) SH-
SY5Y cells were transfected with GPR50 or GPR50∆502-505/T532A (GPR50del)  
and RTN3, Nogo-C, Nogo-A or eGFP as a control. Cells were triple labelled with 
GPR50 G-15 (red), Calreticulin (infrared) and GFP (green) or Nogo-A (H-300, 
green). Scale bar: 50 µm. 




Fig 2.17B. Reticulon proteins alter the cellular localisation of GPR50. (B) Over three 
independent experiments 120 images were collected and the number of cells 
showing GPR50 at the plasma membrane, ER or both were counted.*p<0.05.  
 
 




In this study we have shown that exogenous GPR50 colocalises and interacts with 
Nogo-A, Nogo-C, RTN3, CDH8 and ABCA2 in mammalian cells, although with 
some of the proteins the interaction was only shown when using GFP-tagged 
constructs (Table 2.5), introducing the possibility that the interaction is caused by 
GFP-dimerisation rather than a true interaction. The expression pattern of the 
proteins under overexpressed and endogenous conditions is in agreement with 
previous studies (Kido et al., 1998; Vulevic et al., 2001; Dodd et al., 2005; 
Broccardo et al., 2006; Hamouda et al., 2007). Endogenous expression and 
colocalisation of these proteins is found on axons and dendrites and at synaptic 
contacts, potentially indicating involvement in cell-cell signalling. A synaptic 
location of neuronal Nogo-A has been reported previously (Aloy et al., 2006; Lee et 
al., 2008). Cdh8 expression at the synapse would be in line with its previously 
detected localisation at synaptic junctions and suggested role in cell-cell adhesion at 
synaptic contacts (Suzuki et al., 2007).  
 
2.4.1 GPR50 and RTN3/RTN4 (Nogo) 
 
GPR50 interacts with RTN3, Nogo-C and Nogo-A as shown by colocalisation and 
co-immunoprecipitation (co-IP) of untagged and GFP-tagged constructs (Table 2.5), 
suggesting common pathways and functions for GPR50 and reticulon proteins. 
Reticulons play a role in neurite growth, BACE1 activity, ER structure/function and 
apoptosis (Schwab, 2010) and further research is needed to identify a role for GPR50 
in these processes (also see Chapter 4).   
 
Because reticulons have a mixed membrane topology (Fig 2.1) the exact location of 
the interaction is unclear. Looking at the results in this chapter the interaction could 
take place in the ER, cytoplasm and/or plasma membrane of the cell.  
 
Within SH-SY5Y cells the interaction between overexpressed proteins appears to 
take place predominantly in the ER (Fig 2.11-2.12). This is possibly a result of ER 
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retention of GPR50 by reticulon proteins as is suggested by the results in Fig 2.17. 
RTN3 is known to affect the cellular location of interaction partner BACE1 (Shi et 
al., 2009). HEK293 cells stably expressing RTN3 showed an enrichment of BACE1 
in the ER fraction and decrease on the cell surface. This ER retention results in 
decreased APP processing of BACE1 (Shi et al., 2009). Possible functions of GPR50 
are also likely to be altered by mislocalisation of the receptor.   
 
In neurons endogenous colocalisation was found in dendrites and possibly in 
synaptic spines (Fig 2.9, 2.14). It has been suggested that GPR50 interacts in trans 
with Nogo-A (proteins are present on the membrane of different cells, eg one 
presynaptic the other postsynaptic) and that GPR50 is a neuronal receptor for N-
terminal Nogo-A (Schwab, 2010). This scenario is however unlikely as Nogo-A 
appears to interact with the C-terminal domain of GPR50, which is necessarily 
cytoplasmic. This was however shown with the GFP-tagged constructs only, and the 
experiment needs to be repeated with untagged GPR50 CTD and Nogo-A in order to 
confirm this. Furthermore colocalisation in immortalised cells and primary neurons 
suggest interaction in the same cell. It is however possible that there are more 
binding regions than only the CTD and further experiments are necessary to identify 
exact binding regions (see below). Nogo-A has previously been detected at 
presynaptic sites (Aloy et al., 2006; Lee et al., 2008). Subcellular fractionation 
studies may indicate a pre- and/or postsynaptic localisation for GPR50 and 
interactors, shedding light on whether GPR50-Nogo interactions are in cis (same 
membrane) or in trans (see next chapter).  
 
Because the Y2H study identified several reticulon family members two GPR50 
minimal interacting domains on Nogo/RTN proteins were identified (Grünewald et 
al., 2009) (Fig 2.18). The first binding site comprises 110 amino acids (residues 685-
795), and lies within the Nogo-A-specific region (Fig 18, GPR50 interacting domain 
1, GID1). The second binding site, identified through overlapping of the putative 
binding sites found on Nogo-C and RTN3, is 70 amino acids long and lies within the 
RHD. It therefore shows high homology to all known isoforms of RTN1, RTN3, and 
Nogo (Fig. 2.18, GPR50 interacting domain 2, GID2, residues 1008-1077). These 
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binding sites overlap with the NiG∆20 and Nogo-66 regions that have previously 
shown to have growth cone collapsing and neurite outgrowth inducing properties 
(Oertle et al., 2003b). This may therefore indicate a role for GPR50 in these 
processes. However, these binding regions need to be confirmed by for instance 
deletion mapping and co-IPs with shorter forms of Nogo/RTN3. 
 
 
Figure 2.18 The Y2H screen results predict two interaction sites of GPR50 on 
Nogo-RTNs. GPR50 interacting domain 1 (GID1) lies in the Nogo-A specific region. 
GID1 overlaps with the region homologous to the mapped rat regions NiG-∆20 
(human residues 87-185), which like the NiR-∆2 (human residues 567-748) and 
Nogo-66 (human residues 1055-1120), appear to be responsible for the inhibitory 
effect on neurite outgrowth and the spreading of neurons (Oertle et al., 2003b). 
GPR50 interacting domain 2 (GID2) overlaps with Reticulon Homology Domain 
(RHD) present in all RTN4 isoforms and RTN1 and 3, and overlaps with the Nogo-
66 region. Image from Grünewald et al., (2009) Molecular and Cellular 
Neuroscience. Copyright Elsevier 2009. 
 
 
Another important question is whether the interactions are direct. Reticulon proteins 
are known to interact with each other and complex together and it is therefore 
possible that GPR50 interacts with Nogo-A, Nogo-C or RTN3 only through other 
reticulon proteins. Co-immunoprecipitations with in vitro transcribed and translated 
(IVTT) proteins can be performed to confirm a direct interaction. Similarly, RNAi 
could be used to knock down the various reticulon isoforms to investigate the 
strength of the individual interactions. During this PhD several Nogo-C and RTN3 
antibodies from commercial sources were tested however none of them resulted in a 
specific staining pattern. Therefore only GFP-tagged RTN3 and Nogo-C were used. 
For future studies it is important to acquire good specific antibodies and in the 
literature some RTN3 and Nogo-C antibodies produced ‘in-house’ have been 
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described (Oertle et al., 2003b; He et al., 2004; Shi et al., 2009). It might be 
worthwhile to obtain those in the absence of good commercially available antibodies. 
 
2.4.2 GPR50 and CDH8 
 
Exogenous untagged GPR50 colocalises with CDH8 in the plasma membrane at cell-
cell contacts in SH-SY5Y and endogenous proteins colocalise at synaptic contacts in 
primary cortical neurons. CDH8 has previously been detected at these sites by others 
(Kido et al., 1998; Suzuki et al., 2007). Although positive interactions were detected 
with GPR50 and GPR50 CTD by co-IP, this was when using GFP-tagged constructs, 
and the experiment therefore needs to be repeated using untagged proteins. As was 
discussed above for reticulon proteins, more experiments are needed to investigate 
the interaction between GPR50 and CDH8 in more detail to determine whether there 
is a direct interaction and what the exact binding regions are. 
 
Cadherins mediate adhesive interactions during development, both during axon 
growth and at the synapse (Ranscht, 2000). Each cadherin is predicted to be present 
at a subpopulation of synapses, perhaps acting as a molecular tag or postcode for 
neuronal connections (Ranscht, 2000). A positive GPR50-CDH8 interaction would 
indicate a role for GPR50 in (cortical) development or synapse formation and 
function. Cadherin has a role in promoting neurite extension, via the FGF receptor 
(Skaper et al., 2001), which is apparently opposite to Nogo’s function in outgrowth 
inhibition. Cadherins form tight interactions with catenins and with the actin 
cytoskeleton. The membrane-actin interaction and cadherin activity can be 
modulated by Rho GTPases Cdc42, Rho and Rac1 (Kaibuchi et al., 1999; Kuroda et 
al., 1999). These Rho GTPases are effector molecules of Nogo signalling and are 
though to mediate the growth inhibiting characteristics of Nogo-A (Niederost et al., 
2002). A possible connection between these signalling pathways is intriguing and 
calls for further investigation. 
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2.4.3 GPR50 and ABCA2 
 
Colocalisation of GPR50 and ABCA2 is found in an endolysosomal-like location in 
the cell under overexpressed conditions but was endogenously detected at synaptic 
sites in primary neurons. This is in line with a perceived difference in ABCA2 
expression under overexpessed or endogenous conditions (Vulevic et al., 2001; 
Broccardo et al., 2006). Similarly to CDH8 the interaction needs to be confirmed 
using untagged GPR50. Additionally, follow up experiments are needed to determine 
whether there is a direct interaction between GPR50 and ABCA2 and what 
respective binding regions are. 
An interaction of GPR50 with ABCA2 may indicate a common role in lipid/sterol 
metabolism. ABCA2 is though to play a role in lipid metabolism, through homology 
with the HDL-cholesterol transporter Abca1(Kaminski et al., 2001) and is involved 
in the regulation of sphingolipids (Sakai et al., 2007). An intronic SNP in GPR50 is 
associated higher serum triglyceride and lower HDL (High Density Lipoprotein) 
levels (Bhattacharyya et al., 2006). GPR50 knockout mice have altered metabolism, 
as they display attenuated weight gain and reduced body fat on a high-energy diet as 
compared to wild-type animals. Moreover, on comparison, Gpr50 knockout mice 
displayed hyperactive behaviour and a heightened metabolic rate. Abca2 knockout 
mice also display a stressed, ‘skittish’ behavour (Mack et al., 2007). 
2.4.4 Effects of the polymorphisms on interactions 
 
At first sight there is not a great difference between the co-localisation and co-
immunoprecipitation results when using GPR50 or GPR50∆502-505/T532A. Both forms 
have the ability to bind Nogo-A, Nogo-C, RTN3, CDH8 and ABCA2. Only with 
RTN3 there is the suggestion of an increased interaction with GPR50∆502-505/T532A. As 
the interaction appears to be mainly found in the ER/cytoplasm under overexpressed 
conditions perhaps there is a difference in the ‘basal’ subcellular localisation 
between GPR50 and GPR50∆502-505/T532A. This was however not indicated by the 
results in figure 2.17 and there only seems to be a difference in the presence of 
RTN3.  Co-immunoprecipitation is perhaps too coarse a method to detect subtle 
differences in binding affinities between variants. Several techniques are available 
that may be used to study this (see below).  
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2.4.5 Altered cellular localisation of GPR50 in the presence of 
reticulon proteins 
 
Co-transfection of SH-SY5Y cells with GPR50∆502-505/T532A and RTN3 and Nogo-C 
seemed to decrease the proportion of GPR50 in the plasma membrane and to 
increase the fraction present in the ER (only with RTN3). Although there may be a 
trend towards a similar effect with GPR50 and Nogo-A these differences were not 
significant (Fig 2.17). This suggests a possible ER-retention mechanism of GPR50 
by RTNs, and in increased ‘vulnerability’ for the GPR50∆502-505/T532A compared to 
GPR50. An ER retention mechanism by RTN3 was previously proposed for BACE1 
and it is possible that this causes the negative modulation of BACE1 activity (Shi et 
al., 2009).  
 
In this thesis the subcellular distribution was only investigated by 
immunocytochemistry. Additional subcellular fractionation studies are often 
performed to confirm this (Shi et al., 2009). With these fractionation studies it is 
however difficult to separate the ER membrane fraction from the plasma membrane 
fraction, as would be necessary here. One way of separating these is to perform 
surface biotinylation in living cells, and to test if the surface expression of GPR50 is 
decreased in the presence of RTNs as is predicted from this study. Another 
possibility for looking at surface expression is to use an N-terminal tag or an N-
termial GPR50 antibody without membrane permeabilisation.  
 
2.4.6 Future studies 
 
In order to confirm interactions with CDH8 and ABCA2 co-IPs need to be 
performed using untagged proteins. Endogenous IPs should be attempted when it is 
clear where and when in the brain these proteins are highly co-expressed. In addition, 
to test whether interactions are direct IPs using in vitro transcribed and translated 
(IVTT) protein should be used. To map the interaction sites in more detail peptide 
array mapping should be undertaken, together with fine mapping using deletion 
constructs for co-IPs. With peptide array technology the protein sequence of protein 
1 is spotted on nitrocellulose as short peptides, typically in 25-mers. The array is then 
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overlayed with recombinant protein 2 and probed with antibodies. Binding regions 
can be identified as spots on the array. With peptide arrays more exact data can be 
generated about binding regions, affinities and the effect of mutations of binding. An 
N-terminal GPR50 antibody may be useful to study GPR50 interactions on the 
plasma membrane only. The only GPR50 N-terminal antibodies that have been 
produced and reported of in the literature were however not able to detect GPR50 
(Hamouda et al., 2007). 
 
Although the data in this chapter indicated both GPR50 and GPR50∆502-505/T532A are 
able to bind its interactors there are likely to be differences in binding affinities or 
stoichiometry between the two forms. Isothermal Titration Calorimetry is a very 
accurate if complicated biophysical technique for measuring the binding kinetics 
between two proteins. Another technique for determining binding constants is 
Surface Plasmon Resonance, although these techniques require protein purification. 
Common fluorescence microscopy techniques for assessing direct interactions of 
proteins in real time include FRET (Förster resonance energy transfer or 
fluorescence resonance energy transfer), BRET (Bioluminescence Resonance Energy 
Transfer) and FLIM (Fluorescence Lifetime Imaging Microscopy), where a donor 
(fluorescent) chromophore can transmit energy to an acceptor chormophore if it is in 
close proximity (Wallrabe and Periasamy, 2005).  
These methods would help confirm or refute direct asociation under physiological 
conditions. 
 
The results in this chapter suggest that GPR50 can interact with RTN3, Nogo-A, 
Nogo-C, CDH8 and ABCA2 under overexpressed conditions. The next question is 
where and when these proteins interact in the brain. This information can be used to 
attempt endogenous IPs of GPR50 and interactors. In the next chapter developmental 
expression of GPR50 and interactors in the developing and adult mouse brain is 
undertaken by performing rt-PCR and immunohistochemistry. Additionally 
subcellular fractionation of the adult mouse brain was performed to identify cellular 
compartment of high expression.





Developmental expression of 
GPR50 and interactors in the CNS
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3 Chapter Three: Developmental expression of 




The results in Chapter 2 indicate that GPR50 interacts with Nogo-A, Nogo-C, RTN3, 
CDH8 and ABCA2. The question is where and when are they able to interact. As we 
are interested in the function of the proteins in relation to mental disorders, I set out 
to investigate the expression in the central nervous system. This was studied using 
three methods: subcellular fractionation of adult mouse brain, rt-PCR of developing 
mouse brain, and immunohistochemistry in developing and adult mouse brain. The 
hypothesis is that GPR50 and its interactors are expressed at the same subcellular 
locations. In addition it is hypothesised that they show similar patterns of expression 
in the brain at similar stages of development, and may therefore be co-regulated.  
 
The immunocytochemistry data in Chapter 2 suggest expression of GPR50, Nogo-A, 
CDH8 and ABCA2 along dendrites and in synaptic spines in neurons, suggesting a 
synaptic localisation. Immunocytochemistry in immortalised cell lines indicated co-
localisation in plasma- and internal membrane fractions, such as the ER and the 
endolysosome. In order to test this further subcellular fractionation was performed 
from adult mouse brain including pre- and postsynaptic density fractions, similar to 
Clapcote et al. (2007).  
 
The developmental expression in the mouse brain was also investigated, on the 
mRNA and protein level. Several techniques for mRNA and protein detection and 
quantification are currently available. For mRNA Northern blotting and RNase 
protection assay are considered the gold standards, since no amplification is 
involved, whereas rt-PCR (reverse transcription-polymerase chain reaction) is the 
most sensitive technique available. Compared to Northern blot analysis and RNase 
protection assay, rt-PCR can be used to quantify mRNA levels from much smaller 
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samples. In fact, under certain circumstances, this technique is sensitive enough to 
enable quantitation of RNA from a single cell (Rhoades et al., 2000).  
 
Because we wanted to investigate several genes with varying levels of expression in 
many brain areas and at various timepoints we choose to perform rt-PCR for its 
sensitivity and ease. The rt-PCR experiments allowed us to address several 
questions:  
 
1. Where and when is Gpr50 expressed?  
2. Where are the interactors co-expressed?  
3. Are the genes developmentally co-regulated?  
 
In addition, the rt-PCR experiment allowed us to prioritise regions for future study 
by immunohistochemistry, which would otherwise have been too time consuming 
and costly. More details about the background and the setup of the rt-PCR 
experiment can be found under section 3.1.2.  
 
Immunohistochemistry (and in situ hybridization for mRNA) is qualitative rather 
than quantitative but is best for visualizing exact locations of protein expression 
within regions and tissues. Its greatest disadvantage is that it is impossible to show 
that the staining corresponds to the protein of interest. For this reason primary 
antibodies must be well validated by Western blot or similar procedure. The 
antibodies that are used here were validated in Chapter 2 and all antibodies and 
markers used previously in the literature are detailed in Table 2.4a-b. 
 
In this chapter mRNA levels of Gpr50, Nogo-pan, Nogo-A, Nogo-C, Cdh8, Abca2 
and Srebf2 in the developing mouse brain were determined by rt-PCR. Because good 
antibodies were not available for all of these proteins immunohistochemistry was 
only performed for Gpr50, Nogo-A, Cdh8 and Abca2. For similar reasons subcellular 
distribution in adult mouse brain was investigated for Gpr50, Nogo-A, Cdh8 and 
Abca2. 
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In this introduction to Chapter 3 the expression of GPR50 and Nogo (-A, -B, -C), 
CDH8, ABCA2 and SREBF2 as previously reported in the literature is first 
summarised. Previous findings of expression in adult, embryonic and developing 
brain are described. After this summary concepts in real-time rt-PCR are introduced 
and the setup and optimisation of the rt-PCR experiment are explained in some 
detail. 
 




The first study of adult human GPR50 reported expression in the pituitary and a 
weaker signal in the hypothalamus by Northern blot analysis and in situ hybridisation 
(Reppert et al., 1996). Rt-PCR and in situ results in sheep showed selective high 
expression in the dorsomedial hypothalamus (DMH), the pars tuberalis and –distalis 
of the anterior pituitary (adenohypophysis), the retina and the retinal pigmented 
epithelium (RPE) (Drew et al., 1998). Contrary to findings in human tissue (Reppert 
et al., 1996), expression of GPR50 was not found in the paraventricular nucleus 
(PVN) of the hypothalamus in sheep (Drew et al., 1998). Further studies in rodents 
(mice, rat, hamster) indicate the arcuate nucleus (Arc), subfornical organ (SFO), 
lateral hypothalamus (LH), anterior hypothalamus (AH), bed nucleus of the stria 
terminalis (BST), amygdala, preoptic nuclei and the olfactory bulb as regions of 
Gpr50 expression (Drew et al., 2001) by rt-PCR and in situ hybridisation. In addition 
Gpr50 was found to be expressed at high levels in ependymal cells (possibly 
tanycytes; Ivanova et al., 2008; Sidibe et al., 2010) lining the third ventricle in 
hamster (Barrett et al., 2006), mouse (Vassilatis et al., 2003) and rat (Drew et al., 
2001) by in situ hybridisation. Using β-galactosidase inserted into the GPR50 locus 
to show potential endogenous protein staining in GPR50 knockout mice, Gpr50 
mRNA and putative protein was found to be expressed in the ependymal layer of the 
third ventricle and dorsomedial nucleus of the hypothalamus in mouse (Ivanova et 
al., 2008). Immunohistochemistry data support GPR50 protein expression in the 
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mouse hippocampus and rat pituitary (Hamouda et al., 2007) and mouse, human and 
rat 3rd ventricle and hypothalamus (Sidibe et al., 2010). The results from these 
studies are supported by in situ data in the Allen Brain Atlas database of gene 
expression http://www.brain-map.org/ (Jones et al., 2009), where enhanced Gpr50 
expression is found in the hypothalamus, olfactory bulb and third ventricular wall of 
the adult mouse brain. Although the BGEM website www.stjudebgem.org 
(Magdaleno et al., 2006) shows some in situ data in developing mouse brain, 
indicating high expression in the ventral hypothalamus and brainstem at E15, 
embryonic or developmental expression of GPR50 has not been reported elsewhere.  
 
3.1.1.2 RTN4/Nogo 
Expression of Nogo isoforms -A, -B and –C has been studied by rt-PCR, microarray, 
Northern blot, in situ hybridisation and immunohistochemistry, although the majority 
of studies have focused on rodent Nogo-A (Oertle and Schwab, 2003). Nogo (Rtn4) 
is ubiquitously expressed in the adult mouse brain, as can be seen from in situ data 
on the Allen Brain atlas (http://www.brain-map.org/). High expression of Nogo-C in 
the adult has been reported in the cerebral cortex, hippocampus, spinal cord, retina 
and optic nerve (Oertle and Schwab, 2003).  
 
Using in situ hybridisation and immunohistochemistry, Mingorance-Le Meur et al. 
(2007) detected embryonic Nogo (-A) expression as early as E12.5 in the mouse 
hippocampus. At E14.5 Nogo-A staining was found throughout the entire 
rostrocaudal extent of the telencephalon, most notably in the olfactory bulb, tectum, 
cerebellum and spinal cord, with lower levels in the cortex, thalamus and 
hypothalamus. Nogo-A was also enriched in the CA1 and CA3 in the hippocampus 
at E14.5. At E18.5 Nogo-A is enriched in the white matter tracts of the corpus 
callosum, anterior commissure and fimbria-fornix (Mingorance-Le Meur et al., 
2007). 
 
In the developing brain Nogo-A is most predominantly present in spinal cord white 
matter, oligodendrocyte cell bodies, the cortex, hippocampus, habenula, cerebellum, 
optic nerve and retina (Huber et al., 2002; Oertle and Schwab, 2003). BGEM in situ 
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data indicate highest RTN4 expression at P7 in the cortex, hippocampus and 
olfactory bulb. 
  
3.1.1.3  CDH8 
The type II Cadherin Cdh8 is predominantly expressed in the mammalian brain 
(Suzuki et al., 1991; Korematsu et al., 1998b). In the adult mouse brain Cdh8 mRNA 
is highly expressed in the growth hormone (GH)- negative cells of the anterior 
pituitary (Chauvet et al., 2009). Attempts to identify the cell types that express Cdh8, 
using two previously well-characterised antibodies (Korematsu et al., 1998b; Suzuki 
et al., 2007), were unsuccessful (Chauvet et al., 2009).  
 
Cdh8 is well studied in the embryonic and developing rodent brain. Korematsu and 
Redies (1997) have detected Cdh8 in the embryonic mouse brain by in situ 
hybridisation as early as E11.5/12.5 in the regions that will form the cortex 
(prosencephalon/telencephalon), ventral thalamus (prosencephalon/diencephalon), 
lateral ganglionic eminence and the pons (rhombencephalon). In the neonatal mouse 
brain (2-10 days) Cdh8 mRNA and protein is expressed in the (cingulate) cortex, 
striatum, globus pallidus, thalamus, subthalamic nucleus, entopeduncular nucleus, 
substantia nigra, amygdala, cerebellum and barrel cortex (Korematsu and Redies, 
1997; Korematsu et al., 1998a; Korematsu et al., 1998b; Bekirov et al., 2002; Gil et 
al., 2002). Cdh8 is also highly expressed in the developing (first postnatal weeks) rat 
hippocampus (Bekirov et al., 2002; Bekirov et al., 2008). In the first postnatal weeks 
Cdh8 mRNA is expressed at high levels in the mouse entorhinal cortex (layer II), 
amygdala and in the hippocampal CA1, the distal part of CA3 and the dentate gyrus 
from birth (Bekirov et al., 2002). Korematsu and others (1998) however did not 
detect any expression in the hippocampus of neonatal mouse brain. In situ data show 
strong Cdh8 expression in the cortex and weaker expression in parts of the olfactory 
bulb in P7 mouse brain (Akins et al., 2007). Cdh8 was also detected in the amygdala 
during development (Medina et al., 2004). 
 
Characteristic of Cdh8 (and other cadherins) is a restricted, patterned, layered or 
regional expression within certain brain areas suggesting cadherins play a role in 
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subdivisional organisation of the developing brain (Korematsu and Redies, 1997; 
Suzuki et al., 1997; Korematsu et al., 1998a; Korematsu et al., 1998b; Bekirov et al., 
2002; Gil et al., 2002; Neudert et al., 2008). In the first weeks postnatally Cdh8 is 
expressed in a decreasing dorsal to ventral gradient in the subiculum (Bekirov et al., 
2002). Cdh8 expression may identify and contribute to functional neural circuits 
involving the development of the basal ganglia-thalamocortical (Alexander and 
Crutcher, 1990; Korematsu et al., 1998b) or the fasciculus retroflexus/habenulo-
interpeduncular tract (Marchand et al., 1980). Cdh8 protein is also expressed in a 
patch-like distribution in the neonatal (P0 to P7) rat striatal matrix (Korematsu et al., 
1998a), which has connections to cortical sensorimotor areas (Gerfen, 1984; 
Donoghue and Herkenham, 1986; Gerfen, 1992; Korematsu et al., 1998a). The 
BGEM database of in situ data indicates high expression at P7 in the cortex, basal 
ganglia, thalamus, hippocampus and amygdala. 
 
Several cadherins have been found at the synapse during and after synaptogenesis 
(Fannon and Colman 1996; Uchida et al. 1996; Bozdagi et al. 2000; Togashi et al. 
2002). A role for cadherins in dendritic sprouting and synaptic plasticity has been 
proposed (for a review, see Takeichi 2007). 
 
3.1.1.4 ABCA2 
ABCA2 is highly expressed in the mammalian brain (Luciani et al., 1994; Kikuno et 
al., 1999; Zhao et al., 2000; Vulevic et al., 2001; Warren et al., 2009), most notably 
by neural progenitors in the subventricular zone of the lateral ventricle and the 
dentate gyrus, regions important in adult neurogenesis (Broccardo et al., 2006). 
Abca2 expression was also found predominantly in white matter tracts and to a lesser 
extent in olfactory bulb and cerebellum in adult rat brain (Zhao et al., 2000). It is 
expressed by oligodendrocytes and by a subset of GABAergic and glutamatergic 
neurons (Broccardo et al., 2006). Nothing has been reported about its developmental 
expression pattern. The BGEM database suggest low of no expression around E15 
but high(er) expression in the hippocampus, cerebellum and brainstem at P7. 
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3.1.1.5 Srebp2/SREBF2 
Srebp2 was found to be highly expressed in the hippocampus and to a lesser extent in 
the cortex, striatum, thalamus, hypothalamus brainstem and cerebellum of the adult 
rat brain (Kim and Ong, 2009). In the adult mouse brain Srebf2 mRNA expression is 
found in the cortex, olfactory bulb and hippocampal formation (Allen Brain Atlas, 
http://www.brain-map.org/). Neither embryonic nor developmental expression of 
SREBF2 has been reported in the literature.  
 
3.1.2 Introduction to the real-time rt-PCR experiment 
 
Below some concepts in real-time PCR and the materials used in this chapter are 
described. 
 
3.1.2.1 Origene TissueScan rt-PCR mouse developmental panel  
Although the developmental expression profile of Cdh8 has been extensively 
researched (see 4.1.2.3) not much is known about the developmental expression of 
Gpr50 or the other Y2H interactors. Therefore, mRNA expression of Gpr50, Nogo-
pan, Nogo-A, Nogo-C, Cdh8, Abca2 and Srebf2 was investigated in the developing 
mouse brain. TissueScan Real-Time mouse developmental cDNA panels from 
different brain regions at E13, E15, E18, P7 and week 5 (total 48 samples, Origene) 
were obtained. Using this panel had several advantages: In this way it is possible to 
assess the gene profiles at many timepoints and regions, which would be technically 
difficult and time consuming when done in-house. Because the panel is made up of 
pooled RNAs it is possible to compare expression levels between genes on exactly 
the same sample. Additionally it is possible to assess correlations between genes, 
within regions and across timepoints. Similar use of the Origene TissueScan panels 
has been reported in the literature (De Luca et al., 2004; Gutierrez et al., 2008). More 
information on how the panels were produced can be found in under Materials and 
Methods (this chapter). 
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3.1.2.2 Introduction to real-time rt-PCR  
Real-time quantitative PCR (qPCR) is characterised by the cycle number at which 
the amplified PCR product is first detected above a set threshold, rather than the 
amount of PCR product accumulated after a fixed number of cycles (with end-point 
quantitative PCR). In real time PCR the threshold is set at a point where DNA 
amplification is in the exponential phase. The greater the starting quantity of the 
target molecule, the earlier a significant increase in fluorescence is detected. This is 
measured by the threshold cycle parameter Ct (Fig 3.1). Ct is considered a more 
reliable measure of the starting copy number than end-point measurements, as a 
slight difference in a limiting component can have a large effect on the amount of 
product (Bieche et al., 1998). In addition the advantages of real-time PCR are the 
wide dynamic range, automated sample handling and short run time (Celi et al., 
1994) in (Bieche et al., 1998). Disadvantages of the real-time method are the need 
for specific primer design and optimisation. Reactions need to be performed in a 
thermal cycler (96 wells) and reagents can be costly.  
 
 
Figure 3.1 Real time PCR trace graph for a single well on a 96-well plate. Cycle 
number is shown along the X-axis and arbitrary fluorescence units (these are fold 
increase over background fluorescence) are shown on the Y-axis. Quantitation of 
the amount of cDNA is done when the amplification is exponential, which is at the 
very beginning of the upturn of the curve. The orange horizontal line in the figure 
marks the threshold or Ct. More dilute samples will cross at later Ct values. In this 
example Ct=27.58.   
Ct 
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3.1.2.3 SYBR Green rt-PCR chemistry 
SYBR Green reagent was chosen for quantifying mRNA using the Biorad thermal 
cycler (iCycler). SYBR Green provides the simplest and most economical format for 
detecting and quantifying PCR products in real-time reactions. SYBR Green binds 
double-stranded DNA, and upon excitation emits light. Thus, as a PCR product 
accumulates, fluorescence increases (see Fig 3.2A). The advantages of SYBR Green 
are that it is reasonably inexpensive, easy to use, and sensitive. The disadvantage is 
that SYBR Green will bind to any double-stranded DNA in the reaction, including 
primer-dimers and other non-specific reaction products, which results in an 
overestimation of the target concentration. Fluorescence may also vary with 
amplicon size. Despite this, for single PCR product reactions with well-designed 
primers, SYBR Green can work extremely well, with spurious non-specific 


















Figure 3.2 Real-time PCR graphs (A) Example Real-Time PCR trace graph for a 
series of 10-Fold dilutions of a sample of DNA. The graphs should be equally apart 
at the threshold level (ideally 3.3 cycles). 
 
 





Figure 3.2 Real-time PCR graphs (B) Example Melt Curve. Three replicates are 
shown. With the SYBR green method, primer dimer artifacts may be a problem 
since you are measuring total DNA synthesis and you need to be sure that you are 
measuring a Ct due to the real target for amplification. In this graph there is only one 
clear peak for each replicate, with no smaller ones at lower temperatures, indicating 






Figure 3.2 Real-time PCR graphs (C) Example Standard Curve The Ct values for 
the dilutions are plotted against concentration, resulting in a linear graph. Ideally its 
correlation coefficient is 0.990 or more, with a slope of -3.3 and an efficiency of 
approximately 100%. 
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All antibodies and markers used in this chapter are described in Table 2.4a-b 
Rabbit polyclonal antiserum CDH8 E61 was raised against sequence derived C-
terminal peptide residues 785-799 of human CDH8. Final bleeds from immunized 
rabbits were affinity-purified against both peptides by Eurogentec (Double XP 
program), and these purified anti sera were used in all experiments. Additionally we 
used GPR50 (G-15, goat polyclonal, Santa Cruz), Nogo-A (H-300, rabbit polyclonal, 
Santa Cruz), ABCA2 (Rabbit polyclonal, (Vulevic et al., 2001)), PSD-95 (mouse 
monoclonal, ABR), Synaptophysin (mouse monoclonal, Sigma), α-tubulin (rabbit 
polyclonal, Abcam), NeuN (mouse monoclonal, Abcam), 5-HT (rabbit polyclonal, 
ImmunoStar), GFAP (mouse monoclonal, Sigma), O4 (mouse monoclonal, R&D 
systems), Vimentin (Mouse monoclonal, Abcam), Tyrosine Hydroxylase (mouse 
monoclonal, Abcam) and Dopamine Beta-Hydroxylase (mouse monoclonal, Abcam).  
 
3.2.2 Subcellular Fractionation 
 
Ten 7-10 week old female C57BL/6 mice were purchased from Harlan (UK). Mice 
were sacrificed by cervical dislocation (schedule 1 procedure was performed by the 
animal facility staff) and brains were processed for subcellular fractionation and 
purification of synaptic fractions as described previously (Bradshaw et al., 2008; 
Clapcote et al., 2007; Grünewald et al., 2009). The fractions were analyzed by 
immunoblotting as described in Chapter 2 (section 2.2.14) with anti Nogo-A (H-300, 
1:2000), anti-CDH8 E61 (1:3000), anti-ABCA2 (1:1000), anti-GPR50 (G-15, 
1:1000), anti-PSD-95 (1:2000), anti-synaptophysin (1:10,000) and anti-α-tubulin 
(1:20,000). Rabbit anti-mouse (1:2000), rabbit anti-goat (1:5000) and swine anti-
rabbit (1:3000) horseradish peroxidase conjugated secondary antibodies (DAKO) 
were used and membranes were treated described in Chapter 2 (2.2.14). This 
experiment was performed in triplicate, using three independent samples (30 mice 
total). 
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3.2.3 Real-time Reverse Transcription-Polymerase Chain 
Reaction (rt-PCR) 
 
TissueScan Real-Time mouse developmental cDNA panels from different brain 
regions at E13, E15, E18, P7 and week 5 (total 48 samples) were purchased from 
Origene Technologies Inc. (Lot no.11/06, Rockville, MD). These first strand cDNAs 
were synthesized from poly-A+ RNA using oligo(dT) primers, and were normalized 
to β-actin. The cDNAs were dried into the wells of the panel and were supplied 
frozen.  
Real-time PCR using SYBR Green Supermix (100mM KCl; 40mM Tris-HCl, pH 
8.4; 0.4M of each dNTP; iTaq, DNA polymerase, 50 units/ml; 6mM MgCl2; SYBR 
Green I; 20nM fluoresein, and stabilizers; Bio-Rad Inc., Hercules, CA) was 
performed on the BioRad iCycler. Primers (Table 3.1) were selected using Primer3 
software (http://primer3.sourceforge.net/), except for β-actin, which came supplied 
with the panel. The linear range of each primer pair was determined by producing 
standard curves in the Biorad iCycler, using mouse brain cDNA as template. 
Reactions were performed in duplicate. Amplification was achieved in 35 cycles of 
the following conditions: denaturation at 95°C for 30s; annealing at 60-65°C for 30s; 
and extension at 72°C for 30s. A melting curve was obtained starting at 55°C with 
10s increments of 0.5°C for 80 cycles. Each PCR reaction generated a single 
amplicon as indicated by the melting temperature profiles. All PCR products were 
also checked by gel electrophoresis to confirm correct PCR product size against a 
1kb ladder.  
 
For analysis the fluorescence threshold value Ct (the number of cycles required for 
the fluorescent signal to cross the threshold (ie exceeds background level) of each 
sample was calculated using the iCycler MyiQ system software. 
 
The relative expression of the genes was determined using the deltaCt method, which 
generates raw (not normalized) data, relative to the sample with the highest 
expression. The data are further normalized using a method described by 
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Vandesompele et al. (2002), which is equivalent to using the delta-delta Ct method 
(see 4.2.4 below). It can be performed using the freely available geNorm software: 
(http://medgen.ugent.be/~jvdesomp/genorm/). Normalized expression data were 
obtained by dividing the raw gene-of-interest quantities for each sample by the 
normalization factors, which are the geometric means of the reference genes used in 
this study: ß-actin, Tbp, Hmbs and Cyclophilin B. Spearman correlations (r, (95% 
conficence interval), significance at p≤0.05) were performed using Graphpad Prism. 
 
3.2.4 Normalisation of expression data 
 
The relative expression of the 7 genes was determined using the delta Ct method, 
which generates raw (not normalized) data, relative to the sample (region) with the 
highest expression (lowest Ct value). The data are then further normalized using a 
method described by Vandesompele et al. (2002), which is equivalent to the more 
standard delta-delta Ct method but has the added advantage that it (1) takes the 
difference in amplification efficiency between target and reference gene(s) into 
account (for delta-delta Ct they should be equal), (2) allows easy inclusion of 
multiple reference genes, and (3) is easier to calculate in Excel 
(http://medgen.ugent.be/~jvdesomp/genorm/). 
  
The normalisation of the expression data from the 7 genes of interest (GOI) was 
performed as follows (Vandesompele et al., 2002):  First the Ct values from each 
gene of interest (GOI) were transformed into quantities, using the deltaCt formula, 
with the sample of the highest expression per gene set to 1: 
 
Q = E deltaCt  
Q = E (minCt - sampleCt)   
 
Q = sample quantity relative to sample with highest expression 
E = amplification efficiency (2 = 100%; 1.90 = 90%, 2.10 = 110%) 
minCt = lowest Ct value = Ct value of sample with highest expression 
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Next, the normalization factor (NF) was calculated by analyzing the geometric mean 
of the (selected) four reference genes (relative quantities).  
 
NFn =  
n√REF1 . REF2 …. REFn 
 
Geometric mean was calculated in Microsoft Excel, using the GEOMEAN(a, b, c, d) 
function, where a, b, c and d are the relative quantities of the reference genes. 
Finally, the normalized expression data were obtained by dividing the raw GOI 
quantities for each sample by the normalization factors (Vandesompele et al., 2002). 
 
3.2.5  Immunohistochemistry 
 
Female CD1 mice of approximately 10 weeks old were housed in groups of between 
5-14 animals, depending on cage size. Females were taken to the male cage and left 
until a vaginal plug was found. The female was then housed with other females that 
were plugged on the same date. The date of the plug was E0. Mice were kept on a 
12-hour light/dark cycle with lights on at 7.00h. Mice were fed on SDS RM1 
expanded diet with water available ad libitem. Adult animals were killed by cervical 
dislocation. All the above procedures in 3.2.5 were performed by the animal facility 
staff.  
 
Embryos were removed by hysterectomy and brains were directly transferred to ice 
cold PBS prior to fixation. Three adult female mice and three embryonic day 18 mice 
were used in this study. Brains were fixed in either 70% EtOH, 4% formaldehyde or 
methacarn (60%MeOH, 30% chloroform, 10% glacial acetic acid). E18 brains were 
fixed for 4 hours and adult brains for 16-18 hours. Brains were then transferred to 
70% EtOH and stored at -20ºC until further processing. 
 
Brains were embedded in paraffin wax and cut into 6µm sections on a Leica 
microtome onto gelatin coated superfrost plus slides (Thermo Fisher). Six coronal 
sections per animal from three individual 8-12 week old CD1 female and E18 mouse 
brains were processed for immunofluorescent detection of Gpr50 and interactors. 
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Intact coronal sections corresponding to approximately Bregma –0.655 mm, -1.455 
mm, -2.88 mm, -3.58 mm, -4.655 mm and -5.555 mm were chosen from each animal 
to cover all brain regions evaluated (see Chapter 8 Supplementary information, 
supplementary images 1-6, from Allen Brain Atlas: http://www.brain-map.org/). 
Sections were dried at 37ºC overnight.  
 
Sections were dewaxed in xylene and rehydrated in 100% and 70% EtOH. Before 
staining formalin-fixed sections were incubated in picric acid for 20 min and antigen 
retrieval was performed by microwave boiling slides in 50mM borate buffer pH8.0 
for 15 min (Yamashita, 2007). For DAB staining sections were incubated in 3% 
H2O2 (Sigma) for 10 min to quench endogenous peroxidases, followed by three 
washes with PBS. With all fixation methods sections were loaded into Shandon 
Sequenza slide racks. Tissues were permeabilised in 0.1% triton X-100 (Sigma) in 
PBS for 30 min, washed twice in PBS/0.02%BSA and incubated in 6M guanidine 
hydrochloride to denature the proteins (Peranen et al., 1993). After washing the 
slides 3x with PBS/BSA sections were incubated in 10% serum from secondary 
antibody host in PBS/BSA for 30 min. Slides were incubated with the following 
primary antibodies in PBS for 16-18h: GPR50 (1:50), Nogo-A (1:100), CDH8 E61 
(1:100), ABCA2 (1:500), 5-HT (1:250), Vimentin (1:250), NeuN (1:1000), GFAP 
(1:500), O4 (1:500), Dopamine Beta-Hydroxylase (DBH, 1:250), Tyrosine 
Hydroxylase (TH, 1:250). Slides were washed 3x with PBS/BSA before and after 
incubation with secondary antibodies.  
 
For chromogenic detection of proteins biotinylated rabbit anti-goat (DAKO) was 
used at 1:500 for 30 min followed by ABC elite (Vector labs) for 30 min. Slides 
were removed from the sequenza and proteins were visualised by incubation with 
DAB (Vector labs). After counterstaining in Harris haematoxilin and lithium 
carbonate, slides were dehydrated in 70% and 100% EtOH and xylene. Coverslips 
were then mounted onto slides using pertex. For fluorescent detection slides were 
incubated for 1 hour with donkey anti-sheep (1:500, Alexafluor 488, Invitrogen) and 
donkey anti-rabbit (1:500, Alexafluor 594) of donkey anti-mouse (1:500, 594) in 
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PBS/BSA. Coverslips were mounted onto slides using Vectashield w/DAPI (Vector 
labs). 
 
3.2.6 Imaging and semi-quantitative evaluation of regional 
expression  
 
Confocal images of neurons were captured sequentially (line) on an Olympus 
Fluoview 1000 confocal laser-scanning microscope (UPlanSApo 10, 20 or 40x 
objective) at image size 1024x1024 using Kalman filter mode 3. Brightfield images 
were taken on an Olympus BX light microscope fitted with 4x, 10x, 20x and 40x 
objectives. Secondary antibody controls were performed by leaving out the primary 
antibody. Sections were compared to the adult coronal reference atlas of the Allen 
Brain Atlas: http://mouse.brain-map.org (Lein et al., 2007) (see supplementary 
images 1-6 from Allen Brain Atlas). For the visual evaluation of relative expression 
levels, each brain region was evaluated for DAB and fluorescence staining intensity 
based on the following scale: x, not investigated; −, no expression present; +, weak 
expression; ++, moderate expression; +++, strong expression.  




3.3.1 Subcellular fractionation of adult mouse brain 
 
The colocalisation studies in primary cortical neurons (Chapter 2) suggest GPR50 
and interaction partners are expressed at synaptic sites, while immunocytochemistry 
in HEK293 and SH-SY5Y cells indicated co-localisation in the plasma membrane, 
ER and endolysosome. To further investigate this and to identify the subcellular 
location of Gpr50 expression, subcellular fractionation of whole adult mouse brain 
including postsynaptic density (PSD) fractions 1-3 (Carlin et al., 1980; Cho et al., 
1992; Niethammer et al., 2000; Clapcote et al., 2007) was performed (Figure 3.5A). 
The postsynaptic density is a cytoskeleton specialization at synapses. PSDs are 
usually composed of neurotransmitter receptors, molecular scaffolding molecules, 
cell adhesion molecules and a diverse set of other signalling proteins. The PSD is 
commonly studied in relation to molecular mechanisms of learning and memory, 
which are believed to take place at the synapse. In this experiment three different 
PSD fractions were extracted. The more detergent resistant/insoluble the fractions 
are (Two-Triton (PSD2)) and especially One-Triton plus Sarcosyl (PSD3)), the 
closer they are to the core of the PSD.  
 
Western blotting of fractions (Fig 3.5B) shows that Gpr50, Nogo-A, Cdh8 and 
Abca2 are present in the homogenate, crude synaptosome (P2), light membrane (P3, 
includes ER, golgi, endolysosome) (Fig3.5B) fractions, and in the ER/Golgi-fraction 
of the crude synaptosome (ER/Golgi, Fig 3.5B), although Gpr50 is expressed at low 
levels in these fractions. GPR50 does not appear to be expressed in myelin, as is 
known for Nogo-A (Chen et al., 2000), suggesting it is not expressed by 
oligodendrocytes (Fig 3.5B). 
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Figure 3.3 GPR50 and interactors are enriched at the synapse after subcellular 
fractionation. (A) Subcellular fractionation protocol. Ten adult female mouse brains 
were homogenized and the homogenate (H) was subjected to multiple centrifugation 
steps, resulting in: the crude synaptosome (P2); light membranes (P3); myelin; ER-
Golgi; synaptosome; synaptosomal membrane (LP1); (LS1) which consists of 
synaptosomal cytosol (LS2) and synaptic vesicle enriched fraction (LP2); and the 
three postsynaptic density fractions, PSD1 (One -Triton), PSD2 (Two-Triton), PSD3 
(One-Triton + Sarcosyl). Western blotting of subcellular fractions shows enrichment 
of Gpr50, Nogo-A and Cdh8 in some or all of the post-synaptic density fractions, 
mainly the Two-triton fraction. Nogo-A and Cdh8 are also enriched pre-synaptically 
in the presynaptic membranes (LP1) and presynaptic vesicles (LP2). Controls were 
PSD-95, which is known to be enriched in the postsynaptic density, and 
Synaptophysin, which is enriched presynaptically. A-tubulin was used as a loading 
control. Figure published in part in Grünewald et al., 2009. Molecular and Cellular 
Neuroscience. Copyright Elsevier 2009. 
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Interestingly Gpr50 is enriched in all of the PSD fractions, as indicated by the 
presence of postsynaptic density marker PSD-95 (Fig 3.5B) (Grünewald et al., 2009). 
Neuronal Nogo-A is ubiquitously expressed in almost all the fractions, including the 
PSD and the synaptosomal membrane (LP1) and the synaptic vesicles enriched 
(LP2) fractions (Fig 3.5) (Grünewald et al., 2009), as indicated by presynaptic 
marker synaptophysin. Neuronal Nogo-A has previously been reported to be present 
both pre- and postsynaptically in the developing or adult rat hippocampus (Lee et al., 
2008; Grünewald et al., 2009). Cdh8 was also found to be enriched in the presynaptic 
membrane fraction and in the postsynaptic density fractions (Fig 3.5), in line with its 
previously detected localisation at synaptic junctions and suggested role in cell-cell 
adhesion at synaptic contacts (Suzuki et al., 2007), Although Abca2 was detected at 
low levels in the crude synaptosome, the Abca2 antibody appeared not sensitive 
enough to detect expression in the individual pre- and postsynaptic density fractions 
or it was not enriched in these fractions (Fig 3.5).  
 
In addition to confirming a light membrane localisation for Gpr50, Nogo-A, Cdh8 
and Abca2, this study identifies the synapse as a likely location for the interaction of 
these proteins. 
 
3.3.2 Developmental expression of Gpr50 and interactors by rt-
PCR  
3.3.2.1 Primer design and optimisation 
The primers used in this study (Table 3.1) were selected using Primer3 software 
version 0.4.0 (http://primer3.sourceforge.net/), except for reference gene β-actin, 
which came supplied with the cDNA panel (Origene). Among the selection criteria 
were: size between 100-200 bp, spanning an intron, balanced melting temperature 
(approx. 60ºC) and similar G-C content (between 20-80%). The primers used in this 
study and the parameters are shown in Table 3.1. To assess the quality of the primers 
several curves were generated in the Biorad iCycler, using mouse brain cDNA as 
template, after 35 cycles. 10-fold dilution ranges of template were used to determine 
the linear range of the primers. Samples that differ by a factor of 2 in the original 
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concentration of cDNA would be expected to be 1 cycle apart. Therefore each 10-
fold dilution should result in a threshold cycle increase of 3.3 (see Fig 3.2A). After 
the real-time PCR amplification a melt curve is generated by raising the temperature 
a fraction of a degree and measuring the change in fluorescence (Fig 3.2B). At the 
melting point, the two strands of DNA will separate and the fluorescence rapidly 
decreases. Primer-dimer artifacts are a problem when measuring total DNA synthesis 
and one needs to be sure that a Ct is measured due to the real target for amplification. 
To reduce primer-dimer artifacts Tm and primer concentrations were varied during 
optimisation. In addition, the linear range and PCR efficiency (90-110%) of each 
primer pair was determined by producing standard curves (Fig 3.2 C), of three 
replicates.  
 
After optimization of the primers each PCR reaction generated a single amplicon 
(clear peak) as shown by the melting temperature profiles, and a good linear range, 
and correlation coefficient as shown by the standard curves generated by the iCycler 
(Table 3.1). As is expected from the literature there was quite some variability in 
abundance levels (Ct values) between genes (Table 3.2). The average delta-Ct value 
(35-Ct, ± SE) varied from 4.642 (± 0.270, Gpr50, lowest) to 12.403 (± 0.274, Nogo-
pan, highest). 
 
3.3.2.2 Selection of housekeeping genes 
Although housekeeping gene β-actin was provided with the panel it is recommended 
to use more then one reference gene for normalisation (Vandesompele et al., 2002). 
Ideally a reference/housekeeping gene with a similar abundance level for accurate 
normalization is used. Therefore we choose several reference genes with varying 
abundance levels. Ideally these genes are also from different functional classes 
(Vandesompele et al., 2002). The number of reference genes necessary is dependent 
on how stable the reference genes are expressed in a specific sample, but there is a 
trade off between accuracy and practicality, as the number of target genes tested and 
the amount of cDNA available are also important. Vandesompele et al. (2002) 
recommend the minimal use of 3 reference genes and it was therefore decided to test 
a total of 4 reference genes, Beta-actin (provided with Origene panel), TATA-binding 
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protein (Tbp), hydroxymethylbilane synthase (Hmbs) and Cyclophilin (see Table 
3.3), for stability. These genes were selected because their variation in abundance 
levels and function. β-actin is a high expressor with an average delta-Ct (35-Ct) 
value of 17.57 (±0.28), Cyclophilin has an average delta-Ct of 12.34 (±0.23), 
whereas Hmbs and Tbp expressed at lower levels, ∆Ct = 8.49 (±0.29) and 8.12 
(±0.41) respectively (Fig 3.3; Vandesompele et al., 2002). 
 
We used geNorm, a freely available collection of VBA macros for Microsoft Excel 
to determine the most stable reference (housekeeping) genes 
(http://medgen.ugent.be/~jvdesomp/genorm/) from our set of 4. The most stable 
reference genes were determined by comparing the gene-stability measure (M) of 
these genes. The pairwise variation (V) between multiple reference genes determines 
how many genes should be included as a reference gene (for equations and 
calculations see Vandesompele et al. (2002)). 
 
In our set Hmbs and Cyclophilin are the most stable and Tbp the least stable 
reference gene (Fig 3.4A). The authors suggest a cut-off value of V=0.15 between a 
selection of reference genes, if V>0.15 an extra reference gene should be included, 
provided it lowers the variation. After calculation of M and V using the geNorm 
applet, the pairwise variation of 2/3 strongest genes is 0.246 and when including Tbp 
V3/4= 0.2, which suggests all 4 are required for accurate normalization (See Fig 
3.4B). Ideally more reference genes should be added, however we decided that 4 
reference genes was sufficient, as we are only testing 7 different genes and the 
cDNA panels were costly. This is in line with the recommendations of 
Vandesompele et al. (2002).
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Gpr50 TGGCTGTGACCAAGAACAAG GTGACCAACCCGACCATC 172/2694 bp 50-61 63 0.982 3.625 1.20 
Nogo-pan TTGGCCCTGCTCTCTGTG CCAATTCCTCTGATATGGCAAC 130/2649bp 45-61 63 0.992 12.403 0.68 
Nogo-A GGCTCGGGCTCAGTGG CAGGACAGATGGGAAATCCTC 147/12806 bp 52-75 60 0.989 11.781 0.76 
Nogo-C GGCAAGAAATGGACGATCAG AAGCTGGCACCAAACACC 103/14,853 bp 50-56 63 0.989 6.772 2.87 
Cdh8 TGAGCCGCTCCAAAAGAG TTGTGCCAGCTCCATCAC 156/121,178bp 56 63 0.989 9.153 0.97 
Abca2 TTCATCCCGCTTGTCCTC ATCAGGGCAAAGCGACTG 141/1148 bp 56 63 0.99 6.293 1.81 
Srebf2 AGCCCGTCACCATCCAG GGTCAACACAAGGGAATCTGTC 185/1654 bp 50-65 63 0.987 8.318 1.16 
Control genes         
Actin-B GATCTGGCACCACACCTTCTAC TGGATGGCTACGTACATGGCTG 159/613bp  55 1.000 17.458 0.75 
Tbp GCCAGACCCCACAACTC ACAGCCAAGATTCACGGTAG 182/2877 bp 50-64 60 0.991 8.115 1.01 
Hmbs CTGAAGGATGTGCCTACCATAC AAGGTTTCCAGGGTCTTTCC 122/1084 bp 50 63 0.999 8.491 0.74 
Cyclophilin GGAGATGGCACAGGAGGAAA CCCGTAGTGCTTCAGCTTGAA 75 bp/- 55-52 65 0.998 12.341 0.76 
 
Table 3.1 Primers and parameters used in this study. Shown are primer name, sequence of forward and reverse primer,  
cDNA/genomic DNA size (bp), GC%, Tmelt, calculated correlation coefficient from optimized primers, Average Ct value and 
STD error. 
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Region Gpr50 STD E 
Nogo-
pan STD E NogoA STD E NogoC STD E Cdh8 STD E Abca2 STD E Srebf2 STD E 
E13                             
Prosencephalon 3.933 0.252 11.185 0.245 10.58 0.015 3.395 0.795 7.585 0.355             
0 
            
0 
5.055 0.745 
Mesencephalon  4.770 0.124 11.755 0.005 11.49 0.135 5.105 0.995 8.69 0.01 6.08 0.015 8.55 0.02 
Rhombencephalon  4.118 0.255 12.135 0.445 11.583 0.24 5.955 0.125 7.82 0.17 2.86 0.19 7.735 1.055 
Spinal Cord 3.590 0.077 12.225 0.185 11.657 0.35 4.765 0.335 8.24 0.03 4.5 0.01 9.06 0.97 
E15                           
Telencephalon 2.553 0.316 11.695 0.375 11.217 0.28 4.22 0.37 8.91 0.56 3.125 0.245 7.66 0.59 
Diencephalon 7.280 0.141 14.67 0.12 14.143 0.08 6.305 0.295 11.665 0.355 6.285 0.075 10.41 0.3 
Midbrain 3.550 0.171 12.23 0.22 11.9867 0.11 4.52 0.46 10.455 0.515 5.33 0.23 7.75 0.74 
Pons 5.680 0.190 12.575 0.505 12.737 0.03 4.49 0.31 9.995 0.355 5.245 1.245 7.695 0.185 
Medulla 3.810 0.246 12.71 0.08 12.953 0.03 4.885 0.435 9.23 0.4 4.96 0.13 8.97 0.3 
Spinal Cord 4.228 0.472 12.7 0.28 12.616 0.005 3.695 0.355 9.73 0.5 4.825 1.145 7.335 1.805 
E18                           
Frontal Cortex 4.937 0.786 12.82 0.2 12.38 0.13 2.89 0.28 9.075 0.495 4.61 1.32 7.755 0.875 
Posterior Cortex 4.178 0.234 13.035 0.095 12.273 0.135             
0 
            
0 
9.285 0.165 6.85 0.41 8.56 1.06 
Entorhinal Cortex 2.440 0.296 12.36 0.12 11.87 0.075 2.14 0.5 8.815 0.065 4.275 0.175 6.445 0.255 
Olfactory Bulb 3.435 0.370 12.135 0.055 11.326 0.15 3.365 0.475 8.97 0.85 3.64 0.4 7.3 0.15 
Hippocampus 2.697 0.206 12.125 0.045 11.693 0.185 2.665 0.405 8.44 0.02 4.025 0.055 8.425 0.175 
Striatum 4.143 0.131 13.08 0.39 11.43 0.04 2.655 0.565 9.645 0.075 4.855 0.535 7.895 0.335 
Thalamus 6.615 0.362 12.935 0.105 12.613 0.02 4.245 0.105 10.36 0.04 6.22 0.45 7.68 0.49 
Hypothalamus 7.893 0.275 13.175 0.105 12.36 0.185 4.535 0.965 9.87 0.25 7.06 0.22 8.56 1.03 
Midbrain 5.780 0.212 12.155 0.035 11.966 0.03 3.355 0.635 10.365 0.405 5.935 0.145 8.035 0.075 
Pons 4.563 0.408 11.76 0.31 11.167 0.04 3.3 1.6 9.815 0.145 5.215 0.935 6.685 1.095 
Medulla 5.173 0.225 12.65 0.38 12.34 0.065 4.425 0.565 9.97 0.54 6.575 0.235 7.84 0.56 
Spinal Cord 5.613 0.236 12.79 0.37 11.477 0.025 4.845 0.425 10.38 0.03 6.85             
0 
9.75 0.8 
P7                             
Frontal Cortex 4.048 0.341 12.795 0.215 12.607 0.04 8.01 0.07 10.62 0.05 6.92 0.49 9.22 0.37 
Posterior Cortex 4.843 0.397 13.095 0.115 12.557 0.155 8.255 0.285 9.755 0.255 7.02 0.56 9.655 0.355 
Entorhinal Cortex 1.740 0.301 11.055 0.385 10.777 0.66 6.15 0.23 8.69 0.27 4.365 0.195 7.82 0.22 
Olfactory Bulb 4.760 0.309 12.145 0.015 11.857 0.17 7.73 0.25 8.445 0.135 6.255 0.025 8.035 0.105 
Hippocampus 2.723 0.148 11.305 0.205 11.337 0.035 6.285 0.175 8.625 0.265 4.785 0.115 7.57 0.06 
Striatum 4.268 0.149 12.32 0.05 11.723 0.04 9.42 0.14 9.935 0.035 5.72 0.19 7.545 0.175 
Thalamus 4.708 0.498 12.29 0.25 11.787 0.31 7.275 0.065 9.435 0.205 6.735 0.185 7.855 0.335 
Hypothalamus 6.665 0.227 12.84 0.03 12.31 0.045 8.53 0.34 9.44 0.43 5.275 0.425 8.765 0.365 
Cerebellum 3.973 0.097 11.35 0.98 11.017 0.34 8.29 0.62 8.655 0.465 6.215 0.165 8.56 0.66 
Midbrain 4.760 0.283 12.13 0.08 11.32 0.52 7.25 0.1 9.37 0.36 4.59 0.37 7.85 0.36 
Pons 6.313 0.263 11.92 0.2 11.323 0.02 7.005 0.395 9.085 0.045 6.72 0.31 8.24 0.28 
Medulla 4.175 0.241 11.965 0.455 11.756 0.33 7.545 0.385 8.655 0.005 6.63 0.28 11.435 3.865 
Spinal Cord 5.500 0.159 12.54 0.23 11.853 0.31 5.27 0.27 8.255 0.145 6.055 0.355 8.695 0.095 




                         
Frontal Cortex 4.555 0.142 13.31 0.53 11.177 0.44 12.19 0.11 8.56 0.03 8.61 0.46 9.175 0.385 
Posterior Cortex 1.885 0.215 11.01 0.42 10.433 0.54 10.435 0.185 6.59 0.59 4.655 0.405 7.14 0.04 
Entorhinal Cortex 5.917 0.539 12.235 1.055 10.52 0.435 10.45 0.24 8.7 0.64 7.575 0.575 7.92 0.78 
Olfactory Bulb 5.950 0.398 11.315 0.445 10.98 0.28 10.875 0.015 6.845 0.125 6.755 0.365 8.135 0.045 
Hippocampus 5.623 0.198 13.185 0.595 11.74 0.38 10.72 0.08 9.64 0.51 10.28 0.89 8.775 0.235 
Striatum 3.998 0.280 13.01 0.15 10.703 0.335 11.68 0.12 9.04 0.21 10.11 0.27 8.885 0.085 
Thalamus 5.913 0.258 12.515 0.235 11.5 0.215 9.45 0.35 9.305 0.345 7.68 0.16 8.865 0.205 
Hypothalamus 6.085 0.302 12.29 0.47 11.366 0.38 11.015 0.665 9.825 0.665 8.52 0.78 8.175 0.835 
Cerebellum 3.450 0.294 13.125 0.385 11.193 1.11 10.45 0.96 10.165 0.365 9.185 0.445 7.92 0.8 
Midbrain 4.795 0.253 12.715 0.085 11.243 0.17 10.125 0.195 8.715 0.015 9.105 0.475 8.28 0.23 
Pons 5.660 0.148 12.67 0.31 13.057 0.27 9.705 0.325 8.78 0.02 8.8 0.44 12.23 2.61 
Medulla 5.358 0.194 12.515 0.125 12.95 0.085 9.36 0.01 9.355 0.015 9.725 0.605 9.17 0.21 
Spinal Cord 4.200 0.149 12.81 0.48 12.533 0.37 9.09 0.74 7.555 0.495 8.145 0.195 8.2 0.3 
Average 4.642 0.270 12.403 0.274 11.781 0.215 6.773 0.390 9.153 0.271 6.293 0.389 8.318 0.575 
 
Table 3.2 Non-normalised delta Ct values (35-Ct, plus Standard Error) of Gpr50, Nogo-pan, Nogo-A, Nogo-C, Cdh8, Abca2 and 
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Table 3.3 Reference genes used in this study.   
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 Figure 3.4 Expression of the four control genes used in this study: Tbp, Cyclophilin, 
β-Actin and Hmbs. Graph 1 shows results from real time quantitative rt-PCR on 
Origene mouse developmental panel with 48 regional brain samples from 5 
developmental stages: E13, E15, E18, P7, adult week 5. Quantification of non-
normalised  expression (in 35-CT values) indicates the variation in abundance levels 
between the genes. Variation within each gene is small.  
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Figure 3.5 Determination of optimum number of control genes using GeNORM. The 
optimum number of control genes was determined by calculating the expression 
stabitily (M, graph A) and pairwise variation (V, graph B) between the control genes 
using GeNORM (Vandesomepele et al., 2002). 




3.3.2.3 Normalised results 
To determine where and when Gpr50 is expressed and available to interact with its 
interaction partners, rt-PCR was performed on a developmental mouse brain panel 
(Origene) covering 48 regional samples over 5 timepoints, E13, E15, E18, P7 and 
week 5. Data were normalised against four housekeeping genes with varying levels 
of expression (Ct value, Fig 3.3) to reflect the difference in expression levels 
between our genes-of-interest: ß-actin, Tbp, Hmbs and Cyclophilin (Table 3.3).  
Relative normalised expression of Gpr50, Nogo-pan, Nogo-A, Cdh8 and Abca2 are 
shown in Table 3.4 and visualised in Figure 3.6.  
 
Gpr50 mRNA was detected in low levels from E13, peaked at E18 and increased 
again at week 5. At most developmental timepoints Gpr50 appears to be localized to 
specific regions, with highest expression in thalamus, hypothalamus (diencephalon) 
and in the midbrain, pons and medulla (mesencephalon, rhombencephalon). Gpr50 
shows increased expression in frontal regions at 5 weeks only. Nogo-A mRNA 
expression is constant and was detected throughout all regions and timepoints. Cdh8 
expression is relatively constant but did show an increase in the posterior regions at 
E18 and frontal regions at P7. Both Nogo-C and Abca2 expression is lower during 
development and increases at week 5. Srebf2 expression was increased in spinal cord 
at E18, the medulla at P7 and the pons at week 5. 
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Region Gpr50 Nogo-pan Nogo-A Nogo-C Cdh8 Abca2 Srebf2 
E13               
Prosencephalon 0.398 0.370 0.424 0.021 0.328                      0.066 
Mesencephalon  0.831 0.645 0.871 0.073 0.740 0.495 0.904 
Rhombencephalon  0.545 0.918 0.984 0.137 0.454 0.062 0.511 
Spinal Cord 0.141 0.377 0.395 0.024 0.226 0.071 0.548 
E15               
Telencephalon 0.181 0.689 0.812 0.045 0.950 0.078 0.511 
Diencephalon 0.812 0.933 0.771 0.025 0.740 0.087 0.527 
Midbrain 0.286 0.787 1.024 0.042 1.907 0.255 0.426 
Pons 0.942 0.702 1.150 0.028 0.975 0.165 0.276 
Medulla 0.268 0.881 1.500 0.041 0.680 0.154 0.805 
Spinal Cord 0.499 1.196 1.643 0.026 1.276 0.193 0.335 
E18               
Frontal Cortex 0.637 0.992 1.062 0.011 0.639 0.127 0.347 
Posterior Cortex 0.394 1.270 1.074                 
0 
0.791 0.605 0.676 
Entorhinal Cortex 0.202 1.398 1.522 0.014 1.088 0.204 0.268 
Olfactory Bulb 0.285 0.794 0.718 0.021 0.811 0.090 0.342 
Hippocampus 0.198 0.943 1.095 0.016 0.695 0.140 0.888 
Striatum 0.360 1.232 0.576 0.010 0.930 0.151 0.394 
Thalamus 2.570 1.267 1.449 0.033 1.679 0.430 0.390 
Hypothalamus 7.015 1.620 1.302 0.042 1.310 0.797 0.777 
Midbrain 1.768 0.885 1.204 0.023 2.146 0.454 0.640 
Pons 0.906 0.823 0.893 0.028 1.912 0.355 0.302 
Medulla 1.138 1.307 1.553 0.047 1.687 0.699 0.551 
Spinal Cord 1.559 1.441 0.869 0.062 2.163 0.830 2.286 
P7               
Frontal Cortex 0.368 1.085 1.375 0.384 1.886 0.651 1.143 
Posterior Cortex 0.916 1.891 1.841 0.625 1.512 0.963 2.108 
Entorhinal Cortex 0.187 0.795 1.146 0.311 1.562 0.336 1.101 
Olfactory Bulb 0.931 0.983 1.252 0.476 0.715 0.627 0.687 
Hippocampus 0.229 0.570 0.982 0.201 0.887 0.262 0.533 
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Striatum 0.604 1.050 1.070 1.372 1.708 0.411 0.453 
Thalamus 0.651 0.799 0.869 0.256 0.971 0.627 0.433 
Hypothalamus 2.220 0.980 0.987 0.474 0.782 0.191 0.684 
Cerebellum 0.353 0.361 0.486 0.468 0.553 0.413 0.688 
Midbrain 1.058 1.104 0.997 0.393 1.456 0.237 0.685 
Pons 2.710 0.765 0.814 0.272 0.991 0.789 0.718 
Medulla 0.360 0.509 0.697 0.251 0.486 0.478 4.830 
Spinal Cord 0.799 0.662 0.620 0.046 0.315 0.273 0.564 
Week 5               
Frontal Cortex 0.510 1.536 0.508 5.938 0.490 1.900 1.009 
Posterior Cortex 0.323 1.189 1.415 8.384 0.643 0.630 1.047 
Entorhinal Cortex 2.306 1.111 0.545 3.080 0.885 1.584 0.683 
Olfactory Bulb 2.352 0.544 0.735 4.068 0.273 0.916 0.767 
Hippocampus 0.939 1.168 0.618 1.865 0.810 4.806 0.639 
Striatum 0.445 1.608 0.490 5.573 0.874 6.766 1.092 
Thalamus 2.134 1.279 0.967 1.467 1.204 1.577 1.272 
Hypothalamus 1.906 0.846 0.696 3.276 1.314 2.162 0.610 
Cerebellum 0.169 1.000 0.386 1.397 1.012 2.087 0.314 
Midbrain 1.163 1.857 1.016 2.864 1.033 5.042 1.025 
Pons 1.364 1.110 2.087 1.340 0.666 2.549 10.883 
Medulla 0.635 0.573 1.132 0.619 0.557 2.736 0.705 
Spinal Cord 0.433 1.155 1.379 0.830 0.287 1.544 0.555 
 
 Table 3.4 Normalised relative expression levels of Gpr50, Nogo-pan, Nogo-A, Nogo-C, Cdh8, Abca2 and Srebf2 after rt-PCR. 
 
 





 Figure 3.6 Real-time quantitative rt-PCR on Origene mouse developmental panel 
with 48 regional brain samples from 5 developmental stages. Relative normalized 
expression values of Gpr50, Nogo-pan, Nogo-A, Nogo-C, Cdh8 and Abca2 
normalised to b-Actin, Tbp, Hmbs and Cyclophilin B.  




The results suggest an increased expression of the genes around E18 and/or at 5 
weeks, indicating possible co-regulation. Spearman correlations (r) were performed 
of the overall data (between the genes for all regions and ages, using the above genes 
plus Nogo-pan (detecting Nogo-A, -B and –C) (Fig 3.7). Gpr50 correlates 
significantly with Abca2 (Spearman’s r (95% confidence interval); p-value): (r=0.43 
(0.15-0.64); p=0.0028). Other significant correlations are Nogo-pan with Cdh8 
(r=0.39 (0.11-0.61); p=0.0068), Nogo-pan with Abca2 (r=0.40 (0.12-0.62); 
p=0.0058), Nogo-A with Cdh8 (r=0.32 (0.03-0.56); p=0.0268), Nogo-C with Abca2 
(r=0.77 (0.62-0.87); p<0.0001) and Nogo-C with Srebf2 (r=0.55 (0.30-0.73); 
p<0.0001). As expected Nogo-pan correlates with Nogo-A (r=0.37 (0.09-0.60); 
p=0.0097). Nogo-pan does not correlate with Nogo-C, which is likely caused by the 
relative absence of Nogo-C at embryonic stages compared to Nogo-A. 
 
Because Gpr50 shows increased expression around E18, Spearman correlations were 
calculated for age E18 only (Fig 3.8). At this timepoint Gpr50 correlates 
significantly with Nogo-C (r=0.69 (0.14-0.92); p=0.0186), Cdh8 (r=0.64(0.09-0.89); 
p=0.024) and again with Abca2 (r=0.71(0.20-0.91); p=0.0102). Other significant 
correlations were found between Nogo-pan and Abca2 (r=0.71 (0.20-0.91); 
p=0.0102), between Nogo-C and Cdh8 (r=0.75 (0.24-0.93); p=0.0085), Nogo-C and 
Abca2 (r=0.83 (0.43, 0.96); p=0.0015), and between Cdh8 and Abca2 (r=0.68 (0.15-
0.90); p=0.0153). By contrast, no significant correlations were found at week 5. 
These results indicate possible co-regulation between Gpr50 and Abca2 overall and 
Nogo-C and Cdh8 at E18 only. 
 
The rt-PCR results show an upregulation of Gpr50 and its interactors at E18 and 
week 5. Although the manufacturer of the cDNA panel describes week 5 as an adult 
stage this is generally considered adolescence in rodents, which is from weaning at 
postnatal day (P) 21 to P60 (Laviola et al., 2003; Hefner and Holmes, 2007). 
Adolescence in rodents can be further classified into early adolescence (prepubescent 
or juvenile, P21 to P34), middle adolescence (periadolescent, P34 to P46), and late 
adolescence (young adult, P 46 to 59) (Laviola et al., 2003). The rt-PCR results 
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suggest the late gestation (E18) and adolescent stages are important functional 
timepoints. These ages are relevant to mental illness, as E18 has been found to be an 
important developmental timepoint for processes of synapse formation and function, 
axon growth and guidance and survival and growth (Hinds and Hinds, 1976; Matsuki 
et al., 2005), processes that have been linked to the pathophysiology of psychiatric 
illness (Benes and Berretta, 2001; Coyle and Duman, 2003; Eastwood et al., 2003). 
Adolescence and early adulthood are generally when the first psychiatric symptoms 
(onset) occur (Joyce, 1984; Loranger, 1984). 




Figure 3.7 Spearman correlations between rt-PCR data of all genes across all 
regions and timepoints. Data and correlation matrix were generated using Graphpad 
Prism and StatistiXL. 





Figure 3.8 Spearman correlations between rt-PCR data of all genes across all 
regions at E18 only. Data and correlation matrix were generated using Graphpad 
Prism and StatistiXL (Microsoft). Data and correlation matrix were generated using 
Graphpad Prism and StatistiXL. 




3.3.3  Expression of GPR50 and interactors by 
immunohistochemistry   
 
Next we wanted to follow up the rt-PCR results at the protein level, by performing 
immunohistochemistry in the mouse brain. The rt-PCR results suggest E18 is an 
important developmental timepoint for Gpr50. We wanted to compare this to 
expression in the adult brain. Therefore the expression of Gpr50, Nogo-A, Cdh8 and 
Abca2 was investigated in 8-12 week old adult as well as E18 mouse brains. 
 
3.3.3.1  Optimisation of tissue fixation 
Several methods of tissue fixation are commonly used with 4% formaldehyde (or 
10% formalin) the most common. Formaldehyde fixation however cross-links 
proteins with loss of antigenicity. Antigen retrieval methods are used afterwards to 
improve antibody sensitivity and reduce background staining, but these normally 
involve boiling tissues with possible loss of cell architecture. Fresh frozen tissue is 
also commonly used as it has improved antigenicity, but tissues are less rigid and 
stay less intact when compared to formaldehyde. Other commonly used fixatives are 
organic solvents, such as ethanol, methanol, acetone, acetic acid or a mixture of 
these. Heat-induced antigen retrieval is not necessary with these fixatives so 
antigenicity, tissue structure and cell architecture may be better preserved. 
 
In initial trials on 4% formaldehyde fixed tissues the GPR50 G-15 antibody did not 
appear to give a reliable signal, even at 1:50 dilution, with standardised protocols in 
the lab. Trials with fresh frozen tissues fixed in acetone did produce a better signal 
but the tissues were damaged almost beyond recognition and were not suitable for 
the investigation of expression in specific nuclei. The standardised lab protocols all 
used 4% formaldehyde or 10% formalin fixed tissue with antigen retrieval in citrate 
buffer pH6.0, without further tissue permeabilisation. Kim et al (2004) tested several 
antibodies with different antigen retrieval buffers and noted that buffers at a higher 
pH of 8-9.5 often yield better results (Kim et al., 2004). Therefore a 50mM borate 
Chapter 3: Developmental Expression of GPR50 and Interactors 
 
 133 
buffer at pH8.0 was tested. In addition, pretreatment of the tissues with denaturant 
guanidine HCl/50mM tris buffer pH 7.5 for 10 min after permeabilisation with 0.1% 
triton X-100 for 30 min was tried (Peranen et al., 1993). These treatments improved 
GPR50 staining considerably, but were still not entirely satisfactory (Fig 3.9A).  
 
Therefore fixation with 70% EtOH and Methacarn were also tested (see Materials 
and Methods). With these fixatives Gpr50 staining was found in similar areas but 
antigenicity was much improved (hypothalamic region, Fig 3.9B-C). The 
cytoarchitecture appeared better preserved and nuclei were counterstained more 
clearly then after formalin fixation. It was therefore decided to continue the study 
with adult and E18 brains fixed in 70% EtOH and methacarn. Secondary antibody 
controls showed minimal reactivity in the absence of the primary antibody (Fig 
3.10A-B). 





Figure 3.9 Effects of fixation methods on Gpr50 immunostaining. Adult female CD 
brains were immerse fixed in either 10% formalin (A), 70% EtOH (B) or Methacarn 
(C), before being paraffin embedded. The section above includes the hypothalamus 
around the 3rd ventricle, where Gpr50 is known to be expressed. Formalin fixed 
tissues were subjected to picric acid treatment and antigen retrieval by boiling in 
borate buffer Ph 8.0 for 15 min. All sections were pretreated with 6M GndHCl/50mM 
Tris buffer pH7.5 before staining with GPR50 G-15 (1:50). Sections were 
counterstained with haematoxilin and lithium carbonate. Scale bars 100 µm. 
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Figure 3.10 Secondary antibody controls. (A) Chromogenic detection of biotinylated 
rabbit anti-goat (DAB). Methacarn fixed mouse adult brain tissue was probed with 
secondary antibodies only (left) of with Gpr50 (1:50, right). (B) Fluorescent detection 
with Alexafluor 488 (green) and 594 (red). Methacarn fixed mouse E18 brain tissue 
was stained with Donkey anti-sheep (DAS) and DAR=donkey anti-rabbit (DAR) 
secondary antibodies only (top) or with Gpr50 (1:50) and Cdh8 (1:100). Sections 
were counterstained with Harris haematoxilin (A) or Dapi (B). Scale bars: 100 µm. 
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3.3.3.2  Gpr50 is expressed in several regions and levels in the brain  
In order to find out more about subregional expression and to see if our proteins of 
interest are coexpressed at the cellular level, immunohistochemistry was performed 
in the adult and E18 mouse brain. In accordance with the rt-PCR results the coronal 
planes containing the hypothalamus and 3rd ventricle, the midbrain, pons, medulla 
and cerebellum were investigated (see materials and methods for details and 
supplementary figures for Allen Brain Atlas images of the regions studied). Both 
chromogenic and fluorescent detection methods were used. The relative normalised 
expression levels of Gpr50 mRNA as measured by rt-PCR and levels of protein 
expression as detected by immunohistochemistry in E18 and adult mouse brain are 
summarised in Table 3.5. As was previously reported (Drew et al., 2001) and in 
agreement with the rt-PCR data, Gpr50 is highly expressed in the hypothalamus 
around the 3rd ventricle, the amygdala, amygdalar or piriform cortex, and the 
entorhinal and somatosensory cortices. Hippocampal expression of GPR50 was 
detected on the midbrain level in the adult brain only, in the polymorph layer of the 
dentate gyrus. At the midbrain level GPR50 is also expressed in the cortex and in 
agreement with the rt-PCR data the ventral pons. Gpr50 appeared to be moderately 
expressed in the ventral midbrain, in the substantia nigra pars compacta. If we look at 
more posterior regions in the brain Gpr50 expression is also found at low levels in 
the midbrain and pontine raphe nuclei, the cortex and the superior colliculus. In the 
pons and medulla Gpr50 is moderate to highly expressed in several brainstem nuclei, 
including the locus coeruleus. Gpr50 expression is also found in the inferior 
colliculus and in low levels in the Purkinje cell layer of the cerebellum (Table 3.5, 
for detailed images see 3.3.3.3 and further). There was much agreement in protein 
expression levels as measured by chromogenic and fluorescence detection except for 
the substantia nigra, which showed much clearer Gpr50 expression when using a 
HRP secondary antibody and DAB than when using fluorescent secondary antibodies 
(Fig 3.11). This perhaps reflects the relative sensitivity of these methods (Morris, 
1991).  









Nogo-A Cdh8 Abca2 
E18           
Frontal Cortex 0.637 +++ Y Y N 
Posterior Cortex 0.394 +++ Y Y N 
Entorhinal Cortex 0.202 x x x x 
Olfactory Bulb 0.285 x x x x 
Hippocampus 0.198 - N N N 
Striatum 0.36 - N N N 
Thalamus 2.57 ++ N N N 
Hypothalamus 7.015 +++ N Y N 
Midbrain 1.768 + N N N 
Pons 0.906 + Y Y N 
Medulla 1.138 ++ Y Y N 
Spinal Cord 1.559 x x x x 
Week 5/10           
Frontal cortex 0.51 x  x  x x 
Posterior cortex 0.323 x  x    x  x 
Motor cortex   + Y N Y 
Somatosensory cortex   ++ Y N Y 
Visual cortex   ++ Y N Y 
Entorhinal cortex 2.306 ++ Y N Y 
Piriform cortex   ++ Y N Y 
Olfactory Bulb 2.352 x x  x  x  
Hippocampus 0.939         
dentate gyrus medial blade 
polymorph layer 
  + N N N 
hippocampus other   - N N N 
Amygdala   ++ Y Y Y 
Striatum 0.445 - N N N 
Thalamus 2.134 ++ N N N 
Hypothalamus 1.906         
suprachiasmatic nucleus   ++ N N N 
paraventricular nucleus   + Y N N 
ependyma of 3rd ventricle   +++ N N Y 
dorsomedial hypothalamus   ++ Y N N 
ventromedial hypothalamus   ++ N Y Y 
lateral hypothalamus   + Y N N 
arcuate nucleus   ++ Y N Y 
median eminence   ++ N N Y 
Cerebellum 0.169         
Purkinje cell layer   + N N N 
Cerebellum other   - N N N 
Midbrain 1.163         
superior colliculus   ++ Y N Y 
periaqueductal grey   + N N N 
substantia nigra   +/++ N N N 
Pons 1.364         
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raphe nuclei   + N N N 
locus coeruleus   +++ N N Y 
mesencephalic trigeminal 
nucleus 
  + Y Y Y 
pontine grey   ++ N N N 
Medulla 0.635         
inferior colliculus   ++ Y N Y 
gigantocellular reticular nucleus   ++ N N Y 
magnocellular reticular nucleus   ++ N N Y 
parvicellular reticular nucleus   ++ N N Y 
principal sensory nucleus of the 
trigeminal 
  ++ N N Y 
Spinal Cord 0.433 x       x       x       x 
 
Table 3.5 Expression levels of Gpr50 in the mouse brain.  
Column1: Relative normalized Gpr50 mRNA expression levels as measured by rt-
PCR at E18 and week 5. Column 2: semi-quantitative evaluation of Gpr50 protein 
expression after immunohistochemistry at E18 and the Week 10. Scale: x, not 
investigated; −, no expression present; +, weak expression; ++, moderate 
expression; +++, strong expression. Columns 3-5: Co-localisation of Gpr50 and 
Nogo-A, Cdh8 or Abca2 as measured by by immunohistochemistry. Scale: x, not 
investigated; Y, colocalisation detected; N, no colocalisation detected. 
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Figure 3.11 GPR50 in the substantia nigra. Adult CD1 brains were fixed in 70% 
ethanol and stained with anti-GPR50. Both chromogenic (DAB, left) and fluorescent 
(Alexafluor 488, right) methods were used. These images show a midbrain section 
containing the substantia nigra. Section left was counterstained with haematoxilin. 
Scale bars: 100 µm. 
 
 
3.3.3.3  Gpr50 expression in different cell types 
A few studies have investigated the specific cell type(s) that express GPR50. In the 
ependyma of the third ventricle Gpr50 is thought to be expressed by tanycytes as 
determined by location, morphology or co-labelling with tanycyte marker Vimentin 
(Garcia et al., 2003; Barrett et al., 2006; Sidibe et al., 2010) and by neurons in the 
dorsomedial hypothalamus (Sidibe et al.). However, in Gpr50 knockout mice, β-gal 
expression driven by the GPR50-promotor stains the ependyma of the 3rd ventricle 
but did not co-localise with glucose transporter GLUT1, another marker for α- or β-
tanycytes (Peruzzo et al., 2000; Berger and Hediger, 2001; Garcia et al., 2003), nor 
did the signal colocalise with astrocyte marker GFAP or neuronal progenitor and 
stem cell marker Nestin (Ivanova et al., 2008). There thus appears to be much 
uncertainly about the exact cell type expressing GPR50. As we identified novel 
regions of Gpr50 expression we carried out immunofluorescence colocalisation of 
Gpr50 with cell type markers NeuN (mature neurons), GFAP (astrocytes), O4 
(oligodendrocytes) and Vimentin (tanycytes) in several regions in the adult and E18 
mouse brain. 
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Gpr50 colocalises with NeuN in the ventral anterior hypothalamus (Fig 3.12A) and 
in the other areas of GPR50 expression, the cortex, midbrain, superior colliculus, 
pons, hippocampus and brain stem nuclei (Fig 3.13A-J). In the locus coeruleus 
colocalisation between Gpr50 and NeuN was not as clear (Figure 3.13J) but weak 
NeuN staining in locus coeruleus neurons has been reported before (Coelho et al., 
2005). Gpr50 does not colocalize with GFAP, O4 or vimentin in any of these 
regions. Interestingly, no colocalisation was found with vimentin in the adult mouse 
brain (Fig 3.12B-C). In the anterior hypothalamus Gpr50 is present at the base of the 
ventricular ependyma but vimentin is expressed in the dorsal ependyma (Fig 3.12B). 
However more caudally in the hypothalamus, vimentin is expressed in the ventral 
ependyma, close to the median eminence, where Gpr50 was before but now Gpr50 
has shifted dorsally (Fig 3.12C). When co-labelling with GFAP, some colocalisation 
is found on the lateral sides of the ependyma, although it is minor (Fig 3.13D). A 
similar pattern was detected at E18 (Fig 3.14A-C) where Gpr50 and vimentin 
expression appears to be mutually exclusive rather than colocalizing. In the 3rd 
ventricle at E18 no colocalisation was found with either of the other markers (GFAP 
(Fig 3.14D), O4 (not shown), NeuN (not shown)). 
 
3.3.3.4  Gpr50 is expressed in monoaminergic neurons 
The apparent expression of Gpr50 in several brain stem nuclei of behavioural 
importance is intriguing and was further investigated by co-labelling of Gpr50 with 
5-HT (serotonergic marker), tyrosine hydroxylase (TH, dopaminergic and 
noradrenergic marker) and dopamine beta hydroxylase (DBH, noradrenergic 
neuronal marker) in the adult mouse brain (Fig 3.15A-E). The strongest Gpr50 
expression is found in the locus coeruleus, where we found clear colocalisation with 
DBH (Fig 3.15A). Gpr50 is only expressed in low levels in the nucleus raphe 
magnus where it colocalises with 5-HT (Fig 3.15B). Other areas of 5-HT expression 
include the pontine gray and the substantia nigra, also show colocalisation with 
Gpr50 (Fig 3.15C-D). Gpr50 staining by immunofluorescence was much less clear in 
the substantia nigra than with DAB (Table 3.5), again probably due to the relative 
sensitivity of these methods (Morris, 1991). Colocalisation with 5-HT (Fig 3.15D) 
and TH (Fig 3.15E) was therefore found to be quite weak





Figure 3.12 Co-labelling of Gpr50 with NeuN, GFAP or Vimentin (Vim) throughout the rostrocaudal extent of the adult mouse 
hypothalamus. Adult CD1 brains were fixed in methacarn and stained for Gpr50 and NeuN (A), Vimentin (B, C) or GFAP (D, inset). SCN = 
suprachiasmatic nucleus, 3V=3rd ventricle, AHA=anterior hypothalamic area, ARC=arcuate nucleus, ME=median eminence. Nuclei were 
counterstained with DAPI. Scale bars: 100 µm 






Figure 3.13 Co-labelling of Gpr50 and NeuN in the adult mouse brain. CD1 brains were fixed in 70% EtOH and stained for Gpr50 and 
NeuN (A-J). PIR = piriform cortex, CTX = cortex, HY = hypothalamus, DG PL = Dentate gyrus polymorph layer, PG = pontine grey, MARN 
= magnocellular reticular nucleus, PARN = parvicellular reticular nucleus, PSV = principal sensory nucleus of the trigeminal, LC = locus 
coeruleus. Sections were counterstained with DAPI. Scale bar: 100 µm. 





Figure 3.13. Co-labelling of Gpr50 and NeuN in the adult mouse brain. CD1 brains were fixed in 70% EtOH and stained for Gpr50 and 
NeuN (A-J). PIR = piriform cortex, CTX = cortex, HY = hypothalamus, DG PL = Dentate gyrus polymorph layer, PG = pontine grey, MARN 
= magnocellular reticular nucleus, PARN = parvicellular reticular nucleus, PSV = principal sensory nucleus of the trigeminal, LC = locus 
coeruleus. Sections were counterstained with DAPI. Scale bar: 100 µm. 




Figure 3.14 Co-labelling of Gpr50 with Vimentin (Vim) or GFAP in the 3rd ventricular ependyma and the ventral hypothalamus in the E18 
mouse brain. E18 CD1 brains were fixed in methacarn stained with Gpr50 and Vimentin (A-C) of GFAP (D). VM HY = ventromedial 
hypothalamus, 3V=3rd ventricle. Nuclei were counterstained with DAPI. Scale bars: 100 µm 
 




Figure 3.15  Gpr50 colocalises with noradrenergic, serotonergic and dopaminergic markers. Adult mouse brains were fixed in 70% EtOH 
and stained for Gpr50 with dopamine beta hydroxylase (A), 5-HT (B-D) and Tyrosine Hydroxylase (E). LC = locus coeruleus, NRM = 
nucleus raphe magnus, PG = pontine grey, SN = substantia nigra. Sections were counterstained with DAPI. Scale bars: 100 µm. 
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3.3.3.5 Gpr50 co-localisation with Nogo-A, Abca2 and Cdh8 
Next we investigated whether Gpr50 colocalized with its interactors in the E18 and 
adult mouse brain: Nogo-A, Abca2 and Cdh8. In the adult mouse brain co-
localisation of Gpr50 and Nogo-A was found in several areas in the hypothalamus: 
the paraventricular nucleus (Fig 3.16A and inset), arcuate nucleus/ventromedial 
hypothalamus (Fig 3.16B and inset), dorsomedial hypothalamus (Fig 3.16C and 
inset) and lateral hypothalamus (Fig 3.16D and inset). In each of these areas it 
appears to be a small subset of cells that express both. Colocalisation of Gpr50 and 
Nogo-A is more abundant in the amygdala (Fig 3.17A-B and insets), is also found in 
the superior colliculus (Fig 3.17C and inset) and the somatosensory cortex (Fig 
3.17D and inset). In the brainstem nuclei co-localisation of Nogo-A and Gpr50 could 
be detected in the mesencephalic trigeminal nucleus only (Fig 3.17E). At E18 
colocalisation of Gpr50 and Nogo-A was detected in the forebrain (Fig 3.18A-A’), 
the cortex at several levels (Fig 3.18B’B’, C-C’) and in the medullary hindbrain (Fig 
3.18D-D’).  
 
Extensive colocalisation of Gpr50 and Abca2 in the adult mouse brain was detected 
in the ventral 3rd ventricular ependyma (Fig 3.19A-C, insets) and the lateral side of 
the epithelium (Figure 3.19B, inset). In the piriform and somatosensory cortices 
colocalisation of Gpr50 and Abca2 is widespread (Fig 3.19D-E), as is colocalisation 
in the brain stem nuclei of the medulla and pons: the parvicellular (PARN), 
magnocellular (MARN) and gigantocellular (GRN) reticular nucleus, the principal 
sensory nucleus of the trigeminal (PSV), and the nucleus raphe magnus (NRM) (Fig 
3.19F, inset, G-I). Weak colocalisation between Gpr50 and Abca2 was found in the 
locus coeruleus and mesencephalic trigeminal nucleus (Fig 3.19I). As indicated by 
the rt-PCR results Abca2 expression is much lower in the embryonic than in the adult 
brain and no clear Abca2 staining could be detected at E18.  
 
Our Cdh8 antibody detected weak expression in the adult mouse brain (Fig 3.20A-
C). Here Gpr50 and Cdh8 appear to be expressed in a different subset of cells in the 
median eminence (Fig 3.20A) but are colocalising in the periventricular 
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hypothalamus (Fig 3.20B) and in the amygdala (Fig 3.20C). Cdh8 is also expressed 
in the mesencephalic trigeminal nucleus (Fig 3.20D).  
 
In the embryonic brain Cdh8 expression is stronger then in the adult. At E18 Gpr50 
and Cdh8 co-localise in the dorsal forebrain (Fig 3.21A-A’), the median eminence 
and 3rd ventricular epithelium (Figure 3.21B-B’). Colocalisation is also found in the 
cortex (Fig 3.21C-C’) and roof plate of the pontine/medullary hindbrain (Fig 3.21D-
D’).  
Colocalisation between Gpr50 and Nogo-A, Cdh8 and Abca2 in the E18 and adult 
female mouse brain by immunohistochemistry is summarised in Table 3.5 (Oertle et 
al., 2003b).




Figure 3.16 Co-labelling of Gpr50 with Nogo-A in the adult mouse hypothalamus. Adult CD1 brains were fixed in methacarn or 70% EtOH 
stained with Gpr50 and Nogo-A (A-D). PVN=paraventricular nucleus, ARC=arcuate nucleus, DM HY= dorsomedial hypothalamus, LA HY 
= lateral hypothalamus, 3V=3rd ventricle. Scale bars: 100 µm  




Figure 3.17 Co-labelling of Gpr50 with Nogo-A in the adult mouse brain. Adult CD1 brains were fixed in methacarn or 70% EtOH and 
stained with Gpr50 and Nogo-A (A-D). BL Amyg = basolateral amygdala, PIR = Piriform Cortex, Cl Amyg = Central Amygdala, Sup Coll = 
Superior Culliculus, Somatos CTX = somatosensory cortex, LC= locus coeruleus, Me5= mesencephalic trigeminal nucleus. Scale bars: 
100 µm. 





Figure 3.18 Co-labelling of Gpr50 with Nogo-A in the E18 mouse brain. E18 CD1 
brains were fixed in methacarn and stained with Gpr50 and Nogo-A (A-D with A’-D’ 
enlargements). A-A’: Dorsal forebrain, B-B’: frontal Cortex, C-C: midbrain cortex, D-
D’: Medullary hindbrain. Sections are counterstained with DAPI. Scale bars: 100 µm.  
 




Figure 3.19 Co-labelling of Gpr50 with Abca2 in the adult mouse brain. Adult CD1 brains were fixed in methacarn or 70% EtOH and 
sections were stained with Gpr50 and Abca2 (A-J). ME = median eminence, PT= pars tuberalis  Ant HY = anterior hypothalamus, 3V = 3rd 
ventricle, PIR = piriform cortex, Somatos CTX = Somatosensory cortex., PSV = principal sensory nucleus of the trigeminal, GRN = 
gigantocellular reticular nucleus, PARN = parvicellular reticular nucleus, LC= locus coeruleus, Me5= mesencephalic trigeminal nucleus, 
NRM = nucleus raphe magnus. Nuclei were counterstained with DAPI. Scale bars: 100 µm. 
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Figure 3.19 Co-labelling of Gpr50 with Abca2 in the adult mouse brain. Adult CD1 brains were fixed in methacarn or 70% EtOH and 
sections were stained with Gpr50 and Abca2 (A-J). ME = median eminence, PT= pars tuberalis  Ant HY = anterior hypothalamus, 3V = 3rd 
ventricle, PIR = piriform cortex, Somatos CTX = Somatosensory cortex., PSV = principal sensory nucleus of the trigeminal, GRN = 
gigantocellular reticular nucleus, PARN = parvicellular reticular nucleus, LC= locus coeruleus, Me5= mesencephalic trigeminal nucleus, 
NRM = nucleus raphe magnus. Nuclei were counterstained with DAPI. Scale bars: 100 µm.





Figure 3.20 Co-labelling of Gpr50 with Cdh8 in the adult mouse brain. Adult CD1 brains were fixed in methacarn or 70% EtOH and 
stained with Gpr50 and Cdh8 (A-D). HY=hypothalamus, VMH=ventromedial hypothalamus, ME = median eminence, 3V=3rd ventricle, BL 
Amyg = basolateral amygdala, Me5 =mesencephalic trigeminal nucleus, LC = locus coeruleus. Nuclei were counterstained with DAPI. 
Scale bars: 100 µm.  




Figure 3.21 Co-labelling of Gpr50 with Cdh8 in the E18 mouse brain. E18 CD1 
brains were fixed in methacarn and stained with Gpr50 and Cdh8 (A-D with  A’-D’ 
enlargements). A-A’: Dorsal forebrain, B-B’: hypothalamus and 3rd ventricle, C-C’ : 
cortex, D-D’: Roofplate of the pontine/medullary hindbrain. 3V=3rd ventricle, 
ARC=arcuate nucleus, ME=median eminence. Sections are counterstained with 
DAPI. Scale bars: 100 µm. 
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3.4  Discussion 
 
3.4.1 GPR50 and interactors are enriched in the postsynaptic 
density 
 
Subcellular fractionation of adult mouse brain indicates that Gpr50, Nogo-A, Cdh8 
and Abca2 are all expressed in the light membrane fraction (P3), which includes 
structures such as the ER, Golgi, endolysosome and plasma membrane, and in the 
crude synaptosomal fraction (P2). This is in agreement with previous studies (Kido 
et al., 1998; Vulevic et al., 2001; Oertle et al., 2003b; Levoye et al., 2006), and the 
results of Chapter 2, and indicates the (internal) membrane fractions as an interaction 
site. 
 
Increased expression of Gpr50 was found in the postsynaptic density fractions and 
this is highest in the ‘core’ PSD fraction (PSD3). Nogo-A and Cdh8 are present both 
post and presynaptically. This is in line with previous reports on synaptic expression 
of Nogo-A (Lee et al., 2008) and Cdh8 (Suzuki et al., 2007). This indicates that 
GPR50 and interactors are likely to be interaction partners at the synapse, and that 
GPR50 may interact in cis or in trans with its partners, either across the synapse or 
on the postsynaptic membrane. However, this needs to be confirmed by performing 
co-immunoprecipitations from synaptic fractions. 
 
3.4.2  Developmental expression of GPR50 and interactors 
 
This is the first study looking at the developmental expression of orphan GPR50. By 
rt-PCR, expression of Gpr50 and several interactors is detected at E13 and peaks at 
E18, a developmental stage important for axon growth and guidance, synapse 
formation and function and survival and growth (Matsuki et al., 2005). The 
expression of Gpr50 and Nogo-C and Abca2 is also increased in adolescence, at 5 
weeks. Early adulthood and adolescence are important timepoints in the development 
of psychiatric illness. The average age of onset of bipolar disorder and schizophrenia 
is in early adulthood (between 20 and 30 years) (Joyce, 1984). Early onset (in 
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adolescence) bipolar disorder is however common and is characterised by an 
increase in manic symptoms (Joyce, 1984; Geller and Luby, 1997).  
 
The rt-PCR findings are in line with previous reports in the literature. Gpr50 was 
previously found to be highly expressed in several nuclei of the hypothalamus 
(Reppert et al., 1996; Drew et al., 1998; Drew et al., 2001; Sidibe et al., 2010), which 
can be confirmed by our study. The 3rd ventricular wall is also likely to be part of the 
hypothalamic cDNA from the panel and a high hypothalamic expression could 
reflect this area. Gpr50 was also previously detected in the adult rodent amygdala, 
olfactory bulb (Drew et al., 2001), and in the hippocampus (Hamouda et al., 2007), 
although not specified which part.  
 
As previously published Nogo and Nogo-A are ubiquitously expressed in most 
tissues (Funahashi et al., 2008)(Hasegawa et al., 2005), most highly espressed in 
white matter containing regions (pons, medulla, spinal cord), but also in the cortex 
during development (Oertle and Schwab, 2003). We found increased Nogo-A 
expression in the hippocampus at E18 but not at other stages. A higher expression in 
the cortical areas at P7 is in agreement with BGEM in situ hybridisation data 
(Magdaleno et al., 2006). A general increase in Nogo-A expression around birth was 
also reported by Huber et al. (2002).  
 
Nogo-A protein expression has also previously been detected in the rat primary 
somatosensory cortex (Shin et al., 2006). Nogo-A mRNA was previously reported to 
be expressed in the paraventricular nucleus and ventromedial nucleus of the 
hypothalamus, the amygdala and cortex in the rat and human postmortem brain 
(Hasegawa et al., 2005; Satoh et al., 2005). We did not detect Nogo-A in the brain 
stem nuclei whereas high Nogo-A mRNA expression was previously found in the 
locus coeruleus and the substantia nigra pars compacta, the dorsal raphe and reticular 
nuclei (Hasegawa et al., 2005). We did however find Nogo-A in the adjacent 
mesencephalic trigeminal nucleus as predicted by mRNA expression (Hasegawa et 
al., 2005).  
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We could only detect significant expression of Nogo-C mRNA at 5 weeks, in line 
with previous findings (Huber et al., 2002). An increase in Nogo-C expression in 
adulthood was found previously in the hippocampus (Meier et al., 2003). This should 
be further investigated by performing immunohistochemistry with a Nogo-C-specific 
antibody. 
 
Our observations of increased expression of Cdh8 in cortical, striatal and midbrain 
areas at P7 corresponds to previous findings (Korematsu and Redies, 1997; 
Korematsu et al., 1998a; Korematsu et al., 1998b; Bekirov et al., 2002; Gil et al., 
2002). We find an increase in Cdh8 expression in the midbrain at all timepoints, 
which is in agreement with BGEM data at E15 and P7 (Magdaleno et al., 2006). 
Unlike Bekirov et al. (2002) we could not detect strong hippocampal Cdh8 
expression at any developmental stage, which is in line with Korematsu and others 
(1998). Interesting is our observation of a shift in increased Cdh8 expression from 
anterior to posterior brain regions from E18 to P7.  Similarly, Bekirov et al. (2002) 
detected in a decreasing Cdh8 dorsal to ventral gradient in the subiculum in the first 
few weeks postnatally, suggesting cadherins play a role in subdivisional organisation 
of the developing brain.  
 
ABCA2 expression has only previously been reported in the adult brain, in the 
hippocampus and white matter areas (Zhao et al., 2000; Broccardo et al., 2006). An 
increase in Abca2 expression after birth was previously found (Chen et al., 2004b; 
Tachikawa et al., 2005. We detected a general peak in mRNA expression at 5 weeks, 
especially in the hippocampus, striatum and midbrain (Table 3.4). In the adult brain 
high Acba2 protein expression was mostly detected in the hypothalamus around the 
3rd ventricle, in the cortex and in several brain stem nuclei (Fig 3.18) and also in the 
corpus callosum. Strong Abca2 expression was detected in the median eminence and 
pars tuberalis and looked similar to the vimentin staining in these areas (this study). 
Vimentin has also been shown to be co-regulated with ABCA2 (Chen et al., 2004b; 
Mack et al., 2011). Although Abca2 was detected in the developing brain by rt-PCR 
and previously by in situ hybridisation (Tachikawa et al., 2005) we could not detect 
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any protein expression with our antibody at E18. Other antibodies may detect Abca2 
in the developing brain. 
 
 
We detected high Srebf2 expression in the spinal cord at E18, the medulla at P7 and 
the pons at week 5 (Tabel 3.4) suggesting a posterior to anterior expression gradient 
in the brainstem through development. Srebf2 was previously detected in the 
brainstem (Kim and Ong, 2009). At P7 Srebf2 is also more highly expressed in the 
cortex, and in the cortex, striatum and thalamus at 5 weeks, in agreement with 
previous studies in the adult rat and mouse brain (Jones et al., 2009; Kim and Ong, 
2009). We did however not detect high mRNA expression in the hippocampus as 
was previously found (Kim and Ong, 2009). Protein expression should be 
investigated by performing immunohistochemistry using a specific SREBF2 
antibody.  
 
3.4.3  Novel sites of GPR50 expression 
 
In addition to previously reported sites we found many novel sites of Gpr50 
expression in the adult and E18 mouse brain by immunohistochemistry. Of particular 
interest is the expression in the brain stem nuclei as these include the substantia 
nigra, containing dopaminergic cells, the raphe nuclei (serotonergic cells) and 
perhaps most clearly the locus coeruleus (noradrenergic cells). GPR50 is also 
expressed in the polymorph layer of the dentate gyrus, which is the primary target for 
noradrenergic, serotonergic and cholinergic input to the hippocampus (Berger et al., 
1981). Gpr50 also colocalises with monoaminergic markers TH, 5-HT and DBH 
suggesting a role in neurotransmitter signalling. These areas are highly 
interconnected with other areas in the brain and the neuromodulatory and 
behavioural properties of the monoaminergic neurotransmitters have been well 
researched. Dopamine plays a role in movement, reward and addiction, serotonin is 
implicated in appetite, mood and anxiety, and noradrenaline is involved in fight-or-
flight reaction, stress and depression. 
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Gpr50 is also expressed in specific pontine/medullary nuclei: the parvicellular 
(PARN), magnocellular (MARN) and gigantocellular (GRN) reticular nucleus and 
the principal sensory nucleus of the trigeminal (PSV) 
 
In the absence of a ligand for Gpr50 its expression in the brainstem and 
colocalisation with noradrenergic, dopaminergic, and serotonergic markers is 
intriguing and introduces the possibility that Gpr50 is a receptor for either 
neurotransmitter, or that Gpr50 is involved in the regulation of monoamine 
transmission. Given its localisation at sites controlling the HPA axis a neuropeptide 
ligand may also be possible. 
 
3.4.4 GPR50 expression in neurons  
 
Gpr50 appears to be expressed in grey matter only and is predominantly expressed 
by NeuN-positive postmitotic neurons. The expression pattern and morphology of 
Gpr50 expression neurons in the cortex and hippocampus resemble those of 
interneurons. GABA-expressing cortical interneurons arise from the ventral 
telencephalon/subpallium between E12.5 and E16.5 in mice (Wonders and 
Anderson, 2006). Specific subtypes of these neurons arise from different regions of 
the ganglionic eminence and express proteins and neuropeptides such as 
Parvalbumin, Somatostatin, Neuropeptide Y and Calretinin (Wonders and Anderson, 
2006), which can be used as markers. Double labelling of Gpr50 with these 
interneuronal markers during neurogenesis and in adulthood is necessary to 
investigate which types of interneurons express Gpr50 and what their origins and 
molecular characteristics might be. Identifying the cell type could also give 
indications of a ligand for GPR50.  
 
The other major site of Gpr50 expression is the ependyma of the third ventricle, 
where Gpr50 was previously detected, possibly in vimentin-positive tanycytes 
(Barrett et al., 2006; Sidibe et al.). Tanycytes are glial cells almost exclusively 
expressed in the ependyma at the base of the 3rd ventricle. They are derived from 
radial glia and are morphologically similar to astrocytes although they are GFAP 
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negative. There is some speculation as to the function of tanycytes and there are 
theories that tanycytes form the link between the CSF and portal vasculature and are 
involved in endocrine signalling (Lechan and Fekete, 2007). The fetal ependyma 
may play a role in neurogenesis, neuronal differentiation/axonal guidance, transport, 
and support, whereas the mature ependyma likely regulates the transport of ions, 
small molecules, and water between the CSF and neuropil and functions as a barrier 
that may protect the brain from harmful substances (Lechan and Fekete, 2007). 
Intermediate filament proteins vimentin (Sidibe et al., 2010) and GLUT1 (Garcia et 
al., 2003) are often used as markers for tanycytes although as with any marker there 
are limitations to their use (Peruzzo et al., 2000). 
 
GLUT1 did not associate with Gpr50 in one study (Ivanova et al., 2008). GPR50 
colocalisation with vimentin was only detected by Sidibe et al. (2010) and only in 
what appeared to be a small subset of GPR50-expressing cells in the mouse 3rd 
ventricular epithelium. No colocalisation was found with vimentin in Gpr50-
expressing cells in the median eminence in the adult mouse brain at high 
magnification (Sidibe et al., 2010). This suggests GPR50 is also expressed by 
vimentin-negative ependymal and non-ependymal cells. Using different antibodies 
than Sidibe et al. (2010) we did not find any colocalisation of GPR50 with vimentin 
in the ependyma, median eminence or arcuate nucleus and the results here are 
therefore more similar to those of Ivanova et al. (2008). In our study, vimentin and 
Gpr50 even appeared to be mutually exclusive, both in the adult and E18 brain, 
which is intruiging. A typical elongated morphology of tanycytes in the dorsomedial 
hypothalamus is not visible in the vimentin-positive cells but does resemble the 
vimentin immunoreactivity in response to short day photoperiods (Kameda et al., 
2003). The mice used in our study were kept on 12h day/night cycles so a decrease in 
tanycyte density is not expected. This suggests a different vimentin antibody should 
be tested as well. Although we can confirm the expression of Gpr50 in the ependyma 
of the 3rd ventricle we cannot confirm the type of cells showing expression. 
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3.4.5 GPR50 and interactors 
 
In the E18 and adult female mouse brain Gpr50 colocalises with Nogo-A in neurons 
in the cortex and several nuclei hypothalamic and amygdalar nuclei. Expression in 
the paraventricular nucleus and arcuate nucleus suggests a combined role in 
neuroendocrine functions and control of the HPA axis (Swanson and Sawchenko, 
1980; Herman and Cullinan, 1997). The ventromedial nucleus, dorsomedial nucleus 
and lateral hypothalamus are thought to play a role in metabolic regulation and 
control of food intake (Sakurai et al., 1998; Yang et al., 1999) and reward-seeking 
(Harris et al., 2005). The amygdala plays a role in fear conditioning and emotional 
memory (Adolphs et al., 1995) and reward learning (Baxter and Murray, 2002). 
Gpr50 and Nogo-A seem to colocalize in the same cells, as has been suggested 
previously (this thesis, Chapter 2). Thus Gpr50 does not appear to be a Nogo-A 
receptor on a different cell membrane (Schwab). As Gpr50 is expressed in these 
regions, it leaves open the possibility that Gpr50 influences Nogo-A expression as 
suggested earlier (Grünewald et al., 2009)  
 
Gpr50 colocalisation with Abca2 in the adult female mouse brain is extensive, as was 
perhaps suggested by a significant correlation between Gpr50 and Abca2 mRNA 
expression at the final rt-PCR timepoint (5 weeks old, r=0.43; p=0.0028). 
Colocalisation is found in the ependyma of the 3rd ventricle, the median eminence 
and pars tuberalis but also in the cortex and in several brain stem nuclei in the pons 
and medulla involved in the autonomic regulation of feeding (PARN, MARN, PSV, 
raphe nuclei) (Ter Horst et al., 1991). This is intriguing as Abca2 has previously 
been implicated in lipid metabolism, through homology with the HDL-cholesterol 
transporter Abca1 (Kaminski et al., 2001) and involvement in the regulation of 
sphingolipids (Sakai et al., 2007). Expression in the 3rd ventricular ependyma, 
median eminence and pars tuberalis may indicate a role in transport of lipids from 
the CSF/hypothalamus to the portal blood.  
 
In the adult mouse brain colocalisation between Gpr50 and Cdh8 was detected in the 
periventricular hypothalamus and amygdala but clearest colocalisation was found in 
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the E18 brain, in ependymal cells of the 3rd ventricle, the arcuate nucleus and the 
median eminence, suggesting a combined role in neuroendocine control. 
Colocalisation was also found in a small subset of cells in the dorsal forebrain, cortex 
and pontine/medullary hindbrain. Gpr50 and Cdh8 mRNA expression also correlate 
significantly at E18 (r=0.64; p=0.024). Correlation in prenatal development is 
interesting as cadherins are thought to play a role in subdivisional organisation of the 
developing brain (Korematsu and Redies, 1997; Suzuki et al., 1997; Korematsu et 
al., 1998a; Korematsu et al., 1998b; Bekirov et al., 2002; Gil et al., 2002; Neudert et 
al., 2008). Cdh8 expression is implicated in the formation of functional neural 
circuits involving basal ganglia- thalamocortical (Alexander and Crutcher, 1990; 
Korematsu et al., 1998b) or fasciculus retroflexus/habenulo-interpeduncular tract 
(Marchand et al., 1980) during development (Korematsu et al., 1998b).  We found 
Cdh8 to be expressed in a caudal to rostral peak in the E18 and P7 mouse brain and 
Gpr50 was also high in caudal areas at E18. This may indicate a combined role of 
Cdh8 and Gpr50 in the development of these areas. Gene Ontology-analysis of the 
GPR50 yeast two-hybrid interactors also indicated neural development as a key 
process (Grünewald et al., 2009).  
 
When looking at Table 3.5 there are only a few areas where all four proteins 
investigated are expressed: the amygdala and the mesencephalic trigeminal sensory 
nucleus (Me5). The amygdala is involved in emotional and social behavour, 
especially in fear conditioning (LeDoux, 1993; Adolphs et al., 2002). The Me5 
receives sensory information regarding mastication (biting and swallowing), so is 
involved in the autonomic regulation of feeding. This suggests Gpr50 and interactors 
may have a shared role in emotional and metabolic control. 
 
3.4.6 GPR50 in energy metabolism 
 
Several of the regions where Gpr50 and interactors are expressed are involved in 
energy metabolism. The hypothalamic dorsomedial, paraventricular, and arcuate 
nuclei are involved in the regulation of feeding behaviour (Schwartz et al., 2000). 
The parvicellular (PARN), magnocellular (MARN) and gigantocellular (GRN) 
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reticular nucleus and the principal sensory nucleus of the trigeminal (PSV) play a 
role in autonomic regulation and orofacial motor control of food intake (Ter Horst et 
al., 1991). Whereas parts of the reticular formation control orofacial movements, the 
PSV receives primary efferents from pain, mechano and temperature receptors in the 
oral cavity. Efferents from the PSV transfer this signal to higher areas for instance 
the superior colliculus, cerebellum and the thalamus. The reticular formation receives 
input from the hypothalamus and sends projections to the raphe nuclei (Ter Horst et 
al., 1991).  
 
Nogo-A, Cdh8 and Abca2 were detected in the Me5, which co-expressed Gpr50 in 
the same cells. The mesencephalic trigeminal nucleus is a sensory ganglion 
containing primary sensory neurons involved in the control of mastication, the 
automatic (unconscious) activities of food intake such as biting, chewing and 
swallowing. Me5 contains histaminergic neurons and depletion of neuronal 
histamine in Me5 resulted in a significant decrease in eating speed and longer 
duration of eating time, although the intake was not affected (Sakata, 1995). Me5 
appears to be part of a histamine-controlled reflex, which also includes the 
ventromedial hypothalamus (VMH), and influences food intake through satiety 
(Sakata et al., 1997). These links to autonomic feeding mechanisms are interesting as 
Gpr50 knockout mice appear to show increased energy metabolism, with attenuated 
weight gain and reduced body fat on a high-energy diet compared to wild-type 
animals (Ivanova et al., 2008). An intronic SNP in GPR50 was also associated and 
higher serum triglyceride and lower HDL cholesterol levels (Bhattacharyya et al., 
2006).  
 
3.4.7 Clues to GPR50 functioning: A role in stress and CRH 
signalling? 
 
With GPR50 expression in areas involved in HPA-axis control and in 
monoaminergic cells we identify two systems involved in mediating both 
neuroendocrine responses to stress and the pathophysiology of bipolar disorder 
(Manji and Lenox, 2000). Both Gpr50 and Abca2 knockout mice show hyperactive 
Chapter 3: Developmental Expression of GPR50 and Interactors 
 
 164 
behaviour (Mack et al., 2007; Ivanova et al., 2008) perhaps an indication of stress-
pathway activity. Although there was no significant difference, plasma 
corticosterone levels were consistently higher in the Gpr50 null mice compared to 
wild type (Ivanova et al., 2008). 
 
The mammalian neuroendocrine stress response in the HPA-axis is primarily 
regulated by corticotrophin releasing hormone (CRH) (Vale et al., 1981). CRH has 
been implicated in various diseases such as depression, bipolar disorder and 
Alzheimer’s disease (Behan et al., 1996; Arborelius et al., 1999). Interestingly other 
effects of CRH, such as appetite control, energy metabolism and biological rhythms 
have also been linked to GPR50 expression (Richard et al., 2000; Swaab et al., 2005; 
Barrett et al., 2006; Bhattacharyya et al., 2006; Ivanova et al., 2008). All these 
systems are also disturbed in major mental illness. Investigating the relation between 
GPR50 and CRH or the CRH receptor would therefore be interesting. 
 
3.4.8 GPR50 in neurotransmitter signalling  
 
Investigating the interactions between the HPA axis and the monoaminergic 
neurotransmitter systems is key to understanding mental illness (Swaab et al., 2005). 
We found GPR50 to be highly expressed by noradrenergic neurons in the locus 
coeruleus (LC), and also in the serotonergic raphe nuclei and the dopaminergic 
substantia nigra. In addition Gpr50 was also expessed in the polymorph layer of the 
dentate gyrus, which is the primary target for noradrenergic, serotonergic and 
cholinergic input to the hippocampus (Berger et al., 1981). This suggests a role for 
GPR50 in the control of neurotransmitter signalling or regulation. 
 
Although Gpr50 is expressed in these nuclei, the other proteins investigated appear 
not to be, with the exception of Abca2. Colocalisation of Gpr50 and Abca2 was 
observed in the LC only. The neurons in the LC have many afferent and efferent 
connections often modulated by stress (Cunningham and Sawchenko, 1988). Efferent 
projections to the hypothalamus include the cortex, hippocampus, cerebellum and 
brainstem (Loughlin et al., 1986). Noradrenergic neurons from the brainstem project 
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to paraventricular nucleus of the hypothalamus (PVN) and have a stimulatory role on 
hormonal activity. Blocking this pathway can reduce stress-induced changes in the 
HPA (reviewed by (Palkovits, 1999). LC’s major inputs are from the nucleus 
paragigantocellularis and the nucleus prepositus hypoglossi, both in the rostral 
medulla, with minor afferents coming from the hypothalamic PVN and the spinal 
intermediate gray (Aston-Jones et al., 1986). Other inputs come from the 
medial/lateral preoptic nucleus, Arcuate nucleus and the dorsomedial nucleus of the  
hypothalamus, often in response to nociceptive stimuli (Cedarbaum and Aghajanian, 
1978; Sim and Joseph, 1991). 
 
Approximately 30% of neurons projecting to the LC are CRH-positive (Reyes et al., 
2005). In the LC CRH acts as a neurotransmitter during stress (Valentino et al., 
1993; Van Bockstaele et al., 1996). LC receives CRH input from a specific group of 
neurons in the PVN, the central nucleus of the amygdala and from areas in the pons 
and medulla, areas of Gpr50 expression. Axons containing several opioid receptors 
also innervate the LC (eg enkephalin, proopiomelanocortin, dynein) (Van Bockstaele 
et al., 1995; Reyes et al., 2006; Reyes et al., 2008).  
 
Seasonal expression differences of Gpr50 have been found in the ependyma of the 
3rd ventricle in the Siberian hamster (Barrett et al., 2006) and recently an association 
was found between a GPR50 variant and seasonal affective disorder (Delavest et al., 
2011), suggesting a possible role for GPR50 in biological rhythms.  
 
3.4.9  The importance of sex in studying Gpr50 
 
The GPR50 genetic associations with bipolar disorder and other major mental illness 
were found only in women (Thomson et al., 2005; Macintyre et al., 2010; Delavest et 
al., 2011), for reasons yet unclear. Animal studies so far have not been able to give a 
clear picture of GPR50 functioning and one reason may be that sex has not been 
accounted for. This is a general point as male animals are used more often in studies 
because they are easier to handle and cheaper than females (Wald and Wu, 2010). 
Previous studies on Gpr50 expression and behaviour have either used males only 
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(Barrett et al., 2006; Ivanova et al., 2008; Sidibe et al., 2010) or have not noted the 
sex of the animals (Drew et al., 2010). Some of the most male biased fields are 
endocrinology and physiology (Wald and Wu), where clear sex differences exist 
which cannot be ignored. Women are more vulnerable to stress-related psychiatric 
disorders, such as PTSD and major depressive disorder (Kuehner, 2003).  
 
The locus coeruleus, one of the strongest sites of Gpr50 expression, may play a role 
in this, as it is a sexually dimorphic nucleus. It develops over a longer period and is 
generally larger in female rats (Luque et al., 1992; Pinos et al., 2001). Swim stress-
induced activation of LC-neurons was greater in female then in male rats (Curtis et 
al., 2006) and was related to differential sensitivity of neurons to corticotrophin 
releasing hormone (CRH) postsynaptically. Sex-specific effects on other parts of the 
stress response are also significant. Women have higher cortisol levels and the 
endocrine responses are possibly more complex with oxytocin and female sex 
hormones influencing the HPA axis ACTH, CRH and cortisol levels during the 
oestrus cycle, breastfeeding and parturition (Chiodera et al., 1991; Swaab et al., 
2005). Moreover CRH-BP is also expressed in sexually dimorphic pattern in the 
anterior pituitary, with greater expression in the female mouse, which is regulated by 
estrogen levels (Speert et al., 2002; Westphal and Seasholtz, 2006). Our finding of 
Gpr50 expression in the sexually dimorphic LC and the HPA axis might provide 
clues to its functioning and we stress the importance of taking sex differences into 
consideration in future studies. 
 
3.4.10  Caveats to this study 
 
There are a number of caveats we have to keep in mind when analyzing the 
expression of the genes as measured by rt-PCR. Firstly, the experiment was 
performed on a panel produced by Origene, which gives us little control on how the 
tissue was processed. We will therefore have to assume that this was performed 
correctly. Secondly, the cDNA in the panel was made from pooled RNA from 
different individuals and we used the same batch of panels for all experiments, which 
means no experimental replicates were performed, which will have effects on 
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statistical significance. Thirdly, Origene used β-actin to normalize the RNA to and 
also supplied β-actin primers to normalize the data against in rt-PCR. The company 
has in due time decided that Gapdh is a more stable control gene for developmental 
tissues, which it provides with panel now. This will have some effect on the 
expression levels. However, because we have used 4 reference genes to calculate a 
normalization factor (Vandesompele et al., 2002) we have controlled for the possible 
error that using one reference gene gives.  
 
One might question the decision to perform Spearman correlations between genes 
with only a small number of samples per time point (from 4 regions at E13 to 13 at 
Week 5). The inferences that may be drawn should be viewed with some caution. 
But, in defense, the genes were not selected randomly but a priori, based on the 
interactions between the genes, as found by yeast-two-hybrid, co-
immunoprecipitation and immunocytochemistry, from which a developmental co-
regulation was hypothesized. Also, the correlations reported (Fig. 3.7-3.8) exist 
between genes that are expected to be correlated, like Nogo-pan and Nogo-A, and 
between sterol associated genes Abca2 and Srebf2.  
 
Another potential point of criticism is the age of the mice studied and the relevance 
to mental illness. The developmental panel did not include an adult but an adolescent 
stage (Laviola et al., 2003; Hefner and Holmes, 2007). Mice are able to mate at this 
age but are not fully grown yet. Ideally this needs to be followed up by extending the 
panel to 10 weeks, to be able to compare it with the immunohistochemistry data, and 
even older ages perhaps more relevant to neurodegenerative diseases. Because the 
cDNAs from these timepoints are not available on the same panel they would need to 
be made from fresh mRNA and any results are perhaps difficult to compare with 
those from the panel.  
 
Similarly immunohistochemistry on different postnatal and adult stages may give a 
better picture of the true changes relevant to psychiatric or neurodegenerative 
diseases. Because of the importance of adolescence and early adulthood in the 
development of schizophrenia and bipolar disorder (Joyce, 1984), but also in fear-, 
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anxiety- and depression-related behaviors (Laviola et al., 2003; Hefner and Holmes, 
2007) this calls for further investigation. Therefore it would be interesting to measure 
mRNA and/or protein expression and function of GPR50 and interactors over a 
broader range of ages through adolescence and early adulthood, from 4 to 10 weeks.  
 
The subcellular fractionation was performed using adult (8-10 week old) mice brains. 
It would be interesting to follow this up with different ages in order to detect (subtle) 
changes in synaptic expression. Ages that can be suggested are E18, early postnatal 
and weeks 4-6. In addition co-IP analysis can be followed up by using subcellular 
fractions expressing Gpr50 and interactors (eg P2 and P3 and synaptosome) and also 
immunoprecipications from regions of co-expression in the brain such as the 
hypothalamus and amygdala. 
 
Lastly, in the subcellular fractionation and immunohistochemistry studies we looked 
at female brains only. This was done because of the relevance of using a female 
sample to the results from association studies indicating a female only risk. A true 
comparison between males and females is however necessary in order to determine 
expression differences between sexes.  
 
Another necessary follow-up study would be comparing the expression profiles of 
the interactors in wild-type, GPR50 knockout and heterozygous mice as this would 
provide additional information regarding a direct regulatory role for GPR50 with 




We have found Gpr50 expression in both the embryonic and adult mouse brain and 
in the postsynaptic density. The regions of Gpr50 expression suggest an involvement 
in neurotransmitter signalling and in particular energy metabolism and/or stress 
response, which is consistent with previous studies of Gpr50 expression and 
function. We have identified potential interaction sites of GPR50 with Nogo-A, 
Cdh8 and Abca2, which can be verified by co-immunoprecipitation. The light 
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membrane fractions and the synapse are potential subcellular locations of interaction. 
Within the brain the amygdala, hypothalamus, cortex and brain stem nuclei are 
possible sites of interaction, both in the embryonic and adult brain. More detailed 
research is needed to investigate the role of Gpr50 and its interactors in stress, 
depression and metabolism.






What is the function of GPR50’s 
interactions?
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4 Chapter Four: What is the function of GPR50’s 
interactions? 
 
4.1  Introduction 
 
G protein-coupled receptors (GPCRs) form a link between the cell and their 
environment activating intercellular signalling pathways upon ligand binding. The C-
terminal domain (CTD) is key as it binds ß-arrestin and other interacting proteins. As 
GPR50 is an orphan receptor its ligand and secondary messenger system are still 
unknown, although there is some genetic and functional evidence linking GPR50 to 
mood disorders (Thomson et al., 2005), (lipid) metabolism (Bhattacharyya et al., 
2006; Ivanova et al., 2008) and alteration of melatonin receptor signalling (Levoye et 
al., 2006).  
 
The GPCR CTD can also function as a scaffold for other proteins and its effects may 
therefore be further reaching than simply G-protein activation and signalling 
(Marinissen and Gutkind, 2001). Clues to the function of GPR50 may therefore lie in 
its interaction partners, as identified by yeast-two-hybrid screen (Grünewald et al., 
2009). The screen identified several members of the reticulon family: Nogo-A, 
Nogo-C and RTN3, which have been confirmed as GPR50 interactors in Grünewald 
et al. (2009) and in this thesis. A wide range of functions has been suggested for 
reticulon proteins including neurite outgrowth inhibition, BACE1 activity inhibition, 
intracellular trafficking between the endoplasmic reticulum (ER) and Golgi, ER 
membrane morphogenesis, vesicle formation, and apoptosis (Schwab, 2010; Yang 
and Strittmatter 2007), although the exact mechanisms of action of remain to be 
elucidated.  
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4.1.1 Nogo in axonal outgrowth inhibition and regeneration 
 
The function of the longest variant of RTN4, RTN4A or Nogo-A, in the mammalian 
brain has been characterized extensively to date. Nogo-A mediates neurite outgrowth 
inhibition and growth cone collapse in the nervous system via several regions (Oertle 
et al., 2003b): through its C-terminal Nogo-66 domain by binding to the Nogo 
receptor (NogoR) (Fournier et al., 2001), and through several N-terminal regions 
termed ‘amino-Nogo’, ‘NiR∆2’ and ‘NiG∆20’ (Oertle et al., 2003b; Schwab, 2010) 
for which no specific receptor or signaling mechanisms have been identified.  
 
As shown schematically in Fig 2.18 (Chapter 2), the GPR50-interacting domains on 
RTN proteins, as predicted by the Y2H study (Grünewald et al., 2009), lie in the 
Nogo (-A) N- and C-terminal regions. GID1 overlaps partly with NiG∆20 (Oertle et 
al., 2003b) and GID2 overlaps the first 20 amino acids of the Nogo-66 domain 
(GrandPre et al., 2000). It is therefore hypothesised that GPR50 expression may 
affect the inhibition of neurite outgrowth caused by these domains. 
 
As a consequence of the growth inhibiting characteristics of Nogo-A its function is 
currently being investigated in models of spinal cord regeneration. However, 
although in vitro models of Nogo-A neurite outgrowth inhibition have been 
consistent, in vivo models of axon and spinal cord regeneration in Nogo (-A) 
knockout mice (Kim et al., 2003; Simonen et al., 2003; Zheng et al., 2003) or a triple 
knockout of Nogo with other myelin-derived neurite outgrowth inhibitors OMgp and 
MAG (Cafferty et al., 2010; Lee et al., 2010) have shown inconsistencies and fail to 
clarify the mechanisms of axon regeneration failure common to the mammalian 
CNS. Better results were obtained by blocking Nogo-A and the Nogo receptor 
function using inhibiting molecules and an antibody against Nogo-A is currently 
being tested in a clinical trial as a treatment for spinal cord injuries (reviewed in 
Schwab, 2010). 
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4.1.2 Reticulons and BACE1 activity 
 
Additionally several recent studies have suggested the involvement of Nogo and 
other reticulon proteins in neurodegenerative and psychiatric disorders such as 
amylotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer’s disease (AD) 
and schizophrenia (Yang and Strittmatter 2007). Expression differences for Nogo-A 
and –C have been shown in post mortem forebrain samples from individuals 
diagnosed with schizophrenia, bipolar disorder and Alzheimer’s disease (Novak et 
al., 2002; Gil et al., 2006). An insertion/deletion polymorphism in the 3’ UTR of 
Nogo has shown association to schizophrenia in some, but not all studies (Novak et 
al., 2002; Tan et al., 2005). Mice lacking Nogo-A or the NgR showed behavioural 
changes that mimic some of symptoms of schizophrenia, such as impaired latent 
inhibition and sensorimotor gating, and increased perseverative behaviour and 
sensitivity to stimulants such as amphetamines (Budel et al., 2008; Willi et al., 2009; 
Willi et al., 2010).  
 
AD is the most common form of neurodegenerative dementia, and involves 
progressive loss of neuronal cells and cognitive function (Citron, 2010). A major 
pathological feature in AD is the presence of amyloid plaques in neuronal cells 
(Alzheimer, 1907), which are formed by the aggregation of amyloid (Aβ) peptides. 
Aβ peptides are generated through the sequential proteolytic cleavage of the large 
transmembrane protein APP. APP is cleaved by aspartic protease β-amyloid 
converting enzyme 1 (BACE1) to produce an N-terminal fragment (sAPP), which is 
secreted, and a membrane-bound C-terminal fragment (CTF99). CTF99 is then 
processed by γ-secretase to produce the pathogenic Aβ peptides Aβ40 and Aβ42 
(Vassar et al., 1999; Yan et al., 1999; Selkoe, 2002). He et al. (2004) and Murayama 
et al. (2006) demonstrated that all four human reticulon proteins interact with 
BACE1. The authors further showed that RTN3 and Nogo-C are negative modulators 
of BACE1 by preventing BACE1 access to its APP substrate, resulting in decreased 
production of Aβ peptide. Conversely, reducing the expression of RTN3 led to an 
increase in the production of Aβ peptide (He et al. 2004). Interestingly, expression of 
human RTN3 is decreased in the temporal lobes of AD patients (Yokota et al., 2006). 
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The NgR inhibits BACE1 cleavage and Aß formation by interacting with APP (Park 
et al., 2006). Nogo can also modulate axonal sprouting in AD models in an 
apparently separate mechanism from RTN3/NgR (Masliah et al., 2010). Although 
Nogo depletion on an APPswe background restores axonal sprouting it has no effects 
on APP neuropathology, eg amyloid deposition and microgliosis (Masliah et al., 
2010).  
 
BACE1 has other substrates in addition to APP, suggesting a variety of physiological 
functions for BACE1 (Vassar et al., 2009). All BACE1 substrates identified to date 
are (predominantly type-I (Hemming et al., 2009)) transmembrane proteins and 
include the axonal signal proteins neuregulin-1 (NRG1) and neuregulin-3 (NRG3) 
(Hu et al., 2006; Willem et al., 2006; Hu et al., 2008), cell-adhesion molecules 
NCAM1, L1CAM, Protocadherin 7 and 21, and P-selectin glycoprotein ligand-1, 
voltage-gated sodium channel (Na(v)1) beta2-subunit (beta2), Semaphorins, Ephrins 
and Sortilin (Lichtenthaler et al., 2003; Kim et al., 2007; Hemming et al., 2009) 
These proteins link BACE1 to a wide variety of functions including myelination, cell 
adhesion, contact-dependent intercellular communication and cognitive functions. 
While BACE1 knockout mice fail to produce Aß and showed a reduction in age-
dependent cognitive decline, they also showed deficits in spatial memory and lower 
anxiety levels at younger age compared to littermate controls (Laird et al., 2005). 
BACE1 null mice also show deficits in presynaptic release and synaptic plasticity in 
the hippocampal CA1 and CA3 regions, suggesting a role for BACE in the regulation 
of synaptic signaling (Laird et al., 2005; Wang et al., 2008).  
 
BACE1 substrate NRG1 is a ligand for receptor-tyrosine kinases of the ErbB family 
and induces various signalling pathways, including in synapse formation, plasticity, 
neuronal migration, and myelination of central and peripheral axons (Falls, 2003; 
Michailov et al., 2004). In the absence of BACE1, accumulation of unprocessed 
NRG1 leads to reduced myelination of axons in both the peripheral and central 
nervous system (Hu et al. 2006; Willem et al. 2006). In addition, reduced cleavage of 
NRG1 by BACE1 also decreases remyelination of injured sciatic nerves (Hu et al. 
2008). BACE1 knockout reduced the interaction of ErB4 with PSD-95 and induced 
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schizophrenia-like behaviour of impaired prepulse inhibition (PPI), novelty induced 
hyperactivity, sensitivity to a psychostimulant, reduced social recognition and 
impaired working memory in mice (Savonenko et al., 2008). Moreover a reduction 
of impaired PPI and hyperactivity was seen after the administration of atypical 
antipsychotic Clozapine (Savonenko et al., 2008). This is in agreement with genetic 
and functional data indicating that NRG1 is an important susceptibility gene for 
schizophrenia (Stefansson et al., 2002; Hall et al., 2006).  
 
Because GPR50 has been shown to interact with both Nogo-C and RTN3 (this 
thesis) it is hypothesised that GPR50 has an effect on BACE1 activity. An increase 
in GPR50-immunoreactive cells was detected in the postmortem Alzheimer brain 
(Hamouda et al., 2007) suggesting a link to the illness, perhaps via BACE1.  
 
4.1.3  The GPR50∆502-505/T532A variant 
 
The ∆502-505/T532A variant of GPR50 is associated with an elevated risk in bipolar 
disorder and major depression in women (Thomson et al., 2005; Macintyre et al., 
2010). To date no research has been published on the function of the deletion variant 
specifically, although Levoye et al (2006), seemingly unknowingly, used the deletion 
variant in their study that identified a functional interaction with melatonin receptors 
MT1 and MT2. The deletion has no apparent effect on the ability of GPR50 to bind 
its interactors Nogo-A, Nogo-C and RTN3 (this thesis) but there may be changes in 
the affinity. It would be interesting to find out if there are any functional effects of 
the GPR50∆502-505/T532A variant that may explain its association with mental illness. 
 
4.1.4  Introduction to experiments 
 
In order to find out more about the function of GPR50 I performed neurite outgrowth 
assays in Neuroscreen-1 cells, a subclone of rat pheochromocytoma (PC12) cells 
(Cellomics, Thermo-Fisher). PC12 cells are tumor cells from the adrenal medulla 
and are commonly used for modelling neuronal differentiation and early neurite 
development (Greene and Tischler, 1976). They closely resemble primary 
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sympathetic neurons in response to NGF-treatment when plated on collagen-coated 
(or poly-D-Lysine or poly-L-Lysine-coated) substrates in serum-free RPMI medium 
(Greene and Tischler, 1976). PC12 cells have however the tendency to form clumps, 
which makes visualisation and quantification of individual cells and neurites 
difficult. In addition, PC12 cell need to be treated with NGF every second day for at 
least 7 days before they produce sufficiently long neurites. For these reasons we used 
Neuroscreen-1 cells which grow out quantifiable neurites after 2 days of NGF-
treatment and which are less prone to clumping. I investigated the effect of 
overexpression of GPR50 and/or Nogo-A on neurite length and the number of 
neurites. In addition I assessed the effect of the GPR50 polymorphisms associated 
with mood disorders (Thomson et al., 2005) on neurite outgrowth.  
 
I also performed in vitro BACE1/β-secretase activity assays in HEK293 cells (He et 
al., 2004), assessing the effect of RTN3/Nogo-C/Nogo-A, GPR50 and GPR50∆502-
505/T532A overexpression on BACE1 activity. The fluorescence-based assay of BACE1 
activity makes use of a synthetic peptide BACE1 substrate (Abcam). Two reporter 
molecules, EDANS and DABCYL, are conjugated to amino acids on either side of 
the BACE1 cleavage site. In the absence of BACE1 enzyme activity, the 
fluorescence emissions of EDANS are suppressed due to the physical proximity of 
the dark quencher DABCYL. Cleavage of the substrate by BACE1 results in 
physical separation of the two reporter molecules, thus releasing fluorescence 
emissions by EDANS. The level of fluorescence activity observed is proportional to 
the activity of BACE1 in the respective sample lysates. 
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4.2  Methods 
 
4.2.1 Expression constructs 
 
All expression constructs used in this chapter are the same as those listed in Table 
2.1. Entry clones containing full-length human GPR50 (IOH63602) and RTN4 
transcript variant 1 (Nogo-A, IOH53642), RTN4 transcript variant 3 (Nogo-C, 
IOH4069), RTN3 (transcript variant 1, IOH10268) in pENTR221, were obtained 
from Invitrogen (Paisley, UK). The eGFP construct was a kind gift from Laura 
Hyndman (University of Edinburgh. The empty pDEST40 vector was a kind gift 
from Christoph Grünewald (University of Edinburgh). GPR50∆502-505/T532A was 
generated using Site Directed Mutagenesis (Agilent Technologies, see 2.2.4 Chapter 
2) 
 Entry clones were cloned by recombination into pDEST40 and pDEST53 vectors for 
untagged and N-terminal GFP tags (LR clonase II, Gateway®, Invitrogen). To select 
for expression constructs, the vectors were used to transform competent E. coli (One 
Shot Omnimax 2-Ti, Invitrogen), and plasmid DNA was extracted using Qiagen 
Miniprep or Maxiprep kits (Crawley, UK) as per manufacturer’s instructions. All 
clones were sequenced (see 2.2.5 Chapter 2) and checked for expression of proteins 
of the expected molecular weight by Western Blot (see 2.2.14 Chapter 2) in HEK293 
cells.  
 
4.2.2  Mammalian cell culture  
 
All media and chemicals were purchased from Invitrogen, unless stated otherwise. 
HEK293 cells (ECACC) were cultured in DMEM with 10% fetal bovine serum 
(FBS). Neuroscreen-1 (NS-1, Thermo Scientific/Cellomics, Pittsburgh, PA, USA) 
cells were cultured in RPMI with 10% horse serum (heat inactivated) and 5% FBS 
with Penicillin and Streptomycin (100 unit/ml and 100 µg/ml). Cultures were kept at 
37oC with constant humidity, 95% air and 5% CO2.  For transient transfections 
Lipofectamine 2000 was used according to the manufacturer’s instructions (see 2.2.7 
Chapter 2). 




4.2.3 Primary neuronal culture 
 
Hippocampal neuronal cultures were prepared from embryonic day 18 (E18) CD1 
mice as described previously (Okabe et al., 2003; Bradshaw et al., 2008). Neurons 
were seeded at 50-100 cells/mm2 on poly-D-Lysine (Sigma-Aldrich, St. Louis, USA) 
coated coverslips in 12 well cluster plates and cultured in neurobasal medium 
supplemented with 2% B-27, 2 mM Glutamax-1 and Penicillin/Streptomycin for 14-
28 days-in-vitro (DIV). Cultures were kept at 37oC with constant humidity, 95% air 
and 5% CO2.  For transient transfections Lipofectamine 2000 was used according to 
the manufacturer’s instructions (see 2.2.7 Chapter 2). 
 
4.2.4  Antibodies 
 
Antibodies used are described in 2.3.1 of Chapter 2 and details are provided in Table 
2.4a-b.  
 
4.2.5  Immunocytochemistry  
 
Cells were fixed 24 hours after transfection, by incubation in ice cold methanol for 
10 min. Cells were washed with PBS containing 0.02% bovine serum albumin (BSA, 
Sigma-Aldrich) and blocked for 30 minutes in PBS/BSA with 10% serum from 
secondary antibody host. The following primary antibodies in PBS/BSA were 
incubated for 1 hour at room temperature: anti-GPR50 (C-ter, 1:1000), anti-GPR50 
(G-15, 1:1000); anti Nogo-A (H-300, 1:1000), anti-TUJ1 (1:2000), anti-GFP 
(1:1000), anti-β-actin (1:100,000). After 3x5min washes with PBS/BSA, secondary 
antibodies Alexafluor 488/594 donkey anti-goat, -rabbit or –mouse IgG 
(1:500/1:800) in PBS/BSA with 10% serum, were applied for one hour at room 
temperature. Glass coverslips were mounted onto slides using a drop of mowiol 
(Sigma-Aldrich) with DAPI (Vectashield, Vector Laboratories, Peterborough, UK, 
2µg/ml). Images were taken on a Zeiss Axioskop 2 fluorescent microscope (Zeiss 
Plan-Neofluar 40x/1.3 and 100x/1.3 oil objectives).  




4.2.6  Neurite outgrowth assay 
 
Neuroscreen-1 cells were seeded at low density (50 cells/mm2) on poly-L-Lysine 
(Sigma) coated coverslips and were transfected 24 hours later with 2 µg plasmid 
DNA and 4 µl Lipofectamine 2000 according to manufacturer’s instructions. After 6 
hours the transfection mix was replaced by serum-free RPMI with penicillin, 
streptomycin and 50 ng/ml NGF (from murine submaxillary gland, Sigma). After 48-
72 hours, cells were fixed with ice cold methanol and immunocytochemistry was 
performed as above. 150-500 images of transfected cells were taken randomly per 
condition over three independent experiments on a Zeiss Axioskop 2 fluorescent 
microscope (Zeiss Plan-Neofluar 40x/1.3 objective). Protrusions longer than the 
soma diameter were classified as neurites. The number of neurites per cell was 
counted and the length of the longest neurite per cell was measured using ImageJ 
software (http://rsb.info.nih.gov/ij/), blind to the condition. The mean differences in 
length and number between conditions were calculated using a One Way ANOVA 
with Bonferroni’s Multiple Comparisons Test in Graphpad Prism. A significance 
level of p<0.05 was used. 
 
4.2.7  BACE1 activity assay 
 
All reagents were supplied with the Beta-Secretase Activity Assay Kit (Abcam) 
unless stated otherwise. HEK293 cells were transfected according to the 
lipofectamine transfection protocol (2.2.8 Chapter 2). Equal amounts of each 
individual plasmid were used for single and double transfections. Cells were 
trypsinized with 500 µl TripleExpress solution (Invitrogen) on 10 cm plates 24 hours 
post-transfection, and resuspended in prewarmed DMEM/FBS. Cells were counted 
using a haemocytometer and an equal amount of cells (1 x 107 cells) was used for 
subsequent processing of each sample. Cells were washed in ice cold PBS with 
protease inhibitors (Roche) and lysed in 200 µl of ice cold BACE1 Extraction Buffer 
(Abcam). Cell lysates were incubated on ice for 10 minutes and sonicated (3 x 10 
seconds with 1 min on ice in between each sonication). Cell lysates were centrifuged 
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at 10,000x g for 5 min to remove cell debris. Per condition 50 µl lysate, 50 µl 
BACE1 Reaction Buffer and 2 µl BACE1 substrate were added to a 96-well Costar 
black plate in duplicate. Controls for every experiment included: ‘no substrate’ 
controls for each condition; a ‘background’ control, by adding BACE1 Extraction 
Buffer instead of lysate, a ‘positive control’, containing active recombinant BACE1 
enzyme; and a ‘negative control’, containing a BACE1 inhibitor. The 96-well plates 
were then incubated in the dark at 37ºC for 2 hours. Absorbance readings were 
obtained in an EnVision multilabel plate reader (PerkinElmer) with excitation 
wavelength 335-355 nm and emission wavelength 495-510 nm. The readings from 
no substrate and background controls were subtracted from the experimental 
samples. These absolute BACE1 activity levels were normalised to the readings from  
eGFP and/or pDEST40 transfected cells resulting in the relative normalised BACE1 
activity levels. The mean differences in relative BACE1 activity were calculated 
using a One Way ANOVA with Dunnett’s post hoc test in Graphpad Prism. A 
significance level of p<0.05 was used. 
 
4.2.8 Western Blotting 
 
In the BACE1 activity assay HEK 293 cells were lysed in BACE1 Extraction Buffer 
(Abcam, see above) and processed as in Chapter 2 (section 2.2.14). Western blotting 
was also performed from Neuroscreen-1 cells, lysed with RIPA buffer, and 
processed as in section 2.2.14. Membranes were incubated with the following 
primary antibodies in PBS-T with 5% Marvel: anti-GFP (1:1000), anti-GPR50 (G-
15, 1:5000), anti Nogo-A (H-300, 1:2000), anti-GAPDH (Millipore, 1:100,000) 
overnight at 4ºC. Membranes were washed 3x10 min times in PBS-T, before being 
incubated with secondary horseradish peroxidise (HRP)-conjugated antibodies 
(swine anti-rabbit HRP, 1:3000; rabbit anti-goat HRP, 1:5000; rabbit anti-mouse 
HRP, 1:2000, DAKO), diluted in PBS-T for 30 minutes at room temperature. 
Following three washes with PBS-T, membranes were developed using 
chemiluminescence (ECL-Plus Western Blotting Detection System, Amersham 
Biosciences) and exposure to x-ray film. 
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  Results 
 
4.2.9  GPR50 affects neurite outgrowth 
 
Although most studies have focused on outgrowth inhibition of Nogo-A by 
oligodendrocytes (Schwab, 2004), neuronal Nogo-A is also involved in neurite 
outgrowth (Mingorance-Le Meur et al., 2007; Montani et al., 2009). I therefore 
investigated whether GPR50 affects neurite outgrowth in vitro (Grünewald et al., 
2009). For this we used Neuroscreen-1 (NS-1) cells, a PC12 cell clone, which will 
develop quantifiable neurites after 2 days of treatment with nerve growth factor 
(NGF, 50 ng/ml).  
 
NS-1 cells were transiently transfected with untagged GPR50, GPR50-TTC, GFP-
Nogo-A or eGFP as a control. Overexpressed GPR50, Nogo-A and eGFP all 
localised in the extensions and at the tips of neurites, as shown by co-labelling with 
early neuronal marker β-III tubulin (Fig 4.1B-I), making comparative analysis of 
outgrowth possible (Grünewald et al., 2009).  
 
After transfection and treatment with NGF for 48 hours, immunocytochemistry was 
performed and images of transfected cells were randomly collected for each 
condition. The length of the longest neurite was measured and the total number of 
neurites per cell counted. Analysis of neurite length (Fig 4.1J) shows a significant 
increase in neurite length after transient expression of untagged GPR50 (100±4.11 
µm) or untagged GPR50 ‘TTC’ (110±3.33 µm) when compared to eGFP (79±3.51 
µm) (p<0.0001) (Grünewald et al., 2009). In agreement with previous results 
(Montani et al., 2009), Nogo-A overexpression significantly shortens neurites 
(59±5.56 µm, p<0.0001) (Grünewald et al., 2009). However, in cells cotransfected 
with GPR50 and Nogo-A no significant difference in neurite length was observed as 
compared to eGFP (86±10.33 µm, p>0.05) (Grünewald et al., 2009). GPR50 thus not 
only extends neurites, but also appears to attenuate Nogo-A’s outgrowth inhibition 
phenotype. The number of neurites per cell (Fig 4.1K) was significantly decreased 
upon transfection with Nogo-A (n=2.06±0.097) and Nogo-A plus GPR50 
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(1.99±0.125) as compared to eGFP (2.31±0.085, p<0.001) but no difference was 
found in the GPR50-transfected cells (2.40±0.049, p>0.05) (Grünewald et al., 2009). 
Interestingly, the Nogo-A results show marked similarity to a previous study 
(Montani et al., 2009). When looking at neurite outgrowth in neuronal DRG cultures 
from Nogo-A KO mice, an increase was found in neurite length but no effect was 
detected on the number of neurites. 
 
In addition to longer neurites, the GPR50-overexpressed phenotype shows an 
increase in filopodia and lamellipodia-like structures in which GPR50 colocalises 
with β-actin (Fig 4.2A-C) (Grünewald et al., 2009). GPR50 is not able to induce 
neurite outgrowth in NS-1 cells in the absence of NGF (Fig 4.2D-E), although 
overexpressing GPR50 appears to induce filopodia formation (Fig 4.2E) as compared 
to eGFP (Fig 4.2D). In primary hippocampal neurons transfected with GPR50 an 
increase in synaptic spines is also observed as compared to eGFP (Fig 4.2F).  





Figure 4.1 GPR50 overexpression increases neurite outgrowth. Neuroscreen-1 
cells were transiently transfected with eGFP, full length human untagged GPR50, 
full length untagged human GPR50‘TTC’, full length human Nogo-A or cotransfected 
with GPR50 and Nogo-A. After treatment with 50 ng/ml NGF for 48 h, transfected 
cells were labeled by expression of GFP (A, G) or GPR50 (Abcam, D). Co-staining 
with β-III tubulin (B-C, E-F, H-I) shows all overexpressed proteins are present 
throughout the cell body and into the neurites. Per condition 150-500 cells were 
randomly selected over five independent experiments. The length of the longest 
neurite (J) and number of neurites (K) per cell were determined for each condition. 
Bars show means (±SE). Cells were counterstained with DAPI. Scale bar: 50 µm. *** 
p<0.001, ** p<0.01. Image adapted from Grünewald et al., (2009) Molecular and 
Cellular Neuroscience. Copyright Elsevier 2009.





Figure 4.2 GPR50 induces filopodia in Neuroscreen-1 and primary cultured 
neurons. NS-1 cells were transfected with GPR50-TTC (A-C), incubated for two 
days in serum-free medium with NGF and then labelled with GPR50 C-ter  (A, 
green; B-C, red) and TUJ1 (A, red) and β-actin (B-C, green). NS-1 cells were 
transfected with (D) eGFP or (E) GPR50TTC, were cultured for two days in serum-
free medium without NGF and stained with (D) GFP or (E) GPR50 G-15 and β-actin. 
(F) Primary hippocampal mouse neurons were transfected at 14 DIV with untagged 
GPR50 or eGFP and stained with GPR50 C-term antibody or GFP. Cells were 
counterstained with DAPI. Scale bar: 50 µm. Image partly adapted from Grünewald 
et al., (2009) Molecular and Cellular Neuroscience. Copyright Elsevier 2009 
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4.2.10 GPR50∆502-505/T532A further increases neurite outgrowth 
 
The above neurite outgrowth experiment was repeated using GPR50∆502-505/T532A to 
assess the effects of the deletion variant associated with mood disorders on neurite 
outgrowth. Overexpressed GPR50 and GPR50∆502-505/T532A were both present at the 
tips of neurites, colocalising with β-actin (Fig 4.3A, arrows). A significant increase 
in neurite length was measured after overexpression of GPR50 (88.32±2.470) and 
GPR50∆502-505/T532A (99.71± 2.507) compared to eGFP (72.32±2.207; p<0.001), 
moreover a further significant increase was found in GPR50∆502-505/T532A-
overexpressing cells compared to GPR50 (p<0.01) (Fig 4.3B). Again no difference 
was found in the number of neurites between conditions (p>0.05, Fig 4.3C). To test 
whether this increase was the result of higher GPR50 expression of the GPR50∆502-
505/T532A construct NS-1 cells were transfected with GPR50, GPR50∆502-505/T532A or 
GPR50 TTC or left untransfected. Western blotting was performed using the GPR50 
G-15 antibody and GAPDH as a loading control. The results (Fig 4.3D) indicate that 
there is no difference in expression levels between GPR50 and GPR50∆502-505/T532A 
but that GPR50 TTC is much higher GPR50 expressor as was previously shown 
(Chapter 2). This indicates that GPR50∆502-505/T532A indeed increases neurite 
outgrowth further compared to GPR50. 




Figure 4.3 GPR50∆502-505 overexpression further increases neurite outgrowth. (A) 
NS-1 cells were transfected with GPR50 or GPR50∆502-505/T532A and labelled 
with GPR50 (green) and β-actin (red). Cells were counterstained with DAPI. Scale 
bar: 50 µm. (B-C) After treatment with 50 ng/ml NGF for 48 h, transfected cells were 
labeled by expression of GFP or GPR50. Per condition 300 cells were randomly 
selected over three independent experiments. The length of the longest neurite (B) 
and number of neurites (C) per cell were determined for each condition. Bars show 
means (±SEM). *** p<0.0001, ** p<0.001. (D) NS-1 cells were left untransfected (1) 
or transfected with GPR50 (2), GPR50∆502-505/T532A (3) or GPR50 TTC (4). 
Western blotting was performed using the GPR50 G-15 antibody and GAPDH as a 
loading control.  
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4.2.11 Effect of reticulon proteins and GPR50 on in vitro 
BACE1 activity  
 
As reticulon proteins are known to interact with BACE1 and inhibit its activity (He 
et al. 2004; Murayama et al. 2006), I wanted to establish whether GPR50 has any 
effect on BACE1 activity in vitro. HEK293 cells were used, which endogenously 
express BACE1 at relatively low levels, as they are able to produce small amounts of 
Aβ peptide (Hemming et al. 2009). A commercially available fluorescence-based 
BACE1 activity assay kit (Abcam) was used to assess the effect of overexpressing 
GPR50, the deletion variant GPR50∆502-505/T532A (Thomson et al. 2005) and reticulon 
proteins Nogo-A, Nogo-C, and RTN3 on BACE1 activity, similar to the activity 
assay used by He et al., (2004). 
 
The experiment was performed in two parts. The first part investigated the effects of 
untagged GPR50 (∆502-505/T532A), untagged Nogo-A, GFP-Nogo-C and GFP-
RTN3 on BACE1 activity. The second set of experiments looked at the combined 
effects of GPR50 (or ∆502-505/T532A) with Nogo-C or RTN3. EGFP and 
pDEST40 were used as controls and three independent experiments were performed. 
Two replicates from this first part were performed by MSc student Sophie Hempel 
(as part of her 4year IGMM PhD programme), the rest by myself. The sample lysates 
used in the fluorescence assay were checked by Western blot for correct expression 
of the respective proteins (Fig 4.4A).  
 
The absolute non-normalised BACE1 activity data are shown in Fig 4.4B. These data 
were normalised to either GFP, for GFP-tagged constructs Nogo-C and RTN3, or the 
empty vector control (pDEST40) for all remaining untagged constructs. Cells 
cotransfected with untagged and GFP-tagged constructs were normalised to both 
eGFP and pDEST40. Because the experiment was performed in two parts it is 
necessary to establish whether the conditions between the two parts were similar. 
Only in this case the results from the two parts can justifiably be compared. 
Therefore T-tests were performed to test if absolute BACE1 activity of the control 
conditions was the same in both parts of the experiment. There was no significant 
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difference in absolute BACE1 activity between GFP or pDEST40 between part 1 and 
2 of the experiment (p>0.05) and therefore the normalised data of single- and double-
transfected cells can be compared.  
 
The normalised results are shown in Fig 4.4C. As reported previously Nogo-C and 
RTN3 reduced BACE1 activity (p<0.05) (He et al., 2004; Murayama et al., 2006). 
No significant difference was seen however upon Nogo-A overexpression. 
Interestingly, over-expression of GPR50 significantly increased BACE1 activity 
(p<0.05, Fig 4.4C), whereas the GPR50 deletion variant, GPR50∆502-505/T532A did not 
affect BACE1 activity. No difference in BACE1 activity was found when cells were 
cotransfected with GPR50 or GPR50∆502-505/T532A and RTN3 or Nogo-C compared to 
control. GPR50 thus appears to partially counteract the BACE1 inhibiting 
characteristics of RTN3 and Nogo-C. 




Figure 4.4 Effect of reticulon proteins and GPR50 on BACE1 activity in vitro. (A) 
HEK293 cells were transfected with respective constructs (see legend and materials 
& methods). Cells were lysed using the BACE1 extraction buffer (Abcam), loaded on 
SDS-PAGE and checked for protein expression by Western blotting. ‘GPR50del’ = 
GPR50∆502-505/T532A. (B) After incubation of lysates with reaction buffer (Abcam) 
and BACE1 substrate at 37°C, EDANS fluorescence emission caused by BACE1 
cleavage was measured and absolute BACE1 activity readings taken from three 
independent replicates. (C) Relative BACE1 activity from three independent 
replicates. Absolute values were normalised to either the GFP (for GFP-tagged 
constructs) or to the empty vector control (pDEST40) reading (for untagged 
pDEST40 constructs, or both for cotransfected samples). Bars show means (±SE).  
* p<0.05.






In this chapter two functional assays were performed: neurite outgrowth and BACE1 
activity. In both assays there is a significant effect of GPR50 overexpression. GPR50 
appears to extend neurites and also increases BACE1 activity compared to controls.  
 
4.3.1 GPR50 and neurite outgrowth   
 
We have shown that GPR50 overexpression increases neurite ougrowth in vitro 
contrary to Nogo-A. The results also suggest that GPR50 attenuates the outgrowth 
inhibiting characteristics of Nogo-A. The GPR50∆502-505/T532A variant further 
increases neurite outgrowth compared to GPR50. 
 
Nogo-A is a potent neurite outgrowth inhibitor in vitro and in vivo (Schwab, 2004). 
One of the Nogo-A-signalling pathways is mediated by the neuronal Nogo-66 
receptor (NgR) complex (Fournier et al., 2001) and second messengers RhoA and 
Rac1, which alter actin dynamics and organisation of the cytoskeleton (Fig 4.6) 
(Niederost et al., 2002; Fournier et al., 2003; Montani et al., 2009). GTPases Rho, 
Rac and Cdc42 are involved in actin dynamics by regulating cell adhesion and stress 
fibre formation (Rho), lamellipodia formation (Rac) and filopodia formation (Cdc42) 
(Nobes and Hall, 1995). It is likely that other Nogo-A signalling pathways exist as 
Nogo-A expression in the developing CNS precedes NgR expression (Mingorance et 
al., 2004) and other regions of Nogo-A can also inhibit outgrowth (Oertle et al., 
2003b).  
 
Although the neurite outgrowth inhibiting properties are mainly attributed to 
different regions of Nogo-A in oligodendrocytes (Oertle et al., 2003b), it is expressed 
in many different cell types, including developing and adult neurons (Mingorance et 
al., 2004; Dodd et al., 2005; Richard et al., 2005). In neurons, overexpressing Nogo-
A causes destabilisation of inhibitory synapses in vivo (Aloy et al., 2006), inhibiting 
Nogo-A or the Nogo-receptor in adult mouse hippocampal slices results in an 
increase in long-term potentiation (LTP, Delekate et al., 2011), and ablation of 
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neuronal Nogo-A in knockout mice causes neurite extension (Montani et al., 2009) 
or branching of the major neurite (Mingorance-Le Meur et al., 2007). These studies 
indicate a role for neuronal Nogo-A as a negative regulator of plasticity and growth. 
 
Our observations, that Nogo-A overexpression reduces neurite outgrowth in a 
neuronal-like cell line, support a role for neuronal Nogo in axonal formation and 
growth in development under non-pathological conditions (Mingorance et al., 2004; 
Richard et al., 2005). The opposite effect of increased outgrowth in GPR50-
overexpressing neuronal cells is intriguing as it is remarkably similar to the effects 
seen in neuronal cultures from Nogo-A knockout mice (Fig 4.6) (Grünewald et al., 
2009; Montani et al., 2009). 
 
Whether GPR50 signals via Nogo-A and RhoA/Rac1 to alter neurite outgrowth or 
through Rac1 or another pathway calls for further investigation. Although there are 
indications that GPR50 increases filopodia in the absence of NGF (Fig 4.2), NGF is 
necessary for initiation of neurite outgrowth. This suggest Cdc42 activation by 
GPR50 rather then Rac1 (Nobes and Hall, 1995). Future studies performing 
Cdc42/Rac/Rho activity assays as well as targeting effector molecules of GTPase 
signalling pathways are necessary to confirm this. 
 




Figure 4.5 Rho GPTases (RhoA, Rac1, Cdc42) and the organisation of the actin 
cytoskeleton. Nogo-A on the surface of oligodendrocytes or neurons can bind the 
Nogo receptor (NgR) via its Nogo-66 loop region (Fournier et al., 2001). NgR forms 
a complex with transmembrane proteins p75, LINGO1 and TROY (Nash at al., 
2009). This leads to the activation of RhoA and ROCK pathway, via LIMK and 
Cofilin (Montani et al., 2009; Niederöst et al., 2002), and to neurite outgrowth 
inhibition. A parallel pathway, which is inhibited by Nogo-A (Niederöst et al., 2002) 
leads to Rac1 activation of PAK1 resulting in increased phosphorylation and 
inactivation of LIMK and Cofilin and to actin stabilisation and neurite outgrowth. 
These pathways can also be activated by other membrane receptors and signaling 
proteins (Siehler, 2009), perhaps GPR50 as well.  





Several of the other yeast two-hybrid interactors are also linked to neuronal 
development (CDH8, PCDH 9, SHOT1, PICK1), which increases the possible 
pathways in which GPR50 can affect neurite outgrowth. Cadherins can play a role in 
neurite extension (Skaper et al., 2001), through activating the fibroblast growth 
factor receptor (FGFR). By triggering second messenger cascades phospholipase Cγ 
(PLCγ) is activated and voltage gated calcium channels are opened (Williams et al., 
1994). This calcium influx is required for and sufficient to stimulate neurite 
outgrowth (Doherty et al., 1991). Whether this is also the case for CDH8 and 
PCDH9 needs to be further investigated. 
 
Shootin-1 (SHOT1) is a brain-specific protein expressed during development, with a 
peak around postnatal day 4 (Toriyama et al., 2006). It localises to filopodia and 
lamellipodia and interacts with actin retrograde flow and with neuronal cell-adhesion 
molecule L1-CAM (also known as CDH2) (Shimada et al., 2008). The interaction is 
necessary for L1-dependent neurite outgrowth in hippocampal neurons. SHOT1 
overexpression induces L1-dependent neurite outgrowth (Shimada et al., 2008). 
SHOT1 is involved in the development of neuronal polarisation. SHOT1 localises to 
a single neurite, which later develops into the axon and disrupting SHOT1 alters this 
asymmetric polarisation (Toriyama et al., 2006). Interestingly GPR50 overexpression 
only increase the length of the longest neurite and not the number of neurites 
suggesting it plays a role in axon formation as well.  
 
PICK1 on the other hand has been shown to control and reduce synaptic spine size 
by inhibiting Arp2/3-mediated actin polymerisation (Rocca et al., 2008; Nakamura et 
al., 2011). 
 
Interestingly other GPCRs are known to affect neurite outgrowth. GPR3, GPR6 and 
GPR12 are constituitively active and can induce neurite outgrowth in cerebellar 
granule neurons via activation of Gαs and cAMP and via inhibition of RhoA (Tanaka 
et al., 2007). In PC12 cells PACAP (Pituitary adenylate cyclase-activating 
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polypeptide) signaling through the GPCR PAC1 can induce neurite outgrowth via 
Gαs and Gαq (Vaudry et al., 2002), activating cAMP, PKA and EPAC, ERK and 
CREB. Interestingly there is some overlap with the pathway activated by NGF via 
the TrkA receptor in PC12 cells, although the processes are distinct (Vaudry et al., 
2002). It is likely that many other recptors including GPR50 can influence these 
pathways via crosstalk or downstream signalling.   
 
Without a ligand the GPR50 signalling pathway has remained unclear. This study 
however offers new insights into the pathways that could be investigated. GPCRs are 
able to activate Rho GEF and GTPases via Gα12/13 and several recently deorphanised 
GPCRs couple to Gα12/13 (Lee et al., 2006; Henstridge et al., 2009; Siehler, 2009). A 
preassociation of GPR50 with Gαi, Gαq and Gβ (but not Gαs or Gα12) has been 
found (Levoye et al., 2006). Gαi can activate Rac1 and RhoA (Singh et al., 2010) 
and Gαq was found to be  necessary for morphological changes associated with 
cortical actin cytoskeleton redistribution in Drosophila photoreceptor cells (Kosloff 
et al., 2003). Gαi signalling inhibits cAMP and PKA production and activates 
protein kinases such as mitogen-activated protein kinases (MAPK) 1 and 2 and Akt. 
These kinases can stimulate neurite outgrowth in Neuro2A cells and the CNS 
(Ma'ayan et al., 2009). These pathways were shown to be activated by GPCR 5-
HT1A/B, Cannabinoid 1 receptor and Dopamine D2 receptor stimulation (Ma'ayan et 
al., 2009).  However, non-G-protein signalling is an important mechanism and ß-
arrestins and G-protein-coupled receptor kinases, binding to the C-terminal domain, 
coordinate signal transduction by mediating silencing or desensitisation, trafficking, 
and G-protein independent signalling of 7-transmembrane receptors (Reiter and 
Lefkowitz, 2006). It is therefore possible that GPR50 excerts its function via ß-
arrestin-dependent signalling. 
 
Although neuronal Nogo-A accumulates in axonal growth cones, it remains in the 
central region and does not enter the filopodial processes (Mingorance-Le Meur et 
al., 2007). We have shown that GPR50 overexpression results in an increase in 
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filopodia and lamellipodia, in which GPR50 is present and colocalizes with actin. 
This difference in distribution is interesting and may be related to the opposite 
effects on outgrowth. Besides playing an important role in neurite outgrowth, 
filopodia are seen as precursors of dendritic spines (Mattila and Lappalainen, 2008), 
perhaps indicating a role for GPR50 and in synapse development. 
 
Overexpression of the GPR50∆502-505/T532A variant further increased neurite 
outgrowth, which is perhaps surprising since the polymorphism is associated with an 
increased risk in psychiatric illness. From this perhaps a decrease in neurite length 
would be predicted, in agreement with CNS volume reductions in mood disorders 
and findings that antidepressants and antipsychotics promote neurite outgrowth and 
brain grey matter volume (reviewed in Manji et al., 2000). This may however 
indicate neurite development is disturbed in GPR50∆502-505/T532A variant. Since 
GPR50∆502-505/T532A is a common variant (Thomson et al., 2005), the effects are not 
likely to be drastic, but it would be interesting to investigate possible differences in 
brain connectivity between people with GPR50 vs GPR50∆502-505/T532A using 
functional imaging. 
 
4.3.2 GPR50 and BACE1 activity 
 
We have shown that GPR50 overexpression inceases BACE1 activity in vitro. Like 
He et al. (2004) and Murayama et al. (2006) we report that RTN3 and Nogo-C 
overexpression results in decreased BACE1 activity. Neither Nogo-A nor the 
GPR50∆502-505/T532A variant alter BACE1 activity compared to control.  
 
Interestingly, the effects of GPR50 on BACE1 activity may provide clues to its 
function in psychiatric illness, perhaps via NRG1. BACE1 has multiple substrates in 
addition to APP (see introduction to this chapter) and BACE1 is also responsible for 
the processing of NRG1, a signalling protein responsible for axon myelination 
(Willem et al., 2006). This is summarised in Fig 4.7. It is possible that GPR50, 
perhaps in response to an extracellular ligand, initiates a pathway that leads to the 
up-regulation of BACE1 and subsequent Aβ-generation and myelination. 
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Interestingly NRG1 is also a well-researched candidate gene for schizophrenia 
(Stefansson et al., 2002; Corfas et al., 2004; Hall et al., 2006). This implicates 
GPR50 in two pathological pathways, in Alzheimer’s disease and psychiatric illness 
(Fig 4.7).  
 
Aberrant sprouting of neurites is a common pathlogical feature in AD (Hashimoto 
and Masliah, 2003; Masliah et al., 2003). A similar mechanism has been proposed 
for schizophrenia although there is little evidence to support this (Stevens, 1992). 
GPR50 was detected in postmortem Alzeimer’s brain (Hamouda et al., 2007) so it is 
possible that GPR50 plays a role in this mechanism. Interestingly it is proposed that 
Nogo may negatively regulate aberrant sprouting in AD (Masliah et al., 2010).   
 
Yet another possibility is that GPR50 plays a role in the normal functioning of 
APP/BACE1. There is emerging evidence for a role of APP in neurite outgrowth 
(Leyssen et al., 2005; Hoe et al., 2009) neuronal proliferation and survival and cell 
adhesion (Hughes et al., 2010), synaptic development (Ashley et al., 2005) and 
interestingly G-protein-coupled receptor signaling (via G0), (Nishimoto et al., 1993) 
under non-pathological conditions (Reinhard et al., 2005).  
 
The results obtained in this study strengthen a role for GPR50 in brain disorders like 
AD and psychiatric illness, in agreement with previous studies (Thomson et al., 
2005; Hamouda et al., 2007; Macintyre et al., 2010), and may even suggest a future 
role for GPR50 as a therapeutic target. More detailed research is however needed to 
substantiate these claims. The following questions may be relevant for future 
research. 





Figure 4.5 Possible mechanisms of GPR50 functioning. GPR50 is shown to 
increase neurite outgrowth and BACE1 activity suggesting a link to Aβ deposition 
and Alzheimer’s disease but also to NRG1 cleavage, myelination and psychiatric 
illness. Reticulon proteins on the other hand have been shown to inhibit neurite 
outgrowth and BACE1 acitivity suggesting GPR50 functions through inhibition of 
reticulon proteins. More research is needed to determine whether GPR50 interacts 
directly with BACE1 and what the downstream effects of BACE1 inhibition are. 
Nogo-A is known to signal via Rho kinase (ROCK) to destabilise the Actin 
cytoskeleton resulting in growth cone collapse. The effects of GPR50 
overexpression on ROCK signaling and actin need to be investigated. GPR50, 
Nogo-A, BACE1 and APP all localise to the postsynaptic density suggesting they 
interact at the synapse. APP and BACE1 were previously shown to localise to lipid 
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4.3.3 Future studies 
 
4.3.3.1  What are the effects of GPR50 knockdown/knockout?  
So far we have only worked with overexpressed GPR50. This is due in part to the 
difficulty in obtaining a knockout mouse (mice have been produced by 
Organon/Schering Plough/Merck and Astra Zeneca, and KOMP (Knockout Mouse 
Project, UC Davis) have recently produced one). Knockdown of GPR50 using RNAi 
should however be easier to perform. The endogenous levels of GPR50 in common 
immortalised cell lines are however very low (1-10% of HEK293 cells) or not 
detectable (COS7, SHSY5Y, Neuroscreen-1) by rt-PCR, Western blotting or 
immunocytochemistry. As shown in Chapter 2 Gpr50 is detected in cultured neurons 
by immunocytochemistry. The effects of GPR50 knockdown on neurite outgrowth 
and BACE1 activity could therefore be tested in these cells. 
 
4.3.3.2 Does GPR50 interact directly with BACE1?  
While it has been found that reticulon proteins can directly bind and inhibit BACE1, 
it is not clear how GPR50 would achieve the up-regulation of BACE1 activity. 
Binding studies such as co-immunoprecipitation are needed to determine whether 
GPR50 has any direct or indirect interaction with BACE1, and whether this 
interaction involves reticulon proteins (for instance in a complex). APP has been 
shown to be expressed in presynaptic vesicles and in the PSD (Ashley et al., 2005) 
which suggests that GPR50/RTN3/4 may interact with APP/BACE1 at the synapse. 
Knockout models of reticulon proteins need to be included in order to test whether 
the functional effects are dependent on GPR50-RTN3/Nogo-C interactions. 
 
A cell-based system in which GPR50 is endogenously expressed would be useful. Of 
all the cell lines that have been used in this thesis only HEK293(T) cells express 
GPR50 in 1-10% of cells. In the immunohistochemistry study several regions of the 
brain that express GPR50 were identified, most notably the hypothalamus and the 
locus coeruleus. Perhaps a cell line derived from these regions could be used. 
Recently a catecholaminergic cell-based system has been developed. CAD (Cath.a-
differentiated) cells are a mouse neuronal cell line originating from the locus 
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coeruleus in which a neuronal phenotype can be induced following serum 
deprivation (Qi et al., 1997). Interestingly this system has so far been useful in 
studying APP and Aβ cell biology and Alzheimer’s pathology (Muresan and 
Muresan, 2006; Muresan et al., 2009) and also DISC1 cell biology and psychiatric 
illness (Park et al., 2010).  
 
4.3.3.3 Does GPR50 affect APP and NRG1 processing and Erb signalling? 
Increased BACE1 activity suggests increased APP processing and extracellular Aβ, 
and an increase in NRG processing and myelination. Whether GPR50 
overexpression can cause this needs to be tested. The GPR50∆502-505/T532A variant 
does not increase in vitro BACE1 activity more then control and may thus result in 
reduced processing of NRG1 and myelination or prevent excessive Aβ production 
compared to GPR50. Myelin electrically insulates axons and is essential for the 
proper functioning of neuronal information processing (Sherman and Brophy, 2005). 
Loss of myelination can lead to cognitive defects and is known to be a contributing 
pathological feature in schizophrenia (Dwork et al., 2007) and possibly other 
psychiatric disorders. It is possible GPR50∆502-505/T532A may lead to increased risk in 
psychiatric illness via abnormal myelination.  
 
4.3.3.4 Do GPR50 and interactors affect surface/endomembrane expression 
(and therefore functionality) of BACE1?  
Several of the GPR50 Y2H interactors have a role in cell sorting. SNX5 and SNX6 
are members of the SNX family of proteins involved in membrane trafficking and 
protein sorting. It is believed that SNX5 and SNX6 are part of a retromer involved in 
endosome to trans-golgi network (TGN) transport (Hong et al., 2009). SNX6 was 
recently identified as a BACE1 interactor and a negative modulator of BACE1-
mediated APP processing (Okada et al., 2010). It appears to do this by negatively 
modulating BACE1 retrograde transport from the endosome to the TGN. Y2H 
interactor Consortin (FLJ32001) is another TGN protein involved in the membrane 
targeting of interacting Connexin proteins (del Castillo et al., 2010). It is possible 
that these proteins is also involved in the sorting and targeting of BACE1. 
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RTN3 has been suggested to play a role in cellular trafficking between the Golgi and 
ER (Wakana et al., 2005). Recently it was shown that BACE1 localisation was 
altered upon RTN3 overexpression (Shi et al., 2009). HEK293 cells stably 
expressing RTN3 showed an enrichment of BACE1 in the ER fraction and decrease 
on the cell surface (Shi et al., 2009). BACE1 preferentially cleaves APP in an acidic 
milieu like the early endosome or Golgi and the ER is therefore not favourable. This 
increased retention of BACE1 and APP in the ER may explain the abnormal 
processing of APP and decreased Aß deposition, which is observed upon RTN3 
overexpression. Results in Chapter 2 indicate that reticulon proteins have a similar 
effect of GPR50, decreasing its surface expression in favour of the ER. The strongest 
effects were seen on GPR50∆502-505/T532A upon co-overexpression of RTN3 (Chapter 
2). These results suggest that GPR50∆502-505/T532A is more prone to ER retention and 
association with RTN3 and which perhaps causes a reduction in BACE1 activity 
compared to GPR50. 
 
The transport and sorting of BACE1 to the different membrane compartments of the 
cells is tightly regulated and modulating the proportion of BACE1 in various 
compartments affects the cleavage of APP and other substrates (Small and Gandy, 
2006). APP is cleaved by BACE1 at the cell surface and predominantly in early 
endosomes. BACE1 ad APP appear to be trafficked together from the cell surface to 
the endosomes and Aβ is generated in these areas (Kinoshita et al., 2003) but also in 
the Golgi and ER (Kuentzel et al., 1993; Chyung et al., 1997; Cook et al., 1997; 
Hartmann et al., 1997). Increased surface expression (reduced endocytosis) of APP 
has been shown to result in increased α-secretase and reduced β-secretase cleavage, 
leading to a decrease in secreted Aβ-40 and 42 (Hoe et al., 2009). It would be 
interesting to test if GPR50 overexpression can alter BACE1 localisation, and 
perhaps thereby its activity.  
 
4.3.3.5  Is GPR50 associated with cholesterol-enriched lipid rafts as known 
for APP and BACE1?  
Cholesterol is enriched in the brain, as it can hold 25% of total cholesterol in 2% of 
total body weight (Dietschy and Turley, 2001). Cholesterol has been implicated in 
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AD pathogenesis as total cholesterol and serum LDL correlated with Aß load in AD 
brains (Kuo et al., 1998) and individuals with higher cholesterol levels have a higher 
risk of developing AD (Kivipelto et al., 2001), which could be reversed by treatment 
with cholesterol lowering statins (Jick et al., 2000).  
 
Several of GPR50’s interactors are lipid associated or have a known role in lipid 
metabolism and have links to AD pathology. Oxysterol binding protein 2 is a 
member of a protein family involved in sterol synthesis and regulation (Im et al., 
2005). SREBF2/SREBP2 is a ubiquitously expressed transcription factor that 
controls cholesterol homeostasis by stimulating transcription of sterol-regulated 
genes. Variations in SREBF2 are potential candidate CSF biomarkers in AD (Kim et 
al., 2011). Transgenic mice overexpressing SREBP2 showed accumulation of 
mitochondrial cholesterol and increased oxidative neuronal death in response to 
Aβ1-42 (Fernandez et al., 2009). ABCA2 shares the highest homology with the HDL 
cholesterol transporter ABCA1 and may also influence cholesterol transport 
(Kaminski et al., 2001) and sphingolipids (Sakai et al., 2007). Mace et al., (2005) 
identified a SNP in ABCA2 exon 14 associated with early onset AD. In further 
support of a role in AD, ABCA2 colocalizes with APP and Aβ, and overexpression 
of ABCA2 results in an increase in intracellular protein levels of APP and Aβ (Chen 
et al., 2004b). ABCA2 expression was also linked to the oxidative stress response 
and subsequent cell death, another pathological characteristic of AD (Chen et al., 
2004).  
 
Lipid rafts are small (10-200 µm), heterogeneous glycolipoprotein microdomains 
enriched in cholesterol and sphingolipids, predominantly present on the cell surface 
but also in endomembranes (Pike, 2006; Vetrivel and Thinakaran, 2010) They are 
rich in signalling proteins and are involved in signal transduction, sorting and 
membrane trafficking, regulation of the actin cytoskeleton (by altering cell polarity, 
motility of growth cones and lamellipodia) and cell adhesion (Simons and Toomre, 
2000; Guirland et al., 2004). Lipid rafts have also been shown to be important for the 
functioning of spines and synapses (Hering et al., 2003). Interestingly, lipid raft 
protein Caveolin-1 has recently been shown to promote dentritic growth and 
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neurotransmitter signalling in primary neurons, even in the presence of myelin-
associated inhibitors like Nogo (Head et al., 2011). 
 
Both BACE1 and its substrates APP and NRG1 are present in lipid rafts (Frenzel and 
Falls, 2001; Riddell et al., 2001) as assessed by insolubility by Triton X-100. BACE1 
processing of APP is thought to take place in lipid rafts and is dependent on the 
presence of cholesterol in rafts (Cordy et al., 2003; Ehehalt et al., 2003) however 
more recent data suggest otherwise (Vetrivel et al., 2009). Aβ is released from 
endosomes by specific vesicles and exit the cell membrane as exosomes, which are 
enriched in raft lipids (Rajendran et al., 2006).  
 
APP, BACE1, GPR50, Nogo-A and CDH8 are present in the postsynaptic density, 
which is known to be rich in lipid rafts (Hering et al., 2003). Indeed, PSD-95 is a 
raft-enriched protein. One of the characteristics of the PSD is its insolubility in 
Triton X-100, which has long been used to identify lipid rafts (Hering et al., 2003), 
however other methods of identification and isolation are needed (Lichtenberg et al., 
2005). There is therefore a good possibility that GPR50 (and its interactors) are raft 
proteins, both in the PSD and in other areas. The 2-transmembrane domain of RTN3 
and Nogo-C are critical for modulation of BACE1 activity (Kume et al., 2009) 
suggesting a direct interaction within the membrane, perhaps in lipid raft domains. It 
would therefore be interesting to investigate the effects of GPR50 overexpression on 




To summarise, this study provides evidence that GPR50 plays a role in neurite 
outgrowth and in regulating BACE1 activity. Further studies are needed to establish 
whether GPR50 plays a role in these processes during development and/or 
pathological conditions and whether the effects are direct or via its (other) 
interactors. Building up from previous reports (Thomson et al. 2005; Macintyre et al. 
2010; Hamouda et al. 2007), this study provides further clues for the functional 
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involvement of GPR50 in the pathogenesis of mood disorders and Alzheimer’s 




The BACE1 assay was partly performed by IGMM PhD rotation student Sophie 
Hempel, under my supervision. She performed two replicates of part 1 of the BACE1 
assay. Pilot studies giving a similar result with a different BACE1 activity assay kit 
(R&D systems) were performed by IGMM PhD rotation student Sarah McCulloch 
under my supervision.
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5 Chapter Five: Structural analysis of the GPR50          
C-terminal domain  
 
5.1 Introduction  
 
5.1.1 The GPR50 CTD sequence and structure 
The GPR50 cytoplasmic domain (CTD) in humans spans 320 amino acid (aa) 
residues, roughly half of the total length of the GPR50 protein (617 aa). The GPR50 
CTD is substantially larger than that of the related human Melatonin 1 (MT1) and 2 
(MT2) receptors and its orthologue in non-mammalian species the Melatonin1c 
receptor (Mel1c) (Chapter 1 Fig 1.5). Compared to the relatively conserved 
transmembrane domains in GPCRs (Dufourny et al., 2008) (see also Introductory 
Chapter 1) not much is known about the structure of the CTD. We therefore set out 
to investigate some of the structural properties of the GPR50 CTD, and the 
significance of the polymorphisms within identified by Thomson et al. (2005). 
Interest in the structure of the CTD was raised by an unpublished report by Dinesh 
Soares (University of Edinburgh), as summarised below.  
 
Using bioinformatics tools and through manual observation he detected several 
sequence and structural features. Firstly, an imperfect heptapeptide repeat was found, 
which is largely conserved among orthologues (Fig 5.1A), although the total number 
of repeats differs. Differences in heptapeptide numbers are also observed among the 
primates (e.g. human GPR50 contain 22, whereas chimpanzee and macaque GPR50 
have 23 repeats, Fig 5.1A). This repeat region, albeit to a lesser extent - (only 10 
repeats observed in humans) was also noticed by Dufourny et al (2008) and the 
authors note the resemblance of these repeats to the heptapeptide repeat in the RNA 
polymerase II CTD (Dufourny et al., 2008). From this, they hypothesised that this 
region may act as a functional scaffold for binding partners, as is the case for RNA 
polymerase II (Meinhart et al., 2005; Phatnani and Greenleaf, 2006). The CTD of 
RNA polymerase II can adopt a left-handed polyproline type II helix (PPII) under 
increasing hydrogen bond-promoting solvent trifluoroethanol concentrations 
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(Bienkiewicz et al., 2000), which could indicate a similar structure for the GPR50 
CTD.  
 
Another interesting feature in the GPR50 CTD sequence is the abundance of proline 
residues. Prolines make up 12% of the sequence, whereas the average number for 
SwissProt proteins is around 5% (Table 5.1). Proline-rich motifs and domains have 
been known to play important roles among signalling proteins (Kay et al., 2000) and 
in protein-protein interactions. The number of histidines in the CTD is also grossly 
overrepresented - 8.3% compared with unstructured proteins (1.51%) or to proteins 
in the SwissProt database (2.25%) (Table 5.1). Of course the GPR50 CTD is only 
part of the protein and the rest of GPR50 is highly structured (Fig 5.2 and Chapter 1 
Figure 1.2, Dufourny et al., 2008).







Figure 5.1 Heptapeptide repeats in the GPR50 CTD. (A) Orthologue multiple 
sequence alignment and sequence relationships. The C-terminal tail of GPR50 
alignment was created using PROMALS (Pei and Grishin 2007) and is shown 
according to the colour scheme used in ClustalX version 1.83 (Thompson et al. 
1997).  Strictly conserved columns are shown with an ‘*’, while conservatively 
substituted and semi-conserved columns are highlighted using ‘:’ and ‘.’, 
respectively.  The sequence lengths in each case are indicated and the 
heptapeptide repeats boxed on the alignment. (D. Soares, Unpublished). (B) 
Twenty-two heptapeptide repeats in humans.  The highly repetitive contiguous 
heptapeptide unit consists of an almost invariant histidine (H or aromatic) at position 
‘c’ and lysine (K or charged amino acid) at position ‘e’.  The unit ‘abcdefg’ generally 
follows a semi-conserved pattern: a = S, T or small amino acid; b = G, V, X; c = H or 


























Ala (A)   13.8 14.3 7.15 7.62 
Arg (R)    3.9 4.0 4.21 5.19 
Asn (N)   1.6 1.7 2.06 4.36 
Asp (D)   7.2 7.3 5.05 5.25 
Cys (C)   0.7 0.7 0.61 1.62 
Gln (Q)   1.3 1.3 4.46 3.93 
Glu (E)   3.9 4.0 14.25 6.47 
Gly (G)   3.9 3.7 4.31 6.35 
His (H)   8.5 8.3 1.51 2.25 
Ile (I)       3.0 3.0 3.67 5.85 
Leu (L)    2.6 2.7 5.44 3.54 
Lys (K)  6.2 6.3 10.43 5.97 
Met (M)  1.0 1.0 1.80 2.37 
Phe (F)    2.6 2.7 1.66 4.10 
Pro (P)   11.8 12.0 12.07 4.89 
Ser (S)  13.4 13.6 6.91 7.08 
Thr (T)   6.6 5.6 5.14 5.57 
Trp (W)   0.0 0.0 0.32 1.21 
Tyr (Y)    1.3 1.3 1.42 3.16 
Val (V)   6.6 6.6 8.02 6.61 
 
Table 5.1 Amino acid compositions (in %) of GPR50 CTD insertion and deletion 
forms, along with amino acid frequencies of disordered and SwissProt proteins 
(taken from Tompa (2002)). Alanine, serine, proline and histidine are the most 
frequently occurring residues in the GPR50 CTD. Prolines and histidines occur with 
substantially higher frequency than would normally be expected in proteins. The 
amino acid frequencies in GPR50 CTD were taken from ProtParam 
(http://ca.expasy.org/tools/protparam.html). Data from SwissProt 
(http://www.expasy.org/sprot).  
 
5.1.2 Secondary structure prediction of GPR50 CTD 
 
What could these features mean in terms of secondary structure? Repetitive 
sequences often correspond to repetitive structure (Andrade et al., 2001) and seven-
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residue (heptad) repeats - labelled abcdefg (Fig 5.1B) - are frequently observed 
among coiled-coil proteins (Burkhard et al., 2001). However, the heptapeptide 
repeating unit in GPR50 lacks the two necessary conserved hydrophobic (apolar) 
residues at positions ‘a’ and ‘d’, or at any other register position within a seven-
residue repeat unit, that are characteristic among coiled coil proteins (Fig 5.1B). 
Additionally, coiled-coil prediction using the COILS prediction server (Lupas et al., 
1991) did not suggest any coiled-coil helices to be present (D. Soares, not shown). 
 
Prolines are disorder promoting amino acids (Chakrabartty et al., 1994) and are 
therefore often overrepresented among unstructured proteins (Tompa, 2002) (Table 
5.1). This is because the backbone nitrogen of proline is bonded to the Cδ of its side-
chain, and is not available for hydrogen bond formation, a normally crucial 
ingredient for stable α-helix and β-strand creation. Indeed, secondary structure 
prediction using PsiPred (Jones, 1999; McGuffin et al., 2000) revealed an extended 
random ‘coil’ for the C-terminal region, with the exception of short segments 316-
317 and 352-355, which are predicted to be β-strand and α-helix respectively, 
although with very low confidence (Fig 5.2, D. Soares, unpublished).  
 
From the consensus disorder output (Fig 5.3, D. Soares, unpublished), ~75% of 
residues (243 out of 325 residues) are predicted to be disordered, made up from two 
major regions – residue positions 332-441 (110 residues), and 473-591 (119 
residues). All seven servers/methods agreed on disorder for 123 out of 325 residue 
positions (~38%). This property could render this region intractable to experimental 
structure determination. The N-terminal region spanning residue positions 293-311 
corresponding to a strongly predicted α-helix comprising part of the seventh 
transmembrane (Fig 5.2-5.3) or eighth membrane parallel helix (Palczewski et al., 
2000; Choi et al., 2005; Conner et al., 2008) were predicted to be “ordered” by all 
servers/methods, with the exception of a single amino acid residue for one predictor.      
 





Figure 5.2 PsiPred V2.5 (Jones, 1999; McGuffin et al., 2000) predicted secondary 
structure for full-length GPR50∆502-505/T532A.  The seven strongly predicted α-
helices that correspond to the membrane-spanning regions are highlighted in pink. 
The C-terminal domain is predicted to contain predominantly random coil. Conf: 
Confidence.Pred: Predicted secondary structure (H = helix, E = strand, C = coil) AA: 
Target sequence (D. Soares, unpublished).








Figure 5.3 Predicted regions of disorder for the human GPR50 C-terminal tail 
sequence (blue) is shown using a range of servers/methods: DisEMBLTM version 1.5 
(Linding et al., 2003); VSL2 at DisProt (Obradovic et al., 2005; Peng et al., 2006); 
FoldIndex© (Prilusky et al., 2005); PreLink (Coeytaux and Poupon, 2005); DRIP-
PRED (http://www.sbc.su.se/~maccallr/disorder/) for details on method); PONDR® 
(Romero et al., 2001); and DISOPRED2 (Ward et al., 2004).  In the case of 
DisEMBLTM, the prediction output from REMARK-465 (missing coordinates in X-ray 
structure as defined by REMARK-465 entries in PDB) was considered, and in the 
case of VSL2 and PONDR®, the predictor models “VSL2B” and “VLXT” were used 
respectively. Each position was denoted by ‘D’ (and coloured red) for predicted 
disorder, or ‘O’ for predicted order. The consensus disorder (D), at the bottom of the 
sequence coloured magenta, was derived by applying a simple majority rule for 
each position (greater than or equal to 4) per server/method.  Agreement for all 
servers on a position of disorder is shown by an asterisk ‘*’, and for order indicated 
by an ‘O’ (shown in pink) alongside the consensus disorder prediction.  The three 
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               DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDD 
               *****                      ***** ********** ***       
 
 
DISEMBL        OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOODDDD DDDDDDDDDD 
VSL2           DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD 
FOLDINDEX      DDDDDDDDDD DDDDDOOODD DDDOOOOOOO DDDDDDDDDD DDDDDDDDDD 
PRELINK        OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO ODDDDDDDDD DDDDDDDDDD 
DRIP-PRED      OOOOOOOOOO OOOOODDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD 
PONDR          OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOODDDDDDD DDOOOOODDD 
DISOPRED2      DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD 
           443 SVHFKADSVH FKGDSVHFKP DSVHFKPASS NPKPITGHHV SAGSHSKSAF 492  
                                  DD DDD        DDDDDDDDDD DDDDDDDDDD 
                                                      **** **     *** 
 
 
DISEMBL        DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDOOOO 
VSL2           DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD 
FOLDINDEX      DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD 
PRELINK        DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD 
DRIP-PRED      DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD 
PONDR          DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD 
DISOPRED2      DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD 
           493 SAATSHPKPT TGHIKPATSH AEPTTADYPK PATTSHPKPT AADNPELSAS 542 
               DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD 
               ********** ********** ********** ********** ****** 
 
DISEMBL        OOOOOOOOOO OODDDDDDDD DDDDDDDDDD DDDDDDDOOO OOOOOOOOOO 
VSL2           DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD 
FOLDINDEX      DDDDDDDDDD DDDDDDDDDD DDDDOOOOOD DDDDDDDDDO DDDDDDDDDD 
PRELINK        DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD OOOOOOOOOO 
DRIP-PRED      DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD 
PONDR          DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDO 
DISOPRED2      DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDOOOOOO 
           543 HCPEIPAIAH PVSDDSDLPE SASSPAAGPT KPAASQLESD TIADLPDPTV 592 
               DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDDDDD 
                            ******** ****     * *******   
 
DISEMBL        OOOOOOOOOO OOOOOOOOOO OOOOO 
VSL2           DDDDDDDDDD DDDDDDDDDD DDDDD 
FOLDINDEX      DDDDDDDDDD DDDDDDDDDD DDDDD 
PRELINK        OOOOOOOOOO OOOOOOOOOO OOOOO 
DRIP-PRED      DDDOOOOOOO OOOOOOOOOD DDDDD 
PONDR          OOOOOOOOOO OOODDDDDDD DDDDD 
DISOPRED2      OOOOOOOOOO OOOOOOOODD DDDDD 
           593 VTTSTNDYHD VVVVDVEDDP DEMAV 617 
                                  DD DDDDD   
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Repetitive proline motifs may also indicate a rare type II polyproline helix 
(Areschoug et al., 2002) as appears to be the case for RNA polymerase II 
(Bienkiewicz et al., 2000). To assess this likelihood for GPR50, a polyproline helix 
prediction was performed by D. Soares on the GPR50 sequence, using the method 
described by (Vlasov et al., 2005), and predicts 22% proline residues (Fig 5.4). 
However the results showed clear disagreement with many of the secondary structure 
predictions made by PsiPred (Fig 5.2) in the regions of the seven-transmembrane 
helices, and therefore it is difficult to conclude anything from this prediction.  
  




       sequence ->    1 MGPTLAVPTPYGCIGCKLPQPEYPPALIIFMFCAMVITIVVDLIGNSMVI 
  structure ->    1 HPP-HHEPEHE-HE-HHPPPPHPPPEEEEEEEEEHEEPEEHHHH--HEEH 
 
   sequence ->   51 LAVTKNKKLRNSGNIFVVSLSVADMLVAIYPYPLMLHAMSIGGWDLSQLQ 
  structure ->   51 HHHHHHHHHHH--PEEEEEHHHHHHHHHHHHPPPHHHHHEP--HHHHHHH 
 
   sequence ->  101 CQMVGFITGLSVVGSIFNIVAIAINRYCYICHSLQYERIFSVRNTCIYLV 
  structure ->  101 -EHE-EPE-HPHE-EEE-PHHHHHHHHHE--HHPEEHHHPEEP-EPEEPP 
 
   sequence ->  151 ITWIMTVLAVLPNMYIGTIEYDPRTYTCIFNYLNNPVFTVTIVCIHFVLP 
  structure ->  151 PPHEPHHHHEPP-PHE-EEHPPHHPEEPPHHHH-PPEEPEEPEPPEPPPP 
 
   sequence ->  201 LLIVGFCYVRIWTKVLAARDPAGQNPDNQLAEVRNFLTMFVIFLLFAVCW 
  structure ->  201 PEPHEPPEPPHEHHHHHHHPHH-PPHHHHHHHHHHHHHHEEEPPHHHEHP 
 
   sequence ->  251 CPINVLTVLVAVSPKEMAGKIPNWLYLAAYFIAYFNSCLNAVIYGLLNEN 
  structure ->  251 EPHHPPPEPEEEPHHHHPPPPPHHHHHHHHEPHEEPHHHEEEHHHHHHHH 
 
   sequence ->  301 FRREYWTIFHAMRHPIIFFSGLISDIREMQEARTLARARAHARDQAREQD 
  structure ->  301 HHHPEEEPH-HEEEHHEPPH-PHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
 
   sequence ->  351 RAHACPAVEETPMNVRNVPLPGDAAAGHPDRASGHPKPHSRSSSAYRKSA 
  structure ->  351 HHHHPPHHHHHPHHPHPPPPP-HHHH-HHHEPE-PHPPHHHH-HHHHHEE 
 
   sequence ->  401 STHHKSVFSHSKAASGHLKPVSGHSKPASGHPKSATVYPKPASVHFKADS 
  structure ->  401 EEHHHHHHE-HHHHH-HHHHHE-PPPPH--PPHEHEEEPPPEPEEPPHHH 
 
   sequence ->  451 VHFKGDSVHFKPDSVHFKPASSNPKPITGHHVSAGSHSKSAFSAATSHPK 
  structure ->  451 --PP--PEPPEPHHEPPEHH--PPPPPP-EEP-H-PEHHHHHHHHEHPHE 
 
   sequence ->  501 PTTGHIKPATSHAEPTTADYPKPATTSHPKPTAADNPELSASHCPEIPAI 
  structure ->  501 PHPHHPEPHEHHHEPEPHHEPEPH-PHPHPPPHHH-HHEEEEHEPHEPHH 
 
   sequence ->  551 AHPVSDDSDLPESASSPAAGPTKPAASQLESDTIADLPDPTVVTTSTNDY 
  structure ->  551 HEPEPHHHPPPHPHHPHPH-PPEPPHHHHHEHEHHHPPPPHEPEEEEPHH 
 
    sequence ->  601 HDVVVVDVEDDPDEMAV 
   structure ->  601 HPEPPEPEE-PHHHHHH 
 
H - α-helix 
   E - β-structure 
      P - PPII-(left)-helix 
 
Figure 5.4 Predicted secondary structure including polyproline prediction for full-
length GPR50. The accuracy attained by this method, which is the first to predict 
polyproline helices is reported as ~60% (Vlasov et al. 2005) (D. Soares, 
unpublished).   
Chapter 5: Structural Analysis of the GPR50 C-terminal Domain 
 
 216 
5.1.3  Predicted effects of deletion and missense polymorphisms 
 
The ∆TTGH deletion and Thr532Ala polymorphism in the GPR50 CTD involve 
threonine residues, which were previously suggested to possibly harbour 
phosphorylation sites (Thomson et al., 2005). They are not however predicted by 
NetPhos version 2.0 (Blom et al., 1999) or PROSITE to correspond to potential 
phosphorylation sites (not shown), and hence a loss-of-phosphorylation effect is 
unlikely. However, a species-specific site cannot be ruled out entirely. The deletion 
of four residues would normally have serious consequences for protein folding, 
unless present in a solvent-exposed loop region that is not intimately associated via 
H-bonds or van der Waals interactions with the rest of the protein fold. Additionally, 
the ∆TTGH deletion directly affects the repetitive heptapeptide unit (between the 
16th and 17th repeats). In addition, a putative ‘P-X-X-P’-binding motif (‘PIKP’) is 
created upon the deletion of the ‘TTGH’ sequence in the variant human form, which 
could serve as a scaffold for proteins that recognise proline-motifs, such as Src 
homology 2 and 3 (SH2 and 3), postsynaptic density/disc-large/ZO1 (PDZ), WW 
domains and 14-3-3 proteins (Kay et al., 2000). Interestingly, two of the yeast 2-
hybrid interactors (Grünewald et al., 2009) contain such domains: spectrin alpha, 
non-erythrocytic 1 (SPTAN1) that contains an SH3 domain, and protein interacting 
with PRKCA1 (PICK1) that contains a PDZ domain (D. Soares, unpublished). 
Although the number of clones of SPTAN1 and PICK1 identified in the screen was 
small (2 and 1 respectively), they were only identified as hits using the deletion 
variant of GPR50.  
 
5.1.4 Introduction to experiments 
 
In the absence of any known structural information it is difficult to determine what 
effects the polymorphisms might have on structure and function. Therefore a 
preliminary series of experiments was performed to gain insight into the structure of 
the GPR50 CTD and the effects of the polymorphisms on structure. A method often 
used to confirm secondary structure is circular dichroism (CD), a spectroscopy 
technique that measures the difference in absorption between left- and right handed 
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circularly polarised light (Beychok, 1966; Kelly et al., 2005). Measurements are 
performed in the far-UV spectrum and helical, sheet and disordered content can be 
derived with the use of deconvolution tools (e.g. Dichroweb (Whitmore and Wallace, 
2004)). Far-UV CD spectra associated with various types of secondary structure are 
shown in Fig 5.5 (Kelly et al., 2005). CD is a valuable tool to assess differences in 
conformation as a result of structural, buffer or temperature changes. As with NMR 
and X-ray crystallography membrane proteins are difficult to study in their native 
state due to the sensitivity of the technique to pick up scattering from membrane 
structures. With this in mind the GPR50 CTD and GPR50 CTD ∆TTGH/T532A excluding 
all transmembrane regions, spanning residues 313 to 617, were cloned, expressed 
and purified. After bacterial purification preliminary biophysical characterisation of 
the CTD, including circular dichroism, was undertaken.  
 
Figure 5.5 Far UV CD spectra associated with various types of secondary structure. 
Solid line: α-helix; long dashed line: anti-parallel β-sheet; dotted line: type I β-turn; 
cross dashed line: extended 31-helix or polyproline II (PPII) helix; short dashed line: 
irregular structure. From Kelly et al., (2005). Biochimica et Biophysica Acta (BBA) - 
Proteins and Proteomics. Copyright 2005 Elsevier.  
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Gateway compatible untagged, C-terminal non-cleavable His and N-terminal TEV 
cleavable His-tagged constructs of GPR50 amino acid residues 313-617 (insertion, 
ins) and 313-617 ∆502-505 Thr532Ala (deletion, del), were made via a two-step 
PCR reaction according to a proposed Edinburgh Protein Production Facility (EPPF) 
cloning strategy (Fig 5.6) using human cDNA. The primers used are detailed in 
Table 5.2. 
 
PCR reactions were performed using Phusion high fidelity polymerase (Finnzymes, 
New England Biolabs) with 0.5 µM primers, on an PTC-225 PCR thermal cycler 
(MJ research) using a touch-down programme with an initial denaturation at 93ºC for 
1 minute, followed by 10 cycles at 93ºC for 20 seconds, touch-down annealing from 
65ºC to 55ºC for 30 seconds over 10 cycles, 72ºC for 1 minute, 55ºC for 30 seconds 
over 10 cycles, and a final extension of 72ºC for 10 minutes. PCR products were 
cloned by recombination into pDONR221 and subsequently pDEST14 vectors 
(Gateway, Invitrogen). Plasmids were transformed into competent DH5α cells. DNA 
was purified using the Qiagen Maxiprep kit. Plasmids were checked by sequencing 
using BigDye3.1 reagents (see 2.2.5 Chapter 2). 




Construct PCR step Sense primer Antisense primer 
 



































































Table 5.2 GPR50 CTD Primers used in this study. Step 1 primers were designed 
using Primer 3. Step 2 primers were a kind gift from Martin Wear (CTCB). 
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Figure 5.6 The Edinburgh Protein Production Facility (EPPF) cloning strategy used 
for generating bacterial expression constructs. By Martin A Wear, University of 
Edinburgh.  




5.2.2 Protein purification  
 
For testing of optimal growth conditions DNA was transformed into competent 
BL21(DE3) Star (Invitrogen), C41(DE3) or C43(DE3) E. coli cells. Cultures were 
streaked onto LB-carbenicillin (50 µg/ml) plates and incubated at 37°C overnight. 
Single colonies from each transformation were picked and grown in LB plus (50 
µg/ml) carbenicillin for 4-5 hours at 37°C. Starter cultures were further grown in 
either auto induction medium (TB Overnight Express, Merck Biosciences) at 37⁰C 
overnight (o/n) or LB or 2XTY medium at 37°C until A600 = 0.60. IPTG (1 mM) was 
then added to induce protein expression and cultures were incubated at either 25, 30 
or 37°C for 3 hours.  
 
For bulk growth, DNA was transformed into competent BL21(DE3) and grown in 1l 
auto induction medium at 37°C overnight. Cells were centrifuged at 6000g for 15 
minutes and pellets were resuspended in 30 ml IMAC ‘buffer A’ with added protease 
inhibitors (Complete, Roche). Cells were lysed using a Constant Systems cell 
disruptor at 22 kpsi and 8°C. Lysates were cleared at 50,000g for 45 minutes at 4°C 
and filtered through 0.22 um pore filters before being loaded onto Äkta automated 
liquid chromatography systems. Liquid chromatography was performed at 6°C. 
Lysates were first affinity-purified using a 1 ml HiTrap FF immobilised metal ion 
affinity chromatography (IMAC) column charged with Ni2+-ions and eluted in two 
steps. First, a linear gradient of increasing concentrations (20-500 mM) of imidazole 
in 20 column volumes (CV), followed by 5 CV of 500 mM imidazole, all collected 
in 1 ml fractions. Selected fractions were further purified by size exclusion 
chromatography. Fractions were first concentrated to 4 ml using Vivaspin centrifuge 
columns (Sartorius Stedim Biotech) with a molecular weight cutoff of 10 kDa and 
loaded onto a 320 ml Superdex 200pg XK26/60 gel filtration column. Protein was 
eluted in 1.5 column volumes of PBS pH 7.4 (Gibco) and collected in 2 ml fractions.  




5.2.3  SDS-PAGE and Western blotting 
 
Samples were mixed with 2x laemmli sample buffer with added 300 mM ß-
mercaptoethanol or 100 mM DTT and boiled for 3 minutes before being loaded onto 
Biorad 4-20% gels. Gels were run in MOPS-SDS-Tris buffer for 40 minutes at 150 
V. Gels were stained using Simply Blue Safestain (Invitrogen) and destained using 
dH2O. For Western blotting, proteins were transferred from gels onto PVDF 
membrane using semi-dry transfer buffer at 25 V for 45 minutes. Membranes were 
blocked in TBS (+ 0.2% v/v Tween 20, TBS-T) with 5% w/v bovine serum albumin 
for 1 hour. Membranes were incubated with anti GPR50 E63 (1:5000) (See Chapter 
2 and Table 2.4 for characterisation of E62 antibody) or AP-His (1:2000) for 2 hours 
in blocking buffer. Following three 15 minute washes in TBS-T, membranes were 
incubated in swine anti-rabbit HRP (DAKO) or 5 ml alkaline phosphatase buffer 
with 33 µl NBT and 16.5 µl BCIP (Thermo Fisher, Pierce). GPR50 was visualised 
using ECL plus (Amersham) and exposure to X-ray film. 
 
5.2.4 Desalting using PD-10 columns (GE healthcare) 
 
PD-10 columns were equilibrated in 25 ml elution buffer (20 mM phosphate 100 
mM NaF pH 7.0 or 10 mM ammonium acetate (pH 6.7). Samples were loaded onto 
the column and allowed to enter the resin. Up to 2.5 ml of elution buffer was added 
to the column and allowed to enter the resin. To elute 3 to 3.5 ml elution buffer was 
added to the column and collected as desalted fraction.   
 
5.2.5  Dynamic Light Scattering (DLS) 
 
Samples in ‘IMAC buffer B’ (pH 7.4), PBS (pH 7.4), or desalted using PD-10 
columns (see 5.2.4 above) into 20 mM phosphate with 100 mM NaF (pH 7.0) or 10 
mM ammonium acetate (pH 6.7) were measured on the Zetasizer Auto Plate Sampler 
(Malvern Instruments Ltd, UK). Dynamic light scattering measurements were 
performed on 50 µl aliquots in a 384 well plate, with laser set at 830 nm. Size 
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distribution of GPR50 was determined by performing 3 measurements of 18 x 10 
seconds readings of each sample at 10ºC (± standard deviation). Thermal stability of 
proteins was determined by melting point analysis after heating the sample from 10 
to 80ºC with 2ºC increments. Data was analysed on Zetasizer APS software 
(Malvern).   
 
5.2.6  ESI (Electrospray Ionisation) Mass Spectrometry  
(performed by Dr Elizabeth Blackburn of the CTCB) 
 
Samples were desalted into 10 mM ammonium acetate pH 6.7 using Amersham 
PD10 columns. Protein concentrations were approximately 1 µM as measured on a 
SpectraMax M5 multimode platereader (Molecular Devices) at 280 nm. A 100 µl 
sample was mixed 1:1 with acetonitrile/0.2% v/v formic acid (5 mM ammonium 
acetate, 50% v/v ACN 0.1% v/v formic acid final concentration, pH 2.5) and 
incubated for 15 minutes to denature the protein. Positive ESI mass spectra were 
acquired using a single quadropole mass spectrometer (Micromass, Wyntheshawe, 
UK) equipped with a Z-spray electrospray ionisation source. Samples were injected 
directly into the source using a Harvard Model 22 syringe at a flow rate of 3 µl/min. 
Spectra were acquired over a range of 150 to 2000 m/z and for each sample 100 runs 
were performed.  
 
5.2.7 MALDI (matrix assisted laser desorption/ionization) Mass 
Spectrometry  
 
Protein samples were desalted into 20 mM phosphate 100 mM NaF pH 7.0 using 
PD10 columns (Amersham, see 5.2.4 above), and were used at a concentration of 10-
50 µM. A 10 mg/ml solution of sinapinic acid (3,5-Dimethoxy-4-hydroxycinnamic 
acid) matrix was prepared and 1 µl of sample followed by 1 µl of matrix were 
spotted on a 100 well gold sample plate (Applied Biosystems) and left to dry. The 
plate was loaded into a Voyager DE STR MALDI-TOF (Applied Biosystems) 
instrument and Bovine Serum Albumine (BSA) was used as standard (for proteins of 
20-100 kDa). For each measurement 200 laser shots were fired over different areas 
of the sample. The laser intensity was adjusted until the signal intensity reached 
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2000-8000. Data were processed in Data Explorer (Applied Biosystems) by applying 
baseline correction and noise filters to remove background.   
 
5.2.8  Circular Dichroism  
 
Samples were desalted in 20 mM phosphate 100 mM NaF pH 7.0 using PD10 
columns (see 5.2.4 above). Protein concentrations ranged from 0.02-0.1 mg/ml as 
measured on a JASCO V-550 UV-VIS spectrometer at 280 nm. A 0.1 cm pathlength 
cuvette (Starna) was used for collecting spectra from 300-185 nm at 20ºC on a 
JASCO J-810 Spectropolarimeter. Four scans were acquired for each spectrum at a 
scanning speed of 10 nm/min, bandwidth of 1 nm and response of 2 seconds. Buffer 
spectra were recorded using identical parameters to the sample spectra and, after 
offsetting both spectra to zero at 260 nm, the buffer spectra were subtracted from the 
sample spectra using Spectra Manager software (Jasco).  
No filtering or other smoothing techniques were used to reduce the noise levels. The 
subtracted image was saved as an ASCII file. ASCII files were uploaded into 
Dichroweb (Whitmore and Wallace, 2004, 2008) for data analysis. Analysis was 
performed using the CDSSTR method (Compton and Johnson, 1986; Manavalan and 
Johnson, 1987; Sreerama et al., 2000) and reference databases 2 and 5. CDSSTR is a 
modification of the Varslc algorithm, which uses the variable selection method to 
eliminate proteins from the reference set that do not contain characteristics present in 
the test protein. The NRMSD (normalised root-mean-square deviation) was used to 
assess the quality (precision) of the fitting between experimental data and predicted 
structural content as performed on Dichroweb. Values range from 0 for a perfect fit 
to 1 for no fit) and only values of 0.1 or less were considered. A low NRMSD value 
is necessary for establishing whether results are correct, but it is not sufficient in 
itself.  It enables the user to evaluate the different algorithms and databases for the 
most appropriate conditions for their experiment (Whitmore and Wallace, 2004).  




5.3  Results 
 
In order to experimentally test the protein secondary structure predictions by Dinesh 
Soares, protein purification and circular dichroism (CD) was performed. 
Additionally, purified GPR50 CTD was characterised under different conditions 
using dynamic light scattering and mass spectrometry. Several constructs were 
generated for bacterial protein expression of GPR50 C-term insertion (aa. 313-617) 
and deletion (313-617 ∆502-505, Thr532Ala): N-terminal TEV cleavable His-
tagged-, C-terminal non-cleavable His-tagged- and untagged GPR50 (See Table 5.2). 
Because of time and resource limitations only the TEV cleavable His-tagged 
constructs have been used here.  
 
5.3.1  Optimisation of protein expression 
 
To determine the best conditions for protein expression a small volume trial of 21 
conditions per construct was performed. His-TEV GPR50 CTD (ins) and CTD∆502-
505/T532A (del) were subcloned by PCR from human cDNA using the EPPF cloning 
strategy with Gateway technology (See materials and methods and Fig 8). Plasmids 
were transformed into either BL21Star (DE3), C41(DE3) or C43(DE3) E. coli 
strains. Bacteria were grown under several conditions: in auto-induction medium at 
37 ºC or in LB or 2xTY medium and IPTG induced at 25, 30 or 37ºC (see materials 
and methods). SDS-PAGE (Fig 5.7A: ins, B: del) shows that under several 
conditions a band is detected at approximately 50 kDa that is absent from the 
negative (non-induced) control. These samples were probed with the GPR50 E63 
antibody and strong GPR50 expression at 45 kDa was detected in several conditions 
(Fig 5.7C-D). From these trials, BL21 with auto-induction medium was selected for 
bulk growth for both insertion and deletion variants.  




Figure 5.7 Optimisation of growth conditions for protein expression. Three different 
E. coli strains (BL21 Star, C41(DE3), C43(DE3)) were used under different growth 
conditions and in three types of media: LB, 2xtY and auto induction (AI) medium. (A) 
GPR50 CTD insertion, (B) deletion (only LB and AI are shown here). Several 
conditions produced a band at ~50 kDa (arrows A, B). Lysates from these conditions 
were probed with a GPR50 E63 (C: insertion, D: deletion), which produced strong 
bands at 45 kDa. From these conditions BL21 Star in AI medium (arrows C, D) was 
selected. 
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5.3.2 Protein purification 
 
For purification, GPR50 CTD insertion and deletion were transformed into BL21 
Star (DE3) and grown as 1 litre cultures o/n. Pelleted cells were lysed, and cleared 
lysates were affinity purified on an IMAC column using Äkta liquid chromatography 
systems. The elution profile for His-TEV GPR50 ins is shown in Fig 5.8A. There are 
two peaks in the profile, one from fractions C1-C7 (Sample A, 26%B, 130 mM 
imidazole) and a later one from D8-E1 (Sample B, 100%B, 500 mM imidazole). 
These fractions were loaded onto SDS-PAGE as shown in figure 5.8B. Bands 
migrated slower through the gel than predicted (observed: ~45 kDa, predicted: 
35,106 Da ins and 34,767 Da del). This discrepancy may be attributed to the type of 
gel used; the SDS-PAGE was performed using precast gels from Invitrogen, while 
the Biorad gels produced bands closer to the predicted molecular weight (See Fig 
5.7C-D and Fig 5.9). However it may also be an indication of lack of structure as 
unstructured proteins have the endency to run slower on SDS-PAGE because of their 
unusual amino acid composition and low capacity for SDS binding (Tompa, 2002; Li 
and Song, 2007). Fractions from Sample A were further purified using a size 
exclusion chromatography step. The elution profile shows many peaks corresponding 
to different sizes of proteins (Fig 5.8C), and SDS PAGE of selected fractions shows 
that the largest peak contains bands corresponding to the size of GPR50 CTD 
(“Sample A final”, Fig 5.8D). These fractions were pooled and concentrated using 
<30 kDa size exclusion Vivaspin concentrators, retaining the >30 kDa fraction. This 
sample was further characterised as Sample A. Fractions from IMAC peak 2 appear 
very pure by SDS-PAGE (Fig 5.8B) and were characterised as a separate Sample B. 
His-tagged GPR50 is detected by Western blotting, using both GPR50 and His 
antibodies, in both Samples A and B (Fig 5.9A-B), albeit in different intensities and 
sizes. 
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Figure 5.8 Protein purification of TEV his GPR50 ins (GPR50del not shown but 
profile looked similar). Lysates from GPR50 ins expressing cells were loaded onto 
an IMAC column and the elution profile (A) showed two peaks (Samples A and B). 
Samples were loaded onto SDS-PAGE and stained with Simply Blue safestain (B). 
Samples A were further purified by gel filtration chromatography. The elution profile 
(C) shows many peaks of which the tallest one (C, arrows) was loaded onto SDS-
PAGE (D) and stained with Simply Blue safestain. ‘Sample A final’ (D) was selected 
and further characterised, along with Sample B (A, B). L=whole protein extract 
(Load) F= unbound sample (Flow-through). 




Figure 5.9TEV his GPR50 ins IMAC purified fractions (Sample A: early peak; 
Sample B: late peak, see Fig 9) were loaded onto a tris-actetate gel (Invitrogen) and 
proteins were transferred onto PVDF membrane. The membrane was probed with 
anti-polyHis-AP (A) and anti-GPR50 E63 (B). L=whole protein extract (Load) F= 
unbound sample (Flow-through). 
 
5.3.3  Biophysical characterisation  
 
5.3.3.1 Protein size distribution and stability 
5.3.3.1.1  Dynamic Light Scattering 
To determine particle size, distribution and stability of the GPR50 CTD in different 
samples and buffers Dynamic Light Scattering (DLS), otherwise known as photon 
correlation spectroscopy, was performed 
(http://www.malvern.com/common/downloads/campaign/MRK656-01.pdf) on 
Sample A and Sample B, separately (see Fig 5.8-5.9). See Materials and Methods for 
more details. 
5.3.3.1.1.1 Sample A 
Results from DLS analysis of GPR50ins and del ‘Sample A’ in PBS (pH 7.4) are 
shown in Figure 11. Concentrations of samples measured were 1 mg/ml (ins, 11A; 
del, 11C) and 0.125 mg/ml (ins, 11B; del, 11D). The protein samples appear to be 
single species (99.9%-98.4% pure, indicated by ‘Mass’, Fig 5.10A-D). Although the 
intensity of aggregates was high (indicated by bigger peaks with large diameter on 
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the left hand side of each subfigure), these only formed 0.1% of total mass (note, 
DLS is extremely sensitive at detecting even small traces of aggregation). 
Polydispersity (Pd, a measure of the homogeneity of macromolecules in solution) 
values of  <20% would indicate a monodisperse (monomeric or non-aggregated) 
sample suggesting that GPR50ins A (Fig 5.10A-B) is more polydisperse (multimeric 
or aggregated) than GPR50del A (Fig 5.10C-D). GPR50 ins A has a hydrodynamic 
diameter (Dh) of 7.67 (± 1.86) nm (Fig 5.10A) with a predicted molecular weight of 
78.1 kDa, which may indicate dimerisation of GPR50 CTD (2x 35,107 = 70,241 Da 
(including His-tag)) as is also known for full length GPR50 (Levoye et al., 2006; 
Hamouda et al., 2007; Grünewald et al., 2009), although the prediction should be 
treated with caution as mass estimates are based upon globular proteins, which 
GPR50 CTD is not likely to be. Also, there are no mathematical models to quantify 
the proportions of monomer/dimer/multimer in a given sample (Hubmacher et al., 
2008). GPR50ins A seemed reasonably stable (similar characteristics to undiluted, 
Fig 5.10A) at an 8x dilution (Fig 5.10B, 0.125 mg/ml, 99.6% pure; Dh = 7.035 (± 
1.67) nm; predicted molecular weight (Mw) = 63.9 kDa, Pd = 23.7).  
 
The characteristics for GPR50 del Sample A in PBS (pH 7.4) were similar, although 
more monodisperse (Fig 5.10C, 1 mg/ml; 99.1% pure; Dh = 7.734 (± 1.16) nm; Mw 
= 79.7 kDa, Pd = 15.0), with reasonable stability at 8x dilution (Fig 5.10D, 0.125 
mg/ml, 98.4% pure, Dh = 7.139 (±1.11) nm, predicted Mw of 66.1 kDa, Pd = 15.5). 
GPR50 ins A in PBS had a melting point of 21.9 ºC (12E), indicating it would lose 
its stability around room temperature. The melting point of GPR50 del Sample A in 
PBS was not measured due to time constraints, but is likely to be similar. 
 
5.3.3.1.1.2 Sample B 
DLS was also performed on GPR50 ins and del IMAC ‘Sample B’, which was 
desalted into 20 mM sodium phosphate with 100 mM NaF (pH 7.0) prior to DLS 
measurements. The DLS characteristics of GPR50 ins and del from Sample B at 1 
mg/ml were very different (Fig 5.11). For these, intensity and size measurements 
indicated a single large species with a hydrodynamic radius of 29.44 (± 6.52) nm 
(Fig 5.11A, ins) or 24.67 (±6.62) nm (Fig 5.11C, del), corresponding to a predicted 
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size of 1820 kDa (ins) or 1200 (del). Both GPR50 ins and del B were stable at 4x 
dilution although some aggregation was measured at 8x dilution: (ins B: 0.125 
mg/ml; 99.4% pure; Dh = 28.99 (± 3.98) nm; mass = 1760 (Fig 5.11B); del B: 0.125 
mg/ml; 98.2% pure; Dh = 27.92 (±3.74) nm; mass = 1610 kDa (Fig 13D)). GPR50 
ins Sample B had a Tmelt of 22ºC (Fig 5.11E), indicating loss of stability at or near 
room temperature.  
 
Previous DLS measurements on GPR50 ins Sample B in high salt IMAC ‘buffer B’ 
showed similar characteristics (hydrodynamic radius of 27.55 (±7.94) nm and a 
predicted size of 1560 kDa (Fig 5.12). Thus the formation of the large species is not 
likely a consequence of desalting (reduction in ionic strength of solution) the sample. 
It likely reflects a structural difference between the loosely bound 
monomeric/dimeric GPR50 Sample A and a multimeric Sample B that is tightly 
bound to the IMAC column due to multiple hexahistidine residues.  
 
An increase in anti-His signal is also detected by Western blotting of Sample B as 
compared to Sample A (Fig 5.9A) with a decreased signal of anti-GPR50 in fractions 
B compared to A (Fig 5.9B). The GPR50 signal in Sample A is strong but 
corresponds to different (smaller) size bands, indicating that some of GPR50 may 
have lost its tag (Fig 5.9B). His-immunoreactive bands at lower molecular weight, 
that are not detected by the GPR50 E63 antibody, are also visible in Fig 5.9A. This 
may indicate the presence of His-oligomers or His-tagged C-terminally degraded 
GPR50, of which the E63 epitope is missing. 




Figure 5.10 Distributions of GPR50 C-term ins and del A particles in PBS by dynamic light 
scattering. Measurements were performed at 10°C. Eighteen acquisitions of 10s readings 
were recorded for each measurement and graphs represent the mean of the values for three 
measurements. DLS shows particle size by intensity (left of each subfigure) and volume 
(right of each subfigure). Mass indicates volume percentage (fraction) of a particular particle 
present in total solution. Intensity indicates the percentage (fraction) of light intensity 
scattered by that particular particle from the total amount of particles in solution. The 
intensity is proportional to particle size. Hydrodynamic radius (Dh) is the radius or size of a 
particle. Mw is the molecular weight (in kDa) predicted by the Dh. Pd is the polydispersity 
index, which indicates whether a sample is monomeric or free of aggregation 
(monodisperse, <20) or multimeric or aggregated (polydisperse, >20). (A) GPR50 ins 
Sample A (1mg/ml), (B) GPR50ins Sample A 1:8 dilution( (0.125 mg/ml), (C) GPR50del 
Sample A (1 mg/ml), (D) GPR50del Sample A 1:8 dilution (0.125 mg/ml). (E) A melt curve for 
GPR50 ins A was generated by heating the sample from 10 to 80°C in 2°C increments. The 
recorded denaturing temperature (Tmelt) of GPR50 ins A is 21.9°C. 





Figure 5.11 Distributions of GPR50 CTD ins and del B particles in 20mM sodium 
phosphate 100mM NaF pH 7.0 by dynamic light scattering. Measurements were performed 
at 10°C. Eighteen acquisitions of 10s readings were recorded for each measurement and 
graphs represent the mean of the values for three measurements. DLS shows particle size 
by intensity (left of each subfigure) and volume (right of each subfigure). Mass indicates 
volume percentage (fraction) of a particular particle present in total solution. Intensity 
indicates the percentage (fraction) of light intensity scattered by that particular particle from 
the total amount of particles in solution. The intensity is proportional to particle size. 
Hydrodynamic radius (Dh) is the radius or size of a particle. Mw is the molecular weight (in 
kDa) predicted by the Dh. Pd is the polydispersity index, which indicates whether a sample is 
monomeric or free of aggregation (monodisperse, <20) or multimeric or aggregated 
(polydisperse, >20). (A) GPR50ins B (1 mg/ml), (B) GPR50ins B 1:8 (0.125 mg/ml), (C) 
GPR50del B (1 mg/ml), (D) GPR5 del B 1:8 (0.125 mg/ml). (E) A melt curve for GPR50 ins B 
was generated by heating the sample from 10 to 80°C in 2°C increments. The recorded 
Tmelt of GPR50 ins B is 22°C. 




Figure 5.12 Distributions of GPR50 CTD ins B (1mg/ml) particles in IMAC buffer B 
(25 mM Na2HPO4, 500 mM NaCl, 500 mM imidazole) by dynamic light scattering. 
(A) Measurements were performed at 10°C. Eighteen acquisitions of 10s readings 
were recorded for each measurement and graphs represent the mean of the values 
for three measurements. DLS shows particle size by intensity (left of each subfigure) 
and volume (right of each subfigure). Mass indicates volume percentage (fraction) of 
a particular particle present in total solution. Intensity indicates the percentage 
(fraction) of light intensity scattered by that particular particle from the total amount 
of particles in solution. The intensity is proportional to particle size. Hydrodynamic 
radius (Dh) is the radius or size of a particle. Mw is the molecular weight (in kDa) 
predicted by the Dh. Pd is the polydispersity index, which indicates whether a 
sample is monomeric or free of aggregation (monodisperse, <20) or multimeric or 
aggregated (polydisperse, >20) (A) DLS characteristics of GPR50 CTD ins B in 
IMAC buffer B. (B) A melt curve for GPR50 ins B was generated by heating the 
sample from 10 to 80°C in 2°C increments. The recorded Tmelt of GPR50 ins B is 
43°C.  
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5.3.3.1.2 Mass Spectrometry 
 
5.3.3.1.2.1 ESI mass spectrometry 
In an attempt to obtain accurate measurements of the mass of GPR50 CTD mass 
spectrometry was performed. Electrospray Ionisation (ESI) mass spectrometry 
resulted in a very noisy spectrum and a clear mass/charge pattern could not be 
distinguished (Fig 5.13A). Potentially interesting was the series of peaks with 44 u 
intervals left in the spectrum (400-600 m/z). These peaks were observed in 
GPR50ins/del A and GPR50ins/del B, with apparent increasing abundance of the 44 
u interval peaks in the deletion variant compared to the bulk of the peaks. This is 
likely to be a sign of contamination by the non-ionic surfactant 4-(α,α-
dimethylbenzyl)-phenol ethoxylate (Yokoyama et al., 2002) from glassware or 
instrumentation. As this contamination was not picked up before in the lab it is 
possible that it has high affinity for GPR50 CTD. The intensity of the peaks is no 
measure of how much contamination there is, it could be only a trace amount that is 
very volatile.  
 
5.3.3.1.2.2 MALDI-TOF mass spectrometry 
In order to find out if full length or multimeric intact GPR50 could be detected 
MALDI-TOF mass spectrometry was performed (Fig 5.13B). GPR50 ins/del A and 
B were analysed and peaks close to monomeric and dimeric GPR50 ins/del were 
detected (monomeric ins: 35528 Da, del: 34102/34265 Da; dimeric del: 72382.74 
Da; Fig 5.13C), but also peaks at ~31 kDa again reflecting that some of the GPR50 
CTD may have that lost its His-tag.  





Figure 5.13 Determination of GPR50 CTD molecular mass by Mass Spectrometry 
(A) ESI MS spectrum of GPR50 CTD ins/del Sample A and GPR50 ins/del Sample 
B. GPR50 CTD samples in 5mM ammonium acetate, 50% acetonitrile and 0.1% 
formic acid at pH 2.5 were injected into the electrospray ionisation source. Spectra 
were acquired over a range of 150 to 2000 m/z and for each sample 100 runs were 
performed.  
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Figure 5.13 Determination of GPR50 CTD molecular mass by Mass Spectrometry 
(B) MALDI-TOF analysis of purified GPR50 ins A (top) and del A (bottom) in 10 mM 
phosphate and 50 mM NaF/50% sinapinic acid matrix . The molecular mass 
estimations in daltons (Da) for the single mass ionization peaks are shown. 
Predicted molecular weight of TEV GPR50 del using ProtParam: 34767 Da; 
untagged: 31843 Da. 




Figure 5.13 Determination of GPR50 CTD molecular mass by Mass Spectrometry 
(C) MALDI-TOF analysis of purified GPR50 ins B (top) and del B (bottom) in 10 mM 
phosphate and 50 mM NaF/50% sinapinic acid matrix . The molecular mass 
estimations in daltons (Da) for the single mass ionization peaks are shown. 
Predicted molecular weight of TEV GPR50 del using ProtParam: 34767 Da; 
untagged: 31843 Da; dimer: 69543. 
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5.3.3.2 Protein Secondary Structure 
 
GPR50 CTD was predicted to be either largely unstructured, or some regions may 
form a polyproline type II helix, because of the number of proline residues within the 
repetitive motifs (Antonyraj et al., 1998; Bienkiewicz et al., 2000; Ma et al., 2001; 
Areschoug et al., 2002). In order to test this, circular dichroism (CD) was performed. 
When comparing CD spectra of GPR50ins A with del A (Fig 5.14) they both contain 
a minimum at ~200 nm, and a general profile characteristic of unstructured elements 
(Kelly et al., 2005). The minimum of GPR50del A seems to have however shifted 
slightly to a higher wavelength compared to ins A. This, combined with a slight 
decrease in signal at approximately 225 nm, may indicate that the proportion of α-
helix in GPR50del is slightly higher than GPR50ins. A minimum at 195 nm and 
maximum at 220-230 nm as commonly observed in polyproline II structures was 
however absent. Instead a second minimum was observed around 220 nm 
characteristic of both α-helix and β-sheet (Kelly et al., 2005) (Fig 5.5), which is 
increased in the deletion variant. GPR50ins B and del B show similar spectra but an 
even greater increase of the 220 nm minimum, indicating increased helicity or 
structure (Fig 5.14).  
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Figure 5.14 CD spectra of GPR50 CTD. Comparing GPR50 ins/del samples A and 
B in a 20 mM phosphate and 100 mM NaF buffer, measured at 20°C in a a 0.1 cm 
pathlength cuvette in a Jasco J-810 spectropolarimeter. Background was subtracted 




Using Dichroweb (Whitmore and Wallace, 2004, 2008) the traces were compared to 
databases with proteins whose structures have been determined experimentally by X-
ray crystallography. The choice of database can greatly alter the results (Whitmore 
and Wallace, 2008) and it is therefore important to choose a database that reflects the 
protein of interest. Although there is no information available on the structure of 
GPR50, databases 2 and 5 were selected as they were the only two databases that 
were able to discriminate polyproline II helices. This is because the CD spectra in 
these two databases were collected from 300 to 178 nm increasing the resolution and 
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possibility to detect structures such as PPII helices and 310-Helices (Johnson, 1999). 
Tables 5.3 and 5.4 show the structural information of proteins in databases 2 and 5. 
Thirteen proteins are present in both databases, with 9 proteins unique to database 2 
and 4 unique to database 5.  
 
The CDSSTR deconvolution algorithm (Compton and Johnson, 1986; Manavalan 
and Johnson, 1987) was used as this produced the best fit when compared to 
ContinLL and Selcon3 (not shown). This algorithm produced small normalised root-
mean-square deviation (NRMSD) values, reflecting small differences between the 
calculated and experimental CD spectra. CDSSTR has also been shown to perform 
better than other methods when using a small (29 protein) database (Sreerama et al., 
2000).  
 
Although the fit between experimental data and reconstructed data with databases 2 
and 5 were both excellent (Fig 5.15A-B), the resultant calculations of structural 
content were very different (Fig 5.15C). Analysis of GPR50ins Sample A with 
database 2 predicted predominantly ‘unordered’ (46%), whereas database 5 indicated 
25% helical and 17% sheet structure, with only 19% disorder. The numbers were 
similar using CDSSTR and ContinLL methods, indicating the difference is caused by 
the databases (Fig 5.14C). Although the trend of   
unstructured→GPR50 insA>GPR50delA>GPR50insB>GPR50delB→structured  
was detected when using both databases, the fraction results of database 2 seemed to 
reflect what was seen in the UV spectra better.  
 
These differences are likely caused by difference in dataset content (Tables 5.3 and 
5.4). Although the X-ray data for the 13 proteins in common are the same, the 
method of parsing the structure into secondary structural elements was different, as 
reflected in Tables 5.3-5.4 (Woody & Sreerama, pers comm). The authors of 
reference dataset 5 (Sreerama and Woody, 1994) utilised the Kabsch & Sander 
method (Kabsch and Sander, 1983) for assigning helix, sheet and turn residues, 
supplemented by a method for identifying PPII residues, whereas Johnson (dataset 2) 
used a different method as described in (Johnson, 1999). The two methods are meant 
Chapter 5: Structural Analysis of the GPR50 C-terminal Domain 
 
 242 
to agree well on helix and on PPII content, but database 5 is prone to giving higher β-
sheet and β-turn and lower unordered content than Johnson's. This is because the 
Kabsch & Sander criteria for the ordered structures are ‘looser’ than Johnson's. The 
two methods give more similar results for proteins with high helix content, e.g. 
MGLB (Myoglobin), HBN (Haemoglobin), LDH (Lactate dehydrogenase), THML 
(Thermolysin), but differ with more β-sheet or unordered content, as seems to be the 
case for GPR50 (Woody & Sreerama, pers comm).  
 
From structure predictions (Fig 5.2-5.3, D. Soares), we expect that a high disordered 
content reflects the structure of GPR50 better and the method and database used by 
Johnson (1999) may therefore be better for analysing the data. When using database 
2 only the results indicated a difference between the insertion and deletion variants 
of the GPR50 CTD, with an increase in α-helical content from 14% (sample B: 25%) 
to 25% (B: 51%) in the deletion variant (Fig 5.15D). The polyproline type II content 
was similar in both insertion (8%, B: 9%) and deletion (9%, B: 5%) variants (Fig 
5.15D). 





Figure 5.15 Structure content of GPR50 CTD using Dichroweb. Mean residue 
ellipticity of GPR50 ins A fitted using the CDSSTR method and database 2 (A) and 5 
(B). (C) Databases 2 and 5 differed in their structure content prediction using two 
different methods, CDSSTR and Contin. (D) Structure content of all GPR50 CTD 
samples using the CDSSTR method and database 2. 






α-helix β-sheet turn PPII Unordered 
BNJN 0.028 0.491 0.206 0.159 0.117 
CHYT 0.114 0.314 0.222 0.163 0.186 
CYTC 0.418 0.000 0.164 0.199 0.218 
ELAS 0.108 0.342 0.225 0.145 0.171 
FLVD 0.320 0.218 0.279 0.061 0.112 
HBN 0.760 0.000 0.125 0.035 0.080 
LDH 0.390 0.087 0.228 0.024 0.270 
LYSM 0.397 0.078 0.310 0.085 0.132 
MGLB 0.804 0.000 0.078 0.033 0.085 
PAPN 0.259 0.170 0.271 0.123 0.231 
PRAL 0.063 0.499 0.193 0.055 0.240 
THML 0.415 0.165 0.222 0.095 0.104 
TPI 0.460 0.168 0.144 0.055 0.174 
PGLU1 x x x x x 
RUBR 0.171 0.154 0.269 0.231 0.173 
SUBB 0.302 0.178 0.244 0.078 0.189 
GPD 0.274 0.208 0.246 0.060 0.213 
Average 0.33 0.192 0.214 0.100 0.168 
 
Table 5.3 Proteins in Dichroweb’s reference database 5. X-ray data 
in Sreerama & Woody 1994. Biochemistry. 1. data not available in paper. 




Database 2  
Protein symbol 
α-helix 310-helix β-sheet turn PPII Unordered 
BNJN 0.00 0.00 0.34 0.10 0.12 0.44 
CHYT 0.08 0.03 0.16 0.15 0.14 0.44 
CYTC 0.39 0.03 0.08 0.09 0.08 0.34 
ELAS 0.06 0.04 0.21 0.14 0.11 0.44 
FLVD 0.25 0.06 0.17 0.20 0.02 0.30 
HBN 0.67 0.08 0.00 0.10 0.00 0.15 
LDH 0.35 0.07 0.14 0.12 0.03 0.29 
LYSM 0.30 0.11 0.04 0.19 0.02 0.33 
MGLB 0.70 0.11 0.00 0.05 0.02 0.17 
PAPN 0.24 0.05 0.15 0.11 0.08 0.37 
PRAL 0.05 0.04 0.35 0.07 0.04 0.46 
THML 0.34 0.06 0.14 0.12 0.04 0.30 
TPI 0.33 0.07 0.15 0.10 0.04 0.31 
AZU 0.09 0.08 0.34 0.13 0.06 0.29 
BLAC 0.09 0.04 0.34 0.13 0.04 0.37 
CONA 0.01 0.01 0.36 0.12 0.07 0.42 
HMRT 0.59 0.12 0.04 0.06 0.03 0.17 
PPSN 0.11 0.10 0.39 0.11 0.09 0.19 
RNAS 0.17 0.05 0.19 0.11 0.08 0.40 
SUDS 0.00 0.04 0.24 0.16 0.09 0.47 
T4LS 0.59 0.08 0.06 0.04 0.01 0.22 
TRPN 0.09 0.03 0.19 0.14 0.14 0.41 
Average 0.25 0.06 0.19 0.12 0.06 0.33 
 
Table 5.4 Proteins in Dichroweb’s reference database 2. Ref: X-ray data, Johnson 
PROTEINS: Structure, Function, and Genetics 35:307–312 (1999). 
 





This is the first experimental data looking at the biophysical properties of the GPR50 
CTD, a region of functional importance (Thomson et al., 2005; Levoye et al., 2006). 
Circular Dichroism indicates GPR50 is predominantly unstructured with ~20-30% α-
helix/-β sheet content. Interestingly, structural content increases in the deletion 
variant to ~30-60% α-helix/-β sheet.  
 
5.4.1 Structure in the GPR50 CTD 
 
The overall CD data indicates there is more structure to the GPR50 CTD than 
predicted. The deletion variant of Sample B is even indicated to be 51% α-helical. A 
51% α-helical content is surprising given the consensus among structure predictors 
(Figs 5.2-5.3), the presence of numerous ‘helix-breaking’ proline residues, and is 
thus almost certainly incorrect for GPR50 CTD. One explanation is that the results 
were obtained on a degraded sample that retained only its structured regions, as 
indicated by mass spectrometry and observed on Western blots. Western blotting in 
Fig 5.9 suggests that Sample A is perhaps N-terminally and Sample B C-terminally 
degraded. The C terminus of the CTD is predicted to be more disordered (Fig 5.2-
5.3), with possible β-sheet and α-helical sections (Fig 5.2) providing some structure 
to the N-terminal part of the CTD. The loss of the C-terminal region may be the 
reason why Sample B is more structured. The combined data in this chapter may thus 
suggest that Sample A and B are different regions of the GPR50 CTD. If the above is 
the case the difference in DLS data (Fig 5.10-5.11) suggests that the N-terminal 
region is more prone to multimerising or extension, resulting in a large particle size. 
This may however also be due to the His-tag that appears to be more abundant in 
Sample B (Fig 5.9). Future studies with untagged GPR50 CTD may provide clues. 
 
Although the samples A and B have very different characteristics by DLS and CD, 
the CD spectra show the same pattern of increased helical content in the deletion 
variant. As the deletion lies within a region predicted to be of high disorder it is not 
surprising that removing it will result in an increase in α-helical content (Fig 5.2-5.3 
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and 5.14-5.15). It is likely that an overrepresentation in α-helical content overall is 
caused by a loss of unstructured regions. The unstructured regions are more 
susceptible to proteolysis in vitro (Dyson and Wright, 2005) and are lost from the 
rest of the protein, leaving behind only the residual structured regions in the sample. 
This property makes it difficult to obtain ‘structural’ data from unstructured proteins 
or regions. These technical limitations may thus be more problematic when 
investigating intrinsically unstructured proteins.  
 
5.4.2 Functional consequences 
 
Unstructured regions in proteins facilitate protein-protein interactions and are highly 
advantageous for functions such as signal transduction, regulation, cytoskelletal 
organization and protein-DNA recognition (Dyson and Wright, 2005; Li and Song, 
2007). An increase in secondary structure in the deletion could mean a reduction in 
the binding capacity of interaction partners. Intrinsically unstructured or disordered 
proteins are known to undergo a structural transition into a folded form upon binding 
of a target ligand (Fink, 2005). The ESI MS data showed the presence of a nonionic 
surfactant in the solution. Although the effects of nonionic surfactants on protein 
structure are minimal compared to ionic surfactants (Colonna et al., 1978) it is also 
possible that the increase in α-helical content is caused by this. 
It would be interesting to test GPR50 CTD under different conditions for instance in 
the presence of micelles or ionic detergents, as this has been shown to increase the 
structural propensity of membrane (anchored) proteins (Grimaldi et al.; Vasudevan et 
al.), or in the presence of interacting molecules. The CTD of RNA polymerase II can 
adopt a left-handed polyproline type II helix (PPII) under increasing hydrogen bond-
promoting solvent trifluoroethanol (TFE) concentrations (Bienkiewicz et al., 2000). 
One has to be cautious however with deriving conclusions from CD data obtained 
from solvent media such as TFE, as these are known to be helix-inducing and may 
cause non-native conformations of the protein, distinct from when using aqueous 
solutions (Wallace, 2009). Because of the time constraints of this project 
comparisons between the effects of different solvents or surfactants on structure was 
not possible. 




5.4.3 Methodological constraints 
 
Structure content prediction success with CD is heavily dependent on the presence of 
representative proteins in the database (Janes, 2005). At the moment all databases 
(and most structure identification methods) are biased towards α-helical proteins 
(Dyson and Wright, 2005). The empirical methods in use to date are most accurate at 
defining helical structures from CD spectra because of the dominance of the 
characteristic peaks from helices (they are much larger than the ß-sheet 
contributions) and because the structural nature of helices mean their ϕ/ψ angles fall 
in a much narrower range than those of other types of secondary structures, and as a 
result they are much more well defined (Wallace, 2000). Problems with detecting β-
sheet content and disordered content let alone rarer structures like the 310-helix and 
polyproline II helix will not be resolved unless more of those proteins are added to 
the database. Being able to measure protein spectra down to lower wavelengths will 
increase the accuracy of the predictions (Lees et al., 2006b).  
 
One of the recent developments in CD is synchrotron radiation circular dichroism 
spectroscopy, whereby spectra down to 165 nm can be obtained (Keller et al., 2009), 
making is easier to distinguish between structures with similar spectra such as 
unstructured and polyproline II structures (Miles and Wallace, 2006). Two 
Dichroweb databases that use synchrotron low-wavelength CD data are databases 2 
and 5. However there was little consensus between the two databases used as to how 
much of the content was structured. Using database 5 resulted in a higher structured 
content, much higher than would be expected from looking at the spectra, whereas 
database 2 appeared more accurate. As discussed in the results, this is likely caused 
by the difference in the way the structure content was attributed by the methods used. 
Generally it is considered to be better to use a large dataset, and SP175 is the largest 
available on Dichroweb. Unfortunately, this does not contain information on 
polyproline II helices, although according to (Lees et al., 2006a) this could be made 
available.  
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Other methodological constraints concern the buffering systems for biophysical 
characterisation. Many common components (for instance NaCl is problematic) 
absorb strongly in the far UV spectrum, interfering with the CD signal. NaF is one of 
the few possibilities for maintaining ionic strength (Kelly et al., 2005), in the hope 
that proteins maintain some of their native fold. In previous experiments, solvents 
(Bienkiewicz et al., 2000) or detergents (Grimaldi et al.; Vasudevan et al.) were 
added to the media in order to induce polyproline II structures. This introduces many 




From this preliminary study we conclude that the GPR50 CTD is predominantly 
unstructured with increased structured content in the deletion variant. Overall, 
structured content may however be overpredicted due to degradation of unstructured 
regions and/or multimerisation of specific regions of the GPR50 CTD. However the 
experiment needs to be repeated and CD and NMR with shorter fragments of the 
CTD may be necessary to provide a clearer and more conclusive picture. The 
structure content of different subregions (regions corresponding to predicted eighth 
membrane parallel helix, or heptapeptide region, or C terminus) and the effects of 
proteolytic degradation or multimerisation on the various fragments could then be 
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6 Chapter six: Concluding remarks 
 
6.1 Investigating the function of GPR50 
 
Research into the function of GPR50 is very much at its early stages and in the 
absence of a ligand many questions remain. Since the cloning of the receptor in 1996 
(Reppert et al., 1996) several studies have reported its expression in the brain, most 
notably in the hypothalamus and pituitary, suggesting a role in neuroendocrine 
signaling. Only one loss-of-function study was published, describing a GPR50 
knockout mouse, and suggesting a metabolic role (Ivanova, 2008). A function in 
lipid metabolism was supported by a genetic study (Bhattacharrya et al., 2006). One 
study reported the interaction with the melatonin receptors and its negative effect on 
melatonin signaling (Levoye et al., 2006). The work described in this thesis was 
initiated after the discovery of an association of variants in the GPR50 C-terminal 
domain (CTD) with psychiatric illness in women (Thomson et al., 2005). A sex-
specific association of GPR50 with mental illness has since been reported in other 
studies (Macintyre et al., 2011; Delavest et al., 2011).  
 
Since it was thought at the time that deorphanisation strategies would be initiated by 
others, it was decided to look for interactors with the GPR50 CTD in order to 
elucidate its function. GPCRs are known to interact with non-G-proteins via their 
CTD, resulting in modulation of their function (Ritter and Hall, 2009). The 
hypothesis was that the interactors would also give insight into the way GPR50 and 
its variants are associated with mental illness. The putative interactors that were 
identified by yeast-two-hybrid could be grouped into two classes, neuronal 
development and lipid metabolism, and key proteins from these broad classes were 
selected for follow-up.  
 
To recap, key results from each of the previous chapters will be summarised and 
integrated with other results from this thesis, and past research, into a general 
conclusion. I will end by mentioning some key questions that arise from this study 
and suggesting experiments for future research. 
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6.2 Confirmation of the interactions 
 
In Chapter 2, I showed that GPR50 interacts with Nogo-A, Nogo-C, RTN3, CDH8 
and ABCA2 under overexpressed conditions in mammalian cells. Endogenous Gpr50 
was shown to colocalise with Nogo-A, Cdh8 and Abca2 in cultured mouse neurons. 
The exogenous and endogenous expression of these proteins was in agreement with 
reports in the literature. When investigating the effects of the GPR50∆502-505/T532A 
variant associated with mood disorders, overexpressed GPR50 and GPR50∆502-
505/T532A
 showed a similar subcellular localization in mammalian cells. In addition, 
overexpressed GPR50 and GPR50∆502-505/T532A both colocalise and/or co-
immunoprecipitate with Nogo-A, Nogo-C, RTN3, CDH8 and ABCA2 in a similar 
fashion. Co-transfection of GPR50∆502-505/T532A  (and GPR50 to a lesser extent) with 
RTN3, Nogo-C and Nogo-A was shown to alter its cellular localization, decreasing 
GPR50 plasma membrane expression and increasing its expression in the ER. 
 
6.3 Developmental expression in mouse brain 
 
In Chapter 3, I showed that Gpr50, Nogo-A and Cdh8 protein expression is enriched 
in the postsynaptic density and Gpr50, Nogo-A, Cdh8 and Abca2 are all present in 
the light membrane fraction and crude synaptosome in adult mouse brain. These 
findings are in agreement with results in Chapter 2 and earlier studies. In addition, I 
reported for the first time the early developmental expression of Gpr50. Gpr50 
mRNA expression was detected from embryonic day E13, is highest at embryonic 
stage E18 and was shown to correlate with Abca2 expression over several 
developmental stages, and with Nogo-C, Cdh8 and Abca2 at E18 only. This suggests 
that E18 is an important timepoint for GPR50 functioning. In addition to confirming 
several sites reported earlier (Drew et al., 2001; Sidibe et al., 2010), Gpr50 protein 
was found to be expressed in serotonergic, dopaminergic and noradrenergic nuclei in 
the adult mouse brain. In addition, Gpr50 was shown to colocalise with Nogo-A, 
Cdh8 and Abca2 in the amygdala, cortex, hypothalamus and specific brain stem 
nuclei at E18 and in the adult mouse brain. All three proteins were found to be 
expressed in the amygdala in the adult. 
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6.4 Functional studies of GPR50 
 
In Chapter 4, I showed that GPR50 overexpression induces neurite outgrowth in NS-
1 cells, a PC12 cell line, in which a neuronal phenotype can be induced in response 
to NGF. In these cells GPR50 overexpression also appears to attenuate the outgrowth 
inhibiting characteristics of Nogo-A. Additionally, GPR50∆502-505/T532A 
overexpression further increases neurite outgrowth compared to GPR50. Moreover, 
GPR50 and GPR50∆502-505/T532A overexpression induces filopodia formation in NS-1 
cells and cultured neurons. Reticulon proteins RTN3 and Nogo-C are known to 
reduce BACE1 activity.  In a second assay in HEK293 cells I showed that, GPR50, 
but not GPR50∆502-505/T532A, overexpression increases in vitro BACE1 activity. 
 
6.5 Structural studies of the GPR50 CTD 
 
In Chapter 5, I showed that the GPR50 C-terminal domain (CTD) could be 
succesfully purified, although its stability in various buffering systems calls for 
optimisation. Preliminary data that indicate GPR50 CTD is predominantly 
unstructured and that the GPR50 CTD∆502-505/T532A is more structured than GPR50. 
The increased structure content of GPR50∆502-505/T532A may affect the binding of 




From this, I conclude that GPR50 has interesting interaction partners and potential 
interaction partners, with links to several disease mechanisms and functions. Taken 
together the results indicate a role for GPR50 in neurite outgrowth, BACE1 activity 
and synapse formation and function.  
 
GPR50 is enriched in the postsynaptic density and shows a peak in expression at 
E18, a key stage in synapse development (Hinds and Hinds, 1976; Matsuki et al., 
2005). In addition, GPR50 increases neurite outgrowth and induces the formation of 
filopodia, which may be precursors of synaptic spines (Mattila and Lappalainen, 
2008). Moreover, interactors Nogo-A and Cdh8 are reported to regulate synaptic 
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plasticity (Aloy et al., 2006; Delekate et al., 2011, Suzuki et al., 2007), a mechanism 
that is thought to be important for learning and memory processes (Kandel, 2001).  
 
Expression of GPR50 in noradrenergic, serotonergic and dopaminergic nuclei 
perhaps suggests a role in neurotransmitter signaling and the maintenance of synaptic 
connections (Verhage et al., 2000), although this clearly needs to further 
investigation. One of the strongest paradigms in psychiatric illness is the disturbance 
of neurotransmitter signaling and synaptic functioning, as reflected by the 
mechanisms of action of antidepressants and antipsychotics (Nutt, 2006).  
 
If GPR50 increases BACE1 activity it may be involved in the processing of BACE1 
substrates, such as APP and Neuregulin-1, linking GPR50 to Alzheimer’s disease 
and schizophrenia. The mechanism of BACE1 activity increase and whether GPR50 
acts in a substrate-specific manner however needs to be investigated. GPR50 and 
several of its interactors were found to be expressed in the cortex, in areas where 
BACE1 activity is correlated with Alzheimer’s disease severity (Fukumoto et al., 
2002), indicating possible functional sites.   
 
GPR50 affects both neurite outgrowth and BACE1 activity and these processes may 
be linked. There is emerging evidence for a role of BACE1 and its substrates in 
neurite outgrowth. Overexpression of BACE1 increased neurite length but decreased 
the number of filopodia-like protrusions in Neuro2A cells, through processing of one 
of its substrates, the voltage-gated sodium channel subunit β4 (Miyazaki et al., 
2007). Substantial evidence has been generated implying a function of APP in 
neurite outgrowth (Leyssen et al., 2005; Hoe et al., 2009), neuronal proliferation and 
survival and cell adhesion (Hughes et al., 2010), synaptic development (Ashley et al., 
2005) and interestingly G-protein-coupled receptor signaling (via G0), (Nishimoto et 
al., 1993), under non-pathological conditions (Reinhard et al., 2005). Full length 
APP can either have neurite outgrowth promoting or –inhibiting effects, depending 
for instance on the developmental timepoint investigated (Perez et al., 1997). Soluble 
APP, the product of α-secretase and β-secretase cleavage, stimulates neurite 
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outgrowth, perhaps through interfering with the interaction of integrins with cell 
surface APP (Young-Pearse et al., 2008).  
 
In addition, aberrant sprouting of neurites is a common feature in the pathology of 
AD and GPR50 expression was reported to be increased in cells showing 
degenerative changes (Hamouda et al., 2007). Also, Nogo can negatively regulate 
this outgrowth in AD mouse models (Masliah et al., 2010). Perhaps GPR50 induces 
(aberrant) outgrowth in these cells. 
 
What can be said about the effect of the GPR50∆502-505/T532A variant associated with 
mood disorders? Preliminary structural analysis indicates an increase in structure in 
the deletion variant, which may be less favourable to protein-protein interactions 
(Dyson and Wright, 2005). Although the ability to bind the proteins investigated is 
not affected (Chapter 2) there are perhaps subtle differences in kinetics that are not 
detected by the techniques used. In the functional assays GPR50∆502-505/T532A further 
increased neurite outgrowth compared to GPR50, which may result in abnormal 
‘wiring’ in the brain, which may be linked to the exessive sprouting in AD pathology 
(Hashimoto and Masliah, 2003; Masliah et al., 2003). There is however no indication 
of an increased risk of AD in psychiatric patients. The increase in BACE1 activity 
that is observed after GPR50 overexpression is not seen with GPR50∆502-505/T532A. 
This may indicate differences in the processing of the substrates, for instance 
decreased Aβ load and decreased processing of Neuregulin-1 in GPR50∆502-505/T532A. 
This turn may lead to a decreased risk in Alzheimer’s disease but increase in 
abnormal myelination and schizophrenia (Savonenko et al., 2008). These hypotheses 
are however highly speculative and detailed research is needed to substantiate these 
claims.  A schematic of possible GPR50 functioning is presented in Figure 6.1.  




Figure 6.1 Schematic of GPR50 functioning. Hypothesis based on previous findings 
results in this thesis. GPR50 can interact with CDH8, Nogo, RTN3, ABCA2 and can 
increase neurite ourgrowth and BACE1 activity. GPR50 and interactors have been 
implicated in neuronal development, psychiatric illness and neurodegenerative 
disorders such as Alzheimer’s disease. Further research is needed to elucidate 
these mechanisms and to establish the role of GPR50 and its interaction partners.     




6.7 Future work  
 
As always, the results in this thesis are limited and lead to more questions than 
answers. Here follow some of the key remaining questions and suggestions for future 
research. 
 
1. Are GPR50s interactions direct and are the proteins part of a complex? Results in 
this thesis indicate GPR50 and interactors are expressed in the same brain regions 
and subcellular locations. It is therefore possible they interact in a complex. Detailed 
in-vitro binding studies with endogenous and overexpressed proteins are necessary in 
order to fine map the interaction sites.  
 
2. Does GPR50∆502-505/T532A affect the stochiometry of its interactions? Although 
there isn’t a clear difference between binding of GPR50 and GPR50∆502-505/T532A the 
effects may be subtle. 
 
3. What is the effect of GPR50 knockout/knockdown on its function and the 
expression and function of the protein-protein interactors? In this thesis no loss-of-
function models were used, which are necessary in order to determine the function of 
GPR50. GPR50 knockout mice are viable, at least in one model (Ivanova et al., 
2008), which suggests no major brain or developmental abnormalities in the absence 
of GPR50. These mice have however not been characterized beyond a metabolic 
phenotype or in relation to mental illness. Other GPR50 knockout mouse models or 
stem cells for deriving knockout lines exist (Organon/Schering Plough/Merck and 
KOMP), neither of which have been characterised to my knowledge. We did try to 
obtain these mice from Organon but unfortunately were not successful. Knockdown 
can also be achieved by siRNA in neurons or cell lines. 
 
4. How does GPR50 increase neurite outgrowth and BACE1 activity and is it 
dependent on the interaction with reticulon proteins? The activity of Rho GTPases 
and other modulators of the actin cytoskeleton could be measured in response to 
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GPR50 overexpression and knockout/knockdown. The experiments should be 
performed in the absence of Nogo/RTN3 to determine if the effects are mediated by 
these interactors. As for the effect of GPR50 overexpression on BACE1 activity, 
many questions remain. The possibility of a direct interaction with BACE1 should be 
investigated as well as the effects of GPR50 overexpression or knockdown on the 
processing of APP, Neuregulin-1 and other substrates of BACE1. 
 
5. Are there sex-specific effects on expression and function of GPR50? To this end 
males and females need to be studied separately in order to address sex-specific 
effects as suggested by genetic studies (Delavest et al., 2011; MacIntyre et al., 2010; 
Thomson et al., 2005). 
 
6. Is GPR50 involved in neurotransmitter signaling? Given that deorphanisation 
attempts have been undertaken it is not likely that they would have missed out classic 
neurotransmitters (although this depends on the point at which the assays have 
failed). It may however be possible to detect binding or noradrenaline, serotonin and 
dopamine to GPR50 in a novel assay. Perhaps GPR50 does not signal via these 
transmitters but modulates its signaling. The possibility of cross-talk between GPR50 
and noradrenergic, dopaminergic and serotonergic receptors should also be 
investigated.  
 
7. What parts of the GPR50 CTD are structured and is its structure altered by its 
protein-protein interactions? Smaller regions of the CTD need to be examined as 
necessary for NMR. Purification of GPR50 in the presence of its interactors is 
expected to alter its confirmation. Structural studies with the GPR50 CTD may 
however be very difficult or impossible due to the apparent absence of structural 
elements. 
 
8. What is the role of melatonin or the melatonin receptor-GPR50 heterodimer in 
GPR50 expression and functioning? Although overexpressed GPR50 and MT1/MT2 
have been found to heterodimerise, endogenous dimerisation has not been detected, 
perhaps due to the difficulty in obtaining specific melatonin receptor antobodies 
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(Jockers et al., 2008). Perhaps GPR50 can be studied in Melatonin receptor (MT1) 
knockout mouse, which shows depressive-like behaviour and impaired sensorimotor 
gating (Weil et al., 2006).
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Supplementary figures 1-6: Allen Brain Atlas of adult mouse brain 
http://mouse.brain-map.org/atlas/index.html  
Images of the sections isolated and studied in Chapter 3.
8: Supplementary Information 
 
Supplementary Figure 1 293 
8: Supplementary Information 
 
Supplementary Figure 2 294 
8: Supplementary Information 
 
Supplementary Figure 3 295 
8: Supplementary Information 
 
Supplementary Figure 4 296 
8: Supplementary Information 
 
Supplementary Figure 5 297 
8: Supplementary Information 
 
Supplementary Figure 6 298 
 
 299 
8 Publications from this thesis 
 
 
Grünewald E, Kinnell HL, Porteous DJ, Thomson PA (2009) GPR50 interacts with 
neuronal NOGO-A and affects neurite outgrowth. Molecular and Cellular 
Neuroscience 42:363-371. 
 
